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ABSTRACT 
 
Paediatric ependymomas remain a clinical management challenge, with a relatively 
poor prognosis when compared to other childhood tumours of the central nervous 
system. An improved understanding of underlying ependymoma biology may identify 
new correlates of outcome and potential therapeutic targets. To address this, 
AffymetrixTM 500K SNP arrays were used to establish the nature and range of genomic 
imbalances in 63 paediatric ependymomas (42 primary and 21 recurrent). Over 80 % of 
tumours were analysed against patient-matched constitutional DNA. In addition, the 
Illumina® GoldenGate® Cancer Panel I array was used to identify differences in 
methylation profile across 98 paediatric ependymomas (73 primary and 25 recurrent). 
While collective assessment revealed the most common anomalies, specific aberrations 
were characteristic of certain ependymoma subgroups, particularly those relating to 
tumour location, patient age, disease recurrence and patient prognosis. The genomic 
imbalance of 15 selected candidate genes (NSL1, DNAJC25, NAV1, CDKN2A, CHI3L1, 
HOXA5, TXN, BNIPL, and PRUNE) were confirmed by quantitative Polymerase Chain 
Reaction. Genomic gain involving regions of chromosome 1q were associated with an 
unfavourable patient outcome, such as the focal locus on 1q21.3 encompassing PRUNE. 
The genomic gain of PRUNE correlated with an increased encoded protein expression, 
as assessed by immunohistochemistry (IHC).  
 
This adverse prognostic association with 1q was upheld in the subsequent part of this 
work. Fluorescent in situ hybridisation and IHC were used to evaluate a panel of six 
putative prognostic markers (1q25 gain, PRUNE, Tenascin-C, Nucleolin, Ki-67 and 
NAV1 expression) across a paediatric intracranial ependymoma tissue microarray 
cohort of 107 primary tumours treated within the confines of two aged defined clinical 
trials (UK CCLG 1992 04 and SIOP 1999 04). Within the younger UK CCLG 1992 04 
cohort, copy number gain of chromosome 1q25 and PRUNE overexpression were 
independently associated with an increased risk of disease progression, while strong 
PRUNE expression was also an independent marker of worse overall survival. In 
addition, increased Tenascin-C expression correlated with a reduced overall survival on 
univariate analysis. For older children in the SIOP 1999 04 cohort, strong PRUNE 
expression in ependymomas was again identified as an adverse prognostic marker, 
correlating with increased mortality on univariate assessment.  
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1.1 Paediatric brain tumours 
 
1.1.1 Background 
 
Tumours of the brain and spinal cord are collectively the most common solid 
malignancies in children, accounting for approximately 25 % of all childhood cancers 
(Stiller 2004). The reported incidence of paediatric central nervous system (CNS) 
tumours in the United Kingdom has increased by almost a quarter within the last three 
decades, a presumed consequence of advanced diagnostic and reporting techniques 
(Stiller 2004). However, despite the development of neuroimaging and therapeutics, 
improvements in survival for paediatric brain tumour patients have been modest when 
compared to most other FKLOGUHQ¶VFDQFHUVsuch that they remain the leading cause of 
cancer deaths in this age group (Wong, Tsang et al. 2006).  This implies a need to 
improve undHUVWDQGLQJ RI WKH XQGHUO\LQJ ELRORJ\ RI FKLOGUHQ¶V EUDLQ WXPRXUV DV KDV
been the case with cancers such as paediatric haematological malignancies. Indeed, over 
80 % of children with leukaemia in industrialised countries can now be cured of disease, 
compared to only approximately 50 ± 60 % of those with a CNS tumour (Stiller 2004). 
Such unfavourable cure rates for paediatric brain tumour patients are compounded by 
enduring or progressive neuro-cognitive and psychological deficits experienced by a 
substantial proportion of survivors, acquired as a consequence of the tumour itself or 
therapeutic interventions. 
 
The histological diversity of paediatric CNS tumours contributes to the difficulty of 
tumour classification which underpins all current treatment programmes, potentially 
reflecting biological disparity between tumour subgroups (Stiller 2004). Although 
several classification systems have been proposed, the most frequently used is the 
World Health Organization (WHO) 2007 grading system (Louis, Ohgaki et al. 2007) 
(Table 1.1). It is hoped that an improved knowledge of paediatric brain tumour biology 
would refine these classification systems in use, encouraging novel prognostic 
stratifications and allowing more targeted therapeutic strategies.  
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Table 1.1: WHO grading of tumours of the central nervous system.  
(Reproduced from Louis, Ohgaki et al. 2007)  
 
 
1.1.2 Neural development  
 
7KHWHUPµHPEU\RQDO¶ is often attributed to paediatric brain tumours as they are thought 
to arise in immature tissue environments as a consequence of deviation from normal 
neuro-developmental processes (Scotting, Walker et al. 2005).  
4 
 
The central nervous system (CNS), comprising the brain and spinal cord, is a complex 
three-dimensional structure that originates from the ectodermal neuroepithelium of the 
embryo. During early CNS development, the ectoderm thickens to form the neural plate 
during a process termed neural induction. Dorsal fusion of the rolled neural plate in turn 
creates the neural tube. A subsequent spatio-temporal mediated sequence of 
proliferation, lateral migration from the neural tube and differentiation then ensues to 
define CNS sub-regions demonstrating constitutive cellular diversity.  
 
Initially, neuroepithelial cells are thought to proliferate and give rise to radial glial cells 
in the embryonic ventricular zone (Noctor, Martinez-Cerdeno et al. 2007), such that 
radial glia are considered the principal neuronal progenitors of the primitive CNS  
(Mori, Buffo et al. 2005). As development continues after birth, radial glial cells either 
mature directly into ependymal cells which comprise the ventricular lining of the brain 
and are implicated in CSF circulation, or transform into postnatal/adult multipotent 
neural stem cells (NSCs) (Spassky, Merkle et al. 2005). These NSCs express the 
astroglial marker Glial Fibrillary Acidic Protein (GFAP) and become localised to 
specialised germinative niches (Vescovi, Galli et al. 2006). Two such regions are the 
subventricular and subgranular zones of the postnatal and adult brain, where multipotent 
NSCs have been identified albeit in restricted numbers (Eriksson, Perfilieva et al. 1998; 
Bonfanti and Peretto 2007). The multipotent NSCs can be the source of further stem cell 
progeny or give rise to lineage restricted progenitor cells. In the subventricular zone, 
these latter cells are termed early transit amplifying progenitors which can generate 
either terminally differentiated glia of the mature CNS (astrocytes and 
oligodendrocytes) or Type A migrating neuroblasts committed to neuronal 
differentiation (Doetsch 2003). Similarly, NSCs in the subgranular zone can give rise to 
mature neurons via the formation of intermediate Type D precursor cells (Doetsch 
2003). Since glial cells are the predominant CNS cell type and, unlike neurons, retain a 
capacity to divide, it is unsurprising that most paediatric brain tumours are glial in 
origin (Packer 1999).  
 
The processes responsible for determining the timing and location of these stem cell 
developmental programmes are not fully understood, although they are thought to be 
modulated by a variety of signalling molecules and pathways that control cell 
proliferation, migration, maturation and specification. An improved appreciation of 
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these developmental regulatory mechanisms is imperative as aberrations within these 
processes may contribute to CNS tumour formation. For instance the Sonic Hedgehog, 
Wnt and Notch signalling pathways have been shown to be involved in a range of 
processes essential for embryonic CNS growth and patterning. These include 
stem/progenitor cell self-renewal, proliferation, migration and determination of cell fate 
(Morrison 2001; Hitoshi, Alexson et al. 2002; Lai, Kaspar et al. 2003; Machold, 
Hayashi et al. 2003; Reya, Duncan et al. 2003; Katoh and Katoh 2005; Nyfeler, Kirch et 
al. 2005). Dysregulation of these pathways have been reported in numerous 
malignancies including CNS tumours (Taipale and Beachy 2001; Pardal, Clarke et al. 
2003; Reya and Clevers 2005). Indeed, the association of these signalling systems with 
ependymoma pathogenesis is discussed later in this chapter. Similarly, extrinsic growth 
factors such as epidermal growth factor (EGF) have been have been reported to promote 
the proliferation of multipotent neural stem cells (Gritti, Frolichsthal-Schoeller et al. 
1999). Amplification of the EGF receptor (EGFR) is a frequent finding in adult 
glioblastoma multiforme (Ohgaki and Kleihues 2007) and has been associated with 
adverse prognosis in ependymoma (Mendrzyk, Korshunov et al. 2006). Bone 
morphogenetic proteins (BMPs) are other growth factors which have been reported to 
influence neural stem cell proliferation and terminal differentiation (Furuta, Piston et al. 
1997; Li, Cogswell et al. 1998; Panchision, Pickel et al. 2001), while altered BMP 
signalling has been identified in intracranial ependymomas (Palm, Figarella-Branger et 
al. 2009) and high grade gliomas (Vandeputte, Troost et al. 2002).  
 
Notwithstanding external signalling pathways, intrinsic stem cell regulatory 
mechanisms, such as those facilitating telomeric maintenance, have also been postulated 
to have a role in cancer when disrupted. Telomeres are nucleoproteins derived from 
DNA repeat sequences that can contribute to genomic stability by capping chromosomal 
termini (Ridley, Rahman et al. 2008). Telomere length can be maintained by the 
ribonucleoprotein telomerase which creates new repeat sequences, a process catalysed 
by its enzymatic subunit hTERT.  Murine studies have shown that telomerase 
expression in different regions of the developing CNS correlates with the degree of 
neural progenitor cell proliferation (Prowse and Greider 1995; Ostenfeld, Caldwell et al. 
2000; Klapper, Shin et al. 2001), thereby suggesting alterations in telomeric 
homeostasis play a role in neural development (Rahman, Heath et al. 2009). While 
telomere erosion occurs with sequential mitotic cycles in normal somatic cells, 
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telomerase-mediated telomere maintenance is present in almost all types of malignant 
cells, (Shay and Bacchetti 1997) and overexpression of hTERT has been associated with 
adverse prognosis in paediatric intracranial ependymomas. This is further discussed 
later in this thesis. 
 
1.1.3 Brain tumour stem cells  
 
7KH WHUP µVWHP FHOO¶ is reserved for those with the ability for self-renewal and 
multipotency. The identification of cells with these stem-like characteristics facilitating 
neurogenesis in the adult brain led to the hypothesis that brain tumours were not 
necessarily restricted to originating from terminally differentiated CNS tissue, but could 
result from the malignant transformation of these proliferating neural stem cells into 
cancer inducing stem cells (Vescovi, Galli et al. 2006; Rahman, Heath et al. 2009). 
 
This cancer stem cell hypothesis has underpinned the identification of tumourigenic cell 
subsets that share the properties of corresponding normal tissue stem cells in several 
human malignancies, including leukaemia, breast and colon cancer (Lapidot, Sirard et 
al. 1994; Bonnet and Dick 1997; Al-Hajj, Wicha et al. 2003; O'Brien, Pollett et al. 2007; 
Ricci-Vitiani, Lombardi et al. 2007). The first putative brain tumour stem cells were 
identified within a minority population of cells expressing the cell surface antigen 
CD133, isolated from glioblastoma multiforme and medulloblastoma (Singh, Clarke et 
al. 2003). These cells possessed a marked capacity for self-renewal (as evidenced by the 
formation of floating aggregates termed neurospheres), proliferation and differentiation 
(Singh, Clarke et al. 2003). Moreover, the CD133+ cells initiated tumour formation 
upon xenograft transplantation in non-obese diabetic, severe combined immunodeficient 
(NOD-SCID) mouse brain (Singh, Hawkins et al. 2004). In a subsequent study, cells 
demonstrating a radial glial immunophenotype (CD133+/Nestin+/ RC2+/BLBP+) were 
isolated from ependymoma and also provided evidence of self-renewal in vivo by 
forming orthotopic murine tumours (Taylor, Poppleton et al. 2005). In both cases, very 
few CD133+ cells were required to generate tumour formation.  By contrast, cells 
lacking CD133 expression were not tumourigenic, even when large cell numbers were 
injected (Singh, Hawkins et al. 2004; Taylor, Poppleton et al. 2005).  
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This realisation has modified our appreciation of cancer development by suggesting that 
the majority of cells within paediatric brain tumours are not tumourigenic, with only a 
minority capable of tumour initiation. Currently, the term µEUDLQ WXPRXU VWHP FHOO¶
defines cells with the ability to proliferate, self renew and have a capacity to produce the 
different cell lineages comprising the tumour mass (Clarke, Dick et al. 2006). 
Immunophenotyping is not incorporated in this definition as subsequent studies have 
shown a tumourigenic capacity for cells lacking CD133 expression in glioblastoma 
(Wang, Sakariassen et al. 2008). 
 
Alternative work has focussed on establishing the molecular mechanisms triggering 
malignant stem cell conversion in the CNS. While some studies have considered the 
influence from the cellular microenvironment (Calabrese, Poppleton et al. 2007), others 
have proposed a role for signalling pathways shown to be implicated in both normal 
stem cell regeneration and uncontrolled tumourigenic cell growth, such as the Sonic 
Hedgehog, Wnt and Notch pathways (Gaiano, Nye et al. 2000; Hitoshi, Alexson et al. 
2002; Lai, Kaspar et al. 2003; Machold, Hayashi et al. 2003; Radtke and Raj 2003; 
Reya, Duncan et al. 2003; Nyfeler, Kirch et al. 2005; Reya and Clevers 2005; Romer 
and Curran 2005). 
 
The nature of the neoplastic cell of origin for different CNS tumour groups, 
fundamental to the cancer stem cell hypothesis, is another area of ongoing research. 
While it has been shown that mutations in early neural progenitor cells are sufficient to 
promote tumourigenesis (Yang, Ellis et al. 2008; Alcantara Llaguno, Chen et al. 2009; 
Gibson, Tong et al. 2010; Johnson, Wright et al. 2010), it remains conceivable that a 
more lineage committed precursor or even a de-differentiated mature cell could acquire 
stem-like characteristics on malignant transformation.   
 
1.2 Clinical and pathological aspects of paediatric ependymoma 
 
1.2.1 Epidemiology  
 
Ependymomas are the third most common paediatric CNS tumours after astrocytomas 
and PNETs, with an incidence of approximately 2.2 per million children (Kulkarni 
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2004). They account for 6 ± 12 % of brain tumours in children and almost 2 % of all 
childhood cancers (Pollack 1994; Miller, Young et al. 1995; Bouffet, Perilongo et al. 
1998). Although also reported in adults, over half of all cases occur in children under 
five years of age (Heidemann RL 1997; Duffner, Krischer et al. 1998; Grill, Le Deley et 
al. 2001). While some studies have shown that ependymomas occur predominantly in 
males (Goldwein, Leahy et al. 1990; Horn, Heideman et al. 1999), others have observed 
equal incidence rates between boys and girls (Rousseau, Habrand et al. 1994; 
Robertson, Zeltzer et al. 1998).  
 
1.2.2 Tumour location 
 
Almost 90 % of paediatric ependymomas are intracranial in origin with two-thirds 
arising in the posterior fossa, presumably from the ependymal cell surface of the fourth 
ventricle (Heidemann RL 1997; Grill, Le Deley et al. 2001; Kulkarni 2004). 
Nevertheless, paediatric ependymomas are capable of occurring anywhere within the 
CNS. This includes the parenchyma of the cerebral hemispheres away from the 
ependymal lining and, rarely, the spinal cord (Merchant and Fouladi 2005). This 
contrasts markedly with ependymoma location in adults, where approximately 75 % of 
tumours arise in the spine (Ebert, von Haken et al. 1999). Ependymomas also share 
certain clinical characteristics with germ cell tumours and have been reported outside 
the CNS in the sacrococcygeal area, mediastinum (Aktug, Hakguder et al. 2000) and 
ovary (Hirahara, Yamanaka et al. 1997), suggesting variable aberrant cell migration and 
differentiation pathways during ependymoma tumourigenesis. 
 
1.2.3 Aetiology and predisposing syndromes 
 
The aetiology of ependymoma remains relatively unknown, with cranial exposure to 
therapeutic doses of ionising radiation being the only established environmental risk 
factor (Stiller 2004). While simian virus 40 (SV40) DNA sequences have been found in 
a proportion of tumours (Bergsagel, Finegold et al. 1992), subsequent studies have not 
supported a causal association between SV40 exposure and ependymoma development 
(Krainer, Schenk et al. 1995; Weggen, Bayer et al. 2000; Reuther, Lohler et al. 2001). 
Genetic predisposition has also been implicated as a cause in certain cases. For instance, 
Neurofibromatosis type 2 is an autosomal dominant condition caused by germline 
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mutations in the NF2 gene (22q12.2). This disorder is particularly associated with the 
formation of vestibular schwannomas, although meningiomas and spinal ependymomas 
are also relatively common findings (Ebert, von Haken et al. 1999; Lamszus, 
Lachenmayer et al. 2001; Evans 2009). Spinal ependymomas have also been reported in 
adults with Multiple Endocrine Neoplasia type 1 (MEN1) syndrome, characterised by 
numerous endocrine tumours (Kato, Uchimura et al. 1996), albeit infrequently. 
Intracranial ependymomas have been described as a rare feature of Turcot syndrome 
type 2, otherwise known as brain tumour polyposis 2 (TS2/BTP2) (Onilude, Lusher et 
al. 2006). This familial cancer syndrome is caused by inherited mutations of the APC 
gene (5q22.2) and is characterised by the development of intestinal polyps, yet is more 
commonly associated with medulloblastoma formation (Hamilton, Liu et al. 1995). 
Indeed, somatic mutations of APC have not been identified in ependymoma (Onilude, 
Lusher et al. 2006). While familial ependymomas have been described in the absence of 
such familial syndromes (Dimopoulos, Fountas et al. 2006), these reports are 
uncommon and the majority of paediatric tumours appear to arise without a known 
inherited predisposition.  
 
1.2.4 Histology and ependymoma classification 
 
Ependymomas are neuroepithelial tumours of variable morphological appearance. The 
histology of this tumour group remains an extremely controversial correlate of 
prognosis. The WHO 2007 grading system identifies four major types of ependymoma: 
subependymoma and myxopapillary ependymoma (grade 1), classic or low grade (grade 
II) and anaplastic (grade III) (Louis, Ohgaki et al. 2007) (Figure 1.1 and Table 1.2). The 
latter two grades are the principal variants found in children. Classic ependymomas 
often demonstrate dense cellularity and perivascular pseudorosettes (Goldwein, Leahy 
et al. 1990) while a diagnosis of anaplasia requires the presence of necrosis, 
calcification, increased microvascular proliferation, mitotic activity and cell density 
(Bouffet, Perilongo et al. 1998). 
 
 
 
 
 
10 
 
Table 1.2: Current WHO classifications of ependymomas 
 (Reproduced from Louis, Ohgaki et al. 2007). 
WHO Grading System Subgroups Histopathology 
I Subependymoma 
 
 
 
 
 
Myxopapillary ependymoma 
Isomorphic nuclei embedded in a 
dense fibrillary matrix of glial cell 
processes with frequent microcystic 
change.  
Mitoses rare or absent. 
 
GFAP-expressing cuboidal to 
elongated tumour cells arranged in a 
papillary manner around vascular 
stromal cores. 
II (Classic) Cellular ependymoma 
Papillary ependymoma 
Clear cell ependymoma 
Tanycytic ependymoma 
Monomorphic nuclear morphology.  
Mitoses rare or absent.  
Perivascular pseudorosettes and 
ependymal rosettes. 
III (Anaplastic) 
 
High mitotic activity. Palisading 
necrosis. Microvascular proliferation. 
Perivascular pseudorosettes.  
 
Although specific grades have been recognized, the reality of assigning such 
classifications to an ependymoma remains subjective (Kulkarni 2004). Benign, classic 
and anaplastic morphology probably represent different points along a continuous 
pathological spectrum, while tumour heterogeneity may result in islands of anaplasia 
occurring within classic histological regions (Figure 1.1C), causing uncertainty 
regarding the degree of focal anaplasia that represents true anaplasia. This is highlighted 
by the proportion of anaplastic ependymomas in reported series ranging from 7 ± 89 % 
(Bouffet, Perilongo et al. 1998) and a study of 34 ependymomas where tumour grade 
was revised in almost a quarter of cases (Horn, Heideman et al. 1999). Furthermore, the 
current criteria defining anaplasia has met with criticism from some neuropathologists 
who do not believe endothelial proliferation or necrosis reflect this tumour grade 
(Schiffer, Chio et al. 1991).  
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Figure 1.1:  Histological appearances of paediatric ependymoma. A. Classical (grade II) ependymoma with perivascular pseudorosettes. B. Anaplastic (grade III) ependymoma with high mitotic 
activity (arrows) and vascular proliferation. C. Ependymoma displaying tumour heterogeneity with a grade II region (top right) and a grade III region (bottom left) in the same section. Objectives        
×10, ×40 and ×10 respectively. 
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The inherent ambiguity present in the current histomorphological classification of 
ependymoma undoubtedly contributes to the contradictory results of studies 
investigating a prognostic role for tumour grading. Several studies have linked the 
morphological features of anaplasia to a poor outcome or suggested ependymoma grade 
affects survival post radiotherapy (Horn, Heideman et al. 1999; Figarella-Branger, 
Civatte et al. 2000; Grill, Le Deley et al. 2001; Oya, Shibamoto et al. 2002; Paulino, 
Wen et al. 2002; Korshunov, Golanov et al. 2004; Massimino, Gandola et al. 2004; 
Tihan, Zhou et al. 2008; Merchant, Li et al. 2009). However other studies refuted this or 
fail to establish an association between anaplasia and prognosis, including those 
adopting a WHO classification system (Goldwein, Leahy et al. 1990; Sutton, Goldwein 
et al. 1990; Pollack, Gerszten et al. 1995; Perilongo, Massimino et al. 1997; Duffner, 
Krischer et al. 1998; Robertson, Zeltzer et al. 1998). Moreover, studies analyzing the 
prognostic role of specific histological features such as necrosis, mitotic activity, 
cellularity, pleomorphism and vascular proliferation, have yielded conflicting results 
(Hamilton and Pollack 1997; Rickert and Paulus 2005). 
 
Recent attempts to reduce the prognostic ambiguity of ependymoma histology have 
included the meta-analysis of increased numbers of ependymomas using co-operative 
neuropathology reviews to reduce subjective interpretation bias. Tihan and colleagues 
found that WHO tumour grading was an independent prognostic factor for event-free 
survival, but not overall survival, in 96 paediatric posterior fossa ependymomas where 
histology had been reviewed by three neuropathologists (Tihan, Zhou et al. 2008). In 
contrast, a panel of five neuropathologists devised a novel histological grading scheme 
following consensus review of 233 intracranial ependymomas from children enrolled in 
four European paediatric clinical trials (Ellison, Kocak et al. 2011). The trials were 
designed for younger patients receiving chemotherapy as the primary adjuvant therapy 
(BBSFOP (Grill, Le Deley et al. 2001) and UK CCLG 1992 04 (Grundy, Wilne et al. 
2007)) or patients aged above three years treated primarily with post-operative 
radiotherapy (AEIOP ependymoma (Massimino, Gandola et al. 2004) and SIOP 1999 
04). Using the new scheme, tumours were divided into two grades ± II and III. Cell 
density, nodularity, mitotic activity and angiogenesis were considered important 
histological criteria for re-classification, whereas necrosis and cytological atypia were 
not (Figure 1.2).   
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Figure 1.2: The Ellison classification scheme for paediatric ependymoma histology (Ellison, Kocak et al. 2011). 
 
The group concluded that concordance on grading among the five pathologists 
improved significantly after devising this new classification scheme. Consensus 
regarding grade and the histopathological variables analysed was significantly 
associated with patient survival, but only in older children from the AEIOP clinical trial.  
Therefore while this scheme does not appear appropriate for ependymomas in younger 
children, it may be for ependymomas from older children. An explanation for the 
discrepant outcome results between children in the AIEOP and SIOP 1999 04 trials was 
not given, although there was a significant difference between the proportions of 
tumours with a gross total resection in the two studies.  
 
These recent studies suggest that undertaking large scale histological reviews should be 
encouraged through national and international collaborations. Until consensus is 
reached on uniform classification criteria, potentially for different age categories within 
the paediatric population, the use of tumour grade as a prognostic marker in paediatric 
ependymoma will remain contentious.   
 
 
1.2.5 Treatment of paediatric intracranial ependymoma 
 
Historically, the success of treatment for paediatric brain tumours was measured 
according to survival alone. However, oncology therapy has evolved to adopt a multi-
modal, holistic approach focussing more on the quality of such survival. Treatment 
14 
 
modalities for paediatric ependymoma include surgery and the adjuvant therapies of 
chemotherapy and radiotherapy. 
 
Surgery remains the primary therapy for paediatric ependymoma, with complete tumour 
excision being the ultimate aim. However, the rate of complete resection achieved in 
this tumour group can vary from 31 ± 85 %, reflecting diverse surgical techniques, 
inconsistent criteria for defining complete tumour excision and variable surgical 
accessibility of ependymomas from different CNS locations (Rousseau, Habrand et al. 
1994; Bouffet, Perilongo et al. 1998; Merchant and Fouladi 2005). Historical analysis of 
the natural history of ependymoma in children has demonstrated that the post-operative 
prognosis for children with intracranial ependymomas remained poor with surgery 
alone but improved with the addition of radiotherapy (Mork and Loken 1977). In turn, 
this has led to the general consensus that surgery should be accompanied by adjuvant 
therapy. 
 
The choice of adjuvant therapy used is influenced by the philosophies of different 
national institutions and groups. While radiotherapy is effective, concerns remain about 
its potential long-term toxicity to the immature central nervous system (Grundy, Wilne 
et al. 2007). Consequently, most European centres generally reserve local radiotherapy 
to the site of the primary tumour for children older than three years, following complete 
surgical resection or as a prelude to second-look surgery (Bouffet, Perilongo et al. 1998; 
Merchant and Fouladi 2005). Furthermore, European groups have focussed on adopting 
chemotherapy regimens for young children, with the aim of avoiding or delaying 
radiotherapy (Grundy, Wilne et al. 2007). Results IURP WKH8QLWHG.LQJGRP¶V&&/* 
CNS 1992 04 clinical trial has suggested that such a deferral strategy could benefit up to 
42 % of patients aged younger than three years (Grundy, Wilne et al. 2007), although 
results from other groups attempting to delay or avoid radiotherapy in this age range 
have been less encouraging. The French Society of Paediatric Oncology group, using 
post-operative chemotherapy alone reported a four year progression-free survival of 
only 22 % (Grill, Le Deley et al. 2001), while a five year progression free survival rate 
of 27 % was obtained by the Pediatric Oncology Group using either 12 or 24 months of 
chemotherapy prior to radiotherapy (Duffner, Krischer et al. 1998). 
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Chemotherapy is also used in several current European studies for older children 
following incomplete surgical excision to aid the removal of residual disease, either 
alone or in conjunction with further surgery. However, definitive conclusions on the 
benefit of chemotherapy in paediatric ependymoma remain elusive since several phase 
II trials of single agent chemotherapy in ependymoma have proved disappointing, while 
a paucity of radiological data on tumour response to chemotherapy and follow-up data 
on the long-term neuro-cognitive effects of prolonged chemotherapy exists (Duffner, 
Krischer et al. 1998; Bouffet, Tabori et al. 2007).  
 
In contrast to European treatment strategies, most North American institutions support 
postoperative radiotherapy as the standard of care for localised intracranial 
ependymomas in children aged above 12 months, in favour of the deferral regimens that 
use chemotherapy. Radiotherapeutic advances have improved the precision of CNS 
irradiation, such that focal radiotherapy is now advocated, using doses of 59.4 Gy to the 
primary tumour site (Merchant and Fouladi 2005; Merchant, Li et al. 2009).   
 
The reasoning for this fundamental therapeutic difference is underpinned by data from a 
VWXG\ DW 6W -XGH &KLOGUHQ¶V 5HVHDUFK +RVSLWDO 86$ LQ ZKLFK 153 children with 
localised intracranial ependymoma were treated with this regime (Merchant, Li et al. 
2009). At a median follow up period of 5.3 years, the event-free survival and overall 
survival were 69.1 % and 81 % respectively (Merchant, Li et al. 2009). Although these 
results are encouraging, approximately one-third of all treatment failures were in 
children below three years of age. In addition, almost nine percent of children treated 
with adjuvant radiotherapy alone developed distant relapse, which was substantially 
higher than that seen using the 8QLWHG.LQJGRP¶V&&/*&16chemotherapy-
based clinical trial (Grundy, Wilne et al. 2007). Adverse events attributed to 
radiotherapy were observed for patients LQ WKH 6W -XGH¶V VWXG\ including hearing 
impairment (Hua, Bass et al. 2008), protracted attention deficiency (Kiehna, Mulhern et 
al. 2006) and a decline in reading ability (Conklin, Li et al. 2008), while the follow-up 
period was unable to account for longer term neuro-cognitive impairment and the 
delayed effects from radiotherapy, such as neuro-endocrine sequelae and secondary 
malignancies (Grundy, Wilne et al. 2007).  
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Moreover, other studies exclusively using post-surgical adjuvant radiotherapy for 
paediatric ependymomas have failed to replicate such promising outcome results, with 
five year event-free and overall survival rates ranging from 41 ± 58 % and 54 ± 73 % 
respectively, although this may reflect advances made in current neurosurgical and 
radiotherapeutic approaches (Pollack, Gerszten et al. 1995; Perilongo, Massimino et al. 
1997; Robertson, Zeltzer et al. 1998; Akyuz, Emir et al. 2000; Oya, Shibamoto et al. 
2002; van Veelen-Vincent, Pierre-Kahn et al. 2002; Jaing, Wang et al. 2004; Mansur, 
Perry et al. 2005; Shu, Sall et al. 2007). A forthcoming VWXG\ E\ WKH &KLOGUHQ¶V
Oncology Group of over 300 children with intracranial ependymoma (ACNS0121) will 
provide more information on the safety and effectiveness of conformal radiotherapy in 
young patients.  
 
1.2.6 Survival and clinicopathological prognostic markers 
 
The prognosis for paediatric ependymomas remains relatively poor when compared to 
other brain tumours in children, despite advances in neurosurgery, neuroimaging 
techniques and post-operative adjuvant therapy. The five year survival rate ranges from 
24 ± 75 %, with a five year progression free survival rate of 23 ± 60 % (Messahel, 
Ashley et al. 2009; Wright and Gajjar 2009; Zacharoulis and Moreno 2009). In addition, 
late relapses up to fifteen years after initial treatment are not uncommon (Paulino, Wen 
et al. 2002). The most common site for tumour recurrence is at the site of the primary 
tumour with metastatic relapse occurring in approximately 20 ± 25 % of cases 
(Messahel, Ashley et al. 2009; Wright and Gajjar 2009).  The ability to predict patient 
outcome has been hampered by the heterogeneous clinical behaviour of ependymomas 
in children, insufficient recruitment into large prospective clinical trials and 
contradictory studies regarding the prognostic role of histology, as discussed previously, 
and other clinical markers (Hamilton and Pollack 1997; Tabori, Ma et al. 2006).  
 
(SHQG\PRPD LV FRQVLGHUHG E\ VRPH WR EH D µVXUJLFDO¶ GLVHDVH +RZHYHU ZKLOVW
complete resection is the most consistently reported favourable clinical prognostic 
factor (reviewed by (Bouffet, Perilongo et al. 1998)); (Duffner, Krischer et al. 1998; 
Robertson, Zeltzer et al. 1998; Horn, Heideman et al. 1999; Grill, Le Deley et al. 2001; 
Merchant, Li et al. 2009), this is not a universal finding and some studies fail to 
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demonstrate this relationship for paediatric posterior fossa tumours (Goldwein, Leahy et 
al. 1990; Akyuz, Emir et al. 2000). Furthermore, despite complete excision, local 
tumour recurrence can develop in up to 50 % of cases, even following adjuvant 
radiotherapy (Hamilton and Pollack 1997; Tabori, Ma et al. 2006).  
 
Patient age at diagnosis and tumour location have also been suggested as prognostic 
factors. Historically, children below three years of age and infratentorial ependymomas 
have been associated with a poor outcome (Sutton, Goldwein et al. 1990; Heidemann 
RL 1997; Perilongo, Massimino et al. 1997; Sala, Talacchi et al. 1998). It remains 
unclear whether this reflects tumour biology, the surgical inaccessibility of posterior 
fossa tumours which are more prevalent in younger children, or the avoidance of 
adjuvant radiotherapy in early life resulting from concerns regarding long term clinical 
sequelae (Rousseau, Habrand et al. 1994; Hamilton and Pollack 1997; Duffner, Krischer 
et al. 1998; Sala, Talacchi et al. 1998; Grundy, Wilne et al. 2007). 
 
Poor outcome and the unpredictable behaviour of this tumour in children have turned 
attention to improving our knowledge of ependymoma biology. 
 
1.3 Genetics of cancer 
 
Cancer is a genetic disease of somatic cells characterised by disruption of cell cycle 
control and associated with increased cell proliferation, disturbed differentiation and 
evasion of apoptosis (Tamarin 2002). The two principal categories of genes implicated 
in carcinogenesis are oncogenes and tumour suppressor genes.  
 
1.3.1 Oncogenes and tumour suppressor genes 
 
Oncogenes are the activated form of normal cellular genes, termed proto-oncogenes, 
which contribute to the natural regulation of cell growth, survival and differentiation 
(Pelengaris 2006). Oncogenes are dominant at a cellular level and the majority can be 
classified according to function as growth factors, receptors, signal transducers or 
transcription factors (King 2000). Mechanisms facilitating oncogenic activation include 
translocation of a proto-oncogene to a region of increased transcription activity, 
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genomic amplification resulting in an increased gene copy number and activating gene 
mutations, the most frequent being missense point mutations (Tamarin 2002). In 
addition, epigenetic hypomethylation may increase oncogene expression without 
accompanying mutation, while oncoprotein overexpression can occur in the absence of 
oncogenic anomalies, for instance secondary to dysregulated upstream signalling 
(Pelengaris 2006). 
 
Tumour suppressor genes exert an inhibitory effect on cell cycle regulation or promote 
apoptosis in order to protect cells from becoming neoplastic (Tamarin 2002). The 
functional inactivation of these genes by genetic mutation, deletion or epigenetic 
phenomena can result in tumourigenesis through an imbalance in these protective 
cellular mechanisms (Roussel 2006).  
 
The concept of tumour suppressor genes was inWURGXFHGE\.QXGVRQ¶VSURSRVHGµWZR
KLW¶ hypothesis following his assessment of patients with retinoblastoma, a paediatric 
ophthalmic tumour which can be inherited or sporadic (Knudson 1971). Knudson 
observed that familial cases were often bilateral and presented in very young patients. 
He subsequently hypothesised that familial retinoblastoma arose from the germline 
inheritance of a mutated allele of a gene, later defined as the Retinoblastoma (Rb) gene, 
followed by another somatic PXWDWLRQRUµKLW¶ of the remaining allele. The younger age 
at presentation was explained by DNA instability resulting from the first inherited 
mutation increasing the susceptibility to a second mutation. In contrast, the relatively 
delayed presentation of sporadic retinoblastoma was explained by both functioning 
copies of the functioning wild type Rb allele being present at birth. Inactivating them 
required two independent somatic mutations, the probability of which is low. 
Nevertheless, in either case, both copies of the gene have to be inactivated to initiate 
tumourigenesis.  
 
While most tumour suppressor genes are thought to be recessive at a cellular level, 
thereby requiring such homozygous mutations or genomic deletions to initiate 
carcinogenesis, this is not universally the case. Haploinsufficient tumour suppressor 
genes have been recognised, including the cyclin dependent kinase inhibitors CDKN1B 
(12p13.1) and CDKN2C (1p32.3), where loss of only a single allele is sufficient to 
promote neoplastic susceptibility (Fero, Randel et al. 1998). Similarly, dominant 
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negative mutations in tumour suppressor genes such as TP53 (17p13.1) can generate an 
antagonistic protein that inhibits the function of the wild type product (Baker, Preisinger 
et al. 1990). Moreover, epigenetic gene silencing may render tumour suppressor genes 
inactive without disrupting their DNA sequence (Roussel 2006), as discussed later.  
 
In reality, most cancers are complex phenomena, requiring simultaneous alterations in 
the activity of numerous oncogenes and tumour suppressor genes for initiation (King 
2000). While the significance of these genes to carcinogenesis is well established, other 
potential contributory genomic factors are emerging. For instance, the functional 
importance of copy number variation within regions of the human genome has been 
highlighted as important in the study of human susceptibility to diseases (Redon, 
Ishikawa et al. 2006). Copy number variable regions (CNVRs) span approximately     
12 % of the human genome, although often occurring at non-coding sites (Redon, 
Ishikawa et al. 2006). Nevertheless, hundreds of genes have been identified within 
CNVRs (Redon, Ishikawa et al. 2006), while recent reports suggest that CNVRs and 
encompassed genes may contribute to cancer development (Diskin, Hou et al. 2009). 
 
1.3.2 Loss of heterozygosity 
 
Loss of heterozygosity (LOH)DVGHILQHGE\.QXGVRQ¶VWZRKLWK\SRWKHVLVUHSUHVHQWV
the functional loss of one parental allele of a gene in which the residual allele harbours a 
recessive mutation, thereby producing a mutant phenotype. Four principal mechanisms 
of LOH are observed in cancer; mitotic recombination, gene conversion, gene deletion 
and whole chromosomal loss (Tamarin 2002).  
 
Mitotic recombination and gene conversion (Figure 1.3) can result in acquired 
uniparental disomy (UPD), where LOH has occurred without loss of genomic material 
and both alleles of a gene are derived from one parent. This is also called copy neutral 
LOH and leads to the generation of daughter cells with reciprocal chromosomal 
products (Fitzgibbon, Smith et al. 2005). In contrast, other causes of acquired UPD exist 
which result in altered quantities of genomic material in the cell progeny, such as 
chromosomal duplication and non-disjunction (Tamarin 2002). Acquired UPD has 
already been identified in paediatric malignancies such as neuroblastoma and leukaemia 
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(Fitzgibbon, Smith et al. 2005; George, Attiyeh et al. 2007; Raghavan, Smith et al. 
2008). Moreover, the homozygosity resulting from acquired UPD can identify recessive 
mutational gene targets in cancer. For instance, acquired UPD of FLT3 (13q12) has 
been implicated in the adverse prognosis of patients with leukaemia and lymphoma 
(Fitzgibbon, Iqbal et al. 2007; Gupta, Raghavan et al. 2008).  
 
Figure 1.3: Loss of heterozygosity resulting from either mitotic recombination or gene conversion. Mitotic 
recombination occurs during cell division and involves genomic exchange between two sister chromatids of 
homologous chromosomes. Following a recombinational cross-over event and mitosis, LOH can result (Vrieling 
2001).  Gene conversion is a non-reciprocal DNA transfer between two strands of DNA at recombination, causing 
altered sequence information in the recipient strand. LOH can result from conversion of one gene allele to another 
(Zhang, Lindroos et al. 2006).  
 
1.3.3  Epigenetics  
 
In contrast to genetic regulation of gene function, epigenetic events can modify gene 
expression without alteration of the underlying DNA sequence (Roussel 2006). Two 
principal forms occurring in human cancer are DNA methylation and histone 
deacetylation, both exerting their effects through transcriptional regulation (Esteller 
2008).  
 
DNA methyltransferases are enzymes that can induce methylation of cytosine residues 
within CpG islands. This can directly prevent transcription factors binding to gene 
promoter regions, within which the majority of CpG islands cluster, and consequently 
impede gene expression. Alternatively, methylated DNA can attract methyl-binding 
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domain (MBD) proteins. These proteins interact with further enzymes, including 
histone deacetylases (HDACs), histone methyltransferases and other chromatin 
remodelling proteins in order to chemically modify histones such that chromatin is 
altered into a transcriptionally respressive state (Bird and Wolffe 1999). 
 
Hypermethylation of gene promoters can silence tumour suppressor genes, thereby 
facilitating tumourigenesis (Esteller 2002; Herman and Baylin 2003). Examples of this 
include the hypermethylation of BRCA1 (17q21.31) in breast and ovarian cancer 
(Esteller, Silva et al. 2000), MLH1 (3p22.2) in gastric and colon cancers (Herman, 
Umar et al. 1998; Fleisher, Esteller et al. 1999) and CDKN2A (9p21.3) in a variety of 
cancers (Esteller, Corn et al. 2001). Indeed, the methylation status of several selected 
genes has been assessed in paediatric brain tumours including medulloblastomas 
(reviewed by (de Bont, Packer et al. 2008)) and ependymomas (detailed in section 
1.5.4), identifying the frequent hypermethylation of candidate genes such as RASSF1A 
(3p21.3), CASP8 (2q33.1), CDKN2A and HIC1 (17p13.3) across both tumour groups. 
Global analysis of the medulloblastoma epigenome has also been performed, identifying 
tumour-specific hypermethylation of genes such as COL1A2 (7q21.3), S100A6 (1q21.3), 
HTATIP2 (11p15.1), CDH1 (16q22.1) and LXN (3q25.32) (Anderton, Lindsey et al. 
2008). Hypomethylation is also thought to play an important role in cancer (Ehrlich 
2002). It may enable the increased expression of putative proto-oncogenes genes that 
would be quiescent in normal cells due to inherent promoter methylation (Tao, Yang et 
al. 2000; Ehrlich 2002). Similarly, histone deacetylation has been implicated in 
oncogenesis for a variety of malignancies, including paediatric brain tumours (Rahman, 
Osteso-Ibanez et al. 2010).  
 
Methylation also regulates the process of genomic imprinting where specific parental 
alleles are differentially expressed in the germline and maintained in the somatic cells of 
the offspring. Relaxation of such imprinting can encourage aberrant gene expression 
DQGFRQWULEXWHWRFDUFLQRJHQHVLVDVILUVWUHSRUWHGLQ:LOPV¶WXPRXUV,QQRUPDOWLVVXH
the growth factor IGF2 (11p15.5) is imprinted at the maternal allele which is silenced 
by methylation, with gene expression provided exclusively by the paternal allele. 
+RZHYHU LQ FHUWDLQ :LOPV¶ WXPRXUV ORVV RI LPSULQWLQJ OHDGV WR WKH ELDOOHOLF
transcription and subsequent overexpression of IGF2, thereby conferring a cellular 
growth advantage (Brown, Power et al. 2008). 
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Since epigenetic modification appears to have an important role in human cancer, novel 
therapeutic strategies are being designed to counteract their mechanistic properties, 
including agents that reverse DNA methylation or inhibit histone deacetylation 
(Belinsky, Klinge et al. 2003; Winter-Vann, Baron et al. 2005; Egler, Korur et al. 2008). 
These are being combined with new technologies to rapidly screen the cancer genome 
for DNA methylation and histone acetylation patterns. 
 
1.4 Increasing resolution of genomic profiling 
 
Since the inception of cytogenetic analysis, advances in technology have refined 
coverage of the human genome in a single experiment, through the sequential 
development of comparative genomic hybridisation (CGH), array CGH and single 
nucleotide polymorphism (SNP) arrays (Table 1.3).  
 
Table 1.3: Comparison of the resolution of different techniques used in genomic 
analysis 
Technique Platform Type Number of Probes 
per Array 
Genomic Resolution 
Karyotypic  
analysis 
Light microscopy 
 
5 ± 10Mb 
CGH Fluorescence 
microscopy 
 
1 ± 10Mb 
Array CGH 
(BAC/PAC or Oligo) 
Microarray 6000-240,000 1Mb ± 100Kb 
100K SNP array Microarray 100,000 Mean inter-probe 
distance 23Kb 
500K SNP array Microarray 500,000 Mean inter-probe 
distance 5.8 Kb 
SNP 6.0 array Microarray 1.8 million Mean inter-probe 
distance < 700 bases 
 
1.4.1 Comparative genomic hybridisation 
 
CGH was designed to identify regions of genomic gain and loss in DNA samples of 
interest (Kallioniemi, Kallioniemi et al. 1992).  The procedure involves the 
simultaneous competitive hybridization of test and control DNA, each labelled with 
GLIIHUHQW IOXRUHVFHQW PDUNHUV WR QRUPDO µWDUJHW¶ PHWDSKDVH FKURPRVRPHV which are 
visualised using the DNA counterstain DAPI (Figure 1.4). Test DNA samples are 
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labelled green, while control DNA samples are labelled red (Inazawa, Inoue et al. 
2004). For tumour analysis, control DNA is extracted from normal comparative tissue 
or the constitutional samples of healthy subjects. Cot-1 DNA is included to prevent the 
hybridisation of repetitive genomic sequences. Differences in fluorescent intensities 
between the two markers along the length of each chromosome subsequently identify 
regions of genetic loss (red) and gain (green) within the tumour genome. Regions with 
no copy number difference between the test and the standard DNA appear yellow. Loci 
implicated in neoplastic transformation can thereby be established.  
 
The advantages of CGH is that it allows whole-genome tumour analysis at a higher 
resolution than karyotypic studies (1 ± 10Mb), using DNA isolated from fresh frozen or 
formalin fixed paraffin embedded (FFPE) archival material. However, relatively large 
amounts of tumour DNA are required and the improved resolution is still limited for 
detecting smaller copy number anomalies (Inazawa, Inoue et al. 2004). CGH is also 
unable to detect genomic aberrations that do not alter the net amount of chromosomal 
material, such as balanced translocations and copy number neutral LOH (Carvalho, 
Ouwerkerk et al. 2004; Fitzgibbon, Smith et al. 2005). 
 
 
Figure 1.4: Graphical summary comparing conventional CGH with array CGH. CGH = comparative genomic 
hybridisation. BAC = Bacterial artificial chromosome, PAC = P1-derived artificial chromosome, YAC = yeast 
artificial chromosome, Oligo = oligonucleotide array. 
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1.4.2 Array comparative genomic hybridisation 
 
Array CGH (aCGH) uses a succession of genomic clone probes, incorporated onto a 
glass slide, that span the genome with higher resolution than conventional CGH. Recent 
advances have enabled the probes to consist of short DNA sequences called 
oligonucleotides (oligo arrays) (Carvalho, Ouwerkerk et al. 2004). Alternatively, the 
probes can be derived from bacterial artificial chromosomes (BACs), P1-derived 
artificial chromosomes (PACs) and Yeast artificial chromosomes that can contain an 
insert between 100 ± 300bp in size (BAC/PAC arrays) (Cowell, Matsui et al. 2004). In 
array CGH, the probes are the hybridization targets for the sample DNA. Both test and 
control DNA undergo fluorescent labeling, followed by competitive hybridization to the 
probes on the array and Cot-1 DNA addition. The ratio of red to green fluorescence 
represents differential copy number between the two samples (Warr, Ward et al. 2001) 
(Figure 1.4).  
 
The resolution of aCGH is determined by probe size, inter-probe distance and the 
number of probes per given slide (Johnson, Hamoudi et al. 2006). While BAC arrays 
contain approximately 6000 clone probes and only have a genomic resolution of up to 
1Mb, oligonucleotide (oligo) arrays are preferential as they can contain up to 240,000 
probes, resulting in a resolution as high as 100kb. Consequently, oligo aCGH can detect 
single copy number gains and losses, making it more informative than other aCGH 
methods (Carvalho, Ouwerkerk et al. 2004; Cowell, Matsui et al. 2004). Moreover, the 
process of oligonucleotide probe design is also faster and less expensive than BAC 
clone production (Carvalho, Ouwerkerk et al. 2004). 
 
As with conventional CGH, array CGH can be performed on FFPE tissue although 
DNA integrity can influence the quality of results generated (Johnson, Hamoudi et al. 
2006). Despite an improved genomic resolution, array CGH also remains unable to 
detect genomic alterations in regions without probe coverage, or events occurring 
without a net chromosomal imbalance. Furthermore, artifacts in the copy number data 
generated can be introduced by cross-hybridisation of low copy number repeat 
sequences present in both the clone probes and the test DNA sample, not blocked by the 
addition of Cot-1DNA (Fellermann, Stange et al. 2006). 
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1.4.3 Single Nucleotide Polymorphism arrays 
 
Single nucleotide polymorphisms (SNPs) are single base pair changes that occur in a 
DNA sequence and are the most common genetic variations between human beings.  
Indeed, the human genome project has enabled researchers to identify SNP locations 
throughout the genome and an estimated 10 million SNP loci are thought to exist (Dong, 
Wang et al. 2001; Lander, Linton et al. 2001). 
 
Commercial biotechnology companies, such as Affymetrix®, have subsequently created 
SNP arrays in order to genotype a designated number of SNPs simultaneously in one 
experiment (Affymetrix 2006). Each Affymetrix® array contains several million 
µIHDWXUHV¶ (Figure 1.5A), consisting of more than a million copies of an oligonucleotide 
probe (Affymetrix 2006). Each probe is 25 base pairs in length and is of a defined 
sequence, harbouring a known SNP of interest. Each SNP is interrogated by 6- or 10- 
probe quartets where each probe quartet contains a pair of perfect match (PM) probes 
and a pair of mismatch (MM) probes used to identify non-specific hybridization for 
each allele (Figure 1.5B). Therefore, in total, there are 24 to 40 different oligonucleotide 
probes per SNP (Affymetrix 2006). 
 
Figure 1.5: Visualisation of oligonucleotide probes on an Affymetrix® SNP array. A. Demonstration of an 
Affymetrix® SNP array µfeature¶. B. Demonstration of PM and MM probes. Both figures obtained from the 
Genechip® Human Mapping 500K Set User Guide (Affymetrix 2006). 
 
 
A B 
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DNA from the sample of interest is digested, ligated, amplified and labelled with a 
fluorescent marker, before hybridisation to the oligonucleotide probes which produces 
signal intensity for each SNP. Following hybridisation, the array is washed to remove 
unbound DNA fragments, then stained and scanned for subsequent computerised data 
analysis. 
 
When examining tumours for genomic aberrations using the SNP array, a control 
dataset for comparison must be included. Differential signal intensities between tumour 
and control DNA samples for consecutive SNPs within a region of interest can thereby 
lead to the identification of areas of tumour-specific copy number change and loss of 
heterozygosity. Patient-matched blood DNA samples are often used, as a means of 
differentiating tumour-specific events from the patient¶s own constitutional SNP 
variation. If unavailable, tumour signal intensity data can instead be normalised against 
constitutional samples derived from a population based pool. Since diversity in SNP 
variation has been reported between different ethnicities (Iafrate, Feuk et al. 2004; 
Sebat, Lakshmi et al. 2004; Redon, Ishikawa et al. 2006), this population should be 
selected to most accurately represent WKHSDWLHQW¶Vinherent genomic variation.  
 
With iPSURYHPHQWVLQWHFKQRORJ\WKHµGHQVLW\¶ of SNPs on these arrays has increased 
resulting in a progressively extensive coverage of the human genome (Table 1.3), such 
that SNP arrays are now a standard method for high resolution genomic analysis in 
cancer research. While facilitating the identification of smaller regions of genomic 
imbalance than would be feasible with array CGH technology, the ability to identify 
single base pair changes also enables genotyping SNP arrays to detect copy number 
neutral events such as LOH secondary to gene conversion, mitotic recombination and 
acquired uniparental disomy (section 1.3.2) (Zhao, Li et al. 2004; Paulsson, Cazier et al. 
2008). 
 
In addition to the improved genomic coverage conferred by the SNP array, only 
relatively small amounts of DNA (250 nanograms per chip) are required to process a 
given sample, an important consideration since brain tumour samples obtained at 
surgery are often extremely small. However, only DNA from freshly frozen tumours 
has an acceptable purity for SNP analysis, unlike CGH which can utilize DNA from 
paraffin embedded tissue, albeit with a reduced accuracy. The increased resolution of 
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the SNP array also generates vast amounts of data which takes time to process and 
analyse. Moreover, when using any of the higher resolution platforms for tumour 
genomic analysis, it is assumed that the control DNA sample has a universally diploid 
genomic profile. However, as stated previously, constitutional copy number variation 
exists among different populations (Iafrate, Feuk et al. 2004; Sebat, Lakshmi et al. 
2004; Redon, Ishikawa et al. 2006) and may influence the results obtained. 
 
1.5 Biological aspects of paediatric ependymoma 
 
1.5.1 Cytogenetic studies ± ependymoma karyotypes 
 
A review of data from 21 karyotypic studies of 65 primary paediatric intracranial 
ependymomas revealed abnormal karyotypes in 57 (87.7 %) of cases, which are 
presented in Table 1.4. The abnormalities demonstrated a spectrum of complexity 
ranging from single rearrangements to structural and numerical aberrations. Whilst 
abnormalities involving chromosomes 22 and 1q were present in almost 30 % and 20 % 
of cases respectively, no cytogenetic abnormality was characteristic of paediatric 
ependymoma and the frequency of specific aberrations appeared similar between 
children and adults (Hamilton and Pollack 1997). This suggested that analysis of the 
ependymoma genome at a higher resolution was required to identify age-specific 
anomalies. 
 
Table 1.4: Abnormal karyotypes reported in the literature of 57 paediatric primary 
intracranial ependymomas. 
Sex 
  
Age 
(yrs) 
Site 
  
Hist 
  
Karyotypea 
  
Study 
  
F 2 BS   47,XX,+17 Agamanolis et al., 1995 
M 0-18 PF   50,XY,+7,+8,+9,+9 Bhattacharjee et al., 1997 
F 8     47,XX,+i(1)(q10) Bigner et al., 1997 
 F 8     45,XX,-9/46,idem,+r 
F 3     45,X,-X,t(10;11;15)(p12;q13;p12) Dal Cin et al., 1998 
F 6     46,X,-Y,+7,-10,-14,+18,+20,-22,+mar Debiec-Rychter et al., 2003 
M 4     45,XY,der(1)t(1;3)(q24;p13),der(6)t(2;6)(p11;q22) 
M 1     45,XY,-22 
M 8     44,X,-Y,-22 
M 2 PF   46,XY,+del(1)(p22),-16 Griffin et al., 1988 
F 16 PF   55,XX,+2,+3,+5,+7,+8,+9,+11,+19,+21 Griffin et al., 1992 
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Sex 
  
Age 
(yrs) 
Site 
  
Hist 
  
Karyotypea 
  
Study 
  
M 9     46,XY,+2mar Jenkins et al.,1989 
 M 4     46,XY,inv(11)(?p11-13?q13-14) 
M 5 PF CL 46,fra(X)(q27.3)c LT Kramer et al., 1998 
 M 1 ST CL 46,XY,?der(6) 
F 8 PF CL 46,XX,der(3)t(1;3)(q23;q27-29) 
F 6 PF AN 46,XX,trp(1)(q22q31),der(6)t(1;6)trp(1) 
M 3 PF CL 46,XY,der(1;6)(q10;p10) 
F 2 ST CL 46,XX,?der(6) 
M 2     46,X,-Y,der(1)t(Y;1)(q12;q11) Mazewski et al., 1999 
 F 3     49,XX,add(1)(p36),+i(1)(q10)x2,add(2)(p25), 
inv(2)(p25q21),?t(3;3)(q29;q25), -7,del(7)(q32), 
-9,- 11,+add(14)(p11),+3mar/54,idem,+inv(2), 
+del(7),+add(14), add(16)(q23),+17,+21,+3mar 
F 4     46,XX,der(6)t(1;6)(q11;q11)/46,XX,der(14)t(1;14) 
(q11;p11) 
F 11     45,X,-X,add(19)(p13),add(22)(q?13) 
F 0     46,XX,r(14)(p11q?23),add(16)(q11)/46,XX,der(14)
t(?1;14)(?q11;p11),add(16) 
F 7     47,XX,+i(1)(q10) 
F 6 PF   45,XX,-22 Neumann et al., 1993 
 M 15 PF   46,XY,add(20)(p?) 
M 3 PF   45,XY,der(6)t(6;16)(q11;p11),-16 
F 12 PF   45,X,t(X;18)(p11;q11),t(1;20)(q21;q13),t(2;17) 
(p11;p11),add(5)(p?),t(12;18) (p11;q11),-13,13, 
t(13;14)(q11;p11),del(14)(q?),add(17),der(21) 
t(17;21) (p11;q1?) 
M 10 PF   50,XY,+8,+9,+15,+19 
M 11 PF   93,XXYY,-6,+13,+20 
M 8 PF   48,XY,+1,t(1;2)(p33;q21),t(11;18)(q13;q21), 
+mar/48,X,-Y,+der(1)t(1;8) (p31;q22),t(1;8), 
del(6)(q15),add(16)(p?),+2mar 
M 0-18 PF   46,Y,t(X;22)(p22;q11) Roberts et al., 2001 
 M 0-18 PF   46,XY,add(1)(p12) 
M 3 PF   39-51,XY,del(2)(q?34),t(2;4)(q34;q35), 
+del(6)(q25),+12,-17 
Rogatto et al., 1993 
 
F 3 ST   46,XX[5]/40-51, XX,del(X)(p21), 
der(X)del(X)(p21)del(X)(q26),-X,del(2)(q34), 
t(2;10)(p25;p12),del(4)(q21q25),del(4)(p14),+6, 
+10,+16,-17,+22,-22[cp25] 
M 1     46,XY,t(11;17)(q13;q21) Sainati et al., 1996 
 M 1     50-77,XXY,del(1)(p22),dup(1)(p13p32)x2, 
+i(7)(q10),add(9)(p?),t(12;21),inc 
M 3 BS   47,XY,+11 Sawyer et al., 1994 
 F 4     61-62,XXX,-1,-2,-5,-8,+9,-10,-12,-14,-21,-22 
/61-62,idem,tas(3;11) (q29;q25) 
/61-62,idem,tas(4;22)(p16;p13) 
/61-62,idem,tas(6;11)(q27;q25) 
/61-62, idem,tas(9;11)(q34;q25) 
/61-62,idem,tas(9;17)(q34;q25) 
M 6     46,XY,add(17)(p13) Stratton et al.,1989 
 M 3 PF   45,XY,add(9)(q34),-17,add(17)(p13),add(22)(q11) 
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Sex 
  
Age 
(yrs) 
Site 
  
Hist 
  
Karyotypea 
  
Study 
  
F 5 PF   47,X,-X,+del(1)(q21),t(1;3)(p34;q21), 
+add(7)(p11),+15,del(16)(q13),inv(17) (p11q21), 
-19/46,X,-X,t(1;3),del(4)(q25q31),add(9)(q34), 
del(10)(p13),der (13)t(13;17)(p12;q21),-15,-17, 
del(18)(p11),+mar/??,X?,t(1;2)(q21;q35),inc 
Stratton et al.,1989 
F 1     46,XX,add(11)(q13) Thangavelu et al.,1998 
M 13     46,XY,del(5)(q34),+7,-8/45,XY,del(5),-17/44,XY, 
del(5),-17,-22 
Thiel et al.,1992 
 
F 9     48-49,XX,+16,+16,+20,-22,+mar 
F 3     40-44,X,-X,-8,t(11;12)(q13;q24),-15,-17, 
-22/40-44,idem,der(6;17) (p10;q10)/40-44, 
idem,dic(6;17)(q13;p13) 
Urioste et al., 2002 
F 2     46,XX,t(2;22)(p12;q13)/45,idem,-10 Vagner-Capadano et al., 
1992 M 6     43-46,X,-Y,+7,+19,-22/44-46,X,-Y,+mar 
F 8     46,X,-X,+7,+16,-22 
F 8     46,X,-X,+mar 
M 9     42-47,XY,+mar 
M 6     46-48,XY,t(1;7)(q25;q35),+2,del(3)(q13),der(5), 
del(6)(q12),+7,+11,-12 /45,XY,-22,46-48,XY,   
t(1;7)(q25;q35),+2,del(3)(q13),der(5),del(6)(q12), 
+7,+11,-12 
M 2     45,XY,-22/54,XY,+5,+7,+11,+13,+14,+15,+19,+21  
54,XY,+5,+7,+11,+13,+14,+15,+19,+21 
M 2 PF   46,XY[16] Wernicke et al., 1995 
 M 13 PF   46,XY[12]/46,XY,del(5)(q34),+7, -8[5]/45, XY, 
del(5)(q34),-17[7]/44,XY,del(5)(q34),-17,-22[8] 
F 18 ST   46,XY,der(5)t(5;?)(p;?),der(8)t(8;17)(q24;q23), 
del(17)(q23)[8]/46,XY,der(5)t(5;?)(p;?),-8,           
der(8)t(8;17)(q24;q23),-11,del(17)(q23), 
del(22)(q13)[4] 
M 6     47,XY,+8,+13,-22 Weremowicz et al., 1992 
Adapted from (Dyer 2007). a = Normal cell lines not shown; M = male; F = female; Hist = histology; PF = posterior 
fossa; ST = supratentorial; CL = classic; AN = anaplastic.   
 
1.5.2 Comparative genomic hybridisation meta-analysis 
 
Over the past decade conventional CGH has been collectively performed on 303 
primary and 71 recurrent ependymomas from children and adults in 13 studies (Table 
1.5). A meta-analysis of resulting data was undertaken in order to obtain a more global 
perspective of the ependymoma genome (Kilday, Rahman et al. 2009). The analysis 
revealed distinct genomic profiles for paediatric and adult ependymomas and location 
specific genomic anomalies in paediatric ependymomas.  
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Table 1.5: Summary of studies analysing ependymomas by conventional CGH 
Study Primary 
paediatric 
Recurrent 
paediatric 
Primary adult Recurrent  adult 
Pezzolo et al., 2008 20 - - - 
Rickert et al., 2006 10 - 3 - 
Carter et al., 2002 17 11 44 14 
Dyer et al., 2002 42 11 - - 
Grill et al., 2002 13 3 - - 
Jeuken et al., 2002 5 - 15 - 
Scheil et al., 2001 7 5 10 4 
Ward et al., 2001 28 12 - - 
Hirose et al., 2001 11 7 23 3 
Granzow et al., 2001 1 1 - - 
Zheng et al., 2000 7 - 21 - 
Shlomit et al., 2000 3 - - - 
Reardon et al., 1999 23 - - - 
Total 187 50 116 21 
For each study, the number of samples analysed are shown and categorised according to whether the patient was 
paediatric (aged equal to or below 16 years) or adult (above 16 years) and whether the tumour was primary or 
recurrent. 
 
1.5.2.1 Paediatric versus adult ependymoma 
 
Even accounting for differences in clinical factors and therapy, paediatric ependymomas 
have a worse prognosis than those in adults (Hamilton and Pollack 1997; Ritter, Hess et 
al. 1998; Korshunov, Golanov et al. 2002; Louis, Ohgaki et al. 2007). One interpretation 
of this is that paediatric and adult ependymomas are biologically distinct and evidence 
from the CGH meta-analysis supported this (Kilday, Rahman et al. 2009). Distinct 
patterns of imbalance across the genome were identified between primary paediatric and 
adult ependymomas (Figures 1.6 and 1.7). Paediatric ependymomas most frequently 
demonstrated gain of chromosomes 1q, 7 and 9 and loss of chromosomes 22, 3, 9p,13q, 
6q, 1p, 17 and 6, whereas the commonest genomic aberrations in adult ependymomas 
were gain of chromosomes 7, 9, 12, 5, 18, X and 2 and loss of 22/22q, 10, 13q, 6 and 
14q. 
 
One striking difference between the two age groups revealed by the meta-analysis was 
genomic gain of 1q which was present in over 20 % of paediatric ependymomas but in 
RQO\RIWKHLUDGXOWFRXQWHUSDUWVS)LVKHU¶VH[DFWWHVW. In contrast, gains of 
chromosomes 7, 9 and 12 appeared more prevalent in adults S)LVKHU¶VH[DFW
test). The genomic imbalances seen in ependymomas from different regions of the CNS 
also reflected this distinct pattern (Figures 1.8A ± F), suggesting an inter-relationship 
between patient age and tumour location (Kilday, Rahman et al. 2009). Paediatric 
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ependymomas tend to arise in an intracranial location where 1q gain predominates, 
while adult ependymomas have a predilection for a spinal location, characterised by 
whole chromosome aberrations. Gain of 1q, together with loss of chromosomes 6q and 
22, were also a common finding in recurrent paediatric intracranial ependymal tumours 
(Figure 1.9A ± C) (Kilday, Rahman et al. 2009) which implies that genes on these 
chromosomes may be involved in a more aggressive phenotype. 
 
 
 
Figure 1.6: Genomic anomalies in 187 primary paediatric ependymomas detected by CGH analysis. The most 
frequent genomic gains involve chromosome 1q (40/187), 7 (24/187), and 9 (20/187). The most frequent genomic 
losses involve chromosome 22 (19/187), 3 (18/187), 9p (17/187), 13q (16/187), 6q (15/187), 1p (13/187), 17 
(13/187), and 6 (13/187). 
 
 
 
Figure 1.7: Genomic anomalies in 116 primary adult ependymomas detected by CGH analysis. The most frequent 
genomic gains involve chromosome 7 (46/116), 9 (39/116), 12 (32/116), 5 (29/116), 18 (28/116), X (22/116), and 2 
(20/116). The most frequent genomic losses involve chromosome 22q (29/116), 22 (25/116), 10 (21/116), 13q 
(21/116) 6 (20/116), and 14q (16/116). 
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Figure 1.8: Genomic anomalies in 301 primary ependymomas, grouped by tumour location within the CNS and age, as detected by CGH. The paediatric group (A±C) consisted of 10 spinal (SP), 43 supratentorial 
(ST) and 132 posterior fossa (PF) tumours. The adult group (D±F) consisted of 69 spinal, 17 supratentorial and 30 posterior fossa tumours. The most frequent anomalies in paediatric spinal ependymomas (A) 
included gains of chromosomes 7 (7/10), 9 (7/10), 18 (5/10), and 20 (5/10) and losses of chromosomes 2 (4/10), 1 (3/10), and 10 (3/10). Frequent imbalances in paediatric supratentorial tumours (B) were gain of 
chromosome 1q (8/43) and loss of chromosome 9p (10/43), 3 (8/43), and X (6/43). The most common anomalies in paediatric posterior fossa tumours (C) were gain of chromosome 1q (33/132), yet loss of 
chromosomes 22 (16/132), 3 (11/132), 6 (11/132), 13q (10/132), and 17(10/132). The most frequent anomalies in  adult spinal ependymomas (D) included gains of chromosomes 7 (40/69), 9 (20/69), 18 (23/69), 
12 (22/69), X (20/69), 5 (19/69), and 2 (17/69) and loss of chromosome 22 (20/69), 22q (18/69), 13q (15/69), 14q (12/69), 10 (12/69), and 19 (8/69). Frequent imbalances in adult supratentorial tumours (E) were 
gain of chromosome 13q (3/17) and 8 (3/17) and loss of chromosome 9 (5/17), 18 (5/17), 22q (5/17), 13q (4/17), and 16q (4/17). The most common anomalies in adult posterior fossa tumours (F) were gain of 
chromosomes 9 (10/30), 5 (8/30), 12 (8/30), 1q (7/30), 4 (7/30), 7 (6/30), and 18 (6/30) yet losses of chromosome 6 (10/30), 22q (6/30), and 10 (6/30). 
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Figure 1.9: Genomic anomalies in 50 intracranial recurrent paediatric ependymomas detected by CGH analysis. 
Analysis was conducted collectively (A) then subgrouped according to supratentorial location (B: 10 tumours), or 
posterior fossa location (C: 37 tumours). The location of three tumours was not specified in the literature. Overall 
(A), the most frequent genomic gain involved 1q (24/50), and the most frequent genomic losses involved 
chromosomes 22 (9/50) and 6q (7/50). In addition, location-specific anomalies included the loss of chromosome 9 in 
2/10 supratentorial tumours (B), and the loss of chromosomes 6q (7/37) and 10q (5/37), which were exclusive to 
recurrent posterior fossa tumours (C). 
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In addition to the chromosomal location of genomic imbalances seen, the other 
important distinction between paediatric and adult ependymoma related to the number 
and complexity of genomic anomalies observed. By comparing the meta-analysis data 
from all primary ependymoma CGH studies it was observed that adult tumours 
displayed nearly twice as many chromosomal aberrations as paediatric tumours, 
corresponding with a higher mean number of genomic anomalies per tumour (Table 1.6) 
(Kilday, Rahman et al. 2009). This is supported by the discovery from CGH analyses 
WKDW D µEDODQFHG¶ JHQRPLF SURILOH ZLWKRXW FKURPRVRPDO JDLQ RU ORVV FDQ EH VHHQ LQ   
36 ± 58 % of paediatric ependymomas and is associated with children under three years 
of age. By contrast, a balanced genome is found in less than 10 % of adult cases 
(Reardon, Entrekin et al. 1999; Hirose, Aldape et al. 2001; Ward, Harding et al. 2001; 
Carter, Nicholson et al. 2002; Dyer, Prebble et al. 2002; Modena, Lualdi et al. 2006). 
 
Table 1.6: Comparison of the number of genomic imbalances in 116 adult and 187 
paediatric primary ependymomas by CGH. 
 
Age 
Group 
Number of 
primary 
ependymomas 
Total number 
of gains 
Total number 
of losses 
Total number 
of genomic 
anomalies 
Mean number 
of anomalies 
per tumour 
Adult 116 507 362 869 7.5 
Paediatric 187 331 376 707 3.8 
 
The meta-analysis also revealed that the genomic imbalances characteristic of adult and 
spinal ependymomas regularly involve whole chromosomal rearrangements, unlike the 
partial and complex imbalances frequently seen in paediatric cases and several 
aggressive adult cancers (Figures 1.6, 1.7, 1.8A, 1.8D) (Isola, Kallioniemi et al. 1995; 
Rooney, Boonsong et al. 2001; Kilday, Rahman et al. 2009). This may reflect 
intermediate ploidy, a phenomenon associated with a favourable outcome in acute 
lymphoblastic leukaemia, where imbalances involves whole chromosomes (Chessels, 
Swansbury et al. 1997). This explanation is supported, yet refined further in the 
paediatric population by a CGH analysis of ependymomas from 53 children (Dyer, 
Prebble et al. 2002). This work identified three genetically distinct subgroups within the 
examined FRKRUW  WKH µEDODQFHG¶ genomic group already discussed which was 
significantly associated with an age below three \HDUV D µstruFWXUDO¶ group 
demonstrating infrequent and often partial JHQRPLFLPEDODQFHVDQGDWKLUGµQXPHULFDO¶ 
group showing frequent (13 or greater) whole chromosome gains and losses similar to 
35 
 
those often seen in adult ependymomas. The subdivisions were significantly associated 
with prognosis, with the numerical and structural groups demonstrating the best and 
worst patient outcome respectively. Consistent with this observation, almost all 
recurrent ependymomas analyzed exhibited a structural profile. 
 
1.5.2.2 Paediatric ependymomas from different CNS locations 
 
Despite histological similarities, ependymomas arising from the spinal, infratentorial 
and supratentorial compartments of the central nervous system demonstrate diverse 
clinical behaviour (Miller, Young et al. 1995). Indeed, the conventional CGH meta-
analysis (Figures 1.8A ± C) demonstrated location-specific differences between 
paediatric ependymomas, suggesting biological tumour heterogeneity (Kilday, Rahman 
et al. 2009). As stated, paediatric spinal ependymomas (Figure 1.8A) frequently 
demonstrated whole chromosomal imbalances such as gain of chromosomes 7, 9, 11, 18 
and 20 or loss of chromosomes 1, 2 and 10, whereas intracranial ependymomas were 
characterized by gain of chromosome 1q and often showed loss of chromosomes 22, 3, 
9p and 13q (Figure 1.8B ± C). 
 
While gain of chromosome 1q and loss of chromosome 3 were shared features (Figure 
1.8B ± C), genetic diversity also appeared to exist between paediatric ependymomas 
from different intracranial locations. The genomic loss of 9p occurred preferentially in 
supratentorial ependymomas (Figure 1.8B), while posterior fossa tumours often 
demonstrated loss of chromosomes 22, 6 and 17 (Figure 1.8C). In addition, the loss of 
chromosome 6q at recurrence appeared exclusive to posterior fossa ependymomas 
(Figure 1.9C) (Kilday, Rahman et al. 2009). 
 
1.5.3 Higher resolution genomic analyses of paediatric ependymoma 
 
A limited number of array CGH and SNP array studies have been performed on 
ependymomas, with even fewer exclusively examining paediatric tumours. 
Nevertheless, the conclusions drawn from these studies have supplemented those from 
conventional CGH work.  
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Identified common regions of chromosomal gain in ependymoma using aCGH have 
included 1p34, 1q, 2q23, 3p14, 3q29, 5p15.33, 6p21, 7p21, 7q11.23 ± 22.1, 7q34, 
8q11.2, 9p24.3 ± qter, 11q13 ± q23, 12p, 12q13.13 ± 13.3, 13q21.1, 14q11.2, 14q32.2, 
15q21.3, 16p11.2, 16p13.3, 16pter, 17q21, 18, 19p13.3, 20p12, Xp21.2 and Xq26.3. 
Frequent regions of loss were discovered at 5q31, 6q25.3, 6q26, 7q36, 9p21, 9p23, 
9p24.31, 10q, 14q, 15q21.1, 16q24, 17p13.3, 19p13.2, 22q12 and 22q13.3. In addition, 
focal regions of amplification, encompassing particular genes of interest, were identified 
such as  3q25.2 (DNASE1L3), 7p11.2 (EGFR), 6p21.32 (NOTCH4), 11p13 (TYR), 9p24 
(MYCN), 11q22 (YAP1, BIRC2,BIRC3), 16q22.2 (PRM1), 17p13.3 (CDC6) and 19p13.3 
(VAV1). (Taylor, Poppleton et al. 2005; Mendrzyk, Korshunov et al. 2006; Modena, 
Lualdi et al. 2006; Mack and Taylor 2009; Puget, Grill et al. 2009). 
 
Using DUUD\ &*+ HSHQG\PRPDV ZLWK D µbalanced¶ genomic profile were again 
identified and associated with a young paediatric age group (Taylor, Poppleton et al. 
2005; Mendrzyk, Korshunov et al. 2006; Modena, Lualdi et al. 2006; Puget, Grill et al. 
2009), while the ability to cluster tumours into three genomic profiles according to the 
quantity and structural complexity of identified aberrations was also replicated 
(Mendrzyk, Korshunov et al. 2006; Puget, Grill et al. 2009). One paediatric analysis of 
59 ependymomas accomplished this using the same criteria as the conventional CGH 
study of Dyer et al. (Dyer, Prebble et al. 2002; Puget, Grill et al. 2009), whereas another 
study of 68 ependymomas from a mixed age cohort identified tumours with up to two 
chromosomal aberrations, greater than two imbalances and an almost diploid state or 
greater than two imbalances and aneuploidy (Mendrzyk, Korshunov et al. 2006).    
 
Two large array CGH studies confirmed that chromosome 1q gain was characteristic of 
childhood anaplastic ependymoma, by examining 171 tumours from mixed age cohorts 
(Taylor, Poppleton et al. 2005; Mendrzyk, Korshunov et al. 2006). Two analyses of 83 
paediatric ependymomas refined this further, reporting 9q34 gain and 22q13 loss as 
features of tumours from older children, while gains involving 9q and 11q13 and loss of 
chromosome 16 were associated with infant ependymomas (Modena, Lualdi et al. 2006; 
Puget, Grill et al. 2009). Gains of 1q, 9q34 and loss of loci within 6q and chromosome 
19 have also been correlated with disease progression in the paediatric age group 
(Modena, Lualdi et al. 2006; Puget, Grill et al. 2009; Peyre, Commo et al. 2010).  
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Tumours from different CNS locations were again noted to harbour distinct genomic 
imbalances. Spinal ependymomas often demonstrated gain of chromosome 16 and loss 
of chromosome 14q, whereas intracranial tumours were associated with 1q gain and 6q 
loss (Taylor, Poppleton et al. 2005; Mendrzyk, Korshunov et al. 2006). Within the 
paediatric population, gain of 9q33 and 9q34, together with loss of 17p13.3, were a 
feature of posterior fossa tumours, while loss of regions within chromosome 9p was 
characteristic of supratentorial ependymomas (Modena, Lualdi et al. 2006; Puget, Grill 
et al. 2009).  
 
The only SNP array study of ependymomas to date is an analysis of 204 tumours from a 
mixed age cohort, integrating 500K SNP array copy number data with gene expression 
profiling performed on a sample subset (Johnson, Wright et al. 2010). This corroborated 
the location specific genomic aberrations detected by the discussed previous work. 
Indeed, while supratentorial tumours demonstrated the highest number of focal 
anomalies, broad genomic imbalances were most common amongst spinal tumours 
which were characterised by the gain and overexpression of genes on chromosomes 4, 
7, 9, 12, 15 and 18q, together with the loss and underexpression of genes on 22q 
(Johnson, Wright et al. 2010). In addition, the deletion and underexpression of genes on 
chromosomes 3, 9 and 22q, or genes on chromosome 6q, were features of specific 
supratentorial and posterior fossa subgroups respectively (Johnson, Wright et al. 2010).  
 
Gene expression profiling has attempted to establish candidate ependymoma oncogenes 
and tumour suppressor genes within regions of imbalance demonstrated from genomic 
analyses. For example, by assimilating gene expression and array CGH data, two 
paediatric ependymoma studies identified genes with potentially dysregulated copy 
number driven expression (Modena, Lualdi et al. 2006; Puget, Grill et al. 2009). 
Similarly, the integration of expression array data for a subset of 83 tumours from the 
SNP array cohort of 204 ependymomas enabled Johnson et al. to propose 130 candidate 
tumour suppressor genes and 107 oncogenes (Johnson, Wright et al. 2010).  Various 
putative candidate genes identified from these and other gene expression analyses are 
detailed throughout the remainder of this work, while possible explanations for the 
aforementioned age and location-specific genomic aberrations are also discussed in 
subsequent chapters. 
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1.5.4 Methylation analyses of ependymoma 
 
Various studies have analysed the methylation status of several selected genes with 
purported tumour suppressive functions in ependymoma (Table 1.7)  
 
Table 1.7: Methylated genes identified in ependymoma 
 
Study Number of 
tumours studied 
Methylated gene(s) identified 
 (percentage of tumours methylated) 
Alonso et al., 2003 7 DAPK (9q21.33)                       (57 %) 
MGMT (10q26.3)                      (28 %) 
GSTP1 (11q13.2)                      (28 %) 
CDKN2A/P14ARF (9p21.3)        (28 %) 
TIMP3 (22q12.3)                      (28 %) 
P73 (1p36.2)                             (14 %) 
RB1 (13q14.2)                           (14 %) 
Gonzalez-Gomez et al., 2003 1 RB1 (13q14.2) 
Rousseau et al., 2003 108 
71 
CDKN2A/P16INK4A (9p21.3)      (21 %) 
CDKN2B (9p21.3)                     (32 %) 
Alonso et al., 2004 27 TIMP3 (22q12.3)                      (40 %) 
P73 (1p36.2)                             (33 %) 
THBS1 (15q14)                         (30 %) 
CDKN2A/ P16INK4A (9p21.3)     (18 %) 
MGMT (10q26.3)                      (20 %) 
NF2 (22q12.2)                        (<10 %) 
CASP8 (2q33.1)                      (<10 %) 
RB1 (13q14.2)                         (<10 %) 
Waha et al., 2004 52 HIC1 (17p13.3)                         (83 %) 
Hamilton et al., 2005 35 
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RASSF1A (3p21.3)                    (86 %) 
CASP8 (2q33.1)                        (20 %) 
MGMT (10q26.3)                        (5 %) 
P73 (1p36.2)                               (5 %) 
Michalowski et al., 2006 27 RASSF1A (3p21.3)                    (56 %) 
TNFRSF10D (8p21.3)            (36.4 %) 
CASP8 (2q33.1)                        (30 %) 
FHIT (3p14.2)                           (22 %) 
RARB (3p24.2)                       (14.8 %) 
BLU (3p21.3)                         (13.6 %) 
CDKN2A/P16INK4A (9p21.3)   (11.1 %) 
TNFRSF10C (8p21.3)              (9.5 %) 
DAPK (9q21.33)                      (7.4 %) 
Modena et al., 2006 18 CDKN2A/P16INK4A (9p21.3)      (11 %) 
HIC1 (17p13.3)                         (83 %) 
 
Frequently methylated genes identified to date include the pro-apoptotic genes 
RASSF1A, P73 and CASP8, the metalloproteinase inhibitor TIMP3 and genes 
implicated in transcriptional repression (HIC1), cell cycle regulation (CDKN2A) and 
DNA repair (MGMT). However, only the hypermethylation of gene regulatory regions 
(relative to normal DNA controls) have been established from these studies, whereas 
recent data suggests that hypomethylation of intergenic regions may also be associated 
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with tumourigenesis and progression in several tumours, including ependymoma (Xie, 
Wang et al. 2010). Moreover, all of the previous studies used a methylation specific 
polymerase chain reaction (PCR) technique and, due to technological limitations, 
restricted their analysis to pre-selected candidate genes which were chosen 
predominantly because of their altered methylation states in other malignancies. The 
advent of DNA microarrays has now enabled the methylation status of CpG 
dinucleotide sites within multiple genes across the genome to be analysed 
simultaneously.   
 
1.5.5 Ependymoma-initiating cells 
 
As stated earlier in this chapter (section 1.1.3), there is increasing awareness that the 
genetic and molecular diversity demonstrated by tumours, such as ependymomas, are 
the consequence of being organised as a developmental hierarchy, originating from 
tumour initiating cells with stem-like characteristics.  
 
Embryonic and postnatal ependymal cells have previously been shown to originate from 
a subset of radial glia, indicating their potential as such neural stem or precursor cells 
(Spassky, Merkle et al. 2005). Gene expression analysis has shown that signature genes 
of supratentorial and spinal ependymomas are similarly expressed by murine embryonic 
radial glial cells in the corresponding region of the CNS (Taylor, Poppleton et al. 2005; 
Poppleton and Gilbertson 2007). Using protein markers representative of early 
differentiation stages in the subventricluar zone, Taylor et al. also found that 
ependymoma derived neurospheres displayed both a stem (CD133+/Nestin+) and glial 
(Rc2+/Blbp+) immunophenotype, indicating a radial glial rather than neuroepithelial 
derivation for this tumour. The capability of these radial glial-like cells to self renew 
and exhibit multilineage differentiation in vitro, while form orthotopic tumours in vivo 
(Taylor, Poppleton et al. 2005; Johnson, Wright et al. 2010) renders them a convincing 
candidate for the ependymoma-initiating cell within which an initial malignant 
transformation event occurs.  
 
Further evolution of this concept comes from recent cross-species transcriptomic 
analysis. By correlating the mRNA expression profile of human ependymomas to those 
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of a distinct range of murine radial glia and adult neural stem cells, Johnson et al. 
identified neural stem cells with specific regional, genetic and developmental 
characteristics as potential cells of origin for particular ependymoma variants (Johnson, 
Wright et al. 2010). Human spinal ependymomas had a gene expression profile that 
closely corresponded to that of adult spinal murine neural stem cells. In contrast, 
supratentorial tumours had a transcriptome correlating with embryonic radial glia 
derived from the cerebrum of INK4A/ARF-/- mice. Activation of EphB2 signalling in this 
latter radial glia murine subtype was capable of ependymoma initiation upon xenograft 
transplantation in NOD-SCID mice. The histological appearance and transcriptomic 
profile of the resulting tumours modelled that of a previously identified human 
supratentorial ependymoma subgroup (Johnson, Wright et al. 2010), providing evidence 
that regionally defined radial glia are susceptible to malignant transformation from 
driver mutations. 
 
It could be argued that the mouse may not represent a physiologically relevant 
microenvironment for engraftment and growth of human tumours, thus potentially 
resulting in an underestimation of cell types capable of tumour initiation. An additional 
unresolved question is whether the cell type displaying the 
CD133+/Nestin+/RC2+/BLBP+ immunophenotype with a capacity for self-renewal in 
vitro and tumour development in murine xenotransplantation is the same cell type that is 
ependymoma initiating in humans. Although likely, definitive experiments have not yet 
been established. It also remains unknown whether normal ependymal cells can 
transform directly into a neoplastic cell, although in vitro analysis of other CNS 
tumours suggest the malignant transformation of mature cells is improbable (Alcantara 
Llaguno, Chen et al. 2009; Jacques, Swales et al. 2010).  
 
If the ependymoma-initiating cell hypothesis proves true, future therapeutic strategies 
may deviate away from being centred around the primary tumour mass and focus on 
targeting the putative ependymoma-initiating cells, a topic discussed further in the final 
chapter. 
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1.5.6 Cell signalling pathways  
 
Various cell signalling pathways have been reported to be involved in ependymoma 
pathogenesis. These include Sonic Hedgehog (Modena, Lualdi et al. 2006; Palm, 
Figarella-Branger et al. 2009), Wnt (Suarez-Merino, Hubank et al. 2005; Palm, 
Figarella-Branger et al. 2009; Peyre, Commo et al. 2010) and the EPHB-EPHRIN 
tyrosine kinase pathway (Taylor, Poppleton et al. 2005; Johnson, Wright et al. 2010). 
However, the most consistently implicated pathway is the Notch signalling pathway 
(Taylor, Poppleton et al. 2005; Modena, Lualdi et al. 2006; Poppleton and Gilbertson 
2007; Palm, Figarella-Branger et al. 2009; Puget, Grill et al. 2009; Johnson, Wright et 
al. 2010; Peyre, Commo et al. 2010).  
 
The Notch pathway is thought to contribute to the regulation of cell proliferation and 
determination of cell fate in the CNS by mediating cell to cell interaction (Figure 1.10). 
In summary, a membranous ligand for Notch (Delta/Jagged/Serrate) on the surface of a 
cell binds to the corresponding Notch receptor of a neighbouring cell. This prompts 
enzyme induced Notch cleavage (via tumour necrosis factor alpha converting enzyme 
and gamma-secretase), resulting in the cytoplasmic release of its intracellular domain 
(Notch-ICD) which ultimately penetrates the nucleus. The transcription factor 
recombination signal-binding protein suppressor of hairless (RBPSUH/CSL) then binds 
with the Notch-ICD fragment to activate the transcription of downstream targets, such 
as the HES gene family. The encoded HES proteins are transcriptional repressors from 
the basic helix-loop-helix (bHLH) family which negatively regulate genes known to 
induce neuronal differentiation (Radtke and Raj 2003). Conversely, in the absence of 
Notch/HES activation, other transcription factors from the bHLH family that promote 
differentiation can be expressed. These include the ASH proteins which facilitate 
neuronal maturation through the downstream activation of genes such as those of the 
Neurogenin family and NeuroD (Scotting 2004).  
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Figure 1.10: Overview of the Notch signalling pathway. Adapted from (Bray 2006). See text for an overview of the 
pathway and definition of particular components. In addition to activation, the pathway can be inhibited by 
mechanisms that include the activation of the cytoplasmic Notch inhibitor Numb, or degradation of the Notch-ICD by 
activated nuclear Fbxw7. ICD = intracellular domain, LGL1 = lethal giant larvae 1, Fbxw7 = F box-w7, MAML = 
Mastermind like, RBPSUH = recombination signal-binding protein suppressor of hairless, CBP = CREB binding 
protein. 
 
In this context, activation of the Notch pathway can thereby promote progenitor cell 
proliferation and inhibit differentiation. Indeed, maintenance of the self-renewal and 
multipotential characteristics of adult neural stem cells can be induced by the 
upregulation of the Notch ligand Jagged-1, whereas NOTCH1 (9q34) deletion reduces 
the stem cell proportion within a cell population (Hitoshi, Alexson et al. 2002; Nyfeler, 
Kirch et al. 2005). Inactivation of the Notch inhibitor NUMB1 in the neural stem cells 
of lethal giant larvae-1 (LGL1) null mice has also resulted in asymmetric cell division 
and CNS neoplastic lesions (Klezovitch, Fernandez et al. 2004). Moreover, the 
sustained proliferation of radial glia, the purported ependymoma-initiating progenitors, 
has been achieved through retroviral vector induced activation of NOTCH1 in the 
embryonic murine subventricular zone (Gaiano, Nye et al. 2000) or upregulation of the 
Notch target ERBB2 (17q12), a transcriptional repressor belonging to the HERP gene 
family which also inhibits neuronal differentiation (Ever and Gaiano 2005). 
 
Gene expression and IHC analyses of ependymomas also support involvement of Notch 
signalling in ependymoma pathogenesis and progression by demonstrating the 
overexpression of several pathway members such as Delta-like and Jagged ligands 
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(DLL1 (6q27), DLL3 (19q13.2), JAG1 (20p12.2) and JAG2 (14q32.33)), Notch 
receptors (NOTCH1, NOTCH2 (1p11.2)) and downstream effectors and targets 
(RBPSUH (5q11), MAML2 (11q21), HES1, HES2 (1p36.31), HES5, HEY2 (6q22.1), 
DTX1 (12q24.13), LFNG (7p22.3), FBXW7 (4q31.3), C-MYC (8q24.21), ERBB2) 
(Gilbertson, Bentley et al. 2002; Taylor, Poppleton et al. 2005; Modena, Lualdi et al. 
2006; Palm, Figarella-Branger et al. 2009; Puget, Grill et al. 2009; Johnson, Wright et 
al. 2010; Peyre, Commo et al. 2010). 
 
1.5.7 Biological prognostic markers for paediatric ependymoma 
 
Several putative biological prognostic markers for ependymoma have been suggested 
using immunohistochemistry (IHC) and genomic analysis on retrospective cohorts 
(Table 1.8). However, only a few of these candidates have been analysed in sufficient 
numbers of childhood ependymoma to allow consideration as prognostic markers in this 
age group. Protein markers include human telomerase reverse transcriptase (hTERT) 
and its nuclear chaperone Nucleolin (Tabori, Ma et al. 2006; Ridley, Rahman et al. 
2008), members of the receptor tyrosine kinase 1 (RTK1) family (Gilbertson, Bentley et 
al. 2002) and the Ki-67 labelling index (Bennetto, Foreman et al. 1998; Gilbertson, 
Bentley et al. 2002). While the number and pattern of genomic imbalances in paediatric 
ependymoma have a proposed prognostic significance (Dyer, Prebble et al. 2002; Puget, 
Grill et al. 2009), specific aberrations reported to be implicated in disease progression 
and patient outcome include gains of chromosome 1q and 9q, and loss of 6q and 22q.  
 
Neoplastic cells have a capacity for unlimited proliferation and the ability to avoid 
replicative senescence, both of which require maintenance of telomere length (Cong and 
Bacchetti 2000). As previously stated, telomeres are nucleoproteins which cap human 
chromosomal termini, thereby contributing to genomic stability (Counter, Avilion et al. 
1992; Hackett, Feldser et al. 2001). In normal somatic cells successive mitotic divisions 
result in telomere erosion, culminating in either senescence or apoptosis (Harley, 
Futcher et al. 1990; Feldser and Greider 2007). In contrast telomere maintenance is 
present in almost all types of malignant cells, mediated by the enzyme telomerase (Shay 
and Bacchetti 1997). Telomerase functions as a homodimer and contains a catalytic 
component with reverse transcriptase activity (hTERT) which may be implicated in 
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paediatric tumourigenesis development through avoidance of transcriptional repression 
by histone deacetylation in utero (Cong and Bacchetti 2000). 
 
Amplification of the hTERT locus (5p13.3) has been reported in a proportion of 
intracranial ependymoma cases analyzed by array CGH (Mendrzyk, Korshunov et al. 
2006). Moreover, an IHC analysis of 65 paediatric ependymomas appeared to find 
increased hTERT expression as an independent predictor of adverse patient survival 
(Tabori, Ma et al. 2006). However, re-evaluation of the antibody (NCL-hTERT) used to 
detect hTERT in this study verified its actual target to be Nucleolin, a phosphoprotein 
that acts as a chaperone for hTERT during its transport from nucleolus to nucleoplasm 
(Wu, Dudognon et al. 2006). Indeed, a subsequent retrospective IHC assay of hTERT, 
Nucleolin, RTK1 members, Ki-67 and Survivin expression in 80 paediatric intracranial 
ependymomas only established prognostic significance for altered Nucleolin expression, 
as detected by NCL-hTERT and a second independent monoclonal antibody (Ab13541 
Abcam). Ependymomas exhibiting high Nucleolin expression were associated with a 
poor outcome when compared to tumours with low Nucleolin expression, with a five 
year event-free survival for patients of 31 % versus 74 % respectively (Ridley, Rahman 
et al. 2008). The study also demonstrated telomerase-induced telomere maintenance in 
over 70 % of cases, with telomere lengthening apparent in over half of the relapsed 
tumours. However, neither telomerase activity, nor telomere length correlated with 
patient outcome, possibly due to the small cohort size (Ridley, Rahman et al. 2008).  
 
The RTK1 family of proteins, which includes ERBB2, ERBB3, ERBB4 and epidermal 
growth factor receptor (EGFR), are responsible for a variety of cellular processes such 
as cell division, motility and survival. Indeed, more recent data suggests ERBB2 
overexpression may potentiate radial glia proliferation (Poppleton and Gilbertson 2007). 
Members of the RTK1 family have been assessed as potential prognostic markers in 
paediatric ependymoma. An IHC assay of 59 tumours revealed ERBB2/ERBB4 co-
expression, together with a raised Ki-67 tumour proliferation index, was associated with 
reduced paediatric patient survival although ERBB2/ERBB4 co-expression alone did 
not correlate with outcome (Gilbertson, Bentley et al. 2002). Support for EGFR as a 
prognostic marker comes from two studies analysing mixed age cohorts. An 
immunohistochemical analysis of 46 ependymomas proposed EGFR as a relapse marker 
for low grade tumours, whilst an array CGH study of 68 ependymomas correlated poor 
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prognosis with frequent genomic gains and high-level amplifications covering the 
EGFR locus (Korshunov, Golanov et al. 2002; Mendrzyk, Korshunov et al. 2006). 
However, these findings contrast with results from the aforementioned IHC assay 
performed exclusively on paediatric ependymomas which did not confirm a prognostic 
value for RTK1 markers (Ridley, Rahman et al. 2008). These findings suggest a 
possible difference in the mechanism of EGFR, ERBB2 and ERBB4 expression 
between paediatric and adult ependymomas, reinforcing that these two subgroups are 
distinct genetic entities and raising the possibility that anti-RTK1 therapy may prove 
disappointing for those of a younger age at diagnosis. Current trials of Laptinib 
(GW572016), a dual inhibitor of EGFR and ERBB2 receptor signalling, within the 
Paediatric Brain Tumour Consortium and Collaborative Ependymoma Research 
Networks, may help to resolve this concern. 
 
Expression of the proliferative marker Ki-67 has been identified as a putative prognostic 
marker in studies of ependymoma in children (Bennetto, Foreman et al. 1998; Figarella-
Branger, Civatte et al. 2000; Gilbertson, Bentley et al. 2002; Zamecnik, Snuderl et al. 
2003). In contrast, other analyses have found no association between this marker and 
patient survival (Shuangshoti, Rushing et al. 2005; Ridley, Rahman et al. 2008), thereby 
making definitive conclusions on its use as a paediatric prognostic marker difficult. 
Moreover, Ki-67 has been shown to correlate with tumour grade, supporting the view 
that increased proliferation appears a feature of histological anaplasia (Rushing, Brown 
et al. 1998; Suzuki, Oka et al. 2001; Suri, Tatke et al. 2004; Ridley, Rahman et al. 
2008). 
 
The CGH meta-analysis revealed chromosome 1q gain as the most frequent genomic 
aberration in primary and recurrent paediatric intracranial ependymoma (Figures 1.6 
and 1.9) (Kilday, Rahman et al. 2009), justifying its further assessment as a prognostic 
marker in children. Genomic gain of chromosome 1q is not an observation restricted to 
paediatric ependymomas. Indeed, this aberration is one of the most common in human 
cancer (Schutte, Carpten et al. 2001). Chromosome 1q gain has been identified in other 
paediatric brain tumours such as CNS PNETs (Pfister, Remke et al. 2007), and 
medulloblastomas (Lo, Rossi et al. 2007), while it has been associated with an 
XQIDYRXUDEOH RXWFRPH LQ :LOPV¶ WXPRXUV QHXUREODVWRPDV DQG (ZLQJ¶V VDUFRPDV
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suggesting a generic role in paediatric tumour progression and recurrence (Hirai, 
Yoshida et al. 1999; Hing, Lu et al. 2001; Ozaki, Paulussen et al. 2001). 
 
It has been suggested that smaller regions of chromosome 1q may be of particular 
functional and prognostic importance, thereby warranting further assessment. Indeed, 
gain of 1q21 ± 32 in ependymoma has been associated with an anaplastic histology and 
adverse prognosis (Carter, Nicholson et al. 2002; Dyer, Prebble et al. 2002; Mendrzyk, 
Korshunov et al. 2006; Korshunov, Witt et al. 2010). Specifically, two array CGH 
studies of ependymomas from sizeable mixed age cohorts demonstrated that gain of 
1q25, as validated by fluorescent in situ hybridisation (FISH), represented an 
independent prognostic marker for both recurrence free and overall survival (Mendrzyk, 
Korshunov et al. 2006; Korshunov, Witt et al. 2010). One such analysis also identified a 
particular area of recurrent gain at 1q23.3 (Mendrzyk, Korshunov et al. 2006). Gene 
expression studies have demonstrated the upregulation of candidate oncogenes genes 
located within this 1q21 ± 32 region, including POGZ (1q21.3), S100 family members 
(1q21.3), HSPA6 (1q23) TPR (1q25), LAMB1 (1q31), PRELP (1q32), CHI3L1 (1q32), 
and GAC1 (1q32) (Korshunov, Neben et al. 2003; Suarez-Merino, Hubank et al. 2005; 
Karakoula, Suarez-Merino et al. 2008; Rand, Prebble et al. 2008; Johnson, Wright et al. 
2010). While GAC1 amplification has already been implicated in the pathogenesis of 
malignant gliomas (Almeida, Zhu et al. 1998), overexpression of the nucleoprotein 
encoding gene TPR has been associated with adverse outcome in a small study of 
paediatric patients with intracranial ependymoma (Karakoula, Suarez-Merino et al. 
2008). In addition to the 1q21 ± 32 locus, the recent SNP array analysis of 204 
paediatric and adult ependymomas also identified a novel region of amplification at 
1q42.13 in a subpopulation of posterior fossa ependymomas harbouring potential 
oncogenes such as the RAS superfamily member ARF1 (Johnson, Wright et al. 2010).  
 
Gain of 9q33 ± 34 and the incorporated putative oncogenes TNC and NOTCH1 have 
been associated with paediatric ependymoma recurrence (Puget, Grill et al. 2009), 
which contrasts with reports of 9q gain as a favourable prognostic marker for 
ependymoma patients from a mixed age cohort (Korshunov, Witt et al. 2010). Similar 
dichotomous results are evident in ependymoma for genomic deletions involving 
chromosome 6. While loss of the entire chromosome, or specifically 6q25, have been 
identified as independent markers of improved survival for both children and adults 
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(Monoranu, Huang et al. 2008; Korshunov, Witt et al. 2010), 6q deletion was a feature 
of relapsed ependymomas from paediatric CGH analyses (Figure 1.9) and deletion of 
the 6q23 and 6q25.2 loci have been associated with disease progression (Rajaram, 
Gutmann et al. 2005; Peyre, Commo et al. 2010). 
 
Within chromosome 22, the 22q13.1 and 22q13.3 loci have been highlighted as frequent 
regions of genomic loss in ependymoma (Rousseau-Merck, Versteege et al. 2000; 
Huang, Starostik et al. 2002; Modena, Lualdi et al. 2006; Johnson, Wright et al. 2010). 
Gene expression analyses within these loci have revealed the underexpression of several 
candidate tumour suppressor genes with roles in gene silencing (TNRC6B, CBX7 
(22q13.1)), cell cycle regulation (MCM5 (22q13.1)), DNA repair (G22P1 (22q13.2)) 
and neurotransmitter metabolism (SULT4A1 (22q13.3)) (Korshunov, Neben et al. 2003; 
Suarez-Merino, Hubank et al. 2005; Modena, Lualdi et al. 2006; Johnson, Wright et al. 
2010). In addition, a real-time quantitative PCR analysis of 47 paediatric intracranial 
ependymomas revealed frequent loss of C22orf2 (22q13.1) and RAC2, (22q13.1), the 
latter being associated with a reduced overall survival in the cohort (Karakoula, Suarez-
Merino et al. 2008). 
 
The identification of biological correlates of clinical outcome from a retrospective 
population is an important finding. However, in order to confirm validity, these need to 
be tested in an independent, cohort treated in a homogenous manner, ideally within the 
setting of a clinical trial. Moreover, the detection method for any identified marker must 
be rapid, robust, standardized and easy to interpret to allow diagnostic laboratories to 
identify patients suitable for a particular therapeutic proposal. At present, published 
prospective validation is lacking for putative biological markers in paediatric 
ependymoma.  
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Table 1.8: Statistically significant putative biological prognostic markers (immunohistochemical and genomic) for paediatric ependymoma. 
Immunohistochemical 
marker 
Source Prognostic Feature Patient outcome 
(p-value) 
Use as a prognostic marker in paediatric ependymoma 
Strength Weakness 
Apoptotic index  (AI - using ISEL) 
 
Korshunov et al., 2002 (cohort 
expansion of 1999 study) 
Apoptotic index < 1 % Worse PFS for entire cohort  
(p = 0.002) and high grade tumours 
(p = 0.0001) 
Large cohort size (n = 112). 
Statistical significance in 
univariate analysis. 
No statistically significant 
association in multivariate analysis 
Mixed age cohort.  
No prospective validation. 
bcl-2 Zamecnik et al., 2003 Increased expression Worse PFS and OS (p < 0.001) Paediatric cohort analyzed 
exclusively. 
Statistical significance in 
univariate analysis. 
 
No statistically significant 
association in multivariate analysis. 
Small cohort size (n = 31). 
No prospective validation. 
Other studies refute prognostic 
association (Verstegen et al., 2002) 
Bromodeoxyuridine (BrdU) 
Labelling Index  
Asai et al., 1992 Labelling index > 1 % - inverse 
correlation between BrdU index 
and time to recurrence 
Early recurrence rate (p < 0.05) 
 
Statistical significance in 
univariate analysis 
Mixed age cohort 
Small cohort size (n = 32) 
No prospective validation 
Cyclin D1 Labelling Index Zamecnik et al., 2003 Labelling Index > 5 % Worse PFS (p = 0.049) Paediatric cohort analyzed 
exclusively. 
Statistical significance in 
univariate analysis. 
No statistically significant 
association for OS in univariate 
analysis or OS & PFS in 
multivariate analysis. 
Small cohort size (n = 31). 
No prospective validation. 
Other studies refute association 
with prognosis (Prayson et al., 
1999) 
EVI1  Koos et al., 2011 Increased expression Worse PFS in posterior fossa 
ependymomas (p = 0.02) 
Statistical significance in 
multivariate analysis.  
 
Mixed age cohort. 
Small cohort size (n = 28). 
No prospective validation. 
Glial Fibrillary Acidic Protein 
(GFAP)  
Figarella-Branger et al., 1991 Increased expression in > 30 % 
tumour cells 
 
GFAP/ vimentin ratio < 1 
Improved OS (p < 0.05) 
 
 
Worse OS (p < 0.05) 
Paediatric cohort analyzed 
exclusively. 
Statistical significance in 
univariate analysis. 
Small cohort size (n = 16). 
Other paediatric study refutes 
prognostic association (Zamecnik 
et al., 2003). 
No prospective validation. 
Human Telomere Reverse 
Transcriptase (hTERT) 
Tabori et al., 2006 
 
 
 
 
 
 
Mendrzyk et al., 2006 
Increased expression 
 
 
 
 
 
 
Increased expression 
Reduced PFS and OS (p = 0.002) 
 
 
 
 
 
 
Worse OS (p = 0.01) 
Relatively large cohort size (n 
=87). 
Paediatric cohort exclusively 
analyzed. 
Statistical significance in 
multivariate analysis.  
 
Large cohort size (n = 170). 
IHC validated genomic gains at 
hTERT locus detected by aCGH. 
All studies 
No prospective validation 
Re-evaluation of antibody used to 
detect hTERT verified the actual 
target to be Nucleolin (Wu et al., 
2006) 
 
Mendrzyk study 
Mixed age cohort. 
No statistically significant 
association in multivariate analysis.  
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Immunohistochemical 
marker 
Source Prognostic Feature Patient outcome 
(p-value) 
Use as a prognostic marker in paediatric ependymoma 
Strength Weakness 
Hypoxia related tissue factors Preusser et al., 2005 High hypoxia score (increased 
expression of 2 or 3 of the markers 
VEGF, carbonic anhydrase 9 
(CA9) and hypoxia ± inducible 
factor 1 alpha  
(HIF-1 ) 
Worse OS (p = 0.0402) Large cohort size (n = 100). 
Statistical significance in 
univariate analysis. 
No statistically significant 
association for individual markers 
in univariate analysis. 
No statistically significant 
association for hypoxia score in 
multivariate analysis. 
Mixed age cohort. 
No prospective validation. 
Ki-67/MIB-1 Labelling Index  Rezai et al., 1996 
 
 
 
Ritter et al., 1998 
 
 
Ho et al., 2001 
 
 
Zamecnik et al., 2003 
 
 
 
 
Preusser et al., 2005( cohort 
expansion of other 2005 study) 
 
 
Verstegen et al., 2002 
High MIB-1 labelling index (13 % 
versus 2 %) 
 
 
MIB-1 LI > 20 % 
 
 
MIB-1 LI > 9 % 
 
 
MIB-1 LI > 7 % 
 
 
 
 
MIB-1 LI > 20.4 % 
 
 
 
MiB-1 LI  > 1 % 
Tumour tendency for CSF 
dissemination (p = 0.02) 
 
 
Worse OS (p = 0.0013) 
 
 
Worse OS and PFS (p < 0.001) 
 
 
Worse OS and PFS (p = 0.002) 
 
 
 
 
Worse OS in univariate analysis 
 (p = 0.00001) and multivariate 
analysis  (p = 0.010)  
 
Worse OS in univariate analysis 
 (p = 0.02) 
Statistical significance in 
univariate analysis; large cohort 
size (n = 140). 
 
Statistical significance in CART 
analysis. 
 
Relatively large cohort (n = 81). 
Significance in univariate analysis. 
 
Paediatric cohort analyzed 
exclusively. 
Statistical significance in 
multivariate analysis. 
 
Statistical significance multivariate 
analysis. 
Large cohort (n = 100). 
 
Statistical significance univariate 
analysis. 
Relatively large cohort (n = 51). 
All studies 
No prospective validation. 
Other paediatric studies refute 
association with prognosis 
(Shuangshoti et al., 2005; Ridley et 
al., 2008). 
Variable LI cut-offs to define 
prognostic groups. 
Rezai, Ritter, Ho, Preusser  and 
Verstegen  studies 
Mixed age cohorts. 
Zamecnik and Ritter studies 
Small cohort sizes (n = 36 & 34). 
Verstegen study 
No statistically significant 
association in multivariate analysis. 
 
Benetto et al., 1998 
 
 
 
 
 
Gilbertson et al., 2002 
 
 
 
Figarella-Branger et al., 2000 
Elevated Ki-67 LI in infratentorial 
cases (> 25 %) 
 
 
 
 
Ki-67 LI > 25 % 
 
 
 
Ki-67 LI > 1 % 
Worse OS (p < 0.002) 
 
 
 
 
 
Worse OS (p < 0.009) 
 
 
 
Worse PFS (p = 0.006) 
Paediatric cohorts analyzed 
exclusively. 
Relatively large cohort (n = 74). 
Statistical significance in 
multivariate analysis. 
 
Paediatric cohorts analyzed 
exclusively. 
Relatively large cohort (n = 89). 
   
Paediatric cohorts analyzed 
exclusively. 
All studies 
No prospective validation. 
Variable LI cut-offs to define 
prognostic groups. 
Cohort sizes remain inadequate for 
reliable multivariate analysis. 
Other studies refute association 
with prognosis (Ridley et al., 2008; 
Prayson et al., 1999). 
Gilbertson and Fig-Branger studies 
No statistically significant 
association in multivariate analysis. 
Figarella-Branger study 
Small cohort size (n = 37). 
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Immunohistochemical 
marker 
Source Prognostic Feature Patient outcome 
(p-value) 
Use as a prognostic marker in paediatric ependymoma 
Strength Weakness 
Metallothionine  Korshunov et al., 1999 Increased expression  Lower recurrence risk (p = 0.005) Statistical significance in 
multivariate analysis. 
Relatively large cohort size (n = 
76). 
Mixed age cohort. 
No prospective validation. 
Cohort size remains inadequate for 
reliable multivariate analysis. 
Metalloproteinase (MMP) ± 2 
 
Snuderl et al., 2008 Increased expression  Reduced EFS in completely 
resected tumours (p = 0.02)  
Statistical significance in 
univariate analysis. 
Paediatric cohorts analyzed 
exclusively. 
 
No statistically significant 
association in multivariate analysis. 
No statistically significant 
association for OS. 
Small cohort size (n = 28). 
No prospective validation. 
Metalloproteinase (MMP) ± 14 
 
Snuderl et al., 2008  Increased expression  Reduced OS in completely resected 
(p = 0.046) 
Statistical significance in 
multivariate analysis. 
Paediatric cohorts analyzed 
exclusively. 
Small cohort size (n = 28). 
No prospective validation. 
Mos protein Athanasiou et al., 2003 Labelling index > 10 % Worse PFS (p = 0.05) Statistical significance in 
univariate analysis. 
 
No statistically significant 
association for OS. 
No multivariate analysis. 
Mixed age cohort. 
Small cohort size (n = 34). 
No prospective validation. 
NEFL (Neurofilament light 
polypeptide 70) 
Andreiuolo et al., 2010 Strong expression (> 5 % positive 
cells) 
Better PFS (p = 0.007) Statistical significance in 
univariate analysis. 
Paediatric cohorts analyzed 
exclusively. 
 
No statistically significant 
association for OS. 
Small cohort size (n = 34). 
No multivariate analysis. 
No prospective validation. 
Nucleolin 
 
 
 
Ridley et al., 2008 Increased expression Reduced EFS and OS (p = 0.007) Relatively large cohort size (n = 
80). 
Paediatric cohort exclusively 
analyzed. 
Statistical significance in 
multivariate analysis. 
No prospective validation. 
CDKN2A / p14 ARF Labelling 
Index 
Korshunov et al., 2002 (cohort 
expansion of 1999 study) 
 
 
 
Labelling index < 10 % 
 
 
 
 
Worse PFS for entire cohort  
(p = 0.0001) and high grade 
tumours (p = 0.0001). 
Higher recurrence risk (p = 0.001). 
Large cohort size (n = 112). 
Statistical significance in 
multivariate analysis. 
CDKN2A reported tumour 
suppressor gene in various cancers. 
Mixed age cohort. 
No prospective validation. 
Other work refutes prognostic 
association of CDKN2A (Rajaram 
et al., 2004). 
p27/Kip 1 Labelling Index Korshunov et al., 2002 (cohort 
expansion of 1999 study) 
 
Labelling Index < 20 % Reduced PFS in entire cohort (p = 
0.01) and high grade tumours (p = 
0.00003) 
Large cohort size (n = 112). 
Statistical significance in 
univariate analysis. 
No statistically significant 
association in multivariate analysis. 
Mixed age cohort. 
No prospective validation. 
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Immunohistochemical 
marker 
Source Prognostic Feature Patient outcome 
(p-value) 
Use as a prognostic marker in paediatric ependymoma 
Strength Weakness 
p53 Korshunov et al., 2002 (cohort 
expansion of 1999 study) 
 
 
 
Verstegen et al., 2002 
 
 
 
Zamecnik et al., 2003 
Immunohistochemical positivity 
(LI = 14 to 32 %) 
 
 
 
Increased expression > 1 % 
 
 
 
Increased expression 
Worse PFS for entire cohort  
(p = 0.0001) and high grade 
tumours (p = 0.0001). 
Higher recurrence risk (p = 0.01). 
 
Worse OS in univariate analysis  
(p = 0.02) and multivariate 
analysis(p = 0.013) 
 
Worse PFS (p<0.001) 
Large cohort size (n = 112). 
Statistical significance in 
multivariate analysis. 
 
 
Relatively large cohort size (n = 
51). 
Statistical significance in 
multivariate analysis. 
 
Paediatric cohort analyzed. 
Statistical significance in 
univariate analysis. 
All studies 
No prospective validation. 
p53 antibody detects mutant and 
wild type p53. 
Mutations of p53 appear rare in 
ependymoma. 
Other work refutes prognostic 
association (Shuangshoti et al., 
2005) 
Verstegen and Korshunov studies 
Mixed age cohorts. 
Zamecnik study 
Small cohort (n = 31). 
No statistical significance in 
multivariate analysis. 
P-glycoprotein Korshunov et al., 1999 Increased expression Lower recurrence risk (p = 0.02) Statistical significance in 
multivariate analysis. 
Relatively large cohort size (n = 
76). 
Mixed age cohort 
No prospective validation 
Cohort size remains inadequate for 
reliable multivariate analysis. 
Receptor Tyrosine Kinase 1 family 
(EGFR, ERBB2 ± 4) 
Korshunov et al., 2002 (cohort 
expansion of 1999 study) 
 
 
 
Gilbertson et al., 2002 
 
 
 
 
 
Mendrzyk et al., 2006 
Immunohistochemical positivity 
 
 
 
 
Combination of incomplete tumour 
resection and ERBB2/ERBB4 co-
expression or Ki-67 LI > 25 % 
 
 
 
Immunohistochemical positivity 
Worse PFS for entire cohort  
(p = 0.005) and low grade tumours 
(p = 0.002) 
 
 
Worse OS (p < 0.0001) 
 
 
 
 
 
Worse OS (p=0.002) 
Large cohort size (n = 112). 
 
 
 
 
Relatively large cohort size (n = 
59). 
Paediatric cohort exclusively 
analyzed. 
 
 
Large cohort size (n = 170). 
IHC validated genomic gains and 
amplifications at EGFR locus 
detected by aCGH. 
All studies 
No statistically significant 
association in multivariate analysis.  
No prospective validation. 
Other work refutes prognostic 
association of all RTK1 family in 
paediatric cases (Ridley et al., 
2008) 
Gilbertson study 
ERBB2/ERBB4 co-expression 
alone not associated with poor 
outcome. 
Korshunov and Mendrzyk studies 
Mixed age cohorts. 
Survivin Preusser et al., 2005 Increased expression Worse OS (p = 0.0032) Statistical significance on 
univariate analysis. 
Relatively large cohort size (n = 
63). 
No statistically significant 
association in multivariate analysis.  
Cohort size remains inadequate for 
reliable multivariate analysis. 
Mixed age cohort. 
Other paediatric studies refute 
prognostic association (Ridley  
et al, 2008) or show association 
between low expression and 
aggressive disease (Alturas et al., 
2003) 
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Immunohistochemical 
marker 
Source Prognostic Feature Patient outcome 
(p-value) 
Use as a prognostic marker in paediatric ependymoma 
Strength Weakness 
Tenascin Korshunov et al., 2002 (cohort 
expansion of 1999 study) 
 
 
 
Zamecnik et al., 2004 (cohort 
expansion of 2003 study) 
 
Immunohistochemical positivity 
 
 
 
 
Immunohistochemical detection in 
intercellular spaces and blood 
vessel walls 
Worse PFS for entire cohort  
(p = 0.0001) and low grade 
tumours (p = 0.0001). 
Higher recurrence risk (p = 0.001). 
 
Worse PFS (p = 0.012) 
Large cohort size (n = 112). 
Statistical significance in 
multivariate analysis. 
 
 
Paediatric cohort analyzed. 
Statistical significance in 
multivariate analysis. 
Korshunov study 
Mixed age cohort. 
No prospective validation. 
 
 
Zamecnik study 
Small cohort size (n = 36). 
No prospective validation. 
Topoisomerase-II alpha (Ki-S1) 
Labelling Index 
Korshunov et al., 2002 (cohort 
expansion of 1999 study) 
 
 
Zamecnik et al., 2003 
Labelling Index > 5 % 
 
 
 
Labelling Index > 12 % 
Worse PFS for entire cohort 
(p = 0.001) and low grade tumours 
(p = 0.0001) 
 
Worse PFS and OS (p < 0.001) 
Large cohort size (n = 112). 
Statistical significance in 
univariate analysis. 
 
Paediatric cohort analyzed 
exclusively. 
Statistical significance in 
univariate analysis. 
All studies 
No statistically significant 
association in multivariate analysis. 
No prospective validation. 
Variable LI cut offs between 
studies. 
Korshunov study  
Mixed age cohort. 
Zamecnik study 
Small cohort (n = 31). 
Vitronectin Zamecnik et al., 2004 (cohort 
expansion of 2003 study) 
 
Immunohistochemical detection at 
tumour invasion front 
Worse PFS (p = 0.005) Paediatric cohort analyzed 
exclusively. 
Statistical significance in 
univariate analysis. 
Small cohort size (n = 36) 
No statistically significant 
association in multivariate analysis. 
No prospective validation. 
Vascular Endothelial Growth 
Factor (VEGF) 
Korshunov et al., 2002 (cohort 
expansion of 1999 study) 
 
 
 
 
Immunohistochemical positivity Worse PFS for entire cohort  
(p = 0.003) and low grade tumours 
(p = 0.001) 
Large cohort size (n = 112). 
Statistical significance in 
univariate analysis. 
No statistically significant 
association in multivariate analysis.  
Mixed age cohort. 
No prospective validation. 
Other work refutes prognostic 
association (Pietsch et al., 1997). 
Genomic/Genetic 
 marker 
Source Prognostic Feature Patient outcome 
(P value) 
Use as a prognostic marker in paediatric ependymoma 
Strength Weakness 
Genomic gain of 1q Carter et al., 2002 
 
 
Mendrzyk et al., 2006 
 
 
 
 
 
 
 
Korshunov et al., 2010 
Gain of 1q (CGH) 
 
 
Gain of 1q25 (aCGH/FISH) 
 
 
 
 
Gain of 1q21.1-32.1 (aCGH/FISH) 
 
 
Gain of 1q (aCGH/FISH) 
 
 
Worse OS for intracranial tumours 
(p < 0.05) 
 
Worse PFS (p < 0.001) and OS  
(p = 0.003) in intracranial tumours 
 
 
 
Higher recurrence rate in 
intracranial tumours (p < 0.001) 
 
Worse PFS (p < 0.001) and OS  
(p < 0.001) in intracranial tumours 
Statistical significance in 
univariate analysis. 
 
Statistical significance in 
multivariate analysis. 
Supported by other work 
(Karakoula et al., 2008, Korshunov 
et al., 2010) 
Relatively large cohort (n = 68).  
FISH validated aCGH findings.   
 
Large cohort (n = 122). 
Statistical significance in 
multivariate analysis. 
All studies 
Mixed age cohort. 
No prospective validation. 
Carter study 
Small cohort size (n = 31) 
No statistically significant 
association in multivariate analysis.  
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Genomic/Genetic 
 marker 
Source Prognostic Feature Patient outcome 
(p-value) 
Use as a prognostic marker in paediatric ependymoma 
Strength Weakness 
Genomic gain of 9q33 and 9q34 Puget et al., 2009 9q33 / 9q34 gain (aCGH/FISH) Associated with tumour recurrence 
(9q3, p = 0.003; 9q34, p = 0.009) 
Relatively large cohort size (n = 
59). 
Statistically significant on 
supervised classification. 
Paediatric cohort exclusively 
analyzed. 
No patient survival data. 
No prospective validation. 
Conflicting results from other 
aCGH studies (Korshunov et al., 
2010). 
 
 
Genomic gain of 9q Korshunov et al., 2010 Gain of 9q (aCGH/FISH) Improved PFS (p = 0.01) and OS  
(p = 0.002) 
Large cohort (n = 122). 
Statistical significance in 
univariate analysis. 
Mixed age cohort. 
No statistically significant 
association in multivariate analysis. 
No prospective validation.  
Conflicting results from other 
aCGH work (Puget et al., 2009). 
Genomic gain of 15q Korshunov et al., 2010 Gain of 15q (aCGH/FISH) Improved PFS (p = 0.04 ± 
multivariate analysis) and OS  
(p = 0.002 ± univariate analysis) 
Large cohort size (n = 112). 
Statistical significance for EFS in 
multivariate analysis. 
Mixed age cohort. 
No statistical significance for OS in 
multivariate analysis. 
No prospective validation. 
Genomic gain of 18q Korshunov et al., 2010 Gain of 18q (aCGH/FISH) Improved PFS (p = 0.002) and OS  
(p = 0.001) 
Large cohort (n = 122). 
Statistical significance in 
univariate analysis. 
Mixed age cohort. 
No statistically significant 
association in multivariate analysis. 
No prospective validation.  
Genomic loss of 6q25 Monoranu et al., 2008 Presence of 6q25 deletion in 
anaplastic intracranial tumours 
(microsatellite markers) 
Improved OS (p = 0.013) Statistically significant in 
multivariate analysis. 
Paediatric cohort exclusively 
analyzed. 
Support from other work 
(Korshunov et al., 2010) 
Very small cohort size (n = 15). 
Mixed age cohort. 
No prospective validation. 
6q loss feature of recurrent, not 
primary paediatric disease on CGH 
meta-analysis. 
Conflicting results from other work 
(Rajaram et al., 2005). 
 
Genomic loss of chromosome 6 Korshunov et al., 2010 Loss of chromosome 6 
(aCGH/FISH) 
Improved PFS (p = 0.01) and OS  
(p = 0.003) 
Large cohort (n = 122). 
Statistical significance in 
univariate analysis. 
Support from other work 
(Monoranu et al., 2008) 
Mixed age cohort. 
No statistically significant 
association in multivariate analysis. 
No prospective validation.  
Conflicting results from other work 
(Rajaram et al., 2005). 
Genomic loss of aCGH BAC 
clones on chromosome 19 
Modena et al., 2006 Loss of BAC clones on 
chromosome 19 (aCGH) 
Increased incidence of  recurrence 
(p < 0.0001) 
6WDWLVWLFDOO\VLJQLILFDQWRQ)LVKHU¶V
exact test. 
Paediatric cohort exclusively 
analyzed. 
Small cohort size (n = 24). 
No survival analysis. 
No prospective validation. 
 
Homozygous CDKN2A deletion Korshunov et al., 2010 CDKN2A homozygous deletion 
(aCGH/FISH) 
Worse PFS (p = 0.03 ± univariate 
analysis) and OS (p = 0.02 ± 
multivariate analysis) 
 
Large cohort size (n = 122). 
Statistical significance for OS in 
multivariate analysis. 
No statistical significance for EFS 
in multivariate analysis. 
Other work refutes prognostic 
association of CDKN2A (Rajaram 
et al., 2004). 
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Genomic/Genetic 
 marker 
Source Prognostic Feature Patient outcome 
(p-value) 
Use as a prognostic marker in paediatric ependymoma 
Strength Weakness 
LOC374491 gene Sowar et al., 2006 Over-expression (expression 
microarray) 
Prediction of recurrence 
(p = 8.08x10-5) 
Statistically significant on PAM 
analysis. 
Paediatric cohort exclusively 
analyzed. 
Very small cohort size (n = 13). 
No prospective validation. 
No survival data. 
Not identified in unsupervised or 
supervised hierarchical clustering 
of cohort gene expression. 
1)ț% gene Sowar et al., 2006 Under-expression (expression 
microarray) 
Prediction of recurrence 
(p = 2.05x10-5) 
Statistically significant on PAM 
analysis. 
Paediatric cohort exclusively 
analyzed. 
Very small cohort size (n = 13). 
No prospective validation. 
No survival data. 
Not identified in unsupervised or 
supervised hierarchical clustering 
of cohort gene expression. 
Number and complexity of 
genomic aberrations  
Dyer et al., 2002 µ6WUXFWXUDO¶JURXSRIWXPRXUVZLWK
few and partial chromosomal 
imbalances (CGH) 
:RUVH26WKDQµQXPHULFDO¶
WXPRXUVS RUµEDODQFHG¶
tumours 
 (p = 0.02) 
Statistically significant in 
multivariate analysis. 
Paediatric cohort exclusively 
analyzed. 
Small cohort size (n = 42). 
No prospective validation. 
PLEK gene Sowar et al., 2006 Under-expression (expression 
microarray) 
Prediction of recurrence 
(p = 6.29x10-5) 
Statistically significant on PAM 
analysis. 
Paediatric cohort exclusively 
analyzed. 
Very small cohort size (n = 13). 
No prospective validation. 
No survival data. 
Not identified in unsupervised or 
supervised hierarchical clustering 
of cohort gene expression. 
Protein 4.1 family Rajaram et al., 2005 Deletion of 4.1G locus ± 6q23 
(FISH) 
Worse EFS (p = 0.009) Statistically significant in 
univariate analysis 
Large cohort (n = 84) 
Mixed age cohort. 
No multivariate analysis. 
No prospective validation. 
Contradicting survival findings 
from other studies (Monoranu et 
al., 2008, Korshunov et al., 2010). 
RAC2 (22q13)  
 
 
TPR (1q25) 
Karakoula et al., 2008 
 
 
 
Loss of RAC2 in paediatric 
intracranial tumours (qPCR) 
 
Amplification of TPR in paediatric 
intracranial tumours (qPCR) 
Shorter OS (p = 0.0492  
  
 
Shorter OS (p < 0.0001)  
Statistically significant in 
multivariate analysis. 
Paediatric cohort exclusively 
analyzed. 
Small cohort size (n = 47). 
No prospective validation. 
Studies shown are those performed exclusively on paediatric or patients or have included children in the study cohort which have achieved statistical significance (defined as p < 0.05). Included 
DUHHDFKFDQGLGDWH¶VVWUHQJWKDQGZHDNQHVV as a prognostic marker for paediatric ependymoma. For studies analyzing the same markers in sequentially larger cohorts, the study analyzing the 
largest patient number is shown with reference to the smaller related series. EFS = event-free survival, PFS = progression free survival, OS = overall survival. 
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1.6 Summary and aims 
 
Paediatric ependymomas remain a clinical management challenge. Improvements in the 
understanding of ependymoma biology are important to refine the current histological 
classification systems, define novel prognostic groups and encourage targeted 
therapeutic development. However, previous studies have often analysed mixed age 
cohorts, which may contribute to ambiguous results as evidence exists for biological 
disparity between ependymomas from children and adults. A review of current 
knowledge regarding the biology of paediatric ependymoma, encompassing several 
aspects of this chapter, has been published (Kilday, Rahman et al. 2009). 
 
By using the Affymetrix® 500K SNP array and Illumina® GoldenGate® Cancer Panel I 
methylation array platforms, the initial aim of this study was to determine the scale and 
nature of genomic and epigenetic aberrations present in paediatric ependymomas 
collectively and then correlate specific abnormalities with clinical, histopathological and 
prognostic subgroups. The results of this work are detailed in chapters three, four and 
five. The SNP array analysis enabled a higher resolution analysis of the ependymoma 
genome than conventional or array based CGH studies. Whilst other researchers have 
adopted this technique to examine ependymoma (Johnson, Wright et al. 2010), this was 
the first to predominantly use neoplastic and constitutional DNA from the same patient 
to more accurately define tumour-specific genomic imbalances and correlate such 
aberrations with patient outcome. Moreover, epigenetic array analysis of a paediatric 
ependymoma cohort has yet to be published. 
 
A final objective was to prospectively validate the prognostic significance of a panel of 
putative biological markers in paediatric ependymoma, including candidates established 
from the array analyses. This was performed using immunohistochemistry and FISH on 
two age-defined tissue microarray (TMA) ependymoma cohorts obtained from children 
treated uniformly according to the independent clinical trials UKCCLG CNS 1992 04 
and SIOP CNS 1999 04. The results obtained are shown in chapter six.  
 
Chapter seven summarises the findings of the entire study and considers potential future 
work evolving from this research. 
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2.1 DNA extraction 
 
2.1.1 Frozen ependymoma cohort 
 
DNA was isolated from tumours which had been snap frozen at surgery and blood 
samples collected from paediatric ependymoma patients. The DNA was stored at -80ºC 
for use on either the 500K SNP arrays and/or the methylation arrays. All tumour and 
blood specimens were collected with patient and parental consent, together with 
regional and national ethics approval.  
 
In total, 122 snap frozen tumours were collected from 8QLWHG.LQJGRP&KLOGUHQ¶V
Cancer and Leukaemia Group (UK CCLG) registered medical institutions and the 
Cooperative Human Tissue Network (CHTN) within the United States of America. The 
UK CCLG centres contributing samples to this study included Nottingham, 
Birmingham, Cambridge, Bristol, Newcastle, Liverpool, London (Great Ormond Street 
Hospital), Cardiff, Leeds and Southampton. Forty-five constitutional blood samples also 
had DNA extracted for SNP analysis from patients contributing tumour specimens (i.e. 
paired blood samples). The specific number of samples used on each array and the 
clinical information for each respective patient cohort is presented in the relevant result 
chapters. 
 
All tumour tissues were reviewed locally at each institution by a neuropathologist in 
accordance with current WHO criteria (Louis, Ohgaki et al. 2007) to confirm the 
histological appearance of ependymoma and establish tumour grade. As further 
verification, all tumours were also centrally reviewed by two neuropathologists at 
4XHHQ¶V 0HGLFDO &HQWUH +LVWRSDWKRORJ\ Department, Nottingham (Professor James 
Lowe and Dr. Keith Robson). 
 
2.1.2 Tumour tissue assessment  
 
To ensure the solid tissue samples to be used for DNA isolation were representative of 
viable tumour, a small section was cut from the tissue segment to be used for DNA 
extraction and smeared between two glass microscope slides.  
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Both tumour tissue cutting and smearing were performed in a recirculating laminar flow 
preparation station (Labcaire PCR hood 8), which had been pre-cleaned with 100 % 
(v/v) ethanol and exposed to ultraviolet light for 30 minutes before use to minimise 
contamination. Each tissue sample for cutting was transferred into the preparation 
station from -80 ºC storage in a 1.5 ml vial (Eppendorf, UK) and placed onto a sterile 
petri-dish (Corning, USA) which was rested on a small box of dry ice to ensure the 
sample remained frozen, thereby preventing degradation of genetic material. A sterile 
scalpel blade (Swann-Morton, Sheffield, UK) was used to cut the tissue segments. This 
had also been cleaned in 100 % (v/v) ethanol before use. The tissue segment cut to 
assess tumour viability was subsequently smeared between two glass microscope slides 
which were immediately removed from the station and placed into a coplin jar of 
Carnoy solution for fixation. The slides were immersed in Harris haematoxylin 
(SurgiPath, UK) for 30 seconds, washed in water for 10 seconds and then placed in 
lithium carbonate (Sigma, UK) for 10 seconds. The slides were washed again in water 
for 10 seconds and subsequently stained in 10 % (v/v) eosin (ProSciTech, AU) for 20 
seconds.  Following a third wash in water for 10 seconds, the slides were dehydrated in 
95 % (v/v) ethanol, then 100 % (v/v) ethanol and finally xylene (Fisher Scientific, UK), 
each for 10 seconds. Mounting of the slides was performed using coverslips (SLS, UK) 
and DPX mountant (Surgipath, UK). Stained slides were left to dry on a hotplate. Under 
neuropathological review, only tissue samples with smears demonstrating viable tumour 
underwent DNA extraction (Figure 2.1). 
 
 
Figure 2.1: Haematoxylin and eosin stained smear of a normal brain specimen (A) and an ependymoma specimen 
(B). Objective x40. 
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2.1.3 DNA extraction from frozen tumour tissue 
 
Approximately 10 mg of each tumour sample was homogenized in 1.5 ml vials 
(Eppendorf, UK) containing 0.5 ml of DNA lysis buffer (see section 2.1) and 0.1 ml of 
20 mg/ml proteinase K (Sigma, UK). During homogenisation (performed using the 
Powergen 125 hand-held homogeniser, Fisher Scientific, UK), vials were surrounded by 
dry ice to keep samples frozen and prevent degradation of nucleic acid material. After 
homogenisation, samples were incubated overnight at 37 °C and at 10 g in a 
Thermomixer (Eppendorf, UK). Following incubation, phase lock gel (PLG) tubes 
(Eppendorf, UK) were spun at 12,000 g in a microcentrifuge (Sigma, UK) for 30 
seconds. A 0.7 ml aliquot of each sample was added directly to the pre-spun PLG tubes 
in addition to an equal volume (0.7 ml) of phenol/chloroform isoamyl alcohol (Sigma, 
UK). The contents of each tube were mixed by inversion until a transiently homogenous 
suspension was formed. Microcentrifugation at 16,000 g for five minutes then separated 
the aqueous and organic phases. The nucleic-acid-containing aqueous upper phase was 
transferred by pipette (Gilson, USA) to a fresh 1.5 ml vial. DNA was precipitated on the 
addition of equal volumes of ice-cold isopropanol followed by vial inversion and DNA 
pellets were formed by mirocentrifugation at 12,000 g for five minutes. After 
supernatant removal by pipette, each resulting pellet was twice washed in 0.5 ml of 70 
% (v/v) ethanol, mixed by vial inversion and microcentrifuged at 12,000 g for five 
minutes. Ethanol was then removed from each vial and the pellets were air dried for 20 
minutes. Addition of 50 µl ddH2O re-suspended the dried DNA pellets in a 1.5 ml vial.  
 
2.1.4 DNA extraction from blood 
 
The blood specimens used had been stored frozen in anticoagulated vials (Vacutainer, 
BD, USA). After thawing at room temperature, DNA was extracted from lymphocytes 
by the transfer of 1 ml of blood (Greiner, UK) to 14 ml of distilled water. The resulting 
mixture was incubated on ice for five minutes, using osmosis to lyse red cells whilst 
lymphocytes remained intact. The tubes were then spun in a centrifuge (Sigma 3 ± 18K, 
Sigma, UK) for five minutes at 660 g. Supernatant was discarded by pipette, leaving a 
pellet which was subsequently transferred to a 1.5 ml vial. To each pellet was added 0.5 
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ml of DNA lysis buffer and 0.1 ml of 20 mg/ml proteinase K and the extraction protocol 
was continued from the homogenisation process stated above in section 2.1.3. 
 
2.1.5 DNA quantification and quality control 
 
Each DNA sample was quantified using a spectrophotometer (ND-1000, Nanodrop, 
UK) which also provided qualitative information for the sample by means of 260 
nm/280 nm and 260 nm/230 nm absorbance ratios. A 260/280 ratio of 1.8 ± 2.2 and a 
260/230 ratio of 2.0 ± 2.2 indicate intact DNA without contamination. Low 260 / 280 
and 260/230 ratios suggest RNA and phenol contamination respectively. 
 
DNA quality was secondly analysed by electrophoresis on a 1 % agarose gel (Figure 
2.2). This was made by initially adding 0.5 g agar (Sigma, UK) to 50 ml of 1x TAE 
buffer in a 250 ml conical flask (Pyrex, SciLabware, Germany). The agar was dissolved 
by heating in a microwave (Proline, SM18, 750W) for two minutes on full power. After 
cooling, 0.5 µl of ethidium bromide (Sigma, UK) was added and the mixture was briefly 
swirled before being poured into a gel mould incorporating sample wells and allowed to 
set. The gel was added to a gel tank (Flowgen, UK) filled with 1 x TAE buffer. A 1 µl 
aliquot of sample DNA, combined with 4 µl of gel loading solution (Sigma, UK), was 
added to each of the sample wells adjacent to one well containing 5 µl of 10 kb 
hyperladder (Bioline, UK). The gel was electrophoresed at 120 V for 20 minutes. A 
single band above 10 kb for each sample indicated DNA which was not degraded.  
 
 
Figure 2.2: 1 % agarose gel of DNA samples extracted from six paediatric ependymomas. The presence of a single 
band above 10 kb indicated the presence of DNA that was free from degradation. 
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2.2 The 500K Affymetrix® SNP array 
 
2.2.1 500K SNP array protocol overview 
 
The Genechip® Human Mapping 500K Array Set reliably and accurately detects greater 
than 500,000 single nucleotide polymorphisms (SNPs) in samples of genomic DNA. 
Assays were performed at the Hartwell Centre, St. -XGH¶V5HVHDUFK+RVSLWDO0HPSKLV
USA and the Almac Biotechnology Centre, Belfast, Northern Ireland, UK under the 
under the auspices of Dr. Richard Gilbertson and Dr. Andrea McCulla. Both centres 
adopted the same protocol, an overview of which is given. 
 
A complete mapping set was comprised of two 250K arrays, each with a corresponding 
250K assay kit, incorporating either the restriction enzyme NspI or StyI. This enabled 
the complete set to achieve maximum genomic coverage and reduce the complexity of 
the genome by amplifying NspI and StyI fragments using a single PCR primer from 
only 250 ng DNA per enzyme. The two assays in the mapping set were processed 
independently to minimise error, thereby generating genotype calls for more than 
250,000 SNPs for each array of the set. 
 
A human genomic DNA control of known genotype (Reference Genomic DNA, no. 
103) was used as an experimental positive control on each 250K array for every 10 
complete chips processed and aided troubleshooting by providing comparative results to 
those generated by DNA extracted from samples. Fifty SNP probes within each 250K 
array acted as internal controls by producing genotype calls that intentionally remain 
consistent irrespective of the DNA hybridising to the array. If the genotype calls 
generated by these SNP probes post hybridisation proved different to that expected, the 
result for the entire mapping set was to be discarded. Each NspI and StyI array housed a 
further 50 SNP probes that acted as controls for cross-checking genotype calls produced 
from the same sample, thereby confirming identification in cases of confusion.   
 
The five day protocol consisted of 10 main steps (Figure 2.3).  DNA was initially 
digested by the restriction enzyme for each 250K array. End linkers were then ligated to 
the digested DNA fragments which were amplified by PCR. Following purification, 
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fragmentation reduced the size of the PCR products (from 250 ± 1100 bp to 180 bp), 
which were subsequently end-labeled prior to hybridisation onto each array. After 
overnight hybridisation, washing of the arrays removed any unbound DNA fragments. 
This was followed by Streptavidin Phycoerythrin (SAPE) staining. Each array was then 
scanned to produce raw signal intensity data. 
  
 
Figure 2.3: Schematic overview of the Affymetrix® 500K assay. Adapted from the Genechip® Human Mapping 500K 
Set User Guide (Affymetrix 2006). 
 
2.2.2 SNP array scanning and initial data interpretation 
 
The arrays were scanned using the Affymetrix® Genechip® Scanner 3000, controlled by 
GCOS (Affymetrix® Genechip® Operating Software). Arrays were automatically 
scanned upon loading. On completion, a .dat file was produced containing fluorescent 
intensity data for the probes on the arrays. Examination of the .dat file image at this 
stage was an important quality control checkpoint. The aim was to verify hybridisation 
of B2 oligo, the main component of an Oligonucleotide Control Reagent (OCR) which 
was incorporated iQWRHDFKDVVD\¶VUHDJHQWFRFNWDLOSULRUWRRYHUQLJKWK\EULGLVDWLRQZLWK
sample or control DNA. Successful hybridisation of B2 oligo to the array produced 
characteristic fluorescent designs on the resulting .dat file image including an 
alternating intensity pattern around the border, a checkerboard pattern at every corner 
(Figure 2.4A) and the specific array¶V name at the lower left corner (Figure 2.4B). B2 
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oligo hybridisation also generated a fluorescent grid over the file image for each array 
which aided probe alignment. Arrays lacking these features or demonstrating other 
artefacts were discarded at this stage. 
 
                                                   
Figure 2.4: Fluorescent designs produced by B2 oligo hybridisation on each 250K array. A checkerboard pattern is 
produced on the corner of each array (A) while the array name is found in left lower corner of each array (B). 
Reproduced from the Genechip® Human Mapping 500K Set User Guide (Affymetrix 2006).   
 
 
2.2.3 SNP array analysis ± GTYPE 
 
A fluorescent signal value was generated for every probe on the 250K arrays. Thus, in 
addition to generating .dat files, GCOS also automatically produced .cel files. Each .cel 
file contained the results of probe fluorescent intensity from the .dat file in a binary 
format only compatible for analysis with related Affymetrix® computer programs such 
as GTYPE (Affymetrix® Genechip® Genotyping Analysis Software)8VLQJ WKH µEDWFK
DQDO\VLV¶ IXQFWLRQZKLFK LQFRUSRUDWHGDQDOJRULWKPFDOOHG%5/00Bayesian Robust 
Linear Model with Malanobis distance classifier), GTYPE  incorporated the array data 
from the .cel files into .chp files which contained information such as probe set perfect 
match (PM) and mismatch (MM) intensities and genotype calls (AA, AB, BB) (Figure 
2.5). This allowed the SNP call rate to be evaluated for each array. The SNP call rate for 
an array was defined as the percentage of SNPs on a 250K array with a reliable 
genotype when compared to the total number of SNPs on the array. SNP call rates of  
93 % or above were deemed successful, however lower values were possible because of 
the genomic abnormalities present in tumour DNA. If the calculated SNP call rate was 
below 85 %, the array was viewed as unreliable and discarded from the analysis.  
A B 
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Figure 2.5: GTYPE batch analysis. Results for the NspI array of two samples (A and B) displaying the SNP call 
rates (red circle) and the genotype calls for 10/50 control SNP probes used to cross-check genotype calls between 
the two 250K arrays (red brackets). The genotype calls of these 50 SNP probes should be identical for both arrays 
performed on each sample. 
 
2.2.4 SNP array analysis ± CNAG 
 
The .cel and .chp files for each 250K array were subsequently imported and combined 
using the computer program CNAG (Copy Number Analyser for Genechip®) (Nannya, 
Sanada et al. 2005). After initially normalising probe signal intensity to account for 
factors such as background noise and varying intra and inter-array performance, CNAG 
incorporates an algorithm that calculates the relative copy number (N) at the ith SNP 
between two samples from the log2 ratio of the normalised signal intensities (S): 
 
                               N      = log2             S(test sample)                for ith SNP 
S(reference sample) 
 
For cases where both tumour and normal DNA were available from the same patient, 
the constitutional DNA was used as the reference sample. However, for cases where 
only unpaired analysis was possible, the reference was generated from a pool of the 
available normal tissue DNA. Further normalisation of this data was then peformed to 
account for potential artefacts incurred during the PCR process, thereby strengthening 
the signal to noise ratio obtained. The hidden Markov model was implemented on the 
combined data sets from both 250K arrays so that each tumour copy number log2 ratio, 
relative to either patient-matched constitutional DNA or the pool of unmatched 
references, was designated to one of seven copy number states:  
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a) Copy number state 0 = homozygous deletion 
b) Copy number state 1 = hemizygous deletion 
c) Copy number state 2 = copy neutral (diploid) 
d) Copy number state 3 = single copy gain 
e) Copy number state 4 = multiple copy gain 
f) Copy number state 5 = amplification 
g) Copy number state 6 = amplification 
 
6SHFLILFDOO\ WKH µH[WUDFW GDWD¶ function in CNAG transformed the .chp data for each 
DUUD\VDPSOHLQWRFIKILOHVZKLFKZHUHGHSRVLWHGLQWRDQµDUUD\GDWD¶IROGHU)URPWKH
.cfh files, a µVDPSOHPDQDJHU¶ IXQFWLRQLQ&1$*JHQHUDWHGFIVµVHOI¶UHIHUHQFHGDQG
FIQ µQRQ-VHOI¶ UHIHUHQFHG data files, using either paired, allele specific or unpaired, 
non-DOOHOH VSHFLILF UHIHUHQFH ILOHV UHVSHFWLYHO\ 7KHVH ZHUH VWRUHG LQ D µUHVXOWV ILOHV¶
folder containing the relative copy number values for the SNPs from each 250K array. 
Finally, a µGLVSOD\ VDPSOHV¶ function enabled the combination of data from both arrays 
of a mapping set, while allowing visualisation of the data on a chromosome ideogram 
(Figure 2.6).  In addition, a .txt file containing the copy number results for each sample 
was generated DQGVWRUHGLQDQµDUUD\RXWSXW¶IROGHU 
 
 
 
Figure 2.6: CNAG generated chromosome ideogram for the combined 250K NspI and StyI arrays for sample 30P 
after comparison with patient matched constitutional DNA. Copy number and log2 ratio line graphs can be seen above 
and below each chromosomal caricature respectively. In this case, single copy number gain of chromosome 1q and 
hemizygous deletion of chromosome 10q (arrows) are clearly visible.  
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2.2.5 SNP array analysis ± data visualisation software  
 
The ependymoma .txt files generated in CNAG were imported into the data handling 
and visualisation program Spotfire Decision Site®, in conjunction with a 500K 
annotation .txt file generated by Affymetrix® (Netaffx file build 07.12.07). This 
annotation file enabled classification of each probe of the 500K array according to 
features including probe identification code and number in genomic order, actual 
physical position within the genome, locality in relation to the nearest gene, the name of 
such genes and whether the probe location was within a region of known normal copy 
number variability. The Spotfire Decision Site® program allowed this large dataset to be 
summarised and viewed, through tables and heatmaps, to identify the copy number 
value of each 500K probe for each tumour sample. This facilitated the identification of 
chromosome arm, cytoband and gene copy number alterations either universally or in 
clinically relevant subgroups, in addition to LOH and aUPD detection. Any heatmap 
visualisations produced were transformed to .tif (Tag Image File Format) files using 
Adobe® Photoshop 6.0. 
 
The in-house SNPview program was used as another means of visualising the data 
generated by CNAG and was devised by Dr Alain Pitiot and Francois Morvillier at the 
Brain and Body Centre, University of Nottingham, UK in collaboration with the 
&KLOGUHQ¶V %UDLQ 7XPRXU 5HVHDUFK &HQWUH 613view was used to visualise the data 
generated by CNAG on chromosome ideograms encompassing the genome. After 
importation, the CNAG .txt files were converted to .snp files and incorporated into the 
chromosome ideograms. As with the Spotfire Decision Site®, visualisations were 
transformed to .tif files using Adobe® Photoshop 6.0. An overview of the data analysis 
is shown (Figure 2.7). Details of genomic imbalance analysis methods for chromosome 
arms, cytobands and genes are given in the relevant results chapters (Chapter 3, section 
3.2.1.2 and Chapter 4, section 4.2.1.2). CNAG generated copy number data for all of the 
probes analysed across the SNP array cohort of 63 paediatric ependymomas, together 
with a filtered version of the 500K annotation file incorporating selected probe 
classification features, are included in Appendix 10A. 
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Figure 2.7: SNP array analysis overview using GCOS, GTYPE and CNAG. 
 
 
2.3 Illumina® GoldenGate® Cancer Panel I assay for methylation 
 
2.3.1 GoldenGate® Cancer Panel I assay protocol overview 
 
$VVD\VZHUHSHUIRUPHGDFFRUGLQJWRPDQXIDFWXUHU¶VLQVWUXFWLRQVDWWKH:HOOFRPH7UXVW
Centre for Genetics, Oxford, UK under the guidance of project manager Dr. Joseph 
Trakolo. An overview of the protocol adopted is given below. 
 
The Illumina® GoldenGate® Cancer Panel I methylation assay is a modification of the 
SNP genotyping assay (Fan, Oliphant et al. 2003). It enables simultaneous assessment 
of the methylation status of 1,536 independently selected CpG dinucleotide sites across 
the genome, underpinned by utilising a bead-based array called the Illumina® Sentrix-
Array Matrix® (SAM) (Bibikova, Lin et al. 2006).The SAM configures 96 individual 
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fibre-optic bundle arrays to match the well spacing of a standard 96 well plate format, 
allowing this number of samples to be run per assay. Each bundle array is comprised of 
50,000 fibre strands, each accommodating a single synthetic bead within a 3 µm 
chemically etched well at the end of each strand. 1,536 unique bead types are 
represented with an average 30-fold redundancy. Each bead is covered in hundreds of 
thousands of copies of covalently attached oligonucleotide probes which are 
FRQFDWDPHUV RI D  EDVH SDLU µDGGUHVV¶ VHTXHQFH DQG D &S* VLWH-specific sequence. 
After bead insertion into the array, a hybridisation process is used to physically map or 
µGHFRGH¶HDFKEHDGXVLQJWKHDGGUHVVVHTXHQFH7KLVSURFHVVYDOLGDWHVWKHSHUIRUPDQFH
of the array and is used as a quality control measure prior to use.  
 
Of the 1,536 CpG sites chosen for analysis on the GoldenGate® Cancer Panel I 
methylation assay, 98 % (1,505/1,536) of the sites are targeted from 807 genes mapping 
across the genome which have been implicated in the pathogenesis of cancer. These 
include tumour suppressor genes, oncogenes and genes associated with DNA repair, 
differentiation, cell cycle control, imprinting and apoptosis. The majority of these genes 
(576, 71.4 %) contain two or more CpG sites interrogated by the methylation assay. The 
remaining 31 CpG sites analysed by the assay are designed as internal quality bead 
controls for each experiment performed. Although several CpG sites are present within 
a gene, particularly within CpG islands (Takai and Jones 2002) , the specific CpG sites 
chosen for the GoldenGate® Cancer Panel I methylation assay by Illumina® are those 
allowing robust assay design (i.e. a design score above a pre-determined threshold). 
Other CpG sites in close proximity to the CpG site of interest are assumed to have the 
same methylation status as that of the target site, based on previous evidence (Rakyan, 
Hildmann et al. 2004; Eckhardt, Lewin et al. 2006).  
 
The four day protocol consisted of seven main steps (Figure 2.8).  
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Figure 2.8: Schematic overview of the Illumina® GoldenGate® Cancer Panel I assay for methylation. This 
chronologically illustrates DNA bisulphite conversion (A), oligonucleotide annealing, extension and ligation (B ± D), 
product labeling and bead array hybridization (E), SAM washing (F) and finally array scanning (G). See text for a 
more detailed explanation of the process. Figures B ± D demonstrate allele-specific oligonucleotides (ASOs) in gold, 
while locus specific oligonucleotides (LSOs) are shown in green. Ligation of extended ASOs to their corresponding 
LSOs is designated purple in Figure D. In Figure E, the Illumina® µDGGUHVVFRGH¶ LVFRORXUHGEOXH0RGLILHG IURP
Illumina® SNP Genotyping ±the Illumina® Goldengate® Assay Workflow (Illumina 2006). 
 
Five hundred nanograms of genomic DNA underwent bisulphite conversion.  An 
aliquot of the converted DNA, (corresponding to 250 ng of original genomic DNA) was 
then used on the GoldenGate® assay. Following bisulphite treatment, unmethylated 
cytosines (C) were converted to uracils (U), while methylated cytosines remain 
unchanged (Figure 2.8A). Due to the similarity in hybridisation properties between 
uracil and thymine (T), the methylation status of a particular cytosine was evaluated 
through the use of a C/T polymorphism genotyping assay. For each CpG target site, two 
allele-specific oligonucleotide (ASO) probes and a locus specific oligonucleotide (LSO) 
probe were designed such that an ASO ± LSO pair corresponding to either the 
methylated or unmethylated state of each CpG site existed (Figure 2.8B). All of the 
oligonucleotides were pooled and allowed to anneal to the target DNA sequence, with 
all loci being assayed simultaneously. Extension occurred from the matched ASO 
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towards the corresponding LSO followed by ASO ± LSO ligation (Figure 2.8C and D). 
The ligated products were then amplified by PCR using Cy3- (green) and Cy5- (red) 
fluorescently labelled universal primers. The resulting fluorescent products were 
VXEVHTXHQWO\K\EULGLVHG WR WKH6$0 WKURXJK WKHGHFRGLQJ µDGGUHVV¶ VHTXHQFHRQ WKH
bead array, which hybridised to a complementary sequence residing within the LSO 
sequence of each product (Figure 2.8E). The signal intensity ratio between the Cy5- and 
Cy3- fluors distinguished methylated (red) and unmethylated (green) loci. 
 
2.3.2 Methylation array scanning  
 
Following hybridisation and washing, the Illumina® BeadarrayTM Reader (Illumina, San 
Diego, USA) scanned each array and produced an intensity data file (.idat) (Figure 2.9). 
This file contained the fluorescent intensity, location and identification data for every 
bead of the 96 arrays, together with a .tif image of the signal intensities for each array. 
The information contained within each ependyPRPD VDPSOH¶V LGDW ILOH ZDV
subsequently exported for data interpretation and visualisation to both the BeadStudio 
v3.2 methylation moduleTM (Illumina, San Diego, USA) and the open source software 
package Bioconductor® (Gentleman, Carey et al. 2004), run within the R software 
environment for statistical analysis. The beadarray program within the Bioconductor® 
package was used via the readillumina application of R, as it provided a framework for 
analysing data from bead based arrays (Dunning, Smith et al. 2007). 
 
 
Figure 2.9: Basic workflow for the Illumina® GoldenGate® Cancer Panel I assay for methylation. 
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2.3.3 Methylation array quality control  
 
Initially, the .idat array file data exported to the Illumina® Beadstudio methylation 
moduleTM and the beadarray Bioconductor® program underwent quality assessment.  
 
As stated previously, 31 beads on each array act as internal controls, assessing every 
step of the assay process. These beads can be categorised into nine groups (Table 2.1). 
The Illumina® Beadstudio methylation moduleTM produced a control summary graph for 
these nine sets of control beads across the entire array cohort included in this project 
(Figure 2.10). This allowed a visual overview of the efficacy of the experiment. In 
addition, each of the nine sets of control beads were viewed and assessed individually 
across the cohort to identify samples with aberrant signal intensities that warranted 
exclusion from further analysis (Figure 2.11). 
 
Table 2.1: The nine groups of internal control probes present on each array of a SAM®. 
 
Bead Control Type Description 
Bisulphite conversion controls Tests for the presence of unconverted genomic DNA in assay 
samples. 
First hybridisation controls Test the specificity of annealing ASOs with different Tm to the 
same DNA locus. 
Allele ± specific extension controls Test the extension efficiency of properly matched versus 
mismatched ASOs. 
Extension gap control 7HVWV WKHHIILFLHQF\RIH[WHQGLQJEDVHVIURPWKH¶HQGRI WKH
$62WRWKH¶HQGRIWKH/62 
Second hybridisation controls Tests the hybridisation of single-stranded assay products to address 
code sequences on the bead array. 
Assay intensity controls Shows average signal intensity for all probes on an array. 
Gender ± specific methylation controls Designed against X-linked genes. Cy3- and Cy5- signal should be 
detected in females; Cy3- only in males. 
PCR contamination detection controls Divided into 4 types. Only one type is added to each oligo pool. 
When an experiment is run, only one contamination control should 
have a high signal. If two or more controls have high signal, 
significant contamination has occurred. 
Negative controls ± targets sequences lacking 
CpG dinucleotides 
Define the methylation assay background. LSO probes can 
hybridise to bisulphite converted DNA but ASOs are randomly 
permutated and should not hybridise to the DNA template. As a 
result, an amplifiable target should not be formed and the signal 
should be low. 
Reproduced from the Illumina® Genome Studio Methylation ModuleTM v1.0 User Guide (Illumina 2009). 
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Figure 2.10: Control summary graph of the ependymoma cohort run on the Illumina® Golden Gate® Cancer Panel I. 
This allows visualisation of the signal intensities (measured in relative fluorescence units or RFU) for the nine groups 
of internal controls present on each array, summarised across the sample cohort. 
 
 
 
 
Figure 2.11: Graph demonstrating one of the first hybridisation probe signal intensities for each sample across the 
ependymoma methylation cohort. The x-axis denotes sample number (array index). The y-axis denotes signal 
intensity in RFU. Exact intensities for each sample are marked by the small black squares. Outlier samples with 
aberrant signal intensities are identified by a red ring. 
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The Illumina® Beadstudio methylation moduleTM also allowed a probe detection p-value 
to be calculated which characterised the chance of a target bead summary signal value 
being distinguishable from that of background controls. Significance was defined as a p-
value < 0.05. Summary signal values were calculated by averaging the fluorescent 
intensity of all replicate beads for a bead type on an array. This was performed by the 
Illumina® default method, where outlying beads with a summary signal value that was 
more than three absolute deviations from the median (MADs) for that bead type were 
excluded. The background intensity value for each array was calculated by averaging 
the summary signals of the in-built negative control beads, which were designed to be 
thermodynamically equivalent to the target probes but lack a specific target in the 
transcriptome. Tumour samples were excluded from further analysis if more than 1 % of 
the 1,505 target bead probes had a detection probe p-value > 0.05. 
 
Quality assessment of the arrays was also assessed using the beadarray program within 
the Bioconductor® software package. In addition to using boxplots and image plots to 
identify and remove outlier arrays (Figure 2.12A ± D), spatial artefacts on each array 
were identified using the Beadarray Subversion of Harshlight (BASH) (Cairns et al 
2007). This latter feature is not available through the Illumina® Beadstudio methylation 
moduleTM. Using the median intensity signals calculated from the replicates of each 
bead type and incorporating a formulaic knowledge of the direct neighbours of each 
EHDG %$6+ JHQHUDWHG DQ µHUURU LPDJH¶ IRU HDFK RI WKH KH[DJRQDO DUUD\V VXFK WKDW
significantly large spatial artefacts, defined visually as encompassing greater than 25 % 
of the array area could be identified. Samples contributing such artefacts were thereby 
excluded from further analysis (Figure 2.12E). 
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Figure 2.12: Quality assessment of the methylation array using the Bioconductor® beadarray program. Figures A and 
B are box plots demonstrating the median Cy3- and Cy5- intensity (measured as log2 (intensity)) of all CpG probes 
for 96 ependymoma samples. Outliers with aberrant signal intensities are highlighted (red rings). Figures C and D are 
image plots extrapolated from the box plots demonstrating a suitable (C) and unsuitable (D) array. Median green and 
red fluorescence (measured as log2 (intensity)) are denoted on the x and y axes respectively. Ideally, two focal regions 
should be seen, representing the fluorophore intensity around which most medians fall for the 96 samples on the 
SAM. Figure E represents a BASH induced image of 1 of the 96 hexagonal arrays in a SAM, highlighting areas of 
spatial artefact in red. If > 25 % of the array was attributable to artefact, the sample was excluded from further 
analysis. 
 
2.3.4 Methylation array initial data interpretation 
 
After quality control measures were completed, data analysis was performed, again 
using the Bioconductor® beadarray program. This incorporated an annotation file 
(Illumina® Goldengate® Cancer Panel I CpG List 2007) which enabled each of the 
1,505 CpG probes to be classified according to features such as probe identification 
code and location within the genome, locality in relation to CpG islands and the name 
and function of the encompassing gene.  
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Initially, bead summary signal values were calculated for both red and green 
fluorophores across all of the samples analysed. This was carried out using the MADs 
based Illumina® default method described previously. Background normalisation was 
performed by subtracting the average signal of the in-built negative control beads from 
the target probe Cy3- and Cy5- signals. This enabled a corrected methylation score or 
%HWD YDOXH ȕ WR EH DWWULEXWHG WR HDFK &S* EHDG SUREH EDVHG RQ WKH IROORZLQJ
equation: 
 
Cy5 (corrected red intensity value) 
Cy3 (corrected green intensity value) + Cy5 (corrected red intensity value) + 100 
 
The Beta score could range from zero in the case of completely unmethylated CpG 
target sites, to one in completely methylated sites. The denominator of the equation is 
an absolute value to compensate for any negative values resulting from any global 
background subtraction. A bias of 100 is added to the denominator to standardise the 
Beta score when both Cy3- and Cy5- values are small. 
 
The computer script enabling array quality assessment and probe background correction 
using the Bioconductor® beadarray program within the R software environment is 
included in Appendix 10B. Further downstream analysis including cluster analysis, 
heatmap generation and differential methylation analysis between clinical subgroups 
was also performed using the beadarray program within the Bioconductor® package. 
These methods are described either in the statistics section of this chapter (section 2.7.7) 
or in the relevant chapters (Chapter 3, section 3.2.2.2 and Chapter 4, section 4.2.2.1). 
 
2.4 Real time quantitative Polymerase Chain Reaction  
 
Real time quantitative PCR (qPCR) was used to validate the genomic aberrations of 15 
selected genes from the 500K SNP microarray analysis (Chapter 4, section 4.3.5). 
Initially, the genomic sequence of the target genes and two control genes which had a 
QRUPDO613FRS\QXPEHULQWKHWXPRXUVFKRVHQIRUDSDUWLFXODUWDUJHWJHQH¶VYDOLGDWLRQ
(ULK4 and AJAP1), were identified using the web-based genomic database Ensembl 
(http://www.ensembl.org). This program also allowed exons encompassed within 
regions interrogated by sequential SNPs of interest to be located and selected for primer 
ȕ  
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design. For each gene, the sequence of the exon of choice was imported into Primer3 
(http://frodo.wi.mit.edu/) which generated forward and reverse primer pair sequences 
with a GC content of 40 ± 60 %, such that the optimal product length was between 100 
± 150 bp. The sequences of the primer pairs for each candidate exon were subsequently 
analysed for matches elsewhere in the genome using a BLAST search 
(http://www.ensembl.org/Multi/blastview), in order to prevent incorrect product 
amplification (Figure 2.13). All primers were provided by Operon (MWG Eurofins, 
Germany).  
 
 
Figure 2.13: An example of a Blast search using the genomic database Ensembl 
(http://www.ensembl.org/Multi/blastview). This highlights regions across the genome with identical or similar 
sequences to that of the selected primer pair, to avoid inappropriate product amplification. Results for the primer pair 
interrogating exon 1 of the NSL1 gene on chromosome 1q32.3 are shown. Red arrows represent regions across the 
genome with similar sequences to that of the chosen primer. A boxed red arrow signifies an identical sequence match 
to that of the primer.  The forward primer has only one boxed hit across the genome, located at chromosome 1q32.3. 
The reverse primer has three hits, yet the only boxed hit is also on chromosome 1q32.3. Therefore only one product 
will be produced by this primer pair, incorporating the appropriate region of interest. 
 
The primer sequences for the target and control genes selected for this study are shown 
in Table 2.2. 
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Table 2.2:  Primer sequences for 15 genes of interest identified by the 500K SNP array 
analysis, in addition to those of two control genes, AJAP1 and ULK4. 
 
Gene 
name 
Locus Exon 
Product 
size 
(bp) 
FRUZDUG¶± ¶ Reverse 
AJAP1 1p36.32 3 123 CCCACCACAGAGACTGAGTT TGTCTTCCGTGTTTGTAGGA 
ULK4 3p22.1 37 116 TGTTTCATCCAAGTGCCTGT GGTCCTCCTTGGATGTCAGT 
PRUNE 1q21.2 3 100 CTGCGAGGTGACATTGTCTT CAGCCTGGTATAATGCATGG 
BNIPL 1q21.2 3 107 TGTCTGCCGCCTTTTAATCT CTTGACCTACCTGCCTGTGA 
CHI3L1 1q32.1 4 102 AGGCTCTGCATACAAACTGG GTACAGAGGAAGCGGTCAAG 
NAV1 1q32.1 3 109 CTTTATGAGCCCGAATGGAG ACTTGGACAGCGTCTTGGAC 
NSL1 1q32.3 1 124 ACAGTTCCGACGAAAAATGG AAAGTCTTCTCGGGGAGTGG 
FILIP1 6q14.1 1 104 CCTAATCTCCGAACCCAACA ATCCCGATCAGCAGAAATTG 
FRK 6q22.1 4 104 TTTAAGCGATTGGGATCTGG ATTGTTCTCGCACCTGGTTT 
HOXA5 7p15.2 3 127 TGAAGAAGCCCTGTTCTCGT TCAAGACAAAGCCATTCAGG 
CDKN2A 9p21.3 5 133 CAACGCACCGAATAGTTACG GAGAATCGAAGCGCTACCTG 
TXN 9q31.3 1 105 AGCTCTGTTTGGTGCTTTGG GTAGCGCGTACCTTGCTCTC 
DNAJC25 9q31.3 2 101 CTGCATATGCCCAAGAGGAT ACAAGCAGGGCAATAAGCTC 
COL4A1 13q34 2 113 CCCTCGCTTTGAAAGTGTTC CCTTTTGTCCCTTCACTCCA 
TELO2 16p13.3 18 117 CTTTGTAGCGAGGCCAGGT CCCAGGCCCAGTGTATTTTT 
SEH1L 18p11.21 6 102 GTGGGCCAACAAAGTTTGAA ATGCTAGCACCGTTCCTGTT 
PPARA 22q13.31 2 116 ACTCTGGGTCTTCGGGTTGT GGAAAGCACCTTCTGAGTCG 
 
2.4.1 Primer Optimisation 
 
The optimal annealing temperatures for all qPCR primers were established using a 
temperature gradient on a thermal cycler (C1000 thermal cycler incorporated in the 
CFX96 Real-Time System, Bio-Rad, UK). For each primer set optimisation, a 144 µl 
PCR megamix was made up in the pre-cleaned recirculating laminar flow preparation 
station exposed to ultraviolet light for 30 minutes before use. The megamix contained 
iQTM Custom SYBR Green Supermix (Bio-Rad, UK), forward primer, reverse primer 
and double distilled water. The megamix was vortexed (Whirlmixer, Fisher, UK) for 
one minute, then spun at 16,000 g for 20 seconds in a microcentrifuge. Finally, 24 µl of 
the megamix was aliquoted into five wells of an unskirted white 96-well PCR plate 
(Bio-Rad, UK). A surplus 24 µl remained available in case of error. Four temperatures 
per primer set were selected (ranging between 56 ± 62 ºC). A 1 µl aliquot of control 
DNA (Promega, UK) was added to four of the five wells containing the megamix. A 1 
µl aliquot of ddH2O was added to the fifth well as a negative control. The contents of 
each PCR reaction are shown in Table 2.3.  
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Table 2.3: Primer PCR reaction set up 
 
Reagent Volume (µl) 
iQTM Custom SYBR Green Supermix (Bio-Rad, UK) ± 2 x  
Reaction buffer with dNTPs, iTaq DNA polymerase, 6 mM 12.5 
MgCl2, SYBR Green I, fluoroscein and stabilisers  
Forward primer 2.5 (0.5 µM) 
Reverse primer  2.5 (0.5 µM) 
ddH2O 6.5 
DNA (10 ng/µl) or ddH20  1 
The total reagent volume in each well was 25 µl. The initial megamix volume was 144 µl and comprised of 75 µl of 
iQTM Custom SYBR Green Supermix, 15 µl of forward primer, 15 µl of reverse primer and 39 µl of double distilled 
water. dNTPs = deoxyribonucleotide triphosphates, MgCl2 = magnesium chloride, ddH20 = double distilled water. 
Note: the primer pairs for DNAJC25 and NSL1 worked effectively at a lower concentration of 0.1 µM. 
 
A temperature gradient program was run under the conditions shown in Table 2.4. 
 
Table 2.4: Temperature gradient PCR program 
 
No. of cycles Duration Temperature (oC) 
1 10 minutes 95 
 
40 
30 seconds 95 
1 minute 56 ± 62 
1 minute 72 
 
PCR products were electrophoresed on a 2 % (w/v) agarose gel (1 g agar, 50 ml TAE 
buffer and 0.5 µl ethidium bromide). The brightest band seen at the expected product 
size led to the identification that 57 or 58 °C was the optimal annealing temperature for 
the primers used (Chapter 4, Table 4.21). Every target gene primer set used had an 
annealing temperature that was suitable for either control gene primer pair. 
 
2.4.2 Primer efficiencies 
 
The efficiency of a primer incorporates both the amount of product which is made 
following a given number of cycles and the rate at which the PCR reaction occurs. An 
efficiency of 100 % means that doubling of the target occurs with each PCR cycle. 
Assessment of primer efficiency is important since normalisation of the target gene 
against a control gene with a known normal copy number in both tumour and blood is 
recommended for quantitative assessment (Pfaffl 2001). Two primer sets are required 
regardless of tissue type, which is a potential source of variability in quantification. 
While the commonly used ¨¨Ct equation for quantification always assumes 100 % 
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primer efficiency, the Pfaffl equation incorporates individual calculated primer 
efficiencies in order to provide a more accurate yet robust quantitative analysis. 
Utilising the Pfaffl equation, primer efficiencies were assessed in this study. Serial 
dilution stocks of control DNA containing 10 ng/µl, 5 ng/µl, 2.5 ng/µl, 1.25 ng/µl and 
0.625 ng/µl were prepared for use. For each primer efficiency assessment, a PCR 
megamix was prepared as described in section 2.5.1. This time, 24 µl of the megamix 
was aliquoted into 18 wells of an unskirted white 96-well PCR plate. For each DNA 
concentration, PCR reactions were performed in triplicate in order to reduce pipetting 
error. Therefore 1 µl from each of the five concentrations was placed into three separate 
wells on the plate, with 1 µl of double distilled water being added to the remaining three 
ZHOOV DV D QHJDWLYH FRQWURO 7KH VHOHFWHG 3&5 SURJUDP LQFRUSRUDWHG HDFK SULPHU¶V
optimal annealing temperature and a final melting curve reaction for confirmation of 
product specificity by the dissociation pattern produced (Table 2.5).  
 
Table 2.5: Primer efficiency PCR program 
 
No. of cycles Duration Temperature (°C) 
1 10 min 95 
 30 sec 95 
40 1 min Annealing temp 
 1 min 72 
Melt Curve 
Increments of 5oC 
every 5 seconds Annealing temp to 95oC 
 
Each PCR reaction generated a C(t) value which represents the number of cycles at 
which reaction fluorescence exceeds the background fluorescence threshold (Figure 
2.14).  
 
Since each reaction was performed in triplicate, a mean C(t) for the primer set was 
calculated at each DNA concentration. Using Microsoft Excel 2007 (Microsoft, USA), a 
scatter plot of log DNA concentration versus mean C(t) was produced for each primer 
set, such that a linear regression line could be generated (Table 2.6 and Figure 2.15).  
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Figure 2.14: Amplification plot generated by the CFX-96 real time system to allow calculation of primer efficiencies. 
The results generated by using the DNAJC25 gene primer set on serial dilutions of control DNA is shown as an 
example. A fluorescence threshold for SYBR green was set by the CFX-96 computer program to a baseline reading 
of 750 relative fluorescence units (RFU) (asterisk). Each curve represents the amount of SBYR green fluorescence 
produced per PCR cycle and consequently the amount of PCR product made from each DNA concentration. The C(t) 
value for each reaction was the cycle value at which the reaction fluorescence exceeded the fluorescence threshold 
value.  
 
 
Table 2.6: An example of mean C(t) calculation for a primer pair from serial  
dilutions of DNA. 
 
DNA concentration 
(ng/µl) 
Log DNA 
concentration 
DNAJC25 C(t) 
 
Mean DNAJC25 C(t)  
  24.91  
10 1 24.9 24.93 
  24.99  
  25.93  
5 0.7 25.98 25.93 
  25.87  
  26.88  
2.5 0.4 26.84 26.78 
  26.62  
  28.05  
1.25 0.1 27.97 27.97 
  27.89  
  28.7  
0.625 -0.2 29.09 28.94 
  29.05  
The DNAJC25 primer set is shown as an example.  
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Figure 2.15: Scatter plot of mean C(t) values for the DNAJC25 primer pair at serially diluted concentrations of DNA 
template. The log of DNA concentration is plotted against the mean C(t) values obtained for each reaction. This 
generates a linear regression line, the slope of which can be calculated from the equation y = mx+c. In this case the 
gradient = -3.353. The goodness of fit measure (R2) in this case was 0.997. In all primer sets used, this value was 0.96 
or higher. 
 
The gradient of the resulting line was incorporated into the following equation to allow 
calculation of primer efficiency as a percentage (Pfaffl 2001): 
 
Primer efficiency                  Ef = (10(-1/Slope)) -1 
 
 Example: 
DNAJC25                              Ef = (10 (-1/-3.353)) -1 
                                  = 0.99 
                             To obtain percentage, Ef x 100   = 99 % 
                                                                                  
Before inclusion in the Pfaffl equation, each Ef value was converted into an E number 
signifying the number of copies that would be produced by the primer set per PCR 
cycle. This was achieved by adding one to the Ef value. For instance, a primer with an 
efficiency of 100 % (Ef = 1) would have a final E value of two, generating two copies 
per PCR cycle. For the DNAJC25 example: 
 
                            DNAJC25                                   E = 1.99 
 
Primer efficiencies between 90 and 110 % were deemed satisfactory. The efficiencies of 
the primer sets used for SNP microarray validation are shown in Table 4.21 (Chapter 4, 
section 4.3.5), all achieved at an annealing temperature of 57 or 58 °C as stated above. 
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2.4.3 PCR reactions on tumour and blood samples 
 
PCR was subsequently performed for the target and matched control genes on DNA 
from paediatric ependymomas already run on the 500K SNP microarray and on patient 
matched constitutional DNA where appropriate and possible. The PCR megamixes and 
optimal reaction conditions were as described in section 2.4.2. The precise number of 
samples used varied according to the target gene being analysed (detailed in Chapter 4, 
section 4.3.5).  
 
For intra-assay accuracy, individual tumour and blood PCR was again performed in 
triplicate. For those genes demonstrating a significant correlation between SNP array 
copy number and qPCR derived copy number (as explained in sections 2.4.4 and 2.7.3), 
inter-assay reproducibility was assessed by replicating the entire PCR twice, or thrice if 
a difference of greater than one was found between the two previous qPCR copy 
number values. To avoid specimen depletion, genes not demonstrating copy number 
correlation were not subjected to repeated PCR experiments.  
 
2.4.4 Quantification of target gene copy number in tumour samples 
 
The established E values for both the target and reference gene primers were used in the 
Pfaffl equation (Pfaffl 2001), alongside the calculated mean C(t) values for both target 
and control genes in ependymoma and blood in order to identify the copy number ratio 
(R) for the particular target gene as follows: 
 
The Pfaffl equation: 
 
                                            ¨Ct (Ct target gene blood ± Ct target gene tumour)  
                     R   =    E target                  
                                              ¨Ct (Ct control gene blood ± Ct control gene tumour) 
                                E control  
 
 
In the equation, R is the relative ratio of the difference in fluorescent signal between the 
target gene in the blood and tumour samples when compared to the control gene. 
Therefore if R = 1, this suggested no quantifiable difference in fluorescence intensity 
between the target gene in tumour and blood DNA relative to the difference identified in 
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the control gene, the latter being selected as it had demonstrated a diploid copy number 
in both tissue samples on the 500K SNP microarray.  Since normal copy number is two, 
the qPCR derived copy number for each tumour sample was calculated by doubling the 
resulting R value and rounding to the nearest whole number. Thus a qPCR copy number 
of  KRPR]\JRXVORVV.5 to  KHPL]\JRXVORVV to < 2.5 = normal 
GLSORLGto < 6 = genomic JDLQDQG DPSOLILFDWLRQ  
 
2.5 Fluorescent in situ hybridisation  
 
Fluorescent in situ hybridisation (FISH) was performed on TMAs of formalin fixed 
paraffin embedded (FFPE) tumour to validate the findings of chromosome 1q gain in 
selected ependymomas from the SNP array analysis (Chapter 3, section 3.3.6). The 
technique was also used to establish a prognostic role for gain of chromosome 1q25 in 
paediatric ependymoma (Chapter 6, section 6.3.4.1). 
 
The TMAs were constructed (using the manual tissue arrayer I, Beecher, USA) by 
coring viable and representative tumour regions previously identified from FFPE 
ependymoma tissue blocks by a neuropathologist (Prof. James Lowe). Sections of 4 µm 
thickness were obtained for the microarray and cores were 0.6 mm in diameter. Where 
possible, triplicate cores per tumour sample were taken. In some cases tumour 
heterogeneity had resulted in two different sets of triplicate cores being constructed for 
DSDUWLFXODUVDPSOH7KHVHZHUHODEHOOHGWULSOLFDWHµD¶DQGWULSOLFDWHµE¶ 
 
Detection of 1q25 was performed using a commercial LSI 1p36/LSI 1q25 dual colour 
probe (Vysis, USA). The Spectrum Orange 1p36 probe hybridises to a region extending 
from the SHGC57243 locus to a point telomeric to the EGFL3 locus. The Spectrum 
Green 1q25 probe hybridises to a region extending from a point telomeric to the ABL2 
locus to a point upstream of the SHGC-1322 locus. FFPE normal tonsil tissue was 
assessed in conjunction with the TMA slides as a control to demonstrate that, in normal 
cells, diploid signals for both LSI probes should be predominantly observed. 
 
Prior to use, each TMA slide, together with a positive control slide, were baked in an 
oven (Windsor incubator, Lamb, UK) at 60 ºC overnight. The slides were then 
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deparaffinised in xylene for 15 minutes and dehydrated in 100 % (v/v) ethanol for a 
further 15 minutes. After this, the slides were placed in a coplin jar of 10 % (v/v) neutral 
buffered formalin (Sigma, UK) for one hour. While the slides remained in fixative, a 
plastic container filled with sodium citrate was heated to boiling point in a steamer 
(Tefal, UK). On removal from the formalin, the slides were washed in warm tap water 
for five minutes before being placed into the boiling sodium citrate for one hour. After 
this, the slides were transferred back into warm running tap water for five minutes 
before being immersed in a coplin jar containing pepsin solution at room temperature 
for 30 minutes. The slides were washed in cold running tap water for five minutes 
before being rinsed in distilled water for one minute at room temperature and then air 
dried. Slides were placed in Carnoy fixative for 30 minutes and again air dried. Under 
reduced lighting, the FISH probe (Vysis, UK) was applied to the tissues on each slide. 
Between 10 µl and 20 µl was applied, depending on the size of the tonsil tissue or 
TMA, to ensure probe coverage of the slide. A coverslip was placed over each slide. 
The slides were then placed in a hybridiser (Dako, UK) which was set to conditions of 
90 ºC for 12 minutes followed by 37 ºC overnight. The following day under reduced 
light, the slides were placed in a coplin jar of 2 x SSC for 30 minutes. The coverslips 
were then removed and the slides were placed in 4 M urea in 2 x SSC for two minutes. 
After this, the slides were washed for one minute in 2 x SSC, one minute in distilled 
water and finally air dried. 20 µl of DAPI (750 µg/ml) was applied to each slide 
followed by coverslip placement. 
 
Visualisation of results was performed using a Nikon Eclipse 90i microscope (Nikon, 
Japan) and a Hamamatsu ORCA-ER camera (Hamamatsu, Japan). Resulting images 
were acquired using Improvision Volocity 5.0 software (Perken Elmer, USA). Images 
were taken at x 40 objective. Three filters were used: DAPI (Ex 340 ± 380 nm), 
Spectrum Green (Ex 497 ± 509 nm), and Texas Red (Ex 540 ± 580 nm). As the camera 
was black and white, a colour was applied to each image based on the wavelength of the 
filter: DAPI at 435 nm (blue), Spectrum Green at 535 nm (green), and Texas Red at 588 
nm (orange/red). Maximum light exposure levels were set using the tonsil control 
tissue. Where possible, 3 images were taken per tumour core. The FISH scoring 
regimen used was based on previous studies using FISH on paraffin embedded tumour 
tissue microarrays (Bubendorf, Kononen et al. 1999; Neben, Korshunov et al. 2004; 
Korshunov, Witt et al. 2010). Only samples where signals were obtained for greater 
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than 80 % of available nuclei were analysed. A minimum of 100 nuclei were counted 
per tumour sample, except for one case (9904 ± 39P) where only 62 nuclei were 
assessed due to the cellularity and quantity of tissue available. The number of green and 
red probe signals visualised for each nucleus was recorded. Chromosome 1q25 gain was 
defined to include widespread or focal gain. Widespread gain was observed when at 
least 15 % of the counted nuclei per sample contained three or more copies of the 1q25 
probe, regardless of the 1p36 probe. Focal 1q25 gain was demonstrated when at least  
15 % of the nuclei counted within one tumour core contained 3 or more copies of the 
probe. During prognostic marker assessment, a second scorer (B.M.) was used to verify 
initial scores blindly in a proportion of cases. 
 
2.6 Immunohistochemistry  
 
Immunohistochemistry (IHC) was performed to establish the expression of particular 
proteins encoded by putative prognostic gene candidates resulting from the SNP array 
analysis. In addition, IHC was used to examine a panel of potential ependymoma 
prognostic markers suggested from the literature (Bennetto, Foreman et al. 1998; 
Figarella-Branger, Civatte et al. 2000; Gilbertson, Bentley et al. 2002; Zamecnik, 
Snuderl et al. 2003; Ridley, Rahman et al. 2008; Puget, Grill et al. 2009) (Chapter 6). 
 
Immunohistochemistry was carried out using the Dako Chemate Envision Antigen 
Detection kit (Dako, UK), except for Tenascin-C when the Vector ABC reagent kit was 
used (Vector, UK). The optimal conditions for each antibody used are shown in Table 
2.7. 
 
Table 2.7: The five antibodies used in the immunohistochemical analysis. 
Name Supplier Host Clonality Dilution Incubation 
conditions 
Staining 
pattern 
Positive 
control 
Nucleolin Abcam® 
(ab13541) 
Mouse Monoclonal 1:400 Overnight at  
4 oC 
Nuclear Tonsil 
Tenascin-C 
(E-9) 
Santa-Cruz 
Biotec® 
(sc-25328) 
Mouse Monoclonal 1:50 1 hour at room 
temperature 
Extracellular 
matrix / 
Cytoplasmic 
Epidermoid 
carcinoma 
Ki-67 DAKO® 
(M7240) 
Mouse Monoclonal 1:50 1 hour at room 
temperature 
Nuclear Tonsil 
PRUNE Sigma-
Aldrich® 
(HPA028411) 
Rabbit Monoclonal 1:800 1 hour at room 
temperature 
Cytoplasmic/ 
Membranous 
Breast 
carcinoma 
stromal tissue 
NAV1 Sigma-
Aldrich® 
(HPA018127) 
Rabbit Monoclonal 1:350 1 hour at room 
temperature 
Cytoplasmic/ 
Membranous 
Small 
intestine 
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Each TMA slide was deparaffinised in xylene for 15 minutes, then hydrated by 
immersion in 100 % (v/v) ethanol for five minutes, 95 % (v/v) ethanol for four minutes 
and finally running warm tap water for 10 minutes. Antigen retrieval for Nucleolin and 
Ki-67 IHC was performed using a pressure cooker. Approximately 1.5 litres of sodium 
citrate (pH 6.0) was placed in a pressure cooker (Kern, China) and heated until boiling 
on a digital hot-plate (Cimarec, Cole-Parmer, UK). At this point the slides were added 
and the cooker lid was sealed until full pressure was attained. The slides were treated at 
full pressure for 1 minute then allowed to cool in the sodium citrate for 20 minutes. 
Antigen retrieval for Tenascin-C, PRUNE and NAV1 IHC was performed using pre-
boiled sodium citrate (pH 6.0) in a steamer (Tefal, UK). These slides were treated for 30 
minutes and then cooled in the sodium citrate for a further 45 minutes.  
 
Following antigen retrieval techniques, a protein blocking agent was applied to each 
slide for 15 minutes. Normal goat serum was used for all cases except Tenascin-C IHC 
where normal horse serum diluted to 1:100 (v/v) in PBS solution was used (Vector, 
UK). After a five minute wash with PBS, endogenous peroxidase blocking solution 
(Dako, UK) was then applied to the slides for five minutes, followed by another five 
minute PBS wash. Since the Tenascin-C IHC made use of an avidin-biotin complex 
(ABC) reaction to detect the primary antibody, a further avidin/biotin block was applied 
at this stage (Vector, UK). Slides were immersed in avidin solution for 15 minutes, 
dipped in PBS solution then incubated in biotin solution for a further 15 minutes.  
 
Once blocking was completed, 100 µl of primary antibody (or enough to cover the 
TMA) was applied to each slide, followed by incubation (see Table 2.7). Negative 
controls for each antibody tested had antibody diluent (Dako, UK) applied instead of 
primary antibody. After incubation, the slides were immersed in PBS for five minutes 
then secondary antibody was applied to each slide for 30 minutes, followed by a further 
wash in PBS for five minutes. The secondary antibody used was HRP anti-rabbit/mouse 
(Dako, UK) in all cases except for Tenascin-C where 100 µl of biotinylated universal 
antibody anti-rabbit/mouse (Vector, UK), diluted in 5 ml of normal horse serum, was 
used. At this stage during the Tenascin-C IHC experiments, Vectastain avidin-biotin 
complex reagent (Vectastain-Elite ABC kit, Vector, UK) was subsequently applied for 
30 minutes, followed by a five minute PBS wash.  
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Following secondary antibody application, 100 µl of DAB (20 µl 3-¶-
diaminobenzidine and chromogen in 1 ml substrate buffer, (Dako, UK)) was applied for 
five minutes to each slide, followed by immersion in PBS for five minutes. The slides 
were then stained in Harris haematoxylin for 10 seconds, washed in water for 10 
seconds, then placed in lithium carbonate for 10 seconds. After this, the slides were 
washed again in water for 10 seconds and subsequently dehydrated in 95 % (v/v) 
ethanol, then 100 % (v/v) ethanol and finally xylene, each for 10 seconds. Mounting of 
the slides was performed using coverslips and DPX mountant. The slides were then 
visualised using an Olympus BX41 light microscope (Olympus, UK) at x 10 and x 40 
objectives. 
 
 Ki-67 and Nucleolin labelling indices (LIs) were defined as the percentage of tumour 
cells with immunopositive nuclei divided by the total number assessed. A minimum of 
100 nuclei were counted per core. For samples with two sets of triplicate cores, the 
higher mean LI value for each triplicate was used as the designated LI for that case. For 
Nucleolin analysis, a 50 % LI threshold was used to designate low and high expression 
cohorts, while Ki-67 expression was defined as low (< 1 %), moderate (2 ± 4 %) or high 
(> 5 %). This scoring method and the LI thresholds used replicated that of a previous 
retrospective immunohistochemical analysis of Nucleolin and Ki-67 in paediatric 
ependymoma (Ridley, Rahman et al. 2008). Tenascin-C staining was extracellular and 
defined as negative, weak or moderate to strong, based on the area of highest staining, 
albeit focal or widespread. The expression of NAV1, and PRUNE were cytoplasmic or 
membranous and graded as negative, weak, moderate or strong respectively. For each 
putative prognostic marker assessed, repeat analysis was performed blindly by a second 
scorer on a proportion of the total cases (L.R. for Nucleolin and Ki-67, J.B for NAV1 
and PRUNE, F.A. for Tenascin-C). 
 
2.7 Statistics 
 
Statistical analysis was predominantly performed using SPSSv16 (Statistical Package 
for the Social Sciences, Version 16, Chicago, USA), with the exception of differential 
methylation analysis between clinical subgroups, which was performed through the R 
statistical software environment.  
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2.7.1 Associations of variables in two-way frequency tables 
 
)LVKHU¶VH[DFWWHVWZDVXVHGWRGHWHUPLQHDVVRFLDWLRQVEHWZHHQFRPELQDWLRQVRIFOLQLFDO
and biological variables for a particular patient cohort, in two-way frequency tables. 
Clinical variables included intracranial ependymoma location within the central nervous 
system (infratentorial or supratentorial); patient age at diagnosis (above or below three 
years of age); patient sex (male or female), tumour grade according to centralised 
pathological WHO classification (Grade II or III); tumour resection status (complete or 
incomplete) and the primary or recurrent status of each tumour (using first recurrent 
cohorts unless stated). Biological variables included chromosomal arm imbalances, 
copy number imbalances at a cytoband and gene level, gain of chromosome 1q25 as 
detected by FISH and immunohistochemical staining patterns. In each case, a two-tailed 
significance p-value was generated.  Significance was defined as a p-value below 0.05, 
while a p-value of 0.05 ± 0.1 indicated a trend towards significance.  
 
2.7.2 Associations with patient age 
 
As patient age is a continuous variable, a comparison of mean age values between 
certain clinical and biological categories described above was assessed using either an 
independent sample t-test with 95 % confidence intervals or a one-way analysis of 
variance (ANOVA) if more than two subgroups were assessed simultaneously, for 
instance when comparing spinal, supratentorial and posterior fossa ependymomas. 
ANOVA post-hoc comparisons were performed using the Tukey HSD test and the 
effect size of the ANOVA result was calculated as an eta squared value. A value greater 
than 0.14 represented a large effect (Pallant 2007). Significance was defined as a p-
value below 0.05. 
 
The Mann-Whitney test was performed to compare the number of broad genomic 
imbalances between children with posterior fossa ependymomas who were aged either 
above or below three years. Again, significance was defined as a p-value below 0.05. 
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2.7.3 Correlation of SNP array and qPCR results  
 
6SHDUPDQ¶s rank correlation coefficient (SRCC) was used to determine whether the 
CNAG derived SNP array copy number results for 15 selected genes in a set of tumour 
samples were confirmed by qPCR, as described in section 2.4. A SRCC value (R) of 
zero indicated no correlation whilst a value of one signified an exact correlation. A 
value of R greater than 0.65 accompanied by a p-value less than 0.05, defined a positive 
correlation. 
 
2.7.4 Correlation of methylation array technical replicates 
 
The Kendall-tau coefficient was used to assess the correlation of corrected Beta 
methylation scores between 2 sets technical replicate samples of DNA analysed on the 
methylation array, thereby assessing intra-assay variability. The DNA replicates were 
from high grade JOLRPD VDPSOHV RFFXS\LQJ VXUSOXV ZHOO VSDFH LQ RQH RI WKH 6$0¶V
used for the ependymoma analysis. A SRCC value (R) of zero indicated no correlation 
whilst a value of one signified an exact correlation. Significance was defined as a p-
value below 0.05. 
 
2.7.5 Kappa measure of agreement 
 
When examining the putative prognostic markers by FISH or immunohistochemistry, 
the degree of agreement between two independent scorers was assessed using the Kappa 
measure of agreement. A Kappa value above 0.5 was defined as a moderate agreement, 
while a value above 0.8 was defined as a very good agreement (Pallant 2007). 
Significance was defined as a p-value below 0.05. 
 
2.7.6 Survival analysis  
 
To assess the univariate prognostic impact of the clinical and biological variables described 
above in a particular patient cohort, Kaplan-Meier survival curves were created with 
significance values established by the log rank test. Event-free survival (EFS) time was 
calculated from the date of original diagnosis to the time taken for the first event 
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(recurrence or death) to occur, or the date of last follow-up (censorship) if event free. 
Overall survival was calculated from the date of diagnosis to the date of death, or to the 
time of censorship if the patient remained alive. Significance was defined by a p-value 
below 0.05, while a p-value of 0.05 ± 0.1 indicated a trend towards significance. 
Multivariate prognostic analysis was performed using the Cox proportional hazard 
regression model to determine patient survival comparisons and factor hazard ratios with 
95% confidence intervals. P-values less than 0.05 defined indicated a significant result. 
 
2.7.7 Differential methylation analysis between clinical subgroups  
 
Corrected Beta values were calculated following quality control measures and array 
background normalisation, as discussed in sections 2.3.3 ± 2.3.4. Differentially 
methylated loci between selected clinical subgroups or certain sample subgroups 
established from unsupervised methylation cluster analysis (Chapter 3, section 3.3.7) 
were identified via the R statistical software environment. The clinical subgroups 
analysed and the results obtained are shown in Chapter 4, section 4.3.4. 
 
Differential analysis was performed using Mann-Whitney U tests with a p-value < 0.05, 
after Benjamini-Hochberg False Discovery Rate correction for multiple testing 
(Benjamini, Drai et al. 2001), with an additional filter introduced so that the average 
change in Beta values between analysed subgroups was greater than 0.34. A computer 
script was devised for this aspect of the data analysis by Dr. Edward Schwalbe and Dr. 
Steve Clifford at the Northern Institute for Cancer Research, Newcastle (Appendix 
10C).  
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CHAPTER 3 
 
GENOME-WIDE CHARACTERISATION OF GENOMIC AND 
EPIGENETIC ABERRATIONS IN PAEDIATRIC EPENDYMOMA 
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3.1 Introduction 
 
Notwithstanding the evolution of improved neuro-surgical techniques and adjuvant 
therapeutics, the prognosis for children diagnosed with ependymoma remains inferior in 
relation to other paediatric brain tumours (Zacharoulis, Levy et al. 2007; Messahel, 
Ashley et al. 2009; Wright and Gajjar 2009). In order to achieve significant progress in 
the prediction of both paediatric ependymoma behaviour and subsequent patient 
outcome, a better understanding of underlying tumour biology through high resolution 
molecular characterisation is required, in conjunction with improved patient recruitment 
into large prospective clinical trials. 
 
Although evidence exists for genomic distinctions between certain clinical subgroups of 
ependymoma (Chapter 1, sections 1.5.2 ± 1.5.3), the data is derived from studies which 
were either performed on relatively small cohorts, included paediatric and adult patients 
or were of a lower genomic resolution compared to SNP array analysis. High resolution 
analysis has been performed on this tumour group (Johnson, Wright et al. 2010), yet no 
SNP microarray study has been performed exclusively on paediatric ependymomas, 
examining both neoplastic and constitutional DNA from the same patient to identify 
tumour-specific genomic aberrations and loss of heterozygosity. In addition, no SNP 
array analysis has ever correlated detected anomalies with patient outcome. This study 
aimed to address these compounding issues by examining a relatively large series of 
paediatric ependymomas and relating the genomic imbalances detected with 
accompanying clinical, pathological and patient survival data.  
 
Similarly, to date there has been no reports of epigenetic microarray work being 
exclusively performed on paediatric ependymomas, hence this genome-wide 
methylation analysis of over 1,500 selected CpG dinucleotides on a sizeable tumour 
cohort was also the first and largest study of its kind.  
 
The dual array based analysis was undertaken to initially establish the broad genomic 
and methylation characteristics of paediatric ependymomas, prior to a higher resolution 
assessment detailed in Chapter 4, in order to explore the following hypotheses: 
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 Ependymomas occurring in different anatomical locations within the CNS are 
biologically distinct. 
 Biological differences exist between ependymomas from younger children 
(under three years of age) and older children (over three years of age). 
 Molecular events in paediatric ependymoma pathogenesis are predictive of 
clinical and/or prognostic behaviour. 
 
3.2 Materials and methods 
 
3.2.1 500K SNP array analysis of 63 paediatric ependymomas 
 
3.2.1.1 The sample cohort 
 
Following tumour and blood DNA extraction as described in Chapter 2, sections 2.1.3 ± 
2.1.4, 500K SNP array assays were performed on 63 paediatric ependymomas from 45 
patients (42 primary and 21 recurrent tumours) in two collaborative institutions with 
appropriate facilities. %RWK FHQWUHV DGRSWHG WKH VDPH PDQXIDFWXUHU¶V SURWRFRO DQ
overview of which is given in Chapter 2, section 2.2.1. The DNA of 39 tumours from 
26 patients, together with matching blood DNA samples were processed at the Hartwell 
Centre, St. -XGH¶VResearch Hospital, Memphis, USA under the auspices of Dr. Richard 
Gilbertson. Allied to this, the DNA of 24 ependymomas from 19 children, in addition to 
their blood DNA samples were processed at the Almac Biotechnology Centre, Belfast, 
Northern Ireland, UK under the guidance of project manager Dr. Andrea McCulla.  
 
SNP array signal intensity data from both centres was processed as outlined in Chapter 
2, sections 2.2.2 - 2.2.5. Data on the 39 tumours (but not the blood specimens) 
processed by the Gilbertson group has subsequently been incorporated into a SNP array 
study of 204 adult and paediatric ependymomas discussed elsewhere in this work 
(Johnson, Wright et al. 2010).  Initially it was hoped to analyse the .chp files from all 63 
paediatric ependymomas against those generated from patient matched blood DNA (45 
cases). However, five blood samples were excluded from further analysis as they 
demonstrated a pattern of copy number aberration deemed artefactual when analysed 
against all other blood samples in the cohort, causing the percentage of SNPs with a 
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diploid copy number for these samples to fall below a pre-determined satisfactory 
threshold of 99 % (Appendix 2). As a consequence, 10 ependymomas matching to these 
five blood samples (four primary and six recurrent tumours) were individually re-
analysed against a pool of the remaining 40 constitutional DNA specimens. This 
conforPHG ZLWK PDQXIDFWXUHU¶V UHFRPPHQGDWLRQV WKDW IRU FRS\ QXPEHU DQDO\VLV RI
unmatched patient samples, a minimum of 30 reference samples should be used 
(Affymetrix 2007). SNP probes within the X chromosome were thereby not analysed 
since both genders contributed DNA to the constitutional reference pool required for 
this small proportion of the cohort. 
 
Clinical data for the 45 patients that constitute the 500K SNP array cohort is 
summarised in Figure 3.1. The comprehensive data set is detailed in Table 3.1. The term 
µSDHGLDWULF¶GHIined a patient aged below 21 years. Of the 63 ependymomas analysed, 
57 were from 42 patients who had contributed either a primary tumour alone, or primary 
and subsequent recurrent tumours. Indeed, the cohort incorporated eight sets of primary 
and recurrent ependymomas from the same patient. 
 
 
Figure 3.1: Clinical data summary for the 45 patients that constitute the 500K SNP array cohort. Of the 63 tumours 
analysed, 57 were from 42 patients who had contributed either a primary tumour alone, or primary and subsequent 
recurrent tumours. The remaining six ependymomas from three patients contributing only recurrent tumours. 
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Table 3.1: Clinical parameters of the 500K SNP microarray cohort. 
Sample Age at Diagnosis Sex Tumour WHO Primary Tumour Adjuvant  Status EFS (yrs) OS (yrs) 
ID (yrs)    Location Grade Resection Status therapy   (> if censored) (> if censored) 
1P 1.0 M PF II Complete C D 1.4 2.1 
2P 1.3 F PF III Incomplete C D 1.5 1.6 
3P 1.5 M / III Complete C ADF 1.8 1.8 
4P 1.8 M ST II Complete C ADF 0.8 0.8 
5P 1.8 F PF II Complete C ADF 8.3 8.3 
6P 1.8 M PF II Incomplete C A (palliative) 1.3 1.3 
7P 2.0 F PF III Complete C & RT D 8.8 9.6 
8P 2.4 M PF III Incomplete C ADF 7.3 7.3 
9P 2.5 M PF III Complete C, RT at relapse D 2.2 6.9 
9R2 as above  as above  / / / RT as above  as above  as above 
9R3 as above  as above  PF III / RT as above  as above  as above 
9R4 as above  as above  / / / RT as above  as above  as above 
9R5 as above  as above  PF III / RT as above  as above  as above 
10P 2.5 / / II Incomplete C D 1.2 1.3 
11P 2.6 M PF II Complete C ADF 1.7 1.7 
12P 2.6 M PF III / C ADF 2.8 2.8 
13P 2.8 M PF II Complete C & RT ADF 12.8 12.8 
14P 2.9 M PF II Incomplete C, RT at relapse A (r) 0.3 10.1 
15P 3.5 F PF II Complete C ADF 1.7 1.7 
16P 3.8 F PF II Complete RT A (r) 2.9 8.2 
16R1 as above  as above  PF II Complete RT as above  as above  as above 
17P 3.8 F ST II Incomplete C & RT A (r) 2.3 21.0 
17R1 as above  as above  ST II Incomplete C & RT as above  as above  as above 
17R2 as above  as above  ST II Incomplete C & RT as above  as above  as above 
18P 4.2 M ST III Incomplete C D 2.8 3.5 
18R1 as above  as above  ST III Incomplete C as above  as above  as above 
19R1 4.5 M PF / Incomplete RT  D 1.4 5.8 
19R2 as above  as above  PF / Incomplete RT  as above  as above  as above 
20P 5.6 M ST II Incomplete RT D 0.8 1.0 
20R1 as above  as above  ST II Incomplete RT as above  as above  as above 
21P 6.5 / PF II Incomplete Surgery alone D 0.6 1.4 
22P 6.7 F ST II Complete C & RT ADF 5.8 5.8 
23P 7.1 F ST III Complete RT D 1.5 5.6 
24P 7.1 M SP II Incomplete RT ADF 3.1 3.1 
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6DPSOHV DUH OLVWHG LQ DJH RUGHU ZLWK WKH WHUP µSDHGLDWULF¶ GHILQLQJ D patient aged below 21 years. P = primary, R1 ± R5 = 1st ± 5th recurrence, M = male, F = female, PF = posterior 
fossa/infratentorial, ST = supratentorial, SP = spinal, C = chemotherapy, RT = radiotherapy, A (r) = alive but relapsed, ADF = alive and disease free, D = dead of disease, EFS = event-free 
survival, OS = overall survival.  
Sample Age at Diagnosis Sex Tumour WHO Primary Tumour Adjuvant  Status EFS (yrs) OS (yrs) 
ID (yrs)    Location Grade Resection Status therapy   (> if censored) (> if censored) 
25P 8.0 F PF II Complete RT ADF 2.5 2.5 
26P 8.8 M PF II Incomplete C & RT D 4.0 5.7 
26R1 as above  as above  PF II / C & RT as above  as above  as above 
26R2 as above  as above  PF II / C & RT as above  as above  as above 
26R3 as above  as above  PF II / C & RT as above  as above  as above 
27P 8.9 F SP I Complete Observation only ADF 1.1 1.1 
28P 9.8 M PF III Complete RT ADF 3.5 3.5 
29P 10.0 F PF II Incomplete C & RT ADF 0.5 0.5 
30P 10.0 M PF II Complete C & RT D 2.7 5.7 
31P 10.3 M SP I Incomplete RT at relapse A (r) 0.8 2.3 
32P 11.4 F ST III Complete RT ADF 2.2 2.2 
33R1 12.0 F ST III / RT  A (r) 0.5 8.5 
34P 12.0 F ST III Incomplete C, RT at relapse D 0.3 3.0 
35P 12.2 F PF III Incomplete C & RT A (r) 2.2 5.8 
35R1 as above  as above  PF III / C & RT as above  as above  as above 
35R2 as above  as above  PF III / C & RT as above  as above  as above 
36P 12.7 M ST III Incomplete C & RT A (r) 0.3 9 
37P 13.8 F ST II Incomplete RT ADF 0.7 0.7 
38P 14.6 M SP II Incomplete Surgery alone A (r) /  /  
39P 14.7 M PF III Complete RT ADF 6.6 6.6 
40P 14.7 M PF III Complete 
 RT, CRT at relapse A (r) 1.0 3.3 
40R1 as above  as above  SP III / C & RT as above  as above  as above 
41P 14.8 F ST II Complete Surgery alone ADF 7.8 7.8 
42P 15.3 M SP I Incomplete RT ADF 0.7 0.7 
43R1 15.5 M ST II / C & RT D 7.9 9.3 
43R2 as above  as above  ST II / C & RT as above  as above  as above 
43R3 as above  as above  ST II / C & RT as above  as above  as above 
44P 16.3 M PF III Complete C & RT A (r) 3.1 3.2 
45P 20.9 F SP II Incomplete RT ADF 1.1 1.1 
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3.2.1.2 Global genomic imbalance data analysis 
 
While chromosome arm aberrations could be visualised through Spotfire Decision Site® 
generated heatmaps (Chapter 2, section 2.2.5), the precise designation of chromosome 
arm imbalance was performed using Microsoft Excel 2007. For a chromosome arm to 
be defined as gained or lost, 80 % or more of the SNP probes located on that arm had to 
have a copy number above or below two respectively. Specifically, a copy number of 
three to six represented gain, with a copy number above five signifying amplification. In 
contrast, a copy number of one represented hemizygous loss, whereas a value of zero 
constituted homozygous deletion. While removal of the X chromosome from analysis 
has been discussed, chromosome 21p was also excluded due to the paucity of SNP 
probes on this arm. 
 
The same probe aberration threshold was adopted to identify smaller regional 
imbalances within 783 cytobands (Shaffer 2009) across the 22 autosomes. Gain of a 
region was thereby defined by a copy number of three or above, while loss was 
signified by a copy number of one or below, in at least 80 % of interrogated SNP 
probes. A complete list of cytoband copy number data for all 63 ependymomas in the 
SNP array cohort is included in Appendix 10D. Unsupervised hierarchical clustering of 
this genomic cytoband data was performed in Spotfire Decision Site® where both 
UPGMA (unweighted average) and euclidean distance settings were applied. The 
observed cluster patterns were then validated by principal component analysis (PCA). 
9LD WKH µrgl¶ µpvclust¶ DQG µcluster¶ packages in the R software environment, a 3-
dimensional PCA cluster plot was generated. A computer script was devised for this 
aspect of the data analysis by Dr. Edward Schwalbe and Dr. Steve Clifford at the 
Northern Institute for Cancer Research, Newcastle (Appendix 10E). 
 
Tumours with a balanced genome were defined as those without chromosome arm or 
cytoband imbalance, where at least 95 % of all SNP probes across the tumour genome 
had a diploid copy number. 
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3.2.1.3 SNP array call rates 
 
As described in Chapter 2, section 2.2.3, the SNP call rate for an array was generated by 
GTYPE as a percentage marker of probe, and thereby array, reliability. While values of 
93 % or above were deemed successful, lower values were included because of the 
genomic aberrations present in tumour DNA. Values below 85 % were deemed 
unacceptable for the purposes of subsequent analysis. The SNP call rate results for the 
63 paediatric ependymoma samples and the 40 constitutional bloods analysed were of a 
satisfactory quality (Appendices 3 and 4). The Affymetrix® NspI 250K array results for 
the tumour DNA samples had a mean SNP call rate of 96.38 + 0.31 %, a median of 
97.01 % and a range of 87.76 ± 99.2 %, while the Affymetrix® StyI 250K array results 
had a mean SNP call rate of 95.26 + 0.3%, a median of 95.87 % and a range of 87.27 % 
± 97.97 %. Likewise, the Affymetrix® NspI 250K array results for the blood DNA 
samples had a mean SNP call rate of 96.4 + 0.43 %, a median of 97.2 % and a range of 
88.27 ± 99.5 %, while the Affymetrix® StyI 250K array results had a mean SNP call rate 
of 96.5 + 0.34 %, a median of 97.3 % and a range of 88.28 ± 99.11 %. 
 
3.2.1.4 FISH validation of SNP array results 
 
The protocol adhered to and the method of scoring used is described in Chapter 2, 
section 2.5. 
 
3.2.2 Methylation array analysis of 98 paediatric ependymomas 
 
3.2.2.1 The sample cohort 
 
DNA from 110 paediatric ependymomas (84 primary and 26 recurrent tumours) was 
processed using the Illumina® GoldenGate® Cancer Panel I array for methylation at the 
Wellcome Trust Centre for Genetics, Oxford, UK under the guidance of project 
manager Dr. Joseph Trakolo. An overview of the protocol adopted and data processing 
methods are described in Chapter 2, sections 2.3.1 ± 2.3.4. Two SAMs were used to 
analyse the 110 ependymoma samples. Surplus well spaces on the second SAM were 
occupied by paediatric high grade glioma DNA samples, which were being assessed in 
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an independent methylation analysis. Technical replicates from the high grade glioma 
cohort were used to assess intra-assay variability. After performing the quality control 
measures described in Chapter 2, section 2.3.3, 12 unsatisfactory ependymoma samples 
were excluded from further analysis, resulting in the analysis of 98 tumours from 82 
patients (73 primary and 25 recurrent ependymomas). SNP array analysis was 
performed on 51 of these ependymomas (33 primary and 18 recurrent). 
 
Clinical data for the 82 patients comprising the methylation array cohort is summarised 
in Figure 3.2. The comprehensive data set is detailed in Table 3.2. 7KHWHUPµSDHGLDWULF¶
again defined a patient aged below 21 years.  
 
 
Figure 3.2: Clinical data summary for the 82 patients that constitute the methylation array cohort. Of the 98 
ependymomas analysed, 86 were from 73 patients who had contributed either a primary tumour alone, or primary and 
subsequent recurrent tumours. The cohort also contained 12 ependymomas from nine patients contributing only 
recurrent tumours. 
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Table 3.2: Clinical parameters of the methylation array cohort. 
Sample Age at Diagnosis Sex Tumour WHO Primary Tumour Adjuvant  Status EFS (yrs) OS (yrs) 
ID     Location Grade Resection Status therapy   (> if censored) (> if censored) 
M 1P 0.6 F ST III Incomplete C D 0.3 0.6 
M 2P 1.0 M PF II Complete C A(r) 1.4 2.1 
M 3P 1.3 F PF III Incomplete C D 1.5 1.6 
M 4P 1.3 M PF II Incomplete C & RT D 0.6 2.9 
M 5R1 1.3 M PF II Incomplete C & RT D 5.7 6.0 
M 6P 1.5 M / III Complete C ADF 1.8 1.8 
M 7P 1.6 M ST III Complete C ADF 5.3 5.3 
M 8P 1.7 F PF II Incomplete C, RT at relapse A(r) 1.2 8.1 
M 9P 1.8 M ST II Complete C ADF 0.8 0.8 
M 10P 1.8 F PF II Complete C ADF 8.3 8.3 
M 11R1 1.8 M PF III / C, RT at relapse A(r) 1.4 2.2 
M 12P 1.9 M PF III Incomplete C ADF 0.0 0.0 
M 13P 2.0 F / III Complete C, RT at relapse A(r) 2.3 2.6 
M 14P 2.0 F PF III Complete C ADF 15.2 15.2 
M 15P 2.0 F PF III Complete C & RT D 8.8 9.6 
M 16P 2.0 M PF II / / / / / 
M 17R1 2.2 F PF II Complete C, RT at relapse A(r) 5.8 10.6 
M 18P 2.3 M PF II Complete C, RT at relapse D 5.6 6.4 
M 18R1 as above as above / / Complete RT D as above as above 
M 19P 2.3 M / III Incomplete C A(r) 1.3 1.3 
M 20P 2.3 M PF II / / / / / 
M 21P 2.4 M PF III Incomplete C ADF 7.3 7.3 
M 22P 2.5 M PF III Complete C, RT at relapse D 2.2 6.9 
M 22R2 as above as above / / / RT D as above as above 
M 22R3 as above as above PF III / RT D as above as above 
M 22R5 as above as above PF III / RT D as above as above 
M 23P 2.5 / PF III / / / / / 
M 24P 2.6 M PF II / C ADF 1.7 1.7 
M 25P 2.6 M PF II Incomplete C D 1.8 1.9 
M 26P 2.6 M PF III / C ADF 2.8 2.8 
M 27P 2.8 M PF II Complete C ADF 1.4 1.4 
M 28P 3.5 F PF II Complete C ADF 1.7 1.7 
M29P 3.6 M PF II Incomplete / / / / 
M30P 3.7 M PF II Complete RT ADF 5.5 5.5 
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Sample Age at Diagnosis Sex Tumour WHO Primary Tumour Adjuvant  Status EFS (yrs) OS (yrs) 
ID (yrs)    Location Grade Resection Status therapy   (> if censored) (> if censored) 
M 31P 3.8 F PF II Complete RT A(r) 2.9 8.2 
M 31R1 as above as above / / / / as above as above as above 
M 32P 3.8 F ST II Incomplete C & RT A(r) 2.3 21.0 
M 32R1 as above as above ST II Incomplete / as above as above as above 
M 32R2 as above as above ST II Incomplete / as above as above as above 
M 33P 4.0 F PF II Complete C ADF 2.3 2.3 
M 34P 4.2 M ST III Incomplete C D 2.8 3.5 
M 34R1 as above as above ST III Incomplete C D as above as above 
M 35P 4.3 F PF II Complete RT / / / 
M 36R1 4.5 M PF / Incomplete RT D 1.4 5.8 
M 36R2 as above as above PF / Incomplete RT as above as above as above 
M 37P 4.8 F PF II Incomplete RT D 2.3 3.2 
M 38P 5.0 F PF II Complete RT ADF 1.1 1.1 
M 39P 5.4 M PF III / RT A(r) 2.3 4.3 
M 40R1 5.6 M ST II Incomplete RT D 0.8 1.0 
M 41P 6.0 M / II / / / / / 
M 42R1 6.0 F PF III / / / / / 
M 43P 6.1 M PF III Complete RT D 0.9 1.8 
M 44P 6.3 F ST III Complete C & RT D 1.9 5.1 
M 45R1 6.5 / PF III Incomplete RT A(r) 1.1 2.8 
M 46P 6.5 / PF II Complete RT ADF 2.4 2.4 
M 47P 6.5 / PF II / / D 0.6 1.4 
M 48P 6.7 F ST II Complete C & RT ADF 7.1 7.1 
M 49P 7.1 F ST III Complete / D 1.5 5.6 
M 50P 7.1 M SP II Incomplete RT ADF 3.1 3.1 
M 51P 7.1 F ST III Complete RT A(r) 1.5 3.8 
M 52P 7.3 F SP III Incomplete Surgery alone ADF 2.3 2.3 
M 53P 8.2 M SP II Incomplete C & RT ADF 0.9 0.9 
M 54P 8.8 M PF II / C & RT D 4.0 5.7 
M 54R2 as above as above PF III / C & RT as above as above as above 
M 54R3 as above as above PF III / C & RT as above as above as above 
M 55P 9.3 F PF II / RT, C at relapse D 0.8 1.5 
M 56P 9.8 F ST III Complete C & RT ADF 8.0 8.0 
M 57P 9.8  M  PF III Complete RT ADF 4.8 4.8 
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6DPSOHV DUH OLVWHG LQ DJH RUGHU ZLWK WKH WHUP µSDHGLDWULF¶ GHILQLQJ D SDWLHQW DJHG EHORZ  \HDUV 3   SULPDU\ 5 ± R5 = 1st ± 5th recurrence, M = male, F = female, PF = posterior 
fossa/infratentorial, ST = supratentorial, SP = spinal, C = chemotherapy, RT = radiotherapy, A (r) = alive but relapsed, ADF = alive and disease free, D = dead of disease, EFS = event-free 
survival, OS = overall survival.  
Sample Age at Diagnosis Sex Tumour WHO Primary Tumour Adjuvant  Status EFS (yrs) OS (yrs) 
ID (yrs)    Location Grade Resection Status therapy   (> if censored) (> if censored) 
M 58P 10.0 M PF II Complete C & RT D 2.5 5.6 
M 59P 10.0 F PF II Incomplete C & RT ADF 0.5 0.5 
M 60P 10.0 M SP I / / / / / 
M 61P 10.3 M SP I Incomplete RT at relapse A(r) 0.8 2.3 
M 62P 10.9 F ST III Incomplete C & RT ADF 1.8 1.8 
M 63P 11.0 M SP II Complete Surgery alone ADF 0.9 0.9 
M 64P 11.4 F ST III Complete RT ADF 2.2 2.2 
M 65P 11.6 F SP II Incomplete Surgery alone ADF 1.6 1.6 
M 66P 12.0 F ST III Incomplete C & RT D 0.3 3.0 
M 67P 12.2 F PF III Incomplete C & RT A(r) 2.2 5.8 
M 67R1 as above as above PF III / C & RT as above as above as above 
M 67R2 as above as above PF III / C & RT as above as above as above 
M 68R1 12.5 M SP II / RT, C&RT at relapse A(r) 3.3 5.0 
M 69P 12.7 M ST III Incomplete C & RT A(r) 0.3 9.0 
M 70P 13.2 M SP II Complete Surgery alone ADF 2.3 2.3 
M 71P 13.8 F ST II Incomplete RT ADF 0.7 0.7 
M 72P 14.6 M SP II Incomplete Surgery alone A(r) 3.1 3.3 
M 73P 14.7 M PF III Complete C, C&RT at relapse A(r) 1.0 3.3 
M 73R1 as above as above SP III / C & RT as above as above as above 
M 74P 14.8 F ST II Complete Surgery alone ADF 7.8 7.8 
M 75P 15.3 M SP I Incomplete RT ADF 0.7 0.7 
M 76R1 15.5 M ST II / C & RT D 7.9 9.3 
M 76R2 as above as above ST II / C & RT as above as above as above 
M 76R3 as above as above ST II / C & RT as above as above as above 
M 77P 15.7 M SP I / Surgery alone ADF 2.0 2.0 
M 78P 15.9 F PF II Incomplete RT ADF 3.1 3.1 
M 79P 16.0 M SP I Complete Surgery alone / / / 
M 80P 16.3 M PF III Complete C & RT A(r) 3.1 3.2 
M 81P 16.3 F ST II Complete RT A(r) 1.1 1.1 
M 82P / / / / / / / / / 
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3.2.2.2 Methylation array data analysis 
 
Once corrected Beta methylation scores for the 1,505 probes had been calculated, as 
discussed in Chapter 2, section 2.3.4, 84 probes on the X chromosome were removed 
from the analysis as their inclusion in this mixed gender cohort resulted in clustering of 
samples according to patient sex. The corrected Beta scores across 1,421 GoldenGate® 
Cancer Panel I CpG probes, mapping to 768 genes, for all 98 tumours comprising the 
ependymoma methylation cohort is shown in Appendix 10F. Bootstrapped unsupervised 
hierarchical clustering was performed using the R SDFNDJH µpvclust¶ (Suzuki and 
Shimodaira 2006) using Euclidean distance, average agglomeration and 10,000 
replications. Subgroups with an approximate unbiased probability (p) value of greater 
than 95 % were deemed significant. The observed clustering patterns were assessed 
using principle componenWDQDO\VLVYLDWKH5SURJUDPPHVµrgl¶µpvclust¶DQGµcluster¶.  
A computer script was devised for this aspect of the data analysis by Dr. Edward 
Schwalbe and Dr. Steve Clifford at the Northern Institute for Cancer Research, 
Newcastle (Appendix 10G). 
 
3.2.2.3 Assessment of methylation intra-assay reproducibility 
 
Four superfluous wells were used to assess intra-assay variability, using DNA from two 
high grade glioma samples as technical replicates (Figure 3.3). The correlation of the 
replicates for both samples was high (correlation coefficients 0.868 and 0.812, p < 0.01, 
Kendall tau correlation), indicating low intra-assay variability. 
 
 
Figure 3.3: Kendall tau correlation of corrected Beta scores from the GoldenGate® Cancer Panel I methylation array 
for two sets of high grade glioma technical replicates. (A) Replicate sample A was divided and labelled 
HGG_01_10325 for the first assay and 18_72 for the second assay. (B) Replicate sample B was divided and labelled 
HGG_99_14974 for the first assay and 18_71 for the second assay. Replicate sample A had a correlation coefficient 
of 0.868, p < 0.01, while replicate sample B had a correlation coefficient of 0.812, p < 0.01.  
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3.2.3 Statistical analysis  
 
The statistical tests performed in this chapter are described in Chapter 2, section 2.7. 
The evaluation of genomic imbalances between primary ependymomas categorised 
according to a patient age threshold of three years was restricted to the posterior fossa 
cohort of 24 ependymomas, where tumours were obtained from 12 children aged above 
three years and 12 patients aged below three years. This enabled a comparative 
assessment of sufficient numbers of ependymomas from a standardised CNS location. 
 
Multivariate event-free survival analysis for the SNP and methylation array cohorts 
included the clinical variables of patient age, tumour location, WHO histological grade 
and degree of surgical resection. Since adjuvant therapy commencement dates were 
unavailable for the many patients in both cohorts, radiotherapy and chemotherapy were 
removed as variables for event-free survival as the timing of their use relative to any 
relapses that occurred in these patients could not be determined accurately. Nevertheless 
radiotherapy and chemotherapy remained as variables for overall survival. 
 
3.3 Results 
 
3.3.1 Clinical associations: the SNP array primary tumour cohort 
 
Statistical analysis of the primary tumour cohort from the SNP array study was 
undertaken to initially identify any associations between the clinical variables of tumour 
location, patient age at diagnosis, tumour grade and tumour resection status. This 
revealed posterior fossa ependymomas were associated with patients aged below three 
years (p = 0.005, two-WDLOHG)LVKHU¶VH[DFWWHVW The association of posterior fossa with 
young patients and spinal ependymoma with older age groups was confirmed by one-
way ANOVA. This revealed a significant difference in mean patient age between 
primary posterior fossa tumours (6 + 1 years), supratentorial tumours (8.5 + 1.4 years) 
and spinal tumours (12.8 + 2.1 years) (p = 0.01). Post-hoc comparisons revealed this 
was the result of the patient age difference between posterior fossa and spinal 
ependymomas (p = 0.009, eta 0.2), while the age difference between intracranial 
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ependymoma patients was not significant. No other associations between the variables 
detailed above were observed. 
 
The estimated mean overall survival time for patients of the primary tumour cohort was 
12 + 2 years (range 0.5 ± 21 years). The mean time for follow up was 4.5 + 0.6 years 
(range 0.5 ± 21 years). Disease progression occurred in half of the cases (21/42) with a 
mean time to relapse of 2.4 + 0.5 years (range 0.3 ± 8.8 years). The percentage of the 
primary cohort achieving five year event-free survival was 35.7 + 9.4 %, while five year 
overall survival was achieved by 77.4 + 8 %. Univariate survival analysis revealed 
incomplete resection to be associated with a worse estimated mean event-free survival 
(6.8 + 1.4 years versus 2.4 + 0.6 years, p = 0.007). Resection status had no significant 
effect on overall survival, however. Other variables including patient age, sex, tumour 
location, tumour grade and adjuvant therapy had no association with patient outcome. 
 
3.3.2 Clinical associations: the methylation array primary tumour cohort 
 
Statistical analysis of the primary tumour cohort from the methylation array study was 
also undertaken to initially identify any associations between the clinical variables of 
tumour location, patient age at diagnosis, tumour grade and tumour resection status. 
This revealed supratentorial ependymomas were associated with female patients and an 
anaplastic histology (p = 0.005 and 0.019 respectively, two-tailed )LVKHU¶VH[DFW WHVW 
Posterior fossa ependymomas were again associated with patients aged below three 
years (p = 0.005, two-WDLOHG )LVKHU¶V H[DFW WHVW One-way ANOVA once more 
confirmed significant differences in mean patient age for ependymomas from different 
CNS locations (posterior fossa tumours: 5.2 + 0.7 years; supratentorial tumours: 8.3 + 
1.1 years; spinal tumours: 11.6 + 0.9 years, p = 0.0004). As seen in the SNP array 
cohort, post-hoc comparisons identified the patient age difference between posterior 
fossa and spinal ependymomas was the most significant (p = 4x10-5, eta 0.26), although 
the difference between posterior fossa and supratentorial tumours was also significant (p 
= 0.036).  
 
The estimated mean overall survival time was 10.8 + 2 years (range 0 ± 21 years). All 
spinal cases remained alive. The mean time for follow up was 4 + 0.5 years (range 0 ± 
21 years). Recurrence occurred in 32/73 (44 %) patients with a mean time to relapse of 
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2 + 0.3 years (range 0.3 ± 7.1 years). The percentage of the cohort achieving five year 
event-free survival was 37.2 + 7.6 %, while five year overall survival was achieved by 
76.8 + 6.7 %. As was the case for the primary SNP array cohort, survival analysis 
revealed incomplete resection to be associated with a worse estimated mean event-free 
survival (6.7 years + 1.4 years versus 2.9 years + 0.6 years, p = 0.032). Again, resection 
status had no significant effect on overall survival. Patient age, sex, tumour location, 
tumour grade and adjuvant therapy also had no association with patient outcome. 
 
3.3.3 Chromosomal arm imbalance in 63 paediatric ependymomas 
 
To enable a global visualisation of chromosome arm imbalance across the entire 
paediatric ependymoma SNP array cohort, a copy number heatmap was created in 
Spotfire Decision Site® (Figure 3.4). A table summarising the chromosome arm 
anomalies for each tumour sample in the cohort was also generated (Table 3.3). Net 
gain of chromosomal material occurred more frequently than loss. The most frequent 
aberration was gain of the long arm of chromosome 1 (1q) which was seen in 13/63 (21 
%) cases. Three of these cases (21P, 26R2, 44P) demonstrated a level of 1q gain 
represented by a copy number of four or higher. Gain of either 9p or all of chromosome 
9 was another common feature, seen in 12/63 (19 %) of cases. The most frequent loss 
was of chromosome 22q, present in 5/63 (8 %) tumours, while loss of either 6q or the 
whole of chromosome 6 occurred in 3/63 (5 %) cases. 
 
Table 3.3: Chromosome arm alterations in 63 paediatric ependymomas, analysed using 
the Affymetrix® 500K SNP array platform (80 % imbalance threshold). 
 
Tumour sample Chromosome/arm gain Chromosome/arm loss 
1P - - 
2P - - 
3P - - 
4P - - 
5P - - 
6P - - 
7P - - 
8P - - 
9P - - 
9R2 19, 22q - 
9R3 - - 
9R4 - 6q 
9R5 - - 
10P 1q 16q 
11P - - 
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Tumour sample Chromosome/arm gain Chromosome/arm loss 
12P - - 
13P - - 
14P - - 
15P - - 
16P - - 
16R1 1q - 
17P - - 
17R1 - - 
17R2 - - 
18P - - 
18R1 - - 
19R1 8,9 22q 
19R2 1q, 2, 8, 9p - 
20P - - 
20R1 - - 
21P 1q*, 7 - 
22P - - 
23P - - 
24P 9, 18, 20 - 
25P 9 - 
26P 1q - 
26R1 1q, 2p, 8, 9 - 
26R2 1q*, 2p, 8, 9 - 
26R3 1q, 2p, 8, 9 - 
27P 4, 7, 11, 12, 16, 17, 18, 21q, 22q - 
28P 4, 5, 9, 11, 12, 18, 19, 20 21q 
29P 4, 14q, 15q, 18 - 
30P 1q 10q 
31P 4, 5, 7p, 9, 11, 12, 16, 17, 18, 19, 20, 21q - 
32P - - 
33R1 
- - 
34P 19p - 
35P 1q - 
35R1 - - 
35R2 - - 
36P - - 
37P - - 
38P 20p 22q 
39P 1q, 19 - 
40P 9, 13q, 14q 6, 22q 
40R1 9, 13q, 14q 6, 22q 
41P - - 
42P 9, 16, 17, 20 - 
43R1 1q - 
43R2 - - 
43R3 - - 
44P 1q*, 18 - 
45P 2, 7, 12q, 15q, 17 22q 
Genomic gain is represented by copy number three and loss is represented by copy number one unless stated (see *). 
P = primary, R1 ± R5 = 1st ± 5th recurrence, * = copy number > 4.  
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Figure 3.4: Spotfire Decision Site® copy number heatmap demonstrating Affymetrix® 500K SNP array results across the genome for 63 paediatric ependymomas, ordered by patient age. Diploid 
genomic regions are coloured black. Regions exhibiting genomic loss are coloured red, while regions demonstrating gain are coloured green or yellow, depending on whether the gain represents 
a copy number of three or greater respectively. P = primary, R1 ± R5 = 1st ± 5th recurrence. 
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Figure 3.5: Spotfire Decision Site® copy number heatmaps demonstrating Affymetrix® 500K SNP array results across the genome for (A) 42 primary paediatric ependymomas, categorised 
according to the three locations of these tumours within the central nervous system; the supratentorial region, the posterior fossa and the spinal cord and (B) nine intracranial recurrent 
ependymomas. Diploid genomic regions are coloured black. Regions exhibiting genomic loss are coloured red, while regions demonstrating gain are coloured green or yellow, depending on 
whether the gain represents a copy number of three or greater respectively.  P = primary, R1 = 1st recurrence. 
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Figure 3.6: Frequency plot of the number of chromosome arm gains and losses in (A) 42 primary paediatric 
ependymomas and (B) nine intracranial recurrent ependymomas. Gains are coloured green and losses are coloured 
red. Furthermore, where relevant, the total number of chromosomal arm imbalances in the primary cohort is 
segregated by the frequency with which they occurred in each of the three CNS tumour locations ± supratentorial, 
posterior fossa or spinal. 
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3.3.4 Association of chromosomal arm imbalances with clinical subgroups 
 
Since 10 patients contributed more than one tumour sample to the 500K SNP array 
sample cohort, a more precise method of identifying associations between genomic 
imbalances and clinical subgroups was established by analysing only the primary 
tumours, followed by the intracranial first recurrent ependymomas. Consequently, 
Figure 3.5 illustrates Spotfire Decision Site® generated copy number heatmaps for the 
42 paediatric primary ependymomas (separated according to tumour location within the 
CNS) and nine intracranial first recurrent tumours within the sample cohort, while 
Figure 3.6 provides a summarised view of the arm aberrations present in these two 
groups. Tables 3.4 ± 3.7 order the most frequent chromosome arm imbalances in 
primary supratentorial, posterior fossa, spinal and first recurrent intracranial 
ependymomas. 
 
Table 3.4: Chromosome arm alterations in 11 primary supratentorial ependymomas. 
 
Chromosome arm gain Chromosome arm loss 
Chromosome arm Number (%) of tumours 
demonstrating  gain 
Chromosome arm Number (%) of tumours 
demonstrating  loss 
 19p 1 (9 %)  Nil / 
 
 
Table 3.5: Chromosome arm alterations in 24 primary posterior fossa ependymomas.  
 
Chromosome arm gain Chromosome arm loss 
Chromosome arm Number (%) of tumours 
demonstrating  gain 
Chromosome arm Number (%) of tumours 
demonstrating  loss 
 1q 7 (29 %) 6p 1 (4 %) 
9p 3 (13 %) 6q 1 (4 %) 
9q 3 (13 %) 10q 1 (4 %) 
18p 3 (13 %) 16q 1 (4 %) 
18q 3 (13 %) 21q 1 (4 %) 
4p 2 (8 %) 22q 1 (4 %) 
4q 2 (8 %)   
14q 2 (8 %)   
19p 2 (8 %)    
19q 2 (8 %)   
5p 1 (4 %)   
5q 1 (4 %)   
7p 1 (4 %)    
7q 1 (4 %)   
11p 1 (4 %)   
11q 1 (4 %)   
12p 1 (4 %)    
12q 1 (4 %)   
13q 1 (4 %)   
15q 1 (4 %)   
20p 1 (4 %)    
20q 1 (4 %)   
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Table 3.6: Chromosome arm alterations in six primary spinal ependymomas. 
 
Chromosome arm gain Chromosome arm loss 
Chromosome arm Number (%) of tumours 
demonstrating  gain 
Chromosome arm Number (%) of tumours 
demonstrating  loss 
17p 4 (67 %) 22q 2 (33 %) 
17q 4 (67 %)   
20p 4 (67 %)    
7p 3 (50 %)   
9p 3 (50 %)   
9q 3 (50 %)   
12q 3 (50 %)   
16p 3 (50 %)    
16q 3 (50 %)   
18p 3 (50 %)   
18q 3 (50 %)   
20q 3 (50 %)   
4p 2 (33 %)   
4q 2 (33 %)   
7q 2 (33 %)   
11p 2 (33 %)   
11q 2 (33 %)   
12p 2 (33 %)    
21q 2 (33 %)   
2p 1 (17 %)   
2q 1 (17 %)   
5p 1 (17 %)   
5q 1 (17 %)   
15q 1 (17 %)   
19p 1 (17 %)   
19q 1 (17 %)   
22q 1 (17 %)   
 
 
Table 3.7: Chromosome arm alterations in nine intracranial first recurrent 
ependymomas. 
 
Chromosome arm gain Chromosome arm loss 
Chromosome arm Number (%) of tumours 
demonstrating  gain 
Chromosome arm Number (%) of tumours 
demonstrating  loss 
1q 3 (33 %) 22q 1 (11 %) 
8p 2 (22 %)   
8q 2 (22 %)   
9p 2 (22 %)   
9q 2 (22 %)   
2p 1 (11 %)   
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Distinct patterns of genomic imbalance between primary ependymomas from different 
CNS locations were evident. Spinal ependymomas were characterised by numerous arm 
and whole chromosomal aberrations when compared to intracranial tumours, 
particularly involving gain of chromosomes 17 (p = 1x10-4), 20p (p = 7x10-4), 16 (p = 
0.0019), 12q (p = 0.007), 20q (p = 0.007), 21q (p = 0.018), 9 and 18 (p = 0.03, two-
WDLOHG)LVKHU¶Vexact test). In contrast, a relative paucity of arm imbalances (19p gain in 
1/11 samples) was a feature of supratentorial tumours. Gain of chromosome 1q was 
associated with primary posterior fossa ependymomas (p = 0.0295, two-WDLOHG)LVKHU¶V
exact test) and was the most frequent imbalance seen in the recurrent cohort, while gain 
of chromosome 8 was exclusive to intracranial recurrent tumours (p = 0.036, two-tailed 
)LVKHU¶V H[DFW WHVW 1R VWDWLVWLFDO DVVRFLDWLRQV ZHUH IRXQG EHWZHHQ SDUWLFXODU
chromosome arm imbalances and the clinical parameters of patient sex, tumour grade 
and degree of surgical tumour resection. 
 
In this study, 15/42 (36 %) primary ependymomas were designated balanced (defined as 
> 95% of the analysed SNP probes being assigned a diploid copy number), and were 
associated with children aged below three years (p = 0.041, two-WDLOHG )LVKHU¶V H[DFW
test). Age-related categorical analyses of genomic imbalance was performed exclusively 
on the primary posterior fossa ependymoma cohort, where tumours were obtained from 
12 children aged above three years and 12 patients aged below three years. While no 
association was found with a specific arm imbalance in either age category, the number 
of arm imbalances between the two subgroups was significant (one arm imbalance in 
the under three year group, 46 imbalances in the over three year group; p = 1.2x10-4, 
Mann-Whitney test).  
 
The impact of chromosome 1q gain on patient outcome within the primary 
ependymoma cohort was assessed. While a reduced event-free survival (EFS) and 
overall patient survival (OS) was noted for ependymomas with 1q gain, neither reached 
univariate statistical significance (estimated mean EFS: 2.9 + 0.7 years versus 5.8 + 1.1 
years, p = 0.29, estimated mean OS: 4.8 + 0.8 years versus 13.1 + 2.1 years, p = 0.142, 
Kaplan-Meier analysis). However, 1q gain showed a detrimental effect on overall 
survival from multivariate analysis incorporating the variables of patient age, adjuvant 
radiotherapy and chemotherapy, tumour histology, location and resection status 
(hazards ratio 37.1 (95 % CI 1.712 ± 804.5, p = 0.021) (Table 3.8).  
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Table 3.8: Multivariate overall survival analysis incorporating SNP array gain of 
chromosome 1q. 
The primary SNP array cohort of 42 ependymomas was analysed. ST = supratentorial, PF = posterior fossa, 95 % CI 
= 95 % confidence interval. Significant results are highlighted in yellow. Results with a trend towards significance 
are highlighted in pale yellow.  
 
 
3.3.5 Association of cytoband imbalances with clinical subgroups  
 
Initial cytoband analysis revealed the telomeric region 7p22.3 to be the most frequently 
gained in the primary cohort (14/42 cases, 33 %). The most frequently lost cytobands in 
this group included 6q11.2, 6q12 and 6q22.2 (4/42, 10 %). The most frequently gained 
and lost regions in the intracranial first recurrent cohort were 1q24.1 (5/9, 56 %) and 
TUHVSHFWLYHO\)LVKHU¶VH[DFWWHVWLQJUHYHDOHGDVVRFLDWLRQVEHWZHHQ 
genomic cytoband imbalances and particular clinical tumour groups, in addition to 
refining the cytobands within chromosome 1q that demonstrated significant gain in 
posterior fossa ependymomas (Table 3.9). These associations included gain of 9q34.11-
34.4 in grade 3 intracranial primary ependymomas and gain of 1q24.1, loss of 22q13.1-
13.31 and loss of 22q13.33 in intracranial first recurrent tumours.  
 
 
 
 
 
 
 
 
 
Cox regression multivariate analysis  
(n=42) 
Overall  Survival 
Factor Hazards ratio 95 % CI P value 
Histology (WHO grade II vs III) 
Tumour location (PF vs ST) 
Resection status (complete vs incomplete) 
Patient age (below 3 years vs above 3 years) 
Radiotherapy (received vs not received) 
Chemotherapy (received vs not received) 
Chromosome 1q gain (gain vs no gain) 
1.986 0.532  ± 7.413 0.308 
0.032 0.001 ± 1.422 0.075 
0.849 0.203 ± 3.561 0.823 
13.032 0.353  ± 480 0.163 
0.609 0.112 ± 3.296 0.565 
2.405 0.257 ± 22.501 0.442 
37.117 1.712  ± 805 0.021 
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Table 3.9: Statistically significant associations between cytoband genomic imbalances 
and particular clinical subgroups (as determined by two-WDLOHG)LVKHU¶VH[DFWWHVWLQJ 
 
Clinical Group Cytoband imbalance p-value 
Male patient primary tumours Gain of 20q11.22 0.01 
Gain of 9p11.1 0.02 
Gain of 9q13, 9q21.2, 9q33, 20q13.13 0.029 
Posterior fossa primary tumours Gain of 1q21.3, 1q22, 1q25.3, 1q32.2, 
1q42.12-44 
0.013 
Gain of 1q21.1, 1q23.1, 1q23.3-24.2, 1q25.1-
25.2, 1q31.1-31.3, 1q41 
0.03 
Intracranial grade III primary tumours Gain of 9p11.2 0.005 
Gain of 9p11.1, 9p12, 9p13.2, 9q34.11-12, 
19p13.3 
0.014 
Gain of 11p15.5, 19q13.41, 9q34.13-34.4, 
11q13.2, 12q13.12, 13q11, 18p11.21, 18q11.1, 
19q13.12, 19q13.13, 19q13.32, 19q13.42 
0.035 
Intracranial first recurrent tumours Gain of 1q24.1 0.04 
Loss of 22q13.33 0.006 
Loss of 22q13.1 ± 13.31 0.036 
Note: Statistically significant associations already discovered during chromosome arm imbalance analysis (such as 
those seen with spinal ependymomas) are not shown unless cytoband analysis refined the region associated with the 
clinical subgroup.  
 
Unsupervised hierarchical clustering and PCA was also performed on the cytoband 
imbalance data of the primary paediatric SNP array cohort, so that genetically distinct 
subgroups of tumours could be identified and linked with clinical and/or pathological 
parameters (Figures 3.7A ± C). 
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Figure 3.7A: Unsupervised hierarchical cluster heatmap of copy number imbalances in 783 cytobands across the 22 autosomes for 42 primary paediatric ependymomas (Spotfire Decision Site®). 
Cytobands were imbalanced if > 80 % of the encompassed SNP probes had a copy number of < 1 (loss ± red) or > 3 (gain ± green). Tumour samples divided into three broad groups. The first 
group contained samples with few cytoband imbalances or, in six cases, complete absence of imbalance. The second group was characterised by gain of cytobands within the long arm of 
chromosome one (1q). The third group comprised primary tumours with numerous imbalances, often involving large genomic regions covered by consecutive cytobands.  
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Figure 3.7B: The unsupervised hierarchical cluster dendrogram from Figure 3.7A, with clinical information plotted 
underneath each sample branch. Cluster group one included ependymomas from younger patients compared to the 
rest of the cohort, reflected in 12/14 (86 %) samples from children under three years of age falling into this cluster. 
The mean patient age for cluster group one was 4.8 + 0.9 years, compared to 10.2 + 1.1years for the rest of the 
cohort. Every group two patient had either relapsed or died, which was reflected in a worse event-free (p = 0.001) and 
overall survival (p = 0.04) for this group. Group three contained ependymomas from older children and included all 
of the spinal tumours in the cohort.  
 
C 
 
Figure 3.7C: PCA cluster plot of the cytoband imbalance data on 42 primary paediatric ependymomas. The clustering 
result from unsupervised hierarchical clustering of Figure 3.7A was reinforced by the PCA cluster, demonstrating the 
three groups previously described in the text and in Figures 3.7A and B. 
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Three groups were identified by both methods (DOVR WHUPHG µJURXS RQH¶ µJURXS WZR¶
DQG µJURXS WKUHH¶ 7KH ILUVW FOXVWHU JURXS FRQWDLQHG  HSHQG\PRPDV ZLWK IHZ
genomic aberrations. Indeed, all 15 tumours with a balanced genomic profile were 
found in this cluster group, as were the majority (9/11) of supratentorial tumours. The 
patient age of this cluster was significantly lower than the rest of the primary cohort 
(mean age of 4.8 + 0.9 years versus 10.2 + 1.1 years, p = 0.001, independent t-test). The 
second group consisted of nine tumours and was associated with the gain of 
chromosome 1q or cytobands within chromosome 1q, the most frequently gained region 
being 1q21.2 in 8/9 cases (p = 1x10-4, two-WDLOHG)LVKHU¶VH[DFWWHVW5H-evaluation of 
SNP probe location using the web-based genomic database Ensembl 
(http://www.ensembl.org) found that a small proportion of probes, previously denoted 
as landing within 1q21.2 according to the accompanying annotation file (Netaffx file 
build 07.12.07) actually extended into the 1q21.3 cytoband. Therefore, for improved 
precision, the 1q21.2 cytoband was re-defined as the 1q21.2 ± 21.3 region. Univariate 
survival analysis revealed a significantly worse event-free and overall survival for 
children in this second group compared with the other primary ependymoma patients 
(estimated mean EFS: 1.8 + 0.4 years versus 6.6 + 1.2 years, p = 0.001; estimated mean 
OS: 5.6 + 1.1 years versus 13.5 + 2.7 years, p = 0.041) (Figure 3.8). 
 
 
                          
Figure 3.8: Kaplan-Meier EFS and OS curves for nine ependymoma patients from cluster analysis group two (blue 
lines) compared to the rest of the primary SNP array cohort (green lines). Patients from this group had a significantly 
worse EFS (percentage from each group attaining five year EFS = 0 % (group two) versus 52.4 + 11.4 % (remaining 
primary cohort), p = 0.001) and OS (percentage from each group attaining five year OS = 66.7 + 15.7 % (group two) 
versus 81.5 + 8.8 % (remaining primary cohort), p = 0.041). 
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Multivariate survival analysis was also performed. Since commencement dates were 
unavailable for 13/27 (48 %) patients receiving radiotherapy and almost all patients 
receiving chemotherapy in the primary cohort, these were removed as variables for 
event-free survival as the influence on any relapses that occurred in these patients could 
not be determined accurately. Nevertheless radiotherapy and chemotherapy remained as 
variables for overall survival. The multivariate analysis showed that patients from group 
two had a reduced EFS (hazards ratio 5.843 (95 % CI 1.832 ± 18.641) p = 0.003), 
although the adverse effect on overall survival became a trend towards significance 
(hazards ratio 3.55 (95 % CI 0.971 ± 13) p = 0.055) (Tables 3.10 and 3.11). The     
1q21.2 ± 1.2q1.3 region was also the most frequently gained 1q locus across the entire 
primary ependymoma cohort (9/42, 21 %). Unsurprisingly, an unfavourable event-free 
patient survival finding was again observed when comparing all cases with gain against 
the remaining primary tumours (hazards ratio 4.487 (95 % CI 1.059 ± 19) p = 0.042). 
 
Table 3.10: Multivariate event-free survival analysis incorporating group two from the 
Affymetrix® 500K SNP array analysis. 
 
The primary SNP array cohort of 42 ependymomas was analysed. Radiotherapy and chemotherapy were not included 
as variables for event-free survival due to missing clinical data regarding commencement dates, as discussed in 
section 3.2.3. 95 % CI = 95 % confidence interval. ST = supratentorial, PF = posterior fossa. Statistically significant 
results are highlighted in yellow. Results with a trend towards statistical significance are highlighted in pale yellow. 
 
Table 3.11: Multivariate overall survival analysis incorporating group two from the 
Affymetrix® 500K SNP array analysis. 
 
The primary SNP array cohort of 42 ependymomas was analysed. ST = supratentorial, PF = posterior fossa, 95 % CI 
= 95 % confidence interval. Results with a trend towards statistical significance are highlighted in pale yellow.   
Cox regression multivariate analysis  
(n=42) 
Event-Free Survival 
Factor Hazards ratio 95 % CI P value 
Histology (WHO grade II vs III) 
Tumour location (PF vs ST) 
Resection status (incomplete vs complete) 
Patient age (below vs above three years) 
Group two  (yes vs no) 
1.471 0.607 ± 3.564 0.393 
0.344 0.096 ± 1.232 0.101 
2.370 0.924 ± 6.080 0.073 
2.131 0.544 ± 8.341 0.277 
5.843 1.832 ± 18.641 0.003 
Cox regression multivariate analysis  
(n=42) 
Overall  Survival 
Factor Hazards ratio 95 % CI P value 
Histology (WHO grade II vs III) 
Tumour location (PF vs ST) 
Resection status (incomplete vs complete) 
Patient age (below versus above three years) 
Radiotherapy ( received vs not received) 
Chemotherapy ( received vs not received) 
Group two  (yes vs no) 
1.764 0.491  ± 6.343 0.385 
0.595 0.083 ± 4.251 0.605 
1.024 0.246 ± 4.264 0.974 
1.201 0.099  ± 14.573 0.886 
0.431 0.085 ± 2.202 0.312 
1.822 0.181 ± 18.359 0.611 
3.554 0.971  ± 13.004 0.055 
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The third group comprised of 11 ependymomas characterised by more numerous 
imbalances, often encompassing large genomic regions. This group was associated with 
tumours from older children (mean age of 12.2 + 1.3 years versus 5.9 + 0.8 years,          
p = 2.9x10-4, independent t-test) and contained all of the spinal ependymomas              
(p = 8.8x10-5, two-WDLOHG)LVKHU¶VH[DFWWHVW  
 
Survival analysis did not reveal significant results for either group one or three when 
compared against the remaining tumour cohort. In the case of group three, this was 
despite all 11 patients being alive, although the mean follow-up time was relatively 
short at 2.3 years (Figure 3.9). 
 
 
Figure 3.9: Kaplan-Meier EFS and OS curves for 11 ependymoma patients from cluster analysis group three (blue 
lines) compared to the rest of the primary SNP array cohort (green lines). Although improved, patients from group 
three did not have a significantly enhanced EFS (percentage from each group attaining five year EFS = 58.3 + 19.8 % 
(group three) versus 31.1 + 10 % (remaining primary cohort), p = 0.307). All patients in group three were alive but 
censored after a relatively short mean follow-up time of 2.3 years. The resulting OS data for this group was thereby 
not significantly different from the remaining cohort (percentage from each group attaining five year OS = 100 % 
(group three) versus 72.5 % (remaining primary cohort), p = 0.151). Cum survival = cumulative survival. 
 
3.3.6 FISH validation of chromosome 1q gain results from the SNP array  
 
To validate the chromosome 1q gain result from the 500K SNP array analysis, FISH 
was performed on 21 primary ependymoma tumour samples that had also been 
processed on the 500K SNP array, using a commercial LSI 1p36/LSI 1q25 dual colour 
probe (Vysis, USA) on FFPE based tissue microarrays. The 1q25 FISH probe covered a 
genomic region of approximately 400kb located within cytoband 1q25.2, encompassing 
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35 of the SNP probes on the 500K array (SNP_A-2119283 ± SNP_A-1800896). During 
the FISH analysis, gain of 1q25 was defined by the presence of three or more copies of 
the green (1q25) probe signal per nucleus.  
 
For each of the 21 samples, the percentage of nuclei counted revealing 1q25 gain by 
FISH was initially correlated with the SNP array derived copy number for the 400kb 
FISH probe region (Figure 3.10) and subsequently the presence of entire chromosome 
1q arm gain, as defined by the 80% chromosome arm SNP probe threshold described in 
section 3.2.1.2 (Table 3.12). This analysis found that the presence of 1q25 gain in over 
30 % of nuclei counted by FISH correlated strongly with SNP array gain of the 
corresponding FISH probe region (R = 0.79, p = 2.49x10-5 6SHDUPDQ¶V FRUUHODWLRQ, 
although a positive correlation also existed with SNP derived gain of the whole 
chromosome 1q arm (Table 3.12).  
 
Table 3.12: Correlation of chromosome 1q SNP array data and 1q25 FISH scores  
for 21 primary paediatric ependymomas. 
 
Tumour sample ID SNP copy number of 
region on 1q25.2 covered 
by FISH probe 
Imbalance of chromosome 
1q derived from SNP data 
based on 80% threshold 
(actual percentage) 
Percentage of nuclei 
counted demonstrating 
1q25 gain by FISH 
1P 2 No imbalance  8 % 
2P 2 No imbalance  10 % 
3P 2 No imbalance 13 % 
8P 2 No imbalance 11 % 
9P 2 No imbalance 10 % 
13P 2 No imbalance 9 % 
22P 2 No imbalance 6 % 
23P 2 No imbalance 13 % 
27P 2 No imbalance 8 % 
29P 2 No imbalance  18 % 
34P 2 No imbalance  7 % 
36P 2 No imbalance 11 % 
38P 2 No imbalance  27 % 
40P 2 No imbalance  3 % 
42P 2 No imbalance  10 % 
    
10P 3 Gain  33 % 
14P 3 No imbalance  38 % 
26P 3 Gain  56 % 
30P 3 Gain  31 % 
35P 3 Gain  40 % 
39P 3 Gain  52 % 
    
6SHDUPDQ¶VFRUUHODWLRQ
coefficient in relation to 
FISH score 
R = 0.79, p = 2.49x10-5 R = 0.7, p = 3.76x10-4  
Note: Sample 14P is highlighted as, although it did not exceed the chromosome arm imbalance threshold of 80 %,   
RI WKH613SUREHVZLWKLQFKURPRVRPHTZHUHJDLQHG IRU WKLV VDPSOH.H\3 SULPDU\ 5 6SHDUPDQ¶V
correlation coefficient. 
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Figure 3.10: Chromosome 1q25 FISH validation of the 500K SNP array findings for 21 primary ependymomas. The 
colour of each sample bar represents the SNP array derived copy number for a region of 35 SNP probes on 
chromosome 1q25.2 corresponding to the region covered by the LSI 1p36/LSI 1q25 dual colour FISH probe (Vysis). 
6DPSOHVZLWKJUHHQRUZLWKRXWEODFNFRS\QXPEHUJDLQRIWKHUHJLRQFDQEHVHHQ(DFKEDU¶VKHLJKWUHSUHVHQWVWKH
percentage of nuclei with copy number gain from the 1q25 FISH analysis of that sample, where gain was defined by 
the presence of three or more copies of the 1q25 probe signal per nucleus. A demonstration of 1q25 gain in over 30 % 
of nuclei scored using FISH correlated with SNP derived copy numbHUJDLQRIWKHSUREHUHJLRQ6SHDUPDQ¶V5DQN 
0.79, p= 2.49x10-5). Examples of 1q25 FISH for one diploid sample (A) and 3 gained samples (B ± D) are shown 
(magnification x 40), where green signal = 1q25 probe and red signal = 1p36 probe. 
 
3.3.7 Methylation array cluster analysis identifies clinically relevant 
subgroups 
 
The corrected methylation scores for the 1,421 GoldenGate® Cancer Panel I CpG 
probes for all 98 tumours comprising the ependymoma methylation cohort are shown in 
Appendix 10F. Since normal, control tissue (such as paediatric brain tissue) was not 
available for this analysis, only comparisons between tumour groups were possible. 
Bootstrapped unsupervised hierarchical clustering and PCA were performed on the 
methylation array primary tumour cohort of 73 ependymomas, in order to identify 
distinct molecular tumour subgroups and potentially associate them to known clinical 
and/or pathological demographic factors (Figures 3.11A ± C).  
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Bootstrapped clustering revealed two main sample clusters with an approximate 
unbiased probability (p) value of 99 % (orange and yellow shaded groups in Figures 
3.11A and 3.11B). The first cluster of 13 tumours (shaded orange) contained 
predominantly spinal ependymomas, while the second cluster of 59 tumours (shaded 
yellow) was composed mainly of intracranial ependymomas (p < 0.0001, two-tailed 
)LVKHU¶VH[DFWWHVWFigure 3.11B). The mean patient age of this first cluster was older 
than the second cluster (10.3 + 4.1 years versus 5.9 + 4.5 years, p = 0.003, independent 
t-test). The large intracranial cluster also contained numerous subgroups, although these 
did not attain approximate unbiased probability values above 95 % on bootstrapped 
cluster analysis. For example, a large cluster of 34 posterior fossa ependymomas 
demonstrated a similar methylation profile (Figure 3.11B), yet contained a distinct 
subgroup of nine tumours from children aged under three years (p = 0.01, two-tailed 
)LVKHU¶VH[DFWWHVWWKHPDMRULW\RIZKLFKFDVHVKDGDQDQDSODVWLFKLVWRORJ\
(circled red in Figure 3.11B). In addition, a cluster of five supratentorial ependymomas 
(circled green in Figure 3.11B) demonstrated a distinct methylation profile to that of the 
other supratentorial tumours in the cohort, suggesting biological sub-classification may 
also exist for supratentorial ependymomas, despite sharing the same locality within the 
central nervous system. Survival analysis revealed no significant differences in patient 
outcome between the clusters identified above, while ependymomas with a balanced 
genomic profile from the SNP array analysis did not cluster independently on the 
methylation analysis. Genes found to be differentially methylated between particular 
clusters identified in this chapter, or between selected clinical subgroups are 
subsequently detailed in Chapter 4, section 4.3.4.  
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Figure 3.11A: Bootstrapped, unsupervised hierarchical cluster heatmap of the corrected Beta methylation scores 
across 1,421 GoldenGate® Cancer Panel I CpG probes for 73 primary paediatric ependymomas (10,000 replications). 
Red on the heatmap represents hypermethylated probes while green represents hypomethylation. Two main clusters 
revealed an approximate unbiased probability (p) value greater than the 95 % significance threshold and are shaded in 
orange and yellow for discrimination. The clinical demographics of the samples in these clusters are demonstrated in 
Figure 3.11B.  
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Figure 3.11B: The unsupervised hierarchical cluster dendrogram from Figure 3.11A, with clinical information plotted 
underneath each sample branch. Cluster one (orange) included predominantly spinal ependymomas from older 
children while cluster two (yellow) was comprised mainly of intracranial tumours (p < 0.0001, two-tDLOHG)LVKHU¶V
exact test). Within the intracranial methylation cluster were discrete subclusters including a group of nine posterior 
fossa tumours from patients aged below three years (p = 0.01, two-WDLOHG)LVKHU¶VH[DFWWHVWWZR-thirds of which had 
an anaplastic histology (circled red). In addition, a discreet subcluster of five supratentorial tumours (circled green) 
was evident, with a different methylation profile to the majority of other supratentorial tumours in the primary cohort. 
 
 
 
 
C 
 
 
Figure 3.11C: PCA cluster plot of the corrected Beta methylation scores across the 1,421 GoldenGate® Cancer Panel 
I CpG probes for 73 primary paediatric ependymomas. Samples are labelled according to tumour location within the 
central nervous system (see figure key). The methylation cluster profiles demonstrated by the bootstrap analysis were 
reinforced by PCA, with the majority of spinal ependymomas grouping separately to their intracranial counterparts. 
The clustering of posterior fossa tumours is evident, while subtle methylation profile differences between 
supratentorial ependymomas results in a supratentorial tumour predominant subcluster formation (circled again in 
green), reflecting differences already noted for this tumour group from the bootstrapped cluster analysis. 
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3.4 Discussion 
 
Our current inability to predict the clinical sequelae of paediatric ependymomas based 
on traditional histological and clinical information underlines the distinct management 
challenge presented by these tumours. An improved understanding of ependymoma 
biology in children will help to redress this issue. Two different array-based analyses 
were utilised in this study. The 500K Affymetrix® SNP array was used to assess 
genomic imbalance and loss of heterozygosity in 42 primary and 21 recurrent paediatric 
ependymomas. This is the first 500K SNP array study of ependymomas to normalise 
tumour data against patient matched constitutional DNA in order to identify tumour-
specific alterations and account for genomic alterations already present in the patient 
germline. The Illumina® GoldenGate® Cancer Panel I assay for methylation analysed 73 
primary and 25 recurrent paediatric ependymomas, reporting the methylation status at 
1,421 CpG sites mapping to 768 genes associated with DNA methylation and/or cancer. 
It is the first reported epigenetic array study performed on paediatric ependymomas.   
 
For both array platforms, results from the tumour cohorts were initially analysed for 
broad genomic and epigenetic changes which were correlated with clinical and 
histological factors, together with patient outcome. The results demonstrated distinct 
differences between paediatric ependymomas, particularly relating to tumour location 
within the CNS, patient age at diagnosis and tumour recurrence. Moreover, the SNP 
array work also identified genomic gain involving chromosome 1q to be associated with 
an adverse patient prognosis. Higher resolution gene-level analysis was subsequently 
performed on both ependymoma cohorts, with the results discussed in later chapters. 
 
The two sets of paediatric ependymomas used for both microarray platforms, and the 
patients from which they were obtained, generally reflected the clinical profile reported 
for this tumour group in the literature (Kilday, Rahman et al. 2009; Wright and Gajjar 
2009). The vast majority of paediatric ependymomas in both cohorts were of 
intracranial origin, with primary posterior fossa tumours accounting for the majority of 
the total intracranial cohort.  Almost half of all the patients analysed were below five 
years of age at diagnosis, while approximately one third of children from both cohorts 
(33 % of the SNP cohort, 30 % of the methylation cohort) were aged below 36 months. 
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The predilection of ependymomas from these very young patients for a posterior fossa 
locality and the association of spinal tumours with older children (Dyer, Prebble et al. 
2002; Kilday, Rahman et al. 2009) were also evident in both groups. Most of the 
primary ependymomas in each cohort were of classic histology, in keeping with several 
other series (Rousseau, Habrand et al. 1994; Perilongo, Massimino et al. 1997; Horn, 
Heideman et al. 1999; Grundy, Wilne et al. 2007), while almost 50 % were deemed to 
have had a complete surgical resection. From literature, the reported resection rate 
ranges from 31 ± 85 %, reflecting diverse surgical techniques, inconsistent criteria for 
defining complete tumour excision and variable surgical accessibility of ependymomas 
from different CNS locations (Rousseau, Habrand et al. 1994; Bouffet, Perilongo et al. 
1998; Merchant and Fouladi 2005). A slight predominance of male patients was present 
(male to female ratios of 1.4:1 and 1.3:1 for SNP and methylation cohorts respectively) 
which concurred with several other sizeable studies (Goldwein, Leahy et al. 1990; Horn, 
Heideman et al. 1999; Grundy, Wilne et al. 2007).  
 
While the five year overall survival  for both cohorts of 77 % (+ 8 % (SNP cohort);        
+ 7 % (methylation cohort)) was higher than the 39 ± 71 % generally reported 
(Robertson, Zeltzer et al. 1998; Paulino, Wen et al. 2002; Zacharoulis, Levy et al. 2007; 
Wright and Gajjar 2009), the five year event-free survival rates (36 + 9 % (SNP cohort); 
37 + 8 % (methylation cohort)) and the mean time to relapse (2.4 + 0.5 years (SNP 
cohort); 2 + 0.3 years (methylation cohort)) replicated the findings from current 
literature (Pollack, Gerszten et al. 1995; Perilongo, Massimino et al. 1997; Robertson, 
Zeltzer et al. 1998; Horn, Heideman et al. 1999; Agaoglu, Ayan et al. 2005; 
Zacharoulis, Levy et al. 2007). The deleterious effect of incomplete surgical resection 
on event-free survival was evident from analysis of both SNP and methylation array 
patient groups, supporting complete resection as a consistently reported favourable 
clinical prognostic factor (Bouffet, Perilongo et al. 1998; Robertson, Zeltzer et al. 1998; 
Horn, Heideman et al. 1999; Merchant, Li et al. 2009). However, this effect did not 
translate into a worse overall survival in either patient cohort. 
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3.4.1 Aberrations in paediatric ependymomas from different CNS locations 
 
Both SNP and methylation array analyses highlighted distinct differences in the 
genomic and epigenetic profiles of paediatric ependymomas originating from different 
sites within the CNS, often corroborating the findings of preceding lower resolution, 
low throughput studies (sections 3.3.4, 3.3.5 and 3.3.7).  
 
Paediatric spinal ependymomas were characterised by numerous arm or whole 
chromosome genomic anomalies including gains of chromosome 17p, 12q, 21q, 16, 9, 
18 and 20. Diverse and extensive chromosome imbalances were also a feature of 
paediatric spinal ependymomas from the CGH meta-analysis discussed previously 
(Chapter 1, section 1.5.2) (Kilday, Rahman et al. 2009). While several imbalances were 
different between the two spinal tumour cohorts, the frequent gain of chromosomes 18, 
20 and 9 were common to both. The importance of chromosome 9 gain in spinal 
ependymomas has been highlighted by a recent integrated genome-wide analysis of 
RNA expression and DNA copy number in adult and paediatric ependymomas, as copy 
number gain correlated with a general increase in the level of gene expression across the 
chromosome (Johnson, Wright et al. 2010). This is in keeping with studies of CDKN2A 
(p14ARF), a putative tumour suppressor gene located at 9p21.3 that regulates neural 
stem cell proliferation and whose deletion has been shown to rapidly expand progenitor 
cell numbers in developing neural tissue (Taylor, Poppleton et al. 2005). Whilst FISH 
and microsatellite analysis  have demonstrated that CDKN2A deletion is virtually 
exclusive to supratentorial ependymomas (Taylor, Poppleton et al. 2005; Schneider, 
Monoranu et al. 2009), gene expression analyses have revealed downregulation of 
CDKN2A in intracranial tumours, yet not spinal counterparts (Korshunov, Neben et al. 
2003; Mendrzyk, Korshunov et al. 2006).   
 
Deletion of chromosome 22q was the most frequent genomic loss in the SNP array 
spinal cohort (2/6 cases), a finding that requires confirmation in a larger cohort of 
paediatric spinal ependymomas. Nevertheless, the aforementioned integrated genomic 
and expression analysis performed by Johnson et al. found that spinal ependymomas 
frequently lost chromosome 22q and had an expression signature enriched with genes 
deleted and underexpressed on chromosome 22q such as TNRC6B (22q13.1) (Johnson, 
129 
 
Wright et al. 2010). A sub-region implicated in spinal ependymoma pathogenesis is 
22q12, harbouring the Protein 4.1 superfamily member NF2. Mutation analysis has 
revealed that, in association with LOH for chromosome 22, somatic NF2 mutations 
exist but in a proportion of ependymomas restricted exclusively to spinal cases (Ebert, 
von Haken et al. 1999; Lamszus, Lachenmayer et al. 2001). In addition, NF2 mutations 
are seen in patients with Neurofibromatosis type II, a cancer predisposition syndrome 
regularly associated with the occurrence of spinal ependymomas (Kulkarni 2004). 
Indeed, one of the two spinal ependymomas with 22q loss from this analysis, sample 
38P, was obtained from a patient diagnosed with neurofibromatosis type II, suggesting a 
tumour suppressor role for this gene in ependymomas of the spinal cord. Genetic 
alterations of other Protein 4.1 family members have also been reported for extracranial 
ependymomas, such as 4.1B deletion and 4.1R underexpression (Singh, Gutmann et al. 
2002; Rajaram, Gutmann et al. 2005). This SNP array study also revealed however, that 
deletion of chromosome 22q was not exclusive to spinal ependymomas, lending support 
to the CGH meta-analysis which revealed chromosome 22 loss was a common feature 
of paediatric intracranial ependymomas (Chapter 1, section 1.5.2.2) (Kilday, Rahman et 
al. 2009). 
 
The SNP array analysis additionally highlighted location specific genomic differences 
between primary paediatric intracranial ependymomas. Posterior fossa tumours were 
associated with gain of chromosome 1q, particularly the regions 1q21.3, 1q22, 1q25.3, 
1q32.2 and 1q42.12 ± 44. Supratentorial tumours only demonstrated gain of 
chromosome 19p in a single sample, a region gained in other cerebral tumours such as 
CNS PNETs (Pfister, Remke et al. 2007). This contrasts with the CGH meta-analysis of 
paediatric ependymomas which confirmed 1q gain as the most frequent genomic 
imbalance in both posterior fossa and supratentorial ependymomas (Chapter 1, section 
1.5.2.2) (Kilday, Rahman et al. 2009). The lack of 1q gain in the supratentorial tumours 
of the SNP array cohort may be explained by relatively small sample numbers, although 
the 500K integrated SNP analysis of 204 ependymomas also observed that 
supratentorial tumours were characterised by numerous focal copy number aberrations, 
rather than broad imbalances (Johnson, Wright et al. 2010). The CGH meta-analysis 
further revealed that posterior fossa ependymomas in children often demonstrate loss of 
chromosomes 22, 6 and 17 while at recurrence, the loss of both 6q and 10q appeared 
exclusive to infratentorial tumours (Chapter 1, section 1.5.2.2) (Kilday, Rahman et al. 
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2009). This latter finding was not reflected in the SNP array analysis where 
chromosome 6 loss was seen in a spinal recurrence, albeit of a primary posterior fossa 
ependymoma (samples 40P and 40R1). 
 
The epigenetic array analysis also demonstrated a clear segregation of spinal from 
intracranial ependymomas. This categorisation reflects the results of several gene 
expression profile analyses which have shown differential expression profiles between 
intracranial and extracranial ependymomas (Chapter 4, section 4.1). (Korshunov, Neben 
et al. 2003; Taylor, Poppleton et al. 2005; Lukashova-v Zangen, Kneitz et al. 2007; 
Palm, Figarella-Branger et al. 2009; Johnson, Wright et al. 2010). The methylation 
study further revealed distinct profile differences both between and within posterior 
fossa and supratentorial ependymoma tumour groups, again supporting previous gene 
expression work. For instance, in addition to finding clearly defined expression 
signatures for supratentorial and posterior fossa ependymomas, one study of 103 
tumours identified three infratentorial expression subgroups including one characterized 
by numerous DNA amplifications and one where the samples had recurrent genomic 
gains of chromosome 1q (Taylor, Poppleton et al. 2005). Another analysis of 83 
ependymomas identified eight intracranial ependymoma subgroups based on their 
expression profiles (Johnson, Wright et al. 2010). The findings from this study therefore 
suggest that the distinct expression profiles identified in such subgroups may be a 
manifestation of dysregulated gene methylation mechanisms. Differentially methylated 
genes between ependymomas from the different CNS locations are examined in the next 
chapter. 
 
This analysis has contributed further to evidence demonstrating biological distinctions 
between ependymomas from different locations within the CNS. One explanation for 
this is that the individual tissue environment of each CNS location allows certain 
genetic aberrations to prosper whilst restricting the development of others (Hirose, 
Aldape et al. 2001). Evidence that the signature genes of supratentorial and spinal 
ependymomas are reciprocally expressed by murine embryonic radial glia in the 
corresponding CNS compartments (Taylor, Poppleton et al. 2005; Poppleton and 
Gilbertson 2007), has also led to the view that ependymomas from different locations 
within the CNS are derived from regionally (and developmentally) specified neural 
progenitor cells, presumed to be radial glia, that have undergone malignant 
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transformation (Taylor, Poppleton et al. 2005; Johnson, Wright et al. 2010) as discussed 
previously in Chapter 1, section 1.1.1. This concept is examined again in the final 
chapter. 
 
3.4.2 Aberrations in ependymomas from younger and older children 
 
This work also identified biological disparity between ependymomas from young and 
old paediatric patients (sections 3.3.4, 3.3.5 and 3.3.7). The comparison of genomic 
imbalances between primary ependymomas categorised according to a patient age 
threshold of three years was performed exclusively on the posterior fossa cohort of 24 
ependymomas, since tumour location was standardised and half of this subgroup fell 
either side of the age cut-off. Three years was selected as the threshold since this is the 
age at which craniospinal radiotherapy is routinely introduced as a therapeutic regime 
for paediatric ependymoma in the United Kingdom. While neither age category was 
associated with a particular broad imbalance, the number of chromosome arm 
imbalances was significantly fewer in the younger posterior fossa cohort. This finding 
refined the numerical difference in imbalances found between 116 paediatric and 187 
adult primary ependymomas from the CGH meta-analysis (707 paediatric versus 869 
adult anomalies; Chapter 1, section 1.5.2.1) (Kilday, Rahman et al. 2009).  
 
Unsupervised clustering of cytoband copy number data from the primary tumour cohort 
of the SNP array analysis elucidated this age discrepancy further and identified three 
broad genomic subgroups similar to those found in preceding lower resolution analyses 
(Dyer, Prebble et al. 2002; Mendrzyk, Korshunov et al. 2006; Puget, Grill et al. 2009). 
The first cluster group contained samples with very few or, in six cases, absolutely no 
cytoband imbalances present. All 15 tumours (36 %) with a defined balanced SNP 
profile and the majority of ependymomas from children aged below three years were 
found in this cluster group, which had a mean patient age of 4.8 + 0.9 years, compared 
to 10.2 + 1.1 years for the rest of the primary cohort. This supported the conventional 
and array CGH finding that a balanced genomic profile without chromosomal gain or 
loss, whilst uncommon in adult ependymomas, could be seen in 36 ± 58 % of paediatric 
cases and was particularly associated with children under three years of age (Reardon, 
Entrekin et al. 1999; Hirose, Aldape et al. 2001; Ward, Harding et al. 2001; Carter, 
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Nicholson et al. 2002; Dyer, Prebble et al. 2002; Modena, Lualdi et al. 2006). The 
second group was characterised by infrequent imbalances and gain of cytobands within 
chromosome 1q. In contrast to the first cluster group, the third subgroup showed 
frequent, large genomic anomalies, similar to those seen in the CGH meta-analysis of 
adult and spinal ependymomas (Chapter 1, section 1.5.2) (Kilday, Rahman et al. 2009). 
Indeed, all of the spinal tumours in the SNP analysis were located in this third group 
which had a relatively older mean patient age of 12.2 + 1.3 years compared to the 
remaining primary cohort.  
 
Bootstrapped unsupervised hierarchical cluster analysis of the methylation array data 
also grouped the ependymoma samples into two cohorts with significantly different 
mean patient ages, although this may have reflected the high proportion of spinal 
tumours in the older cluster and intracranial tumours in the younger cluster. 
Nevertheless, such clustering further isolated a small subgroup of nine ependymomas 
within a larger cluster of 34 posterior fossa tumours which were from children aged 
below three years, suggesting ependymoma methylation profiles may differ according 
to patient age.  
 
These global array findings demonstrate clear genomic and potential epigenetic 
differences between ependymomas from younger and older children. Ependymomas 
with a balanced genomic profile are often seen in children below three years of age, 
while the number of genomic imbalances that occur escalates with increasing patient 
age at diagnosis. At present, the explanations for this remain unclear. A difference in the 
number of genomic aberrations between ependymomas from both age groups may 
reflect the increasing genomic instability seen during the ageing process (Lombard, 
Chua et al. 2005) and appears consistent with a canonical multi-step cancer 
initiation/progression model for ependymomas from older children and adults. It also 
suggests that fewer defects in cell regulating processes are needed to initiate 
ependymoma in young children, since the behaviour of cells from immature normal 
tissue is similar to that of cancer cells with respect to differentiation, survival and self-
renewal (Knudson 1971; Scotting, Walker et al. 2005). Paediatric ependymomas 
demonstrating balanced genomic profiles or subtle imbalances substantiate this theory. 
This would imply that the genes affected by mutation in the younger age group are 
potent oncogenes or tumour suppressor genes, or are genes responsible for regulating 
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cell differentiation and self renewal that only possess an oncogenic effect restricted to a 
developmentally determined temporal window, environment, or indeed cell type as 
purported by comparative human and murine ependymoma expression work (Johnson, 
Wright et al. 2010).  
 
Alternatively, epigenetic phenomena may be affecting the expression profiles of an 
unknown number of genes in ependymomas from young children by altering their 
transcription and expression without a corresponding detectable genomic imbalance. 
The observation that tumours with a balanced SNP genome did not cluster 
independently on the GoldenGate® Cancer Panel I analysis reduces the possibility of 
methylation being a responsible mechanism, although the relatively low resolution and 
design of the current array for pre-selected genes cannot preclude it. Novel methylation 
arrays may help to address this uncertainty by interrogating over 27,000 CpG sites to 
provide a more comprehensive map of the tumour epigenome. Furthermore, the 
involvement of alternative epigenetic mechanisms such as histone deacetylation remains 
plausible and warrants further consideration (Peyre, Commo et al. 2010).  
 
3.4.3 Aberrations in potential prognostic groups 
 
3.4.3.1 Cytoband imbalance group two / chromosome 1q gain 
 
The most frequent chromosome arm imbalance seen in the primary SNP array cohort 
was gain of chromosome 1q (7/42 tumours, 17 %), where it was associated with a 
posterior fossa location and a worse overall patient survival on multivariate analysis. It 
was also the most frequent aberration seen in the intracranial first recurrent cohort (3/9 
tumours, 33 %) (section 3.3.4). Moreover, the unsupervised hierarchical clustering of 
cytoband copy number data across the primary tumour cohort identified a set of 
ependymomas characterised by gain of either the entire arm of chromosome 1q or 
cytobands confined to this region (group two) (section 3.3.5). Such tumours were 
associated with adverse outcome on univariate survival analysis and tumour progression 
on multivariate analysis. Whilst mirroring the CGH meta-analysis findings which 
demonstrated 1q gain as the most frequent anomaly in paediatric primary and recurrent 
ependymomas (Chapter 1, section 1.5.2) (Kilday, Rahman et al. 2009), the SNP array 
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results also imply a role for this aberration as a marker of both disease progression and 
ultimately, patient survival in this tumour group. This thereby lends support to the 
proposal of chromosome 1q gain, in conjunction with CDKN2A deletion, as detected by 
aCGH and FISH, being an adverse risk stratification marker that could be introduced 
into forthcoming clinical trials for ependymomas regardless of patient age (Korshunov, 
Witt et al. 2010). 
 
Conventional cytogenetic analyses have tried to decipher the mechanism for 1q gain in 
paediatric ependymoma (Kramer, Parmiter et al. 1998; Mazewski, Soukup et al. 1999) 
(Chapter 1, section 1.5.1). They have suggested that chromosome 1q gain results from a 
variety of unbalanced rearrangements with material from numerous partner 
chromosomes rather than a single, recurrent translocation. Therefore, a dosage effect for 
genes on 1q could be more important for initiating and propagating tumour growth than 
the influence of a translocated regulatory gene from a second chromosome. 
Furthermore, it has been hypothesized that the association between partial chromosomal 
rearrangement, such as chromosome 1q gain and poor prognosis in paediatric 
ependymoma could be anticipated since the acquisition of partial imbalances may have 
biological effects that exceed those preserving a broad genomic balance across 
individual chromosomes (Dyer, Prebble et al. 2002). 
 
As chromosome 1q spans a relatively large genomic area, previous cytogenetic and 
genomic studies have attempted to localise important regions of imbalance within 
chromosome 1q in paediatric ependymoma, associating gain of the region 1q21 ± 32 
with an anaplastic histology, tumour recurrence and adverse prognosis (Carter, 
Nicholson et al. 2002; Dyer, Prebble et al. 2002; Mendrzyk, Korshunov et al. 2006). 
Aberrations within this genomic sub-region were also observed by the SNP array 
cytoband analysis. In particular, gain of the region 1q21.2 ± 21.3 was identified as the 
most frequent regional imbalance within cluster analysis group two which was 
associated with an adverse patient outcome (section 3.3.5). Indeed, it was the most 
frequently gained chromosome 1q locus across the primary cohort (9/42, 21 %), being 
associated independently with an adverse event-free survival. It was also the most 
common region of gain from cytoband analysis of the entire recurrent cohort (9/21 
cases, 43 %) and one of the most frequent aberrations in the intracranial first recurrent 
cohort (4/9 cases, 44 %). This suggests that gain of 1q21.2 ± 21.3 could be implicated in 
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ependymoma progression and thus patient prognosis, warranting further analysis to 
establish candidate oncogenes. This is explored in subsequent chapters. Literature 
supports this theory, with gain of 1q21 associated with adverse prognosis in 
haematological malignancies (Fonseca, Van Wier et al. 2006) and solid cancers such as 
ovarian cancer (Kudoh, Takano et al. 1999), where it has been associated with disease 
recurrence in tumours resistant to cisplatin, a chemotherapeutic agent used regularly in 
paediatric ependymoma management. 
 
3.4.3.1.1 Refining the SNP definition of 1q gain 
 
In this SNP array analysis, an ependymoma was defined as having gain of chromosome 
1q if 80 % or more of the 19, 252 SNP probes mapping to this arm demonstrated a copy 
number greater than two.  This imbalance threshold was chosen as an unambiguous 
marker of true regional genomic gain or loss. FISH validation of chromosome 1q gain 
was performed on a cohort of 21 tumours using a LSI 1p36/1q25 dual colour probe 
(section 3.3.6). The presence of chromosome 1q gain as denoted by SNP analysis was 
found to correlate with the presence of 1q25 gain in over 30 % of nuclei counted by 
FISH (R = 0.7, p = 3.76x10-4) which validated the 5/21 ependymomas with SNP array 
evidence of chromosome 1q gain. However, one tumour sample (14P) revealed 1q25 
FISH gain in 38 % of nuclei counted, yet did not exhibit SNP array evidence of arm 
imbalance. Retrospective analysis of this sample revealed that 69 % of the SNP probes 
confined to chromosome 1q had a copy number of three or above, below the designated 
80 % threshold but still relatively high. Consequently, a higher correlation was achieved 
if the FISH percentage scores were compared to the copy number of the SNP probes 
confined to the actual region on 1q25.2 covered by the FISH probe (where gain in 
sample 14P was accounted for), or alternatively, if the arm imbalance SNP threshold 
was dropped from 80 % to 50 %.  (R = 0.79, p = 2.49x10-5). This collectively suggests 
that the accuracy of defining chromosome arm imbalance in SNP array analysis could 
be improved by lowering the proportion of encompassed SNP probes demonstrating 
copy number gain to 50 %. Indeed, such a threshold has been used recently in other 
large SNP array analysis of paediatric and adult high grade gliomas and ependymomas 
(Johnson, Wright et al. 2010; Paugh, Qu et al. 2010).  
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3.4.3.2 Cytoband imbalance group three 
 
Survival analysis was performed on all three primary ependymoma groups established 
from unsupervised cluster analysis of cytoband copy number data from the SNP array 
study (section 3.3.5). As with the first cluster, the 11 older patients with ependymomas 
comprising group three, incorporating all the spinal cases and characterised by 
numerous and often large genomic imbalances, did not demonstrate a statistically 
significant difference in event-free or overall survival compared to the remaining cohort 
(p = 0.307 and 0.151 respectively). This contrasted with the results of CGH and DNA 
cytometry studies which have suggested that a high number of genomic anomalies in 
ependymoma are associated with tumours of a lower histological grade and a favourable 
patient outcome (Scheil, Bruderlein et al. 2001; Carter, Nicholson et al. 2002; Gilhuis, 
van der Laak et al. 2004; Louis, Ohgaki et al. 2007).  
 
It has been argued that the association of numerous, sizeable copy number aberrations 
with improved patient outcome could reflect intermediate ploidy involving specific 
whole chromosomal imbalance patterns (Carter, Nicholson et al. 2002). This 
phenomenon has been associated with favourable outcome in other paediatric 
neoplasms such as acute lymphoblastic leukaemia (Chessels, Swansbury et al. 1997) in 
addition to spinal ependymomas, which predominate in group three of this SNP array 
analysis (Ebert, von Haken et al. 1999).  Studies have also suggested that cells of 
intermediate ploidy exhibit increased chemosensitivity compared to cells of a near 
diploid state (Synold, Relling et al. 1994; Kaspers, Veerman et al. 1995). Indeed, one 
particular CGH analysis of 53 paediatric intracranial ependymomas found that 
µQXPHULFDO¶ WXPRXUV FKDUDFWHULVHG E\  RU PRUH FKURPRVRPDO LPEDODQFHV KDG DQ
improved overall survival when compared to tumours with a balanced genomic profile 
(Dyer, Prebble et al. 2002) (Chapter 1, section 1.5.2.1).  
 
There are explanations for the discrepancy in results between this study and the work of 
Dyer et al. The average number of arm or whole chromosome imbalances seen in the 
third group from the SNP array analysis was five, below the threshold of 13 set in the 
CGH study. Indeed, none of the ependymomas in the SNP array cohort would have had 
HQRXJKEURDGLPEDODQFHVWREHFODVVLILHGDVµQXPHULFDO¶LQWKH'\HUVWXG\SODFLQJWKHP
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in an inferior prognostic category. The categorisation adopted by an aCGH analysis of 
68 ependymomas (Mendrzyk, Korshunov et al. 2006)ZKHUHµQXPHULFDO¶VDPSOHVZHUH
those with greater than two imbalances, may therefore be more appropriate for the SNP 
array cohort examined. Moreover, all of the patients in group three of the present study 
remained alive although several of the cases were relatively new diagnoses, with a short 
mean follow up time of 2.3 years. This implies that a significant improvement in overall 
survival for this patient subgroup may be realised if their follow up period was extended 
to match the rest of the primary tumour cohort, in keeping with the findings from 
literature noted above.  
 
3.4.3.3 Other aberrations in recurrent intracranial ependymomas 
 
Although the SNP array analysis found that gain of either the entire chromosome 1q 
arm or confined sub-regions within it were associated with paediatric ependymoma 
recurrence and a worse relapse free patient survival, other genomic imbalances with a 
potential role in disease progression were also noted (sections 3.3.4 and 3.3.5).   
 
The gain of chromosome 9 was a frequent occurrence in the SNP array cohort, 
including the entire recurrent cohort where it was observed in 5/21 cases (24 %). Gain 
of chromosome 8 was observed exclusively in intracranial recurrent tumours of the SNP 
array cohort, being significantly associated with the first recurrent cohort when 
compared to primary tumours. In one posterior fossa ependymoma patient (samples   
26P ± R3), gain of both chromosomes 8 and 9 was acquired at recurrence and 
maintained through three subsequent local recurrences. In another case (sample 40P and 
40R1), gain of chromosome 9 was present in the primary posterior fossa tumour and 
maintained in the spinal recurrence.  
 
Deletion of chromosome 22q was the most frequent chromosome arm loss in the 
primary cohort (3/42 cases, 7 %), occurring in both intracranial and extracranial 
tumours. However, 22q deletion was also present in the intracranial first recurrent 
cohort (1/9 cases, 11 %), with 22q13.1 ± 13.31 and 22q13.33 loss being significantly 
associated with this recurrent group. Furthermore, chromosome 22q loss was identified 
as another maintained aberration in the spinal recurrence (40R1) of the primary 
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posterior fossa sample 40P, along with chromosome 6 loss and the aforementioned 
chromosome 9 gain.  
 
These findings indicate that imbalances involving chromosomes 1q, 6, 9 and 22 may be 
implicated in primary ependymoma tumourigenesis and subsequent tumour 
maintenance. Furthermore these chromosomal anomalies, along with the acquired gain 
of chromosome 8, may also be implicated in disease progression and therapeutic 
resistance. Many of these genomic aberrations are examined at a higher resolution and 
discussed further in the fifth chapter which explores maintained and acquired genomic 
alterations in primary and recurrent paediatric ependymoma paired samples.   
 
3.5 Summary  
 
Paediatric ependymomas continue to present a management challenge, largely due to 
the difficulty in predicting a clinical course from current histopathological and putative 
prognostic markers. Indeed, present treatment regimens for childhood ependymomas in 
the United Kingdom are stratified according to patient age and degree of tumour 
resection, both of which have been inconsistently reported as markers of outcome. As a 
consequence, attention has focussed on an improved understanding of ependymoma 
biology to improve patient survival.  
 
Initially, this study has shown clear genomic and epigenetic disparity between 
paediatric ependymomas, particularly with respect to tumour location, patient age, 
tumour recurrence and patient outcome. Underpinning this biological diversity is the 
purported concept of the ependymoma-initiating cell. 
 
The SNP array analysis found that spinal ependymomas were characterised by 
numerous and often broad genomic imbalances including gains of chromosome 17p, 
12q, 21q, 16, 9, 18 and 20. In contrast supratentorial tumours demonstrated few large 
anomalies, while posterior fossa tumours were associated with gain of chromosome 1q. 
Likewise, the differentiation of spinal and intracranial ependymomas was evident from 
the methylation array analysis, which also observed distinct profiles both between and 
within posterior fossa and supratentorial groups. The SNP array data also revealed 
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ependymomas from younger children had fewer broad genomic aberrations than older 
children, while anomalies found at tumour recurrence included gains of chromosome 
1q, 6, 8 and 9 and loss of chromosome 22.  Moreover, clustering of imbalances enabled 
paediatric ependymomas to be categorised into three genomic groups. One such group, 
characterised by gain of either the entire arm of chromosome 1q or cytobands confined 
to this region, was associated with adverse patient survival thereby suggesting that this 
aberration warrants further consideration as a prognostic marker in paediatric 
ependymoma.  
 
Many of the global aberrations detected in this work were subsequently analysed at an 
increased genomic resolution, the results of which are presented in subsequent chapters. 
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CHAPTER 4 
 
PUTATIVE CANDIDATE GENES IN THE PATHOGENESIS 
OF PAEDIATRIC EPENDYMOMA 
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 4.1 Introduction 
 
Previous expression analyses have implicated a variety of genes in ependymoma 
pathogenesis, particularly when considering tumour location, grade or genomic 
imbalance. Intracranial ependymomas have been shown to upregulate RAF1 (3p25) and 
members of the Notch, EPHB-EPHRIN, Hedgehog and bone morphogenetic protein 
pathways. In contrast, spinal ependymomas overexpress genes responsible for peptide 
production and activity including PLA2G5 (1p36.1) and ITIH2 (10p14), together with 
homeobox (HOX) family members involved in normal anteroposterior tissue 
development (Korshunov, Neben et al. 2003; Taylor, Poppleton et al. 2005; Modena, 
Lualdi et al. 2006; Lukashova-v Zangen, Kneitz et al. 2007; Palm, Figarella-Branger et 
al. 2009). The overexpression of EVI1 is reported to be exclusive to infratentorial 
ependymomas (Koos, Bender et al. 2011), while the disparate expression of CDKN2A 
(9p21.3) between spinal and supratentorial ependymomas and the association of spinal 
tumours with mutations of NF2 (22q12.2) and other Protein 4.1 family members have 
already been highlighted in Chapter 3. Differential gene expression profiles between 
classic and anaplastic intracranial ependymomas have been identified (Korshunov, 
Neben et al. 2003; Palm, Figarella-Branger et al. 2009), while the dysregulated 
expression of certain genes within regions of frequent genomic alteration such as 
chromosome 1q and 22q has also been demonstrated, including the overexpression of 
DUSP12 (1q23.3), PRELP (1q32) and HSPA6 (1q23) and the underexpression of 
G22P1 (22q13.2) and MCM5 (22q13.1) (Almeida, Zhu et al. 1998; Korshunov, Neben 
et al. 2003; Suarez-Merino, Hubank et al. 2005; Mendrzyk, Korshunov et al. 2006; 
Modena, Lualdi et al. 2006). However, almost all of the cohorts examined in these 
analyses were either wide-ranging in age or comprised entirely of adults, questioning 
the relevance of such findings for ependymomas in children.  
 
Where feasible, some studies have detected age-related differences in the biological 
profile of particular genes in ependymomas from mixed-age cohorts. These include the 
overexpression of cell proliferation regulator genes LDHB (12p12.1) and STAM 
(10p12.3), upregulation of TNC (9q33), NTRK2 (9q21.33), ASS (9q34.1), KIAA0368 
(9q31.3), hypomethylation of CDKN2A and CDKN2B (9p21.3) and hypermethylation of 
HIC1 (17p13.3) in younger patients (Korshunov, Neben et al. 2003; Rousseau, Ruchoux 
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et al. 2003; Waha, Koch et al. 2004; Modena, Lualdi et al. 2006). Although uncommon, 
exclusive expression analyses of paediatric ependymomas have been performed, finding 
supratentorial tumours differ from posterior fossa counterparts in the overexpression of 
neuronal markers NEFL (8p21.2), LHX2 (9q33.3), FOXG1 (14q12), TLX1 (10q24.3), 
and NPTXR (22q13.1) yet underexpression of RELN (7q22.1) and TNC (Andreiuolo, 
Puget et al. 2010), whilst also revealing aberrant expression of further genes on 
chromosomes 1q and 22q such as laminin (1q31), GAC1 (1q32) and CBX7 (22q13.1) 
(Suarez-Merino, Hubank et al. 2005). However, whether these findings are 
representative of the wider paediatric ependymoma population remains uncertain as the 
examined cohort sizes were small. 
 
Until recently, the limited resolution of CGH to examine the ependymoma genome for 
copy number alterations meant that candidate genes within identified regions of gain or 
loss could only be postulated. Two subsequent array CGH studies refined this approach 
by assimilating genomic data with gene expression profiling for a subset of their 
cohorts, identifying genes with potentially copy number driven dysregulated expression. 
These included the putative tumour suppressor genes PTGDS (9q34), SULT4A1 
(22q13.3) and oncogenes RXRA (9q34), TNC (9q33), ANAPC2 (9q34), PTGES (9q34), 
NTRK2 (9q21), COL27A1 (9q32) and NOTCH pathway members JAG1 (20p12) and 
NOTCH1 (9q34) (Modena, Lualdi et al. 2006; Puget, Grill et al. 2009). However, both 
studies analysed small cohorts and could not exclude other genes encompassed within 
these regions of imbalance from involvement in ependymoma pathogenesis.  
 
The resolution of SNP array technology addresses the latter issue, allowing a more 
precise identification of copy number alteration boundaries. Using this platform, 
Johnson and colleagues integrated copy number data for 204 ependymomas with 
expression array profiles for a subset of 83 tumours (Johnson, Wright et al. 2010). This 
identified 107 putative ependymoma oncogenes including THAP11 (16q22.1), PSPH 
(7p11.2), EPHB2 (1p36.12), RAB3A (19p13.11), PCDH family members, PTPRN2 
(7q36.3) and again, NOTCH1. Likewise, 130 potential tumour suppressor genes were 
detected including PTEN (10q23.31), CDKN2A (9p21.3), STAG1 (3q22.3) and TNRC6B 
(22q13.1). Moreover, overexpression of EPHB2 in CDKN2A/Ink4a/Arf -/- mice 
generated highly penetrant tumours that modelled the histology and expression profile 
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of certain human supratentorial ependymomas, supporting the suggestion that these two 
genes are implicated in the pathogenesis of a particular ependymoma subtype. However, 
ZKLOVW WKH ODUJHVW UHSRUWHG VWXG\ RI LWV NLQG -RKQVRQ¶V DQDO\VLV GLG QRW H[FOXVLYHO\
assess a paediatric population. The cohort also comprised primary and recurrent 
ependymomas, often from the same patient, leading to the potential over-representation 
of certain anomalies, while the blood reference DNA used for the SNP analysis was 
obtained from a pool of adult leukaemia patients in remission post treatment.   
 
The objective of this 500K SNP array analysis was to refine the copy number 
aberrations of ependymomas occurring in a paediatric age range, by normalising tumour 
DNA predominantly against patient-matched constitutional DNA. After an initial global 
analysis, the subsequent aim was to look with higher resolution for frequent and novel 
alterations both across the cohort and within clinical subgroups, then associate 
particular focal regions of imbalance in intracranial ependymoma with patient survival. 
The ability to generate copy number and LOH data for each SNP probe also enabled a 
unique opportunity to look for regions of acquired uniparental disomy (aUPD), a 
mechanism resulting in mutational homozygosity despite copy number neutrality as 
described in Chapter 1, section 1.3.2. While aUPD has been identified in other 
paediatric cancers (Fitzgibbon, Smith et al. 2005; George, Attiyeh et al. 2007; 
Raghavan, Smith et al. 2008), this was the first analysis attempting to establish its 
existence in childhood ependymoma.  
 
As with the SNP array work, methylation array analysis performed as part of this study 
has already demonstrated distinct epigenetic profiles between different paediatric 
ependymoma groups, such as those according to tumour location within the CNS. 
Subsequent high resolution analysis of this epigenetic work aimed to identify 
differentially methylated genes responsible for such differences. Of interest were 
putative tumour suppressor genes demonstrating hypermethylation and thereby potential 
epigenetic inactivation or, conversely, candidate oncogenes conceivably upregulated 
through hypomethylation. 
 
The following hypotheses were explored: 
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 High resolution genomic analysis will identify genes and/or pathways 
potentially involved in paediatric intracranial ependymoma pathogenesis. 
 Ependymomas occurring in different anatomical locations within the central 
nervous system (CNS) harbour genes demonstrating distinct genomic and/or 
epigenetic aberrations. 
 Intracranial ependymomas from younger children (under three years of age) 
harbour genes exhibiting different genomic and epigenetic alterations to 
intracranial ependymomas from older children (over three years of age). 
 The genomic copy number alteration or methylation status of particular genes 
can define other groups with a clinical and/or prognostic relevance in paediatric 
intracranial ependymoma. 
 Acquired uniparental disomy is a tumourigenic mechanism in paediatric 
ependymoma. 
 
4.2 Materials and methods 
 
4.2.1 500K SNP array analysis of 45 paediatric ependymomas 
 
4.2.1.1 The sample cohort 
 
Tumour and blood DNA extraction is outlined in Chapter 2, sections 2.1.3 ± 2.1.4. An 
overview of the 500K SNP array protocol and data processing procedures followed are 
described in Chapter 2, sections 2.2.1 ± 2.2.5. Clinical data for the entire SNP array 
cohort is summarised in Chapter 3, Figure 3.1 and the comprehensive data set is 
detailed in Chapter 3, Table 3.1. Of the cohort, 39 tumours (62 %) were incorporated 
into the SNP array study by Johnson and colleagues (Johnson, Wright et al. 2010). For 
the high resolution genomic imbalance analysis presented in this chapter, 36 primary 
and nine first recurrent intracranial ependymomas were assessed. Subsequent 
recurrences (2nd ± 5th) were examined but are presented and discussed in Chapter 5. 
High resolution analysis of spinal ependymomas was not performed. It was deemed 
uninformative since the aberrations seen in these tumours predominantly involved 
whole chromosomal changes. As in Chapter 3, probes on chromosome X were excluded 
from the analysis (Chapter 3, section 3.2.1.1), while the analysis of genomic imbalance 
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between patients aged above and below three years was again performed exclusively on 
the primary posterior fossa cohort of 24 ependymomas. 
 
Acquired UPD (aUPD) analysis requires the comparison of blood and tumour DNA 
from the same patient. Since five erroneous blood DNA samples had been removed 
from the study (Chapter 3, section 3.2.1.1), ten ependymomas corresponding to these 
five patients were also excluded from this particular analysis (samples 14P, 17P ± R2, 
19R1 ± R2, 35P ± R2 and 39P). Primary spinal tumours were included in this aspect of 
the analysis which resulted in an aUPD cohort of 38 primary and six intracranial first 
recurrent ependymomas. 
 
4.2.1.2 Genomic imbalance data analysis ± gene list formation 
 
Annotated copy number data for each SNP probe within a tumour sample was available. 
Using the Excel 2007 program (Microsoft, USA), this information was collated and 
ordered according to the frequency with which a particular SNP probe demonstrated 
copy number gain or loss within a given collection of tumours. Genomic loss was 
defined by a copy number value below two, which was further divided into hemizygous 
(copy number one) and homozygous (copy number zero) deletion. Lower level copy 
number gain was defined by a copy number of three or four, while amplification was 
achieved with a copy number of five or six. At least five consecutive SNPs spanning 
regions greater than 10kb had to reveal the same imbalance before the corresponding 
region, HVWDEOLVKHG IURP WKH DQQRWDWLRQ GDWD FRXOG EH LQFRUSRUDWHG LQWR D ILQDO µJHQH
OLVW¶ IRU WKHSDUWLFXODU WXPRXUJURXSDVVHVVHG7KHVHSDUDPHWHUVZHUH LQNHHSLQJZLWK
other SNP array analyses (Baker, Preisinger et al. 1990; Northcott, Nakahara et al. 
2009; Johnson, Wright et al. 2010) and thereby provided a means of identifying genes 
with the most common copy number aberrations across a chosen number of 
ependymomas. Gene lists generated for particular clinical subgroups were also 
compared against each other to establish group specific genomic aberrations. 
 
The annotation file (Netaffx file build 07.12.07) used to generate the gene lists only 
accounted for genes assigned to SNPs on the array and thereby not all genes within a 
given focal region. However, as the lists were prepared manually, only SNP-assigned 
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genes were created in order to avoid the presentation of exhaustive lists and satisfy the 
inherent time constraints on the project. This was adhered to except for focal regions 
encompassing the genes of interest selected for subsequent qPCR validation. All genes 
within these regions were identified using the web-based genomic database Ensembl 
(http://www.ensembl.org) and included in the gene lists presented. Established gene 
functions were derived from the Genecard database (www.genecards.org) unless 
referenced. 
 
4.2.1.3 aUPD data analysis and visualisation 
 
Genotyping data was also available for each probe on the 500K array, as a result of 
processing through GTYPE (Chapter 2, section 2.2.3). By comparing probe genotype 
calls between patient-matched tumour and blood DNA through CNAG, regions of LOH 
throughout the genome were identified. Combining LOH results with the copy number 
data for each SNP probe in Microsoft Excel 2007 enabled sites of copy number neutral 
LOH (aUPD) to be identified across the analysed cohort (Appendix 10H). A true region 
of focal aUPD was defined when five or more consecutive SNP probes covering a 
distance greater than 10kb had demonstrated copy number neutral LOH. The aUPD data 
from Excel 2007 was exported to Spotfire Decision Site® for data visualisation, whilst 
aUPD regions within genes were used to formulate subsequent gene lists. An overview 
of the method used to calculate aUPD for each tumour sample is shown in Appendix 5.   
 
4.2.1.4 Real time qPCR validation of SNP array results 
 
The SNP derived copy number for selected genes of interest was validated using real 
time qPCR as detailed in Chapter 2, section 2.4. Where possible, tumour and blood 
DNA processed on the SNP microarray was also used for qPCR analysis. However in 
42/63 ependymomas from the SNP array cohort (67 %; 26 primary and 16 recurrent 
tumours), the DNA stock had been exhausted, either from the microarray analysis itself 
or subsidiary collaborative projects. Consequently, the DNA from 31 ependymomas 
from the SNP array cohort (58 %; 24 primary and seven recurrent tumours) was used 
for qPCR validation. Within this sample set, 18 tumours (12 primary and six recurrent) 
required DNA re-extraction from a different cut of tumour (performed as detailed in 
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Chapter 2, section 2.1.2 and 2.1.3). Furthermore, in certain qPCR experiments, control 
DNA (Promega, UK) was used as an alternative to three of the erroneous samples of 
blood DNA (17P ± R2 bl, 19R ± R2 bl and 35P ± R2 bl) discussed previously. 
 
For validated target genes, up to eight tumours demonstrating imbalance of that gene 
from the microarray analysis were evaluated with between three and eight tumours 
exhibiting a normal SNP copy number for that gene. The precise number of samples 
used varied depending on the target gene being analysed (section 4.3.5). The gene copy 
numbers derived from the SNP array and real time qPCR methods were correlated using 
6SHDUPDQ¶VFRUUHODWLRQChapter 2, section 2.7.3). Tables documenting all qPCR results 
for the genes of interest are included in Appendix 10I. 
 
4.2.2 Methylation array analysis of 98 paediatric ependymomas 
 
An overview of the methylation array protocol adopted and subsequent data processing 
methods are described in Chapter 2, sections 2.3.1 ± 2.3.4. Clinical data for the entire 
methylation array cohort is summarised in Chapter 3, Figure 3.2 and the comprehensive 
data set is detailed in Chapter 3, Table 3.2. The methylation data for all tumours of the 
array cohort is included in Appendix 10F. 
 
4.2.2.1 Differential gene methylation analysis 
 
This was performed as described in Chapter 2, section 2.7.7. Probes on the X 
chromosome were removed from the analysis as detailed in Chapter 3, section 3.2.2.2. 
The clinical subgroups of patient sex (male versus female), age (below three years of 
age versus above three years of age), tumour resection status (complete versus 
incomplete), tumour grade (WHO grade II versus WHO grade III), tumour location 
(spinal versus intracranial, supratentorial versus alternative locations, posterior fossa 
versus alternative locations) and patient survival status (alive versus dead) were 
assessed on the primary cohort of 73 tumours. In addition, the intracranial primary 
cohort of 56 ependymomas was initially compared against 11 first recurrent intracranial 
tumours and then the entire intracranial recurrent cohort.  
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Genes differentially methylated between ependymomas from different CNS locations 
were cross-checked for matches against a list of signature genes of ependymomas from 
the three principal CNS sites as identified by the expression array work of Taylor and 
colleagues (Taylor, Poppleton et al. 2005). This was performed to establish whether 
such characteristic expression profiles could be a manifestation of dysregulated gene 
methylation mechanisms.  
 
4.2.3 Other statistical analysis 
 
Gene lists from particular clinical subgroups were compared statistically to identify 
group-specific focal imbalances. An overview of the formulaic method used to perform 
this is shown in Appendix 6. Imbalances associated with a particular group were ranked 
in order of statistical significance as deemed by two-WDLOHG)LVKHU¶VH[DFWWHVWLQJ6366
16). Only associations with a p-value below 0.05 were considered. The clinical 
subgroups were derived from the variables of tumour location (supratentorial versus 
posterior fossa), patient age (posterior fossa ependymomas: patients under three years 
versus over three years) and tumour grade (WHO grade II versus grade III).  
 
Other statistical tests performed in this chapter are described in Chapter 2, section 2.7. 
The variables included in multivariate survival analysis are as described in Chapter 3, 
section 3.2.3.  
 
4.3 Results 
 
4.3.1 Gene copy number imbalance in paediatric intracranial ependymoma  
 
4.3.1.1 Common focal regions of genomic gain in primary intracranial 
ependymomas 
 
In keeping with the lower genomic resolution analysis (Chapter 3, section 3.3), copy 
number gain was a more frequent event than loss. Focal regions of genomic gain in the 
primary intracranial cohort of 36 ependymomas were identified and ranked according to 
frequency (Figure 4.1 and Table 4.1). The most common regions were predominantly 
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located on chromosome 1q and chromosome 18, specifically within 1q44 (18/36 
samples; 50 %), 1q32.3 (up to 17/36; 47 %), 18p11.21 (16/36; 44 %) and 18q23 (16/36; 
44 %). Genes found to be encompassed within the regions on chromosome 1q included 
the transcriptional regulators ZNF672 and ZNF692 (1q44) and NSL1 (1q32.3), a gene 
encoding part of a protein complex required for kinetochore formation Within the 
18p11.21 region was the SEH1L gene which encodes another protein complex 
component responsible for promoting kinetochore function. Other common sites of 
genomic gain included foci within 4q35.2, 11q24.3 and 9q31.3. These encompassed 
genes such as DNAJC25 (9q31.3) which encodes a member of the DNAJ/HSP40 heat 
shock protein family.  
 
 
Figure 4.1: The most frequent focal regions of increased copy number in 36 primary intracranial ependymomas. For 
each gene region, samples with low level copy number gain (copy number 3 or 4) are differentiated from those with 
amplification (copy number 5 or 6) by light and dark green shading respectively. bp = base pair, i = intronic, u = 
XSVWUHDP RI DQQRWDWHG JHQH G   GRZQVWUHDP RI DQQRWDWHG JHQH ¶875   ¶ XQWUDQVODWHG UHJLRQ &'6   FRGLQJ
sequence. 
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Table 4.1: The most frequent focal regions of increased copy number in 36 primary intracranial ependymomas. 
 
Locus Start (bp) End (bp) Gene symbol Additional genes in this region Total CN 3 or 4 CN 5 or 6 
1q44 247069146 247135059 OR5BU1 (d) ±  ZNF692 (d) SH3BP5L, ZNF672, ZNF692 18 17 1 
1q32.3 210937704 211013542 SNFT (i) ± NSL1 (i)  17 14 3 
1q32.3 210801617 210925420  ATF3 (u) ± FAM71A (d) FAM71A 16 16 0 
4q35.2 187326127 187353221 DKFZP564J102 (i) ± CYP4V2 (i)  16 11 5 
9q31.3 113426420 113463254 ENST00000374304 (i)  ± LOC552891 (i) DNAJC25 16 9 7 
11q24.3 129371863 129473754 PRDM10 (i) ± APLP2 (i)  16 13 3 
18p11.21 12918541 12979722 SEH1L (u ± d)  16 11 5 
18q23 72613722 72670749 ZNF236 (u ± i)  16 13 3 
18q23 75474284 75507191 FLJ25715 (u-i)  16 14 2 
18q23 75602382 76017006 CTDP1 (i) ± PARD6G ¶875 PQLC1,TXNL4A, C18orf22, ADNP2 16 16 0 
Note: The gene symbols representing the start and end of each specified genomic region are shown, together with additional encompassed genes identified from the Affymetrix® annotation file 
(Netaffx file build 07.12.07). The total number of samples within the cohort demonstrating genomic gain of the region is also shown. This total is then split according to numbers exhibiting low 
level gain (CN 3 or 4) or amplification (CN 5 or 6). CN = copy number, bp = base pair, i = intronic, u = upstream of annotated gene, d = downstream of DQQRWDWHGJHQH¶875 ¶XQWUDQVODWHG
region, CDS = coding sequence. Genes highlighted in red had their copy number validated by real time qPCR. Focal regions encompassing these highlighted genes were additionally examined 
using the web-based genomic database Ensembl to identify all other interrogated genes which are duly included. 
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4.3.1.2 Common focal regions of genomic loss in primary intracranial 
ependymomas 
 
Focal regions of copy number loss in the primary intracranial cohort of 36 tumours were 
identified and ranked according to frequency (Figure 4.2 and Table 4.2). Several of the 
most common regions were located across chromosome 6q, specifically within        
6q13 ± 14.1 (4/36 samples; 11 %), 6q16.1 (up to 5/36; 14 %), 6q22.1 ± 22.31 (4/36;    
11 %) and 6q27 (4/36; 11 %). Other foci of deletion were found at 11q12.2, 16q24.1, 
22q11.21, 22q12.3 and 22q13.31 (4/36 samples; 11 %). Putative tumour suppressor 
genes reported from other studies were encompassed by certain focal regions detected 
on chromosome 6q. These included FILIP1 (6q14.1), a gene encoding a filament 
interacting protein (Shimada, Shiratori et al. 2009) and the tyrosine kinase encoding 
FRK/RAK (6q22.1) (Yim, Peng et al. 2009). 
 
 
Figure 4.2: The most frequent focal regions of decreased copy number in 36 primary intracranial ependymomas. For 
one gene region, samples with hemizygous deletion (copy number 1) are differentiated from the sample with 
homozygous deletion (copy number 0) by light and dark red shading respectively. bp = base pair, i = intronic, u = 
upstream of annotated gene, d = downstream of annotated gene. 
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Table 4.2: The most frequent focal regions of decreased copy number in 36 primary intracranial ependymomas. 
 
Locus Start(bp) End(bp) Gene symbol Additional Genes in this region Total CN 1 CN 0 
6q16.1 92913726 92951742 ENST00000363622 (d)  ± ENST00000386471 (u)  6 5 1 
6q13 72646417 72967122 RIMS1 (u-i)  4 4 0 
6q13-14.1 75809165 76249718 CD109 (d) ± FILIP1 (i) TMEM30A, COL12A1, COX7A2 4 4 0 
6q14.1 79252979 79544001 IRAK1BP1 (u)  4 4 0 
6q14.1 80951883 81916795 BCKDHB (i-d)  4 4 0 
6q14.1 82398726 83098352 FAM46A (d) ± TPBG (u) FAM46A, IBTK 4 4 0 
6q16.1 92449499 92760201 MAP3K7 (d)  ± ENST00000386565 (u)  4 4 0 
6q22.1 115407082 115764663 FRK (d)  4 4 0 
6q22.1 116381423 116642944 FRK (i) ± NT5DC1 (i) COL10A1 4 4 0 
6q22.1 116926752 117126249 ENST00000356128 (i)  ± KPNA5 (i) FAM26D, FAM26E, RWDD1, RSHL3 4 4 0 
6q22.31 123841038 125314016 TRDN (i) ± RNF217 (u) ENST00000334268, TCBA1 4 4 0 
6q27 164971699 165411821 C6orf118 (d)  4 4 0 
11q12.2 61327359 61365899 FADS1 (i) ± FADS2 (i)  4 4 0 
16q24.1 83628627 83640211 KIAA0513 (i)  4 4 0 
22q11.21 18411964 18433554 C22orf25 (i-d)  4 4 0 
22q12.3 32986814 33103088 ISX  (u)  4 4 0 
22q13.31 46653061 46744848 LOC388915 (u)   4 4 0 
Note: The gene symbols representing the start and end of each specified genomic region are shown, together with additional encompassed genes identified from the Affymetrix® annotation file 
(Netaffx file build 07.12.07). The total number of samples within the cohort demonstrating genomic loss of the region is also shown. This total is then split according to numbers exhibiting 
hemizygous (CN 1) or homozygous genomic deletion (CN 0). CN = copy number, bp = base pair, i = intronic, u = upstream of annotated gene, d = downstream of annotated gene. Genes 
highlighted in red had their copy number validated by real time qPCR. Focal regions encompassing these highlighted genes were additionally examined using the web-based genomic database 
Ensembl to identify all other interrogated genes which are duly included. 
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4.3.1.3 Common focal regions of genomic gain in recurrent intracranial 
ependymomas 
 
Focal regions of copy number gain in the first recurrent intracranial cohort of nine 
ependymomas were identified and ranked according to frequency (Table 4.3 and Figure 
4.3). Genomic gain was again observed more often than loss and was seen particularly 
on chromosome 1q. The most common regions were located within 1q23.3, 1q25.3 and 
1q32.1 (6/9 samples; 67 %). This latter site encompassed the gene NAV1 which encodes 
a member of the neuron navigator protein family. 
 
Other common regions of gain spanning chromosome 1q were identified in over half of 
the cohort (5/9 samples 55 %). Numerous genes were encompassed by these locations 
including CHIT1 and CHI3L1/YKL40 (1q32.1), both members of the chitinase family 
and NES (1q23.1) which encodes the neuronal stem cell marker Nestin. Genes involved 
in a variety of cellular processes required for tumourigenesis and recurrence were also 
evident. For instance, genes reported to be involved in cell migration and invasion, 
neurite growth and the inhibition of apoptosis were identified such as BCAN/BEHAB 
(1q23.1), ASTN1, TNN (1q25.1), ABL2 (1q25.2), LAMC1 (1q25.3), MDM4 (1q32.1), 
PIK3C2B, NFASC and CDC42BPA (1q42.13) (Jaworski, Kelly et al. 1996; Volkmer, 
Leuschner et al. 1996; Fink, Hirsch et al. 1997; Migliorini, Lazzerini Denchi et al. 2002; 
Neidhardt, Fehr et al. 2003; Wiksten, Liebkind et al. 2003; Wilkinson, Paterson et al. 
2005; Katso, Pardo et al. 2006; Srinivasan and Plattner 2006). Genes encoding 
kinetochore associated proteins were also detected, including PMF1 (1q23.1), NUF2 
(1q23.3), KIF14 (1q32.1) and CENPF (1q41).  
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Table 4.3: The most frequent focal regions of increased copy number in nine first recurrent intracranial ependymomas. 
 
Locus Start (bp) End (bp) Gene symbol Additional genes in this region Total CN 3 or 4 CN 5 or 6 
1q23.3 163712154 163733164 RXRG (u)   6 5 1 
1q25.3 180381192 180429300 ZNF648 (u)  6 5 1 
1q32.1 199876870 199934485 NAV1 (i)  6 6 0 
1q21.1 142756696 144232761 ENST00000360154 (i)  ± PEX11B (i) PDE4DIP, ENST00000369338, HFE2, 
LIX1L 
5 5 0 
1q21.3 151712798 152059582 S100A7 (d) ± GATAD2B (i) S100A1-6/A13,14,16,  C1orf77, SNAPAP, 
NPR1, INTS3 
5 5 0 
1q21.3 152834710 153070269 ADAR (i) ± KCNN3 (i)  5 5 0 
1q23.1 154245657 158107790 SSR2 ¶875± SLAMF8 (d) MAPBPIP, LMNA, SEMA4A, SLC25A44, 
PMF1, SMG5, CCT3, C1orf182, C1orf161, 
RHBG, MEF2D, IQGAP3, APOA1BP, 
GPATCH4, BCAN, NES, ISG20L2, 
MRPL24, PRCC, INSRR, SH2D2A, NTRK1, 
ARHGEF11, FLJ16478, ETV3, FCRL1-5, 
CD5L, KIRREL, SLAMF8, 
ENST00000368172, CD1C-E, OR10T2, 
CADM3, ENST00000368153, OR10R2, 
OR6Y1, DARC, SPTA1, 
ENST00000368153/361688/334632, 
OR6N1, OR6N2, MNDA, 
ENST00000359709, IFI16, FCER1A, 
FCRL6, PYHIN1, APCS, 
ENST00000328408/289731/356104/368102 
5 5 0 
1q23.3 161675875 161768950 NUF2 (u) ± ENST00000385703 (d) NUF2 5 5 0 
1q23.3 163423053 163710084 LMX1A (u) ± RXRG (d) LMX1A, RXRG 5 5 0 
1q23.3-24.1 163776914 165356012 LRRC52 (u) - ENST00000361200 (i) LRRC52, MGST3, ENST00000367888, 
ALDH9A1, TMCO1, UCK2, FAM78B,  
ENST00000367877,ENST00000336247, 
POGK, TADA1L, C1orf32, MAEL, GPA33 
5 5 0 
1q24.2 167194079 167400429 NME7 (u-i) ATP1B1 5 5 0 
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Locus Start (bp) End (bp) Gene symbol Additional genes in this region Total CN 3 or 4 CN 5 or 6 
1q25.1 173357037 176182097 TNN (i) ± SEC16B (i) KIAA0040, TNR, ENST00000367674, 
RFWD2, PAPPA2, ASTN1, FAM5B 
5 5 0 
1q25.2 176881837 
 
179132968 RALGPS2 (u) ± STX6 (u) RALGPS2, ANGPTL1, FAM20B, TOR3A, 
ABL2, SOAT1, C1orf125, TDRD5, C1orf76, 
TOR1AIP1, XPR1, TOR1AIP2, CEP350, 
QSOX1, LHX4, ACBD6,  
5 5 0 
1q25.3 179453720 179830712 IER5 (d)  ± CACNA1E (i) ENST00000367573 5 5 0 
1q25.3 180249013 180378729 ZNF648 (u-d)  5 5 0 
1q25.3 180571770 181488636 ENST00000361845 (CDS)  ± 
NMNAT2 (i) 
TEDDM1, C1orf120, RGSL1, RGSL2, 
RNASEL, RGS8, NPL, DHX9, 
ENST00000367557, ENST00000384741, 
LAMC1, LAMC2 
5 5 0 
1q25.3 182920164 183870395 C1orf21(d)  ± HMCN1(u) EDEM3, FAM129A, RNF2, C1orf26, 
IVNS1ABP 
5 5 0 
1q32.1 198509033 199328441 ENST00000367356 (u)  ±  
CACNA1S (i) 
ENST00000367356, KIF14, DDX59, 
CAMSAP1L1, C1orf106, KIF21B 
5 5 0 
1q32.1 199741167 199873895 CSRP1(i)  ±  ENST00000367302 (i) ENST00000362085 5 5 0 
1q32.1 200080574 200298931 IPO9 (i) ±  ELF3 (d) LMOD1, TIMM17A, RNPEP, ELF3 5 5 0 
1q32.1 201414285 201590259 CHI3L1 (u)  ± FMOD (d) CHI3L1, CHIT1, BTG2, FMOD 5 5 0 
1q32.1 201910943 201930848 ATP2B4 (i)  5 5 0 
1q32.1 202096179 202785465 SNRPE (u) ± MDM4 ¶875 SNRPE, SOX13, ETNK2, REN, KISS1, 
GOLT1A, PLEKHA6, PIK3C2B,  
5 5 0 
1q32.1 202922030 203238108 LRRN2 (d) ± NFASC (i) ENST00000367173 5 5 0 
1q32.1 206609806 206620808 PLXNA2 (u)  5 5 0 
1q32.2 207669983 208414613 ENST00000367032 (5¶UTR)  ± 
SERTAD4 (u) 
CAMK1G, LAMB3, HSD11B1, 
ENST00000367026, TRAF3IP3, C1orf74, 
ENST00000367021, IRF6, C1orf107, SYT14 
5 5 0 
1q32.3 209708573 210010455 RD3 (d) ± LPGAT1 (i) ENST00000367000, SLC30A1, NEK2 5 5 0 
1q41 211087402 212921197 LOC149643(i) ± KCNK2 (u) FLVCR1, VASH2, ANGEL2, RPS6KC1, 
PROX1, SMYD2, PTPN14, CENPF 
5 5 0 
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Locus Start (bp) End (bp) Gene symbol Additional genes in this region Total CN 3 or 4 CN 5 or 6 
1q42.13 224703718 225258279 ENST00000363938 (d)  ±  
CDC42BPA (i) 
C1orf95, ITPKB, PSEN2, 
ENST00000313259, 
ENST00000366779, CABC1 
5 5 0 
1q42.13 228770808 229925804 COG2 (u) ± DISC1 (i) COG2, AGT, CAPN9, C1orf198, TTC13, 
ARV1, FAM89A, ENST00000366656, 
TRIM67, C1orf131, GNPAT, EGLN1, 
TSNAX 
5 5 0 
1q42.2 231650194 231813713 ENST00000366656 (i)   5 5 0 
1q42.3 233488558 234652165 ARID4B (i) ± EDARADD (i)  TBCE, B3GALNT2, GNG4, LYST, NID1, 
GPR137B, ERO1LB 
5 5 0 
1q43 240824595 241218126 PLD5 (u)  5 5 0 
1q44 243485054 243810042 ENST00000366519 (d)  ±  
ENST00000366518 (i) 
ENST00000329504 5 5 0 
8p21.3 21344076 21350938 ENST00000387608 (u)  5 4 1 
8q24.23 139139534 139368001 FAM135B (u-i)  5 5 0 
Note: The gene symbols representing the start and end of each specified genomic region are shown, together with additional encompassed genes identified from the Affymetrix® annotation file 
(Netaffx file build 07.12.07). The total number of samples within the cohort demonstrating genomic gain of the region is also shown. This total is then split according to numbers exhibiting low 
level gain (CN 3 or 4) or amplification (CN 5 or 6). CN = copy number, bp = base pair, i = intronic, u = upstream of annotated gene, d = downstream of DQQRWDWHGJHQH¶875 ¶XQWUDQVODWHG 
region, CDS = coding sequence. The gene highlighted in red had its copy number validated by real time qPCR.  
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Figure 4.3: The most frequent focal regions of increased copy number in nine first recurrent intracranial 
ependymomas. For each gene region, samples with low level copy number gain (copy number 3 or 4) are 
differentiated from those with amplification (copy number 5 or 6) by light and dark green shading respectively. bp = 
base pair, i = intronic, u = upstream of annotated gene, d = downstream of annotated gene, ¶875 ¶XQWUDQVODWHG
region, CDS = coding sequence. 
 
4.3.1.4 Common focal regions of genomic loss in recurrent intracranial 
ependymomas 
 
Focal regions of copy number loss in the first recurrent intracranial cohort of nine 
ependymomas were identified and ranked according to frequency (Table 4.4 and Figure 
4.4). The most common regions spanned the length of chromosome 22q, particularly 
within 22q12.3, 22q13.1 and 22q13.31 ± 13.33 (3/9 samples 33 %). Putative tumour 
suppressor genes reported from other studies were encompassed within these regions, 
such as the chromobox protein encoding CBX7 (22q13.1) (Suarez-Merino, Hubank et 
al. 2005) and PPARA (22q13.31) which encodes a member of the peroxisome 
proliferator receptor family (Niho, Takahashi et al. 2003; Grabacka, Plonka et al. 2006; 
Urbanska, Pannizzo et al. 2008). 
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Table 4.4: The most frequent focal regions of decreased copy number in nine first recurrent intracranial ependymomas. 
 
Locus Start(bp) End(bp) Gene symbol Additional genes in this region Total CN 1 CN 0 
22q12.3 34247255 34362917 MCM5 (d) ± LOC284912 (u) RASD2, MB 3 3 0 
22q13.1 37451984 38282044 GTPBP1 (CDS) ± RPS19BP1 (u) UNC84B, DNAL4, NPTXR, APOBEC3 
family, CBX7, PDGFB, SYNGR1, 
MAP3K7IP1, MGAT3, SMCR7L 
3 3 0 
22q13.31 43444530 43664982 LOC553158 (u) ± PHF21B (i)  PRR5, LOC553158, ARHGAP8,  3 3 0 
22q13.31 44861612 45167944 FLJ27365 (i) ± CELSR1(i) PPARA, LOC150383, PKDREJ, 
FLJ20699, GTSE1  
3 3 0 
22q13.31 45441994 45481189 DIP (i) ± CERK (i)  3 3 0 
22q13.32 47241222 47347102 FAM19A5 (u) ± ENST00000336769 (i)  3 3 0 
22q13.32 47404665 47446381 FAM19A5 (i)  3 3 0 
22q13.33 48960405 49576671 PANX2 (d)  ± MGC70863 (i) TRABD, TUBGCP6, HDAC10, SAPS2, 
ADM2, NCAPH2, CPT1B, ARSA 
3 3 0 
Note: The gene symbols representing the start and end of each specified genomic region are shown, together with additional encompassed genes identified from the Affymetrix® annotation 
file (Netaffx file build 07.12.07). The total number of samples within the cohort demonstrating genomic loss of the region is also shown. This total is then split according to numbers 
exhibiting hemizygous (CN 1) or homozygous genomic deletion (CN 0). CN = copy number, bp = base pair, i = intronic, u = upstream of annotated gene, d = downstream of annotated 
gene.  
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Figure 4.4: The most frequent focal regions of decreased copy number in nine first recurrent intracranial 
ependymomas. Samples with hemizygous deletion (copy number 1) are shown, coloured in light red. bp = base pair, i 
= intronic, u = upstream of annotated gene, d = downstream of annotated gene. 
 
4.3.1.5 Common focal regions of amplification in intracranial 
ependymomas 
 
Focal regions of amplification (copy number five or six) in the primary and first 
recurrent intracranial tumour cohorts were identified and ranked according to frequency 
(Tables 4.5A and B). The most common regions in the primary cohort were located 
within 1q41 and 7p15.2 (8/36 samples; 22 %). The latter region encompassed members 
of the HOX transcription factor family which, intriguingly, are reported to be relatively 
underexpressed in intracranial ependymomas when compared to corresponding 
extracranial tumours (Korshunov, Neben et al. 2003; Taylor, Poppleton et al. 2005; 
Palm, Figarella-Branger et al. 2009; Johnson, Wright et al. 2010). This finding is 
discussed later in this chapter. Less common regions of amplification were found on 
9q31.3, 10q21.1, 13q31.1 and 18q22.3 (7/36, 19 %). The DNAJC25 gene within 9q31.3 
had already been identified as one of the most frequently gained genes in the cohort 
(Table 4.1). Within the recurrent cohort, the most frequent regions of high level gain 
encompassed genes such as PLXNC1 (12q22) (2/9 samples; 22 %) which encodes a 
member of the plexin receptor family. 
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Table 4.5A: The most frequent focal regions of amplification in 36 primary intracranial ependymomas. 
 
Locus Start (bp) End (bp) Gene symbol Additional genes in this region Frequency 
1q41 219025582 219031421 MOSC2 (d) ± MOSC1 (i)  8/36 
7p15.2 27147941 27208884 HOXA5 ¶875± EVX1 (u) HOXA6, HOXA7, HOXA9, 
HOXA10, HOXA1, HOXA13 
8/36 
9q31.3 113434096 113466466 DNAJC25 (i)  7/36 
10q21.1  59937923 59951522 TFAM (d)  ±  ENST00000373886 (i)  7/36 
13q31.1  79810102 79825947 SPRY2 (i-d)  7/36 
18q22.3  67022770 67037233 CBLN2 (d)  7/36 
 
Table 4.5B: The most frequent focal regions of amplification in nine first recurrent intracranial ependymomas. 
 
Locus Start (bp) End (bp) Gene symbol Additional genes in this region Frequency 
3p21.31 45331970 45350074 LARS2 (u)  3/9 
1p22.2  90012111 90026999 LRRC8D (u)  2/9 
2p24.1  20688172 20704649 HS1BP3 (i)  2/9 
5p15.33 1789711 1802215 MRPL36 (d)  2/9 
6p22.1 26065088 26125150 TRIM38 (u) ± HIST1H1A (u) TRIM38 2/9 
6p21.1 42388855 42417178 TRERF1 (i)  2/9 
6q25.3 159831048 159845349 FNDC1 (d)  2/9 
8p23.1 11389950 11403101 BLK (i)  2/9 
10p15.2 3045000 3046044 PFKP (u)  2/9 
11p12 41059394 41075935 ENST00000386948 (d)  2/9 
12q22 93148834 93173234 PLXNC1 (i)  2/9 
15q23 67367475 67384434 PAQR5 (u)  2/9 
Note: The gene symbols representing the start and end of each specified genomic region are shown, together with additional encompassed genes identified from the Affymetrix® annotation file 
(Netaffx file build 07.12.07). The total number of samples within the cohort demonstrating amplification of the region is also shown. CN = copy number, bp = base pair, i = intronic, u = 
upstream of annotated gene, d = downstream of annotated gene. The genes highlighted in red had their copy number validated by real time qPCR. Focal regions encompassing these highlighted 
genes were additionally examined using the web-based genomic database Ensembl to identify all other interrogated genes which are duly included. 
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4.3.1.6 Focal regions of homozygous loss in intracranial ependymomas 
 
Only two focal regions of homozygous deletion (copy number zero) were identified in 
the cohort of 36 primary and nine first recurrent intracranial paediatric ependymomas. 
The regions were detected only once in separate tumour samples. One such site, 
detected in ependymoma 23P, was located within chromosome 6q16.1. It did not 
encompass any genes, mapping downstream of ENST00000363622 and upstream of 
ENST00000386471. This was verified from the Ensembl database. Hemizygous deletion 
of this region was also detected in five other primary intracranial tumours. The other 
region of homozygous deletion was located within chromosome 9p21.3 of recurrent 
sample 18R1, encompassing the recognised ependymoma tumour suppressor genes 
CDKN2A and CDKN2B (Taylor, Poppleton et al. 2005; Johnson, Wright et al. 2010).  
 
4.3.1.7 Focal regions of genomic imbalance associated with posterior fossa 
ependymomas 
 
Within the primary intracranial cohort, focal regions of copy number gain associated 
with posterior fossa ependymomas (compared to supratentorial tumours) were identified 
and ranked according to statistical significance (Table 4.6). The most significant regions 
were all located on chromosome 1q. Numerous genes were encompassed, including 
genes already noted as being among the most frequently gained in the intracranial 
recurrent cohort (Table 4.3). Such genes included the aforementioned CHIT1 (1q32.1;  
p = 0.033), CHI3L1/YKL40 (1q32.1; p = 0.015), CDC42BPA (1q42.13; p = 0.033) and 
ASTN1 (1q25.2; p = 0.033), a gene encoding a neuronal adhesion molecule which has 
been reported to mediate the migration of primitive neurons in the cerebellum 
(Edmondson, Liem et al. 1988). Other regions of 1q gain associated with posterior fossa 
tumours encompassed genes such as the kinase encoding AKT3 (1q44; p = 0.033) and 
PARP1 (1q42.12; p = 0.033) which encodes the chromatin-associated enzyme, poly 
(ADP-ribosyl) polymerase, involved in a range of cellular processes such as DNA 
damage repair and cell proliferation. No regions of focal genomic loss associated with 
posterior fossa ependymomas were identified. 
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4.3.1.8 Focal regions of genomic imbalance associated with supratentorial 
ependymomas 
 
Focal regions of copy number gain associated with supratentorial ependymomas 
(compared to posterior fossa tumours) were also identified in the primary intracranial 
cohort and ranked according to statistical significance (Table 4.7). Again, several genes 
encompassed within significant regions were detected, including TULP4 (6q25.3;           
p = 0.006) which is implicated in protein ubiquitination and the Type IV collagen 
encoding COL4A1 (13q34; p = 0.02). The only significant region of genomic loss 
associated with supratentorial tumours was within 11q12.2 (p = 0.025), encompassing 
FADS1 encoding one of the fatty acid desaturase family members.   
 
4.3.1.9 Focal regions of genomic imbalance associated with posterior fossa 
ependymomas from patients aged below three years 
 
Within the primary posterior fossa cohort, focal regions of copy number gain associated 
with tumours from patients below three years of age (compared to those from children 
aged above three years) were identified and ranked according to statistical significance 
(Table 4.8). Genes detected within these regions included TELO2/CLK2 (16p13.3; p = 
0.014) and HDAC10 (22q13.33; p = 0.037). TELO2 encodes a putative cell cycle S-
phase checkpoint protein, while HDAC10 encodes a member of the histone deacetylase 
family. Genes encoding transmembrane proteins such as TMEM18 (2p25.3; p = 0.037) 
were also identified. No regions of focal genomic loss associated with the younger age 
group were identified.  
 
4.3.1.10 Focal regions of genomic imbalance associated with posterior 
fossa ependymomas from patients aged above three years 
 
Focal regions of copy number gain associated with tumours from patients above three 
years of age (compared to those from children aged below three years) were also 
identified in the posterior fossa cohort and ranked according to statistical significance 
(Table 4.9). The most significant regions were located on chromosomes 1q, 9 and 18. 
These regions encompassed genes such as the dynamin family member DNM3 (1q24.3; 
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p = 0.027) and the putative oncogene TXN (9q31.3; p = 0.014) which encodes an 
oxidoreductase enzyme overexpressed in several malignancies (Grogan, Fenoglio-
Prieser et al. 2000; Kakolyris, Giatromanolaki et al. 2001; Raffel, Bhattacharyya et al. 
2003). No regions of focal genomic loss associated with the older age group were 
identified. 
 
4.3.1.11 Focal regions of genomic imbalance associated with anaplastic 
histology in intracranial ependymomas 
 
Focal regions of copy number gain associated with a WHO grade III tumour 
classification (compared to a WHO grade II classification) were identified for both 
primary supratentorial and posterior fossa tumours and ranked according to statistical 
significance (Tables 4.10 and 4.11). The supratentorial cohort comprised six grade II 
and five grade III tumours, while the posterior fossa cohort comprised 13 grade II and 
10 grade III tumours.  
 
Anaplastic supratentorial ependymomas were associated with focal gains across 
chromosomes 7q, 11q, 13q and 19. Numerous genes were encompassed within these 
regions, such as COL4A1 (13q34; p = 0.015). Other genes included the fibroblast 
growth factor family member FGF3 (11q13.3; p = 0.015), the cyclin dependent kinase 
encoding CDK8 (13q12.13; p = 0.015) and the VEGF (vascular endothelial growth 
factor) receptor gene FLT1 (13q12.2; p = 0.015). Few focal regions of gain were 
associated with high grade posterior fossa ependymomas. Most were located on 
chromosome 12, specifically within 12q24.31, encompassing genes such as 
KNTC1/ROD (p = 0.024) which encodes a mitosis checkpoint protein. In contrast, sites 
of genomic loss were not associated with grade III ependymomas from either CNS 
location. 
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Table 4.6: Focal regions of genomic gain associated with primary paediatric posterior fossa ependymomas.  
 
Locus Start (bp) End (bp) Gene symbol Additional genes in this region  PF ST p-value 
1q23.3 163763105 163772128 RXRG (d) ± LRRC52 (u)  10/24 0/11 0.015 
1q32.1 201414285 201432734 CHI3L1 (u) ± CHIT1 (u) CHI3L1 10/24 0/11 0.015 
1q42.13 225822390 225908366 ZNF678 (i)  10/24 0/11 0.015 
1q42.13 225925871 226167742 ENST00000323562 (d)  ± WNT9A (u) C1orf142, MPN2 10/24 0/11 0.015 
1q42.2 230984253 231057198 ENST00000366656 (i)  10/24 0/11 0.015 
1q42.2 232617486 232651815 TARBP1 (i)  10/24 0/11 0.015 
1q42.3 232704412 232792979 TARBP1 (u)  10/24 0/11 0.015 
1q21.1 146183314 146292286 ENST00000386140 (d) - 
ENST00000365538 (d) 
ENST00000365538 9/24 0/11 0.033 
1q23.3 159925404 159951193 FCGR2C (d) ± FCRLA (d) FCRLA 9/24 0/11 0.033 
1q23.3 159971944 160297525 FCRLB (d)  ± OLFML2B (d) ATF6, OLFML2B 9/24 0/11 0.033 
1q24.1 165086908 165099823 POGK (i) ± TADA1L (i)  9/24 0/11 0.033 
1q24.3 170104490 170339258 DNM3 (i)  9/24 0/11 0.033 
1q25.2 175395635 175413784 ASTN1 (i) ± FAM58B (i)  9/24 0/11 0.033 
1q25.3 180687071 180723046 RGSL2 (i)  9/24 0/11 0.033 
1q25.3 181989553 182289682 RGL1 (i) ± C1orf19 (i) GLT25D2 9/24 0/11 0.033 
1q32.1 199371212 199529953 TMEM9 ¶875± PKP1 (i) ENST00000263947, ENST00000367325 
DKFZp434B1231 
9/24 0/11 0.033 
1q32.1 201339300 201412789 ADORA1(i) ± MYBPH (u)  9/24 0/11 0.033 
1q32.1 201454716 201475471 CHIT1 (i-d)  9/24 0/11 0.033 
1q32.1 201955555 202096361 ATP2B4 (i) ± ZC3H11A (d) ZC3H11A, LAX1 9/24 0/11 0.033 
1q41 212643105 212714251 PTPN14 (i)  9/24 0/11 0.033 
1q42.12 224512151 224652139 LIN9 (i) ± PARP1 (i)  9/24 0/11 0.033 
1q42.12 224703718 224738529 ENST00000363938 (d)  ±  
ENST00000317080 (u) 
 9/24 0/11 0.033 
1q42.12 224749874 224777493 C1orf95 (u)  9/24 0/11 0.033 
1q42.13 225330114 225488622 CDC42BPA (i)  9/24 0/11 0.033 
1q42.2 230505719 230525587 ENST00000366656 (i)  9/24 0/11 0.033 
1q42.2 232486852 232542353 SLC35F3 (i) ± GNPAT (u)  9/24 0/11 0.033 
1q42.3 232826070 232893942 IRF2BP2 (u)  9/24 0/11 0.033 
1q43 237772841 237847789 CHRM3 (u)  9/24 0/11 0.033 
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Locus Start(bp) End(bp) Gene symbol Additional genes in this region  PF  ST p-value 
1q44 241777030 242064416 AKT3 (i)  9/24 0/11 0.033 
1q44 243159455 243272300 HRNPU (d) ± EFCAB2 (i)  9/24 0/11 0.033 
1q44 243448255 243490562 ENST00000329504 (u)  9/24 0/11 0.033 
1q44 243515509 243720615 ENST00000366519 (d)  ±  
ENST00000366518 (u) 
ENST00000329504 9/24 0/11 0.033 
1q44 245790293 246010859 C1orf150 (i) ± OR1C1 (d) OR6F1, OR1C1 9/24 0/11 0.033 
1q44 246038341 246071237 OR5AT1(d) ± OR11L1 (CDS)  9/24 0/11 0.033 
1q44 246098389 246346107 TRIM58 (i) ± OR2L13 (d) OR2AK2, OR2L13 9/24 0/11 0.033 
1q44 246531667 246645245 OR2T12 (d) ± OR2T2 (u) OR2T6 9/24 0/11 0.033 
1q44 74268812 74352226 ENST00000362858 (d)  9/24 0/11 0.033 
20q13.33 60094968 60121514 TAF4 (d)  ± LSM14B (u)   9/24 0/11 0.033 
Note: The gene symbols representing the start and end of each specified genomic region are shown, together with additional encompassed genes identified from the Affymetrix® annotation file 
(Netaffx file build 07.12.07). Gained regions associated with posterior fossa tumours are ranked in order of statistical significance, as deemed by a two-WDLOHG)LVKHU¶VH[DFW WHVW (SPSS 16) 
performed against supratentorial tumours. The precise numbers of samples within the posterior fossa and supratentorial cohorts demonstrating genomic gain for each region are included. PF = 
posterior fossa, ST = sXSUDWHQWRULDOES EDVHSDLUL LQWURQLFX XSVWUHDPRIDQQRWDWHGJHQHG GRZQVWUHDPRIDQQRWDWHGJHQH¶875 ¶XQWranslated region. The gene highlighted in red 
had its copy number validated by real time qPCR. 
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Table 4.7:  Focal regions of genomic gain associated with primary paediatric supratentorial ependymomas.  
 
Locus Start (bp) End (bp) Gene symbol Additional genes in this region ST  PF p-value 
1p35.1 33741021 33753817 CSMD2 (u-¶875  5/11 0/24 0.001 
1p32.3 52966384 52983591 ZYG11B (i)  6/11 2/24 0.006 
1p33 47592596 47647450 CMPK (i) ± FOXE3 (u)  4/11 0/24 0.006 
2q13 113700504 113745190 PAX8 (i-d) ENST00000333145 4/11 0/24 0.006 
6q21 107137365 107147668 RTN4IP1 (i)  4/11 0/24 0.006 
6q25.3 158788606 158801752 TULP4 (i)  4/11 0/24 0.006 
6q25.3 159639229 159650534 FLJ27255 (d)  4/11 0/24 0.006 
10q26.3 131615303 131697615 EBF3 (i-d)  6/11 3/24 0.015 
19q13.31 49678063 49691015 ZNF180 (i)  6/11 3/24 0.015 
6p25.1 4666045 4718085 CDYL (i)  5/11 2/24 0.02 
8p12 38229372 38345434 DDHD2 (i) ± WHSC1L1 (i)  5/11 2/24 0.02 
11p11.2 44632464 44649769 TP53I11 (d) - TSPAN18 (u)   5/11 2/24 0.02 
13q34 109634045 109748036 COL4A1 (i)  5/11 2/24 0.02 
Note: The gene symbols representing the start and end of each specified genomic region are shown, together with additional encompassed genes identified from the Affymetrix® annotation file 
(Netaffx file build 07.12.07). Gained regions associated with supratentorial tumours are ranked in order of statistical significance, as deemed by a two-WDLOHG)LVKHU¶V H[DFW WHVW (SPSS 16) 
performed against posterior fossa tumours. The precise numbers of samples within the supratentorial and posterior fossa cohorts demonstrating genomic gain for each region are included. ST = 
supratentorial, PF = poVWHULRUIRVVDES EDVHSDLUL LQWURQLFX XSVWUHDPRIDQQRWDWHGJHQHG GRZQVWUHDPRIDQQRWDWHGJHQH¶875 ¶XQWranslated region.  
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Table 4.8: Focal regions of genomic gain associated with primary paediatric posterior fossa ependymomas from patients aged below three years. 
 
Locus Start (bp) End (bp) Gene symbol Additional genes in this region U3 O3  p-value 
2q37.3 240534261 240740155 FLJ45964 (d)  ± GPC1 (u) NDUFA10, MYEOV2, OTOS 6/12 0/12 0.014 
6p23 13895819 13944145 CCDC90A (u)  ± RNF182 (u) CCDC90A 6/12 0/12 0.014 
6q27 168073683 168101356 MLLT4 (i)  6/12 0/12 0.014 
16p13.3 1499839 1566706 TELO2 (CDS) ± IFT140 (i)  6/12 0/12 0.014 
2p25.3 129574 168356 SH3YL1(d)  5/12 0/12 0.037 
2p25.3 435185 604210 ENST00000389719 (i)  5/12 0/12 0.037 
2p25.3 658618 926687 TMEM18 ¶875± SNGT2 (u)  5/12 0/12 0.037 
2p25.3 959866 1484084 SNTG2 (i) ± TPO (i)  5/12 0/12 0.037 
2q21.1 131525906 131671717 ENST00000354183 (i)  ± PLEKHB2 (i)  5/12 0/12 0.037 
2q37.3 241674555 241787007 ENST00000310397 (i)  ± TMEM16G (i) MTERFD2, PASK, PPPR17 5/12 0/12 0.037 
3q21.2 127614144 127665610 CCDC37 (i) ± ZXDC (i)  5/12 0/12 0.037 
3q21.3 127698840 127772052 UROC1 (i) ± TR2IT1 (u)  5/12 0/12 0.037 
3q21.3 127812600 127922704 ENST00000360201 (CDS) ± CHCHD6 (i)  5/12 0/12 0.037 
6p25.3 402748 549537 IRF4 (d) ± EXOC2 (i)  5/12 0/12 0.037 
6p25.2 4045539 4074092 C6orf201 (i)  5/12 0/12 0.037 
6p25.1 4093181 4118652 PECI (d)   5/12 0/12 0.037 
6q27 167062637 167279633 ENST00000366867 (i) ± RNASET2 (i)  5/12 0/12 0.037 
6q27 167927207 167967136 C6orf123 (u-d)  5/12 0/12 0.037 
6q27 169654969 169714869 THBS2(d) ± WDR27 (i)  5/12 0/12 0.037 
10p15.3 1406472 1660999 ADARB2 (i)  5/12 0/12 0.037 
10p15.2 3063036 3138116 PFKP (u-i)  5/12 0/12 0.037 
16q24.2 86333714 86349893 KLHDC4 (i)  5/12 0/12 0.037 
17q21.2 36488761 36499917 ENST00000332991 (u-d)  5/12 0/12 0.037 
17q21.2 36542729 36586246 KRTAP4-2 (d) ± ENST00000377726 (u)  5/12 0/12 0.037 
22q12.3 30905149 30918352 RP1-127L4.6 (d) ±  ENST00000248983 (i)  5/12 0/12 0.037 
22q13.33 48481817 48564816 C22orf34 (d)  ±  BRD1 (i)  5/12 0/12 0.037 
22q13.33 48993966 49205915 RP3-402G11.5 (i) ±  SAPS2 (i)  TUBGCP6, HDAC10 5/12 0/12 0.037 
Note: The gene symbols representing the start and end of each specified genomic region are shown, together with additional encompassed genes identified from the Affymetrix® annotation file 
(Netaffx file build 07.12.07). Gained regions associated with posterior fossa tumours from children aged less than three years are ranked in order of statistical significance, as deemed by a two-
WDLOHG)LVKHU¶VH[DFW WHVW (SPSS 16) performed against posterior fossa tumours from children aged above three years. The precise numbers of samples within the posterior fossa age cohorts 
demonstrating genomic gain for each region are included. U3 = posterior fossa tumours from children aged under three years, O3 = posterior fossa tumours from children aged over three years, 
bp = base pair, i = intronic, u = upstream of annotated gene, d = downstream of annotated gene.  
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Table 4.9: Focal regions of genomic gain associated with primary paediatric posterior fossa ependymomas from patients aged above three years. 
 
Locus Start (bp) End (bp) Gene symbol Additional genes in this region U3 O3 p-value 
9p24.1 6889149 6953799 JMJD2C (i)  0/12 6/12 0.014 
9q21.11 70922928 70936691 TJP2 (u)  0/12 6/12 0.014 
9q21.11 70938747 70985333 FXN (d) ± TJP2 (i)  0/12 6/12 0.014 
9q31.3 111892156 111904290 AKAP2 (i)  0/12 6/12 0.014 
9q31.3 112050484 112063686 TXN (i) ± TXNDC8 (u)  0/12 6/12 0.014 
9q32 115654279 115684020 ZNF613 (u)  0/12 6/12 0.014 
9q32 115973270 116134866 COL27A1 (i) ± ORM2 (i) ORM1 0/12 6/12 0.014 
9q33.3 125900331 125913604 NEK6 (u)  0/12 6/12 0.014 
18q21.1 43913365 43948279 ZBTB7C (d) - ENST00000384217 (d) ENST00000384217 0/12 6/12 0.014 
1q23.3 161319642 161340376 RGS4 (d) ± RGS5 (u)  1/12 7/12 0.027 
1q24.2 167176576 167249654 ATP1B1 (u)   1/12 7/12 0.027 
1q24.3 170360753 170394207 DNM3 (i)  1/12 7/12 0.027 
1q41 219488068 219510247 HLX (d) ± C1orf140 (u)  1/12 7/12 0.027 
1q43 237490347 237768272 CHRM3 (u)  1/12 7/12 0.027 
9p13.1 38512055 38761831 IGFBPL1 (d) ± CNTNAP3 (u) ANKRD18A, ENST00000377689 
ENST00000357927 
1/12 7/12 0.027 
Note: The gene symbols representing the start and end of each specified genomic region are shown, together with additional encompassed genes identified from the Affymetrix® annotation file 
(Netaffx file build 07.12.07). Gained regions associated with posterior fossa tumours from children aged above three years are ranked in order of statistical significance, as deemed by a two-
WDLOHG)LVKHU¶VH[DFW WHVW (SPSS 16) performed against posterior fossa tumours from children aged below three years. The precise numbers of samples within the posterior fossa age cohorts 
demonstrating genomic gain for each region are included. U3 = posterior fossa tumours from children aged under three years, O3 = posterior fossa tumours from children aged over three years, 
bp = base pair, i = intronic, u = upstream of annotated gene, d = downstream of annotated gene. The gene highlighted in red had its copy number validated by real time qPCR. 
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Table 4.10: Focal regions of genomic gain associated with primary paediatric supratentorial ependymomas of WHO grade III. 
 
Cytoband Start (bp) End (bp) Gene symbol Additional genes in this region Gd3  Gd2 p-value 
7q34 138643716 138814158 ENST00000384116 (d) ± KLRG2 (i) C7orf55, LUC7L2 4/5 0/6 0.015 
7q36.3 155958047 156088256 C7orf13 (d)  4/5 0/6 0.015 
7q36.3 156454985 156476488 NOM1 (CDS-d)  4/5 0/6 0.015 
11q13.2 68933687 68990408 FLJ44258 (d) ± CCND1 (u)  4/5 0/6 0.015 
11q13.3 69198344 69363887 ORAOV1 (i) ± FGF3 (d) FGF3 4/5 0/6 0.015 
11q13.4 72082606 72206621 CENTD2 (i) ± ATG16L2 (i)  4/5 0/6 0.015 
11q13.4 118774194 118861892 USP2 (u) ± THY1 (d) THY1 4/5 0/6 0.015 
11q23.3 118896089 119078599 PVRL1 (u-i) NM_001001681 4/5 0/6 0.015 
13q12.11 19666144 19748497 GJB6 (u) ± CRYL1 (d) GJB6 4/5 0/6 0.015 
13q12.12 23996413 24011645 PARP4 (u)   4/5 0/6 0.015 
13q12.13 25651251 25734780 RNF6  (i) ± CDK8 (i)  4/5 0/6 0.015 
13q12.2 27299578 27312265 GSX1  (d) ± PDX1 (u)  4/5 0/6 0.015 
13q12.2 27443268 27482744 CDX2 (u) ± FLT3 (i)  4/5 0/6 0.015 
13q12.2 27724983 27806090 PAN3 (i) ± FLT1 (i)  4/5 0/6 0.015 
13q14.11 40530244 41053103 ELF1 (d) ± C13orf15 (d) KBTBD6, WBP4, MTRF1, NARG1L, 
C13orf15 
4/5 0/6 0.015 
13q13.2 97622038 97645101 FARP1 (i)  4/5 0/6 0.015 
13q32.3 99051217 99063992 TM9SF2 (d) ± CLYBL (i)  4/5 0/6 0.015 
13q34 109605936 109629867 COL4A1 (i)  4/5 0/6 0.015 
19p13.3 6147373 6218757 ACSBG2 (d) ± MLLT1 (i)  4/5 0/6 0.015 
19p12 23092981 23156405 ENST00000327867 (u)  4/5 0/6 0.015 
19q13.43 63631939 63731511 TRIM28 (i)  ZNF132 4/5 0/6 0.015 
Note: The gene symbols representing the start and end of each specified genomic region are shown, together with additional encompassed genes identified from the 
Affymetrix® annotation file (Netaffx file build 07.12.07). Gained regions associated with WHO grade III supratentorial tumours are ranked in order of statistical significance, 
as deemed by a two-WDLOHG)LVKHU¶VH[DFWWHVW6366SHUIRUPHGDJDLQVW:+2JUDGH,,WXPRXUV7KHSUHFLVHQXPEHUVRIVDPSOHVZLWKLQWKHVXSUDWentorial grade cohorts 
demonstrating genomic gain for each region are included. Gd3 = WHO grade III supratentorial tumours, Gd2 = WHO grade II supratentorial tumours, bp = base pair,              
i = intronic, e = exonic, u = upstream of annotated gene, d = downstream of annotated gene. 
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Table 4.11: Focal regions of genomic gain associated with primary paediatric posterior fossa ependymomas of WHO grade III. 
 
Cytoband Start (bp) End (bp) Gene symbol Additional genes in this region Gd3 Gd2 p-value 
11p15.1 16984904 17034804 PLEKHA7 (i) ± RPS13 (u)  4/10 0/13 0.024 
12q24.31 121469421 121557232 CLIP1 (i) ± RSRC2 (i) ZCCHC8 4/10 0/13 0.024 
12q24.31 121628547 121729801 KNTC1 (i) ± GPR109A (u)  4/10 0/13 0.024 
12q24.31 124022488 124105945 DHX37 (i) ± AACS (u) BRI3BP 4/10 0/13 0.024 
19p13.2 9447719 9462391 ZNF560 (i)  4/10 0/13 0.024 
Note: The gene symbols representing the start and end of each specified genomic region are shown, together with additional encompassed genes identified from the 
Affymetrix® annotation file (Netaffx file build 07.12.07). Gained regions associated with WHO grade III posterior fossa tumours are ranked in order of statistical 
significance, as deemed by a two-WDLOHG)LVKHU¶VH[DFWWHVW6366SHUIRUPHGDJDLQVW:+2JUDGH,,WXPRurs. The precise numbers of samples within the posterior fossa 
tumour grade cohorts demonstrating genomic gain for each region are included. Gd3 = WHO grade III posterior fossa tumours, Gd2 = WHO grade II posterior fossa tumours, 
bp = base pair, i = intronic, u = upstream of annotated gene, d = downstream of annotated gene. 
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4.3.2 Genomic gain encompassing selected genes on chromosome 1q in 
intracranial ependymoma and association with patient survival 
 
Survival analysis was performed across the primary SNP array cohort to establish 
whether ependymomas demonstrating focal gain of regions harbouring selected genes 
within chromosome 1q were associated with an adverse patient outcome. The genes 
NSL1, NAV1, CHI3L1/YKL40, PRUNE and BNIPL were chosen as a result of preceding 
findings from the SNP array analysis. NSL1 (1q32.3) was within one of the most 
frequently gained focal regions in the primary intracranial cohort. NAV1 (1q32.1) was 
located in the most common focal region of increased copy number in the intracranial 
recurrent cohort. Gain of the locus encompassing CHI3L1/YKL40 (1q32.1) was 
associated exclusively with posterior fossa ependymomas and was also a common 
feature of intracranial recurrent tumours. The 1q21.2 ± 21.3 region was previously 
identified to be the most common imbalanced cytoband in a set of ependymomas       
DVVRFLDWHGZLWKDQDGYHUVHSDWLHQWRXWFRPHµJURXSWZR¶DQGZDVWKHPRVWIUHTXHQWO\
gained chromosome 1q locus across the primary cohort (Chapter 3, section 3.3.5). High 
resolution analysis of the 1q21.2 ± 21.3 region was thus performed across the primary 
ependymoma cohort to detect the most commonly shared site of focal gain (at least five 
consecutive SNPs spanning a region greater than 10kb) which was associated with the 
most unfavourable outcome for the group from accompanying survival data. This 
process identified a small region on 1q21.3, which encompassed two genes according to 
the accompanying annotation data file. These were the nucleotide phosphodiesterase 
encoding PRUNE and BNIPL, a gene involved in regulating apoptosis. This locus was 
thereby WHUPHGµPRUNE/BNIPL¶ although subsequent Ensembl database analysis also 
identified two other genes encompassed within the region, the Rho-GTPase modulator 
CDC42SE1 and AF1q, a gene of unknown function that has been reported to promote 
the proliferation and invasion of breast cancer cells in vitro (Chang, Li et al. 2008).      
 
Univariate analysis (Table 4.12) revealed NAV1 gain was associated with a significantly 
worse event-free patient survival (estimated mean EFS: 2.3 + 0.5 years versus 6.6 + 1.3 
years, p = 0.013) (Figure 4.5). This finding was replicated on multivariate analysis 
(hazards ratio 3.18 (95 % CI 1.065 ± 9.52), p = 0.038) (Table 4.13). No association with 
NAV1 gain and overall survival was observed. 
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Figure 4.5: Kaplan-Meier EFS curve, comparing 11 ependymoma patients demonstrating SNP array gain of NAV1 
(blue lines) against the rest of the primary SNP array cohort (green lines). Patients with NAV1 gain had a significantly 
worse EFS (percentage from each group attaining five year EFS = 9.1 + 8.7 % (NAV1 group) versus 53.3 + 11.6 % 
(remaining primary cohort), p = 0.013). 
 
Univariate analysis (Table 4.12) also revealed gain of the PRUNE/BNIPL region was 
associated with a significantly worse event-free and overall patient survival (estimated 
mean EFS: 3.1 + 0.8 years versus 7.4 + 1.3 years, p = 0.045; estimated mean OS: 5.9 + 
1 years versus 16.6 + 2 years, p = 0.023) (Figure 4.6).  
 
 
Figure 4.6: Kaplan-Meier EFS and OS curves, comparing 12 ependymoma patients demonstrating SNP array gain of 
the PRUNE/BNIPL region (blue lines) against the rest of the primary SNP array cohort (green lines). Patients with 
gain of this focal region had a significantly worse EFS (percentage from each group attaining five year EFS = 16.7 + 
10.8 % (PRUNE/BNIPL gain group) versus 50.8 + 12.1 % (remaining primary cohort), p = 0.045) and OS 
(percentage from each group attaining five year OS = 65.6 + 14 % (PRUNE/BNIPL gain group) versus 84.1 + 8.6 % 
(remaining primary cohort), p = 0.023).  
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Table 4.12: Univariate survival data for gain of selected genes on chromosome 1q identified from the 500K SNP array analysis. 
The primary SNP array cohort of 42 ependymomas was analysed. The number of tumours demonstrating gain of each selected gene within the cohort is shown both numerically and as a 
percentage of the primary cohort. Statistically significant differences in survival between cases with and without gain of the selected gene are highlighted in yellow. Trends towards significance 
are highlighted in pale yellow. 
 
Table 4.13: Multivariate event-free survival analysis incorporating SNP array gain of NAV1. 
Cox regression multivariate analysis  (n=42) Event-Free Survival 
Factor Hazards ratio 95 % CI p-value 
Histology (WHO grade II vs III) 
Tumour location (ST vs PF) 
Resection status (complete vs incomplete) 
Patient age (below 3 years vs above 3 years) 
NAV1  (gain vs no gain) 
1.069 0.432 ± 2.648 0.885 
0.609 0.195 ± 1.901 0.393 
2.261 0.871 ± 5.87 0.094 
1.634 0.429 ± 6.232 0.472 
3.183 1.065 ± 9.520 0.038 
The primary SNP array cohort of 42 ependymomas was analysed. Radiotherapy and chemotherapy were not included as variables for event-free survival due to missing clinical data regarding 
commencement dates (Chapter 3, section 3.2.3). 95 % CI = 95 % confidence interval, ST = supratentorial, PF = posterior fossa. Statistically significant results are highlighted in yellow.  Trends 
towards significance are highlighted in pale yellow. 
 
Table 4.14: Multivariate overall survival analysis incorporating SNP array gain of the PRUNE/BNIPL region. 
 
 
 
 
 
 
 
 
The primary SNP array cohort of 42 ependymomas was analysed. ST = supratentorial, PF = posterior fossa, 95 % CI = 95 % confidence interval. Significant results are highlighted in yellow.  
Gene identified 
from SNP analysis 
Number of cases 
with gain (%) 
Percentage of cases attaining five year 
EFS (cases with gain versus without gain) 
P value Percentage of cases attaining five year OS 
(cases with gain versus without gain) 
p-value 
NSL1 18 (43 %) 30.3 %  + 11.2 % vs 46.4 % + 14.6 % 0.365 76  % + 10.4 % vs 77.7 % + 11.8 % 0.479 
CHI3L1 11 (26 %) 10.6 %  + 10 % vs 51.5 % + 11.2 % 0.09 71.6  % + 14 % vs 79.7 % + 9.4 % 0.293 
NAV1 11 (26 %) 9.1 %  + 8.7 % vs 53.3 % + 11.6 % 0.013 71.6  % + 14 % vs 81 % + 8.8 % 0.220 
PRUNE & BNIPL 12 (29 %) 16.7 %  + 10.8 % vs 50.8 % + 12.1 % 0.045 65.6  % + 14 % vs 84.1 % + 8.6 % 0.023 
Cox regression multivariate analysis  (n=42) Overall  Survival 
Factor Hazards ratio 95 % CI p-value 
Histology (WHO grade II vs III) 
Tumour location (ST vs PF) 
Resection status (complete vs incomplete) 
Patient age (below 3 years vs above 3 years) 
Radiotherapy (received vs not received) 
Chemotherapy (received vs not received) 
PRUNE/BNIPL region (gain vs no gain) 
1.074 0.291  ± 3.961 0.914 
0.540 0.066 ± 4.413 0.565 
1.176 0.274 ± 6.242 0.819 
1.499 0.209  ± 10.773 0.687 
0.308 0.064 ± 1.472 0.14 
1.752 0.226 ± 13.567 0.591 
4.295 1.071  ± 17.227 0.04 
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While the adverse effect on event-free survival reached a trend towards statistical 
significance on multivariate analysis (hazards ratio 2.425 (95 % CI 0.89 ± 6.59)              
p = 0.083), gain of the PRUNE/BNIPL region remained significantly associated with a 
worse overall patient survival (hazards ratio 4.295 (95 % CI 1.071 ± 17.227, p = 0.04) 
(Table 4.14). 
 
No statistically significant association with survival was identified for gain of the 
regions encompassing NSL1 or CHI3L1/YKL40 on univariate (Table 4.12) or 
multivariate analysis.  
 
4.3.3 Candidate regions of focal aUPD in paediatric ependymoma. 
 
SNP probes demonstrating aUPD were present, albeit not extensively, in all 44 
paediatric ependymomas analysed against patient-matched constitutional DNA (Figure 
4.7). In the majority of tumours (33/44, 75 %), aUPD was evident in fewer than 5 % of 
the total number of SNP probes examined. Indeed, in six cases (samples 6P, 27P, 30P, 
31P, 32P and 45P), less than 1 % of the probes revealed aUPD.   
 
Focal, gene-specific regions of aUPD were detected in 12/38 (32 %) primary and 4/6 
(67 %) intracranial first recurrent tumours (Appendix 10H). Of the twelve primary 
ependymomas that demonstrated focal aUPD, five were located in the posterior fossa 
(samples 9P, 21P, 25P, 28P, 40P), four were spinal tumours (24P, 27P, 38P, 42P), two 
were supratentorial (20P, 23P) and for one case the location was unknown (3P). Of the 
four recurrent ependymomas that demonstrated focal aUPD, three were supratentorial 
tumours (18R1, 20R1 and 43R1) and one was located in the posterior fossa (16R1). All 
of the regions of focal aUPD detected in the recurrent ependymomas were not present in 
WKHFRUUHVSRQGLQJSDWLHQW¶VSULPDU\WXPRXU 
 
Focal regions of aUPD were not frequently shared across the primary ependymoma 
cohort, the most common regions being observed in only two tumours (2/38, 5 %). 
Nevertheless, various loci were identified across chromosomes 1p, 2, 6 and 13q (Table 
4.15). These focal regions encompassed genes reported to be associated with DNA 
replication (RPA2 (1p35.3); RBMS1/MSSP2 (2q24.2)), cell motility and invasiveness 
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(ITGB6 (2q24.2), tumour angiogenesis (BAI3 (6q12); ELF1 (13q14.11)) and neurite 
growth and guidance (DPYSL5/CRMP5 (2p23.3); TIAM2/STEF (6q25.2)) (Takai, 
Nishita et al. 1994; Shiratsuchi, Nishimori et al. 1997; Fukada, Watakabe et al. 2000; 
Matsuo, Hoshino et al. 2002; Weisshart, Pestryakov et al. 2004; Huang, Brown et al. 
2006; Ramsay, Keppler et al. 2007). Other genes identified included DNAJC6 (1p31.3), 
which encodes a HSP40 heat shock protein family member and ERBB4 (2q34), a gene 
encoding a member of the RTK1 (Receptor Tyrosine Kinase 1) protein family also 
which also comprises ERBB2, ERBB3 and EGFR.  
 
Table 4.15: The most common focal regions of aUPD in 38 primary ependymomas. 
 
Locus Shared region (physical position bp) Gene symbol Number of samples 
1p35.3 28093071 - 28106912 RPA2 2/38 (5 %) 
1p31.3 65578142 - 65616570 DNAJC6 2/38 (5 %) 
1p22.3 85207201-85228120 MCOLN2 2/38 (5 %) 
2p24.3 15335505 - 15368097 NAG 2/38 (5 %) 
2p23.3 26934210 - 26986326 DPYSL5 2/38 (5 %) 
2p13.2 73593933 -73647562 ALMS1 2/38 (5 %) 
2q13 111344951 - 111357734 ACOXL 2/38 (5 %) 
2q14.1 115957656 -115994455 DPP10 2/38 (5 %) 
2q21.2 132932549 - 132944012 GPR39 2/38 (5 %) 
2q21.3 135328892 - 135373941 ACMSD 2/38 (5 %) 
2q22.1 137685713 - 137700731 ENST00000272643 2/38 (5 %) 
2q24.2 159792719 - 159815318 TANC1, WD50B1 2/38 (5 %) 
2q24.2 160692135 - 160722430 ITGB6 2/38 (5 %) 
2q24.2 160950541 - 161037890 RBMS1 2/38 (5 %) 
2q31.3 182597228 - 182623659 ENST00000280295 2/38 (5 %) 
2q32.1 183013344 - 183024436 PDE1A 2/38 (5 %) 
2q33.3 207693709 - 207715065 KLF7 2/38 (5 %) 
2q34 212395736 - 212409273 ERBB4 2/38 (5 %) 
2q36.3 225978417 - 225998949 ENST00000272907 2/38 (5 %) 
6p25.2 3364148 - 3379241 ENST00000380298 2/38 (5 %) 
6p22.3 16754457 - 16767074 ATXN1 2/38 (5 %) 
6q12 69597671-69611902 BAI3 2/38 (5 %) 
6q14.1 83709716-83724186 C6orf157 2/38 (5 %) 
6q25.2 155277331 - 155287746 TIAM2 2/38 (5 %) 
13q13.1 32221486 - 32246568 PDS5B 2/38 (5 %) 
13q14.11 40436259 - 40476109 ELF1 2/38 (5 %) 
Note: The physical genomic position of each shared region of aUPD is shown, together with the corresponding gene 
symbol from the annotation file (Netaffx file build 07.12.07) and the frequency of occurrence across the cohort. bp = 
base pairs. 
 
Only one site, within chromosome 9p22.1, was found to be the most common focal 
region of aUPD across the intracranial first recurrent cohort. This was observed in two 
tumours (2/6 samples, 33 %) (Table 4.16). The region encompassed a gene of unknown 
function, C9orf138. 
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Figure 4.7: Spotfire Decision Site® heatmap identifying regions of aUPD across the genome for 38 primary and six intracranial first recurrent paediatric ependymomas, as detected using the 
Affymetrix® 500K SNP array.  Regions of aUPD are coloured red, while regions not demonstrating aUPD are coloured white. P = primary, R1 = 1st recurrence. 
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Table 4.16: The most common focal region of aUPD in six intracranial first recurrent 
ependymomas. 
 
Locus Shared region (physical position bp) Gene symbol Number of samples 
9p22.1 18984588 - 19003483 C9orf138 2/6 (33 %) 
Note: The physical genomic position of each shared region of aUPD is shown, together with the corresponding gene 
symbol from the Affymetrix® annotation file (Netaffx file build 07.12.07) and the frequency of occurrence across the 
cohort. bp = base pairs. 
 
4.3.4 Genes differentially methylated between clinical subgroups in 
paediatric ependymoma  
 
Of all the clinical subgroups analysed (section 4.2.2.1), significant differential gene 
methylation was only identified between ependymomas from different CNS locations 
(Tables 4.17 ± 4.19).  
 
4.3.4.1 Differentially methylated genes characterising spinal and 
intracranial ependymomas 
 
Compared to spinal ependymomas, intracranial tumours demonstrated hypermethylation 
of genes such as the protein kinase encoding RIPK3 (14q11.2) and potential tumour 
suppressor RASSF1A (3p21.3), both of which have been reported to promote apoptosis 
(Yu, Huang et al. 1999; Oh, Lee et al. 2006) (Table 4.17). Spinal ependymomas 
revealed relative hypomethylation of the transcription factor EYA4 (6q23), an 
upregulated signature gene for spinal ependymomas (Taylor, Poppleton et al. 2005).  
 
In contrast, intracranial ependymomas demonstrated comparative hypomethylation of 
genes such as the RAS oncogene superfamily member RAN (12q24.3) responsible for 
regulating DNA synthesis. Other genes included the transcription factor encoding 
SPDEF (6p21.3), the transforming growth factor gene TGFB3 (14q24) and BCR 
(22q11.23), a gene of uncertain function that can form the BCR-ABL fusion gene found 
in chronic myeloid leukaemia. The hypomethylation profile of the latter three genes in 
intracranial ependymomas was attributed to the contribution from posterior fossa 
tumours (Table 4.19 and section 4.3.4.2). 
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The methylation status of the HOX family members, including HOXA5 (7p15.2), were 
not significantly different between spinal and intracranial tumours. 
 
Table 4.17: Genes with a differential methylation profile between paediatric spinal and 
intracranial ependymomas. 
 
SP hypomethylated genes SP  ȕYDOXH Intracranial  ȕYDOXH ȕGLIIHUHQFH p-value 
CRIP1           (probe P874R) 0.146 0.749 0.603 5.18 x 10-4 
KLK11          (probe P103R) 0.487 0.897 0.410 5.72 x 10-4 
GP1BB            (probe E23F) 0.486 0.838 0.352 9.38 x 10-4 
IRAK3           (probe P185F) 0.315 0.715 0.400 2.06 x 10-3 
RIPK3             (probe P24F) 0.441 0.865 0.424 2.43 x 10-3 
MEST                (probe P4F) 0.406 0.767 0.361 6.19 x 10-3 
RASSF1         (probe E116F) 0.439 0.783 0.344 7.48 x 10-3 
EYA4             (probe P794F) 0.276 0.699 0.423 7.92 x 10-3 
SP hypermethylated genes SP  ȕYDOXH Intracranial ȕYDOXH ȕGLIIHUHQFH p-value 
MC2R          (probe P1025F) 0.873 0.243 0.630 3.3 x 10-4 
JAK3           (probe P1075R) 0.817 0.331 0.486 3.4 x 10-4 
TGFB3           (probe E58R) 0.863 0.326 0.537 5.18 x 10-4 
BCR               (probe P346F) 0.835 0.272 0.563 5.72 x 10-4 
SPDEF              (probe P6R) 0.655 0.285 0.370 6.19 x 10-4 
HRASLS        (probe P353R) 0.821 0.428 0.393 6.53 x 10-4 
MBD2            (probe P233F) 0.766 0.303 0.463 6.82 x 10-4 
PYCARD       (probe P393F) 0.617 0.192 0.425 9.77 x 10-4 
IL1RN             (probe P93R) 0.683 0.319 0.364 1.46 x 10-3 
AOC3            (probe P890R) 0.759 0.397 0.362 2.43 x 10-3 
TRPM5          (probe P721F) 0.789 0.401 0.388 3.1  x 10-3 
CCKAR           (probe E79F) 0.709 0.329 0.380 3.37 x 10-3 
RAN              (probe P581R) 0.798 0.438 0.360 4.22  x 10-3 
Genes with a methylation profile differentiating paediatric spinal ependymomas from intracranial tumours are shown. 
A methylation score ȕYDOXH RIRQHUHSUHVHQWVFRPSOHWHPHWK\ODWLRQRIDJHQH¶V&S*WDUJHWVLWHZKLOHDVFore of 
zero represents no methylation of a CpG target site. The p-values shown are post Benjamini-Hochberg False 
Discovery Rate correction. The gene highlighted in red is an upregulated signature gene of spinal ependymomas 
established from gene expression array work (Taylor, Poppleton et al. 2005). SP = spinal. 
 
4.3.4.2 Differentially methylated genes characterising supratentorial and 
posterior fossa ependymomas 
 
Several genes revealed distinct methylation profiles that were associated with either 
supratentorial or posterior fossa ependymomas (Tables 4.18 and 4.19).  Moreover, 
certain genes demonstrated significantly different methylation states between tumours 
from the two intracranial locations. For instance, the Wnt pathway member WNT10B 
(12q13) and tyrosine kinase encoding gene HCK (20q11) demonstrated 
hypomethylation amongst supratentorial ependymomas, yet were both relatively 
hypermethylated across the posterior fossa cohort.  
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Likewise, particular genes were hypermethylated in the supratentorial tumour group yet 
hypomethylated in posterior fossa ependymomas, such as the growth factor encoding 
gene LEFTY2/TGFB4 (1q42.1) and PPARG (3p25), a member of the peroxisome 
proliferator receptor family. Indeed, correlation of the differential methylation data with 
the expression array findings of Taylor and colleagues (Taylor, Poppleton et al. 2005) 
identified PPARG, together with the aforementioned SPDEF and BCR, as genes 
demonstrating both significant hypomethylation and characteristic overexpression in 
posterior fossa ependymomas. MMP2 (16q13) and CHI3L2 (1p13.3) were also 
comparatively hypomethylated in the posterior fossa cohort. While MMP2 encodes an 
extracellular matrix enzyme that degrades type IV collagen, CHI3L2 belongs to the 
chitinase gene family already associated with infratentorial ependymomas through 
genomic gain, as established from the SNP array work (section 4.3.1.7).  
 
Table 4.18: Genes with a methylation profile characterising paediatric supratentorial 
ependymomas. 
 
ST hypomethylated genes 67ȕYDOXH Other location  ȕYDOXH ȕGLIIHUHQFH p-value 
EMR3              (probe P39R) 0.435 0.911 0.476 1.29 x 10-5 
WNT10B        (probe P993F) 0.238 0.758 0.520 1.61 x 10-4 
HCK              (probe P858F) 0.202 0.702 0.500 4.53 x 10-4 
ST hypermethylated genes 67ȕYDOXH Other location  ȕYDOXH ȕdifference p-value 
NAT2               (probe P11F) 0.897 0.539 0.358 1.29 x 10-5 
MAP3K1         (probe E81F) 0.631 0.210 0.421 4.84 x 10-5 
SH3BP2          (probe E18F) 0.528 0.148 0.380 1.93 x 10-4 
RBP1             (probe P426R) 0.633 0.122 0.511 6.8 x 10-4 
LEFTY2         (probe P719F) 0.836 0.433 0.403 1.05 x 10-3 
PPARG          (probe P693F) 0.863 0.383 0.480 1.6 x 10-3 
LCN2              (probe P86R) 0.672 0.300 0.372 1.95 x 10-3 
ASCL2           (probe P609R) 0.712 0.276 0.436 2.73 x 10-3 
EYA4             (probe P794F) 0.925 0.527 0.398 3.72 x 10-3 
Genes with a methylation profile differentiating paediatric supratentorial ependymomas from tumours located in the 
posterior fossa and spinal canal are shown. A methylation score ȕYDOXH of one represents complete methylation of a 
JHQH¶V&S*WDUJHWVLWHZKLOHDVFRUe of zero represents no methylation of a CpG target site. The p-values shown are 
post Benjamini-Hochberg False Discovery Rate correction. ST = supratentorial. 
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Table 4.19: Genes with a methylation profile characterising paediatric posterior fossa 
ependymomas 
 
PF hypomethylated genes PF  ȕYDOXH Other location  ȕYDOXH ȕGLIIHUHQFH p-value 
VAMP8             (probe E7F) 0.260 0.800 0.540 2.5 x 10-13 
EPHX1        (probe P1358R) 0.182 0.655 0.637 2.12 x 10-13 
B3GALT5     (probe E246R) 0.444 0.845 0.401 6.36  x 10-11 
OSM                (probe P34F) 0.400 0.895 0.495 9.72 x 10-11 
KRT5             (probe P308F) 0.483 0.844 0.361 1.37 x 10-10 
PPARG          (probe P693F) 0.259 0.836 0.577 4.79 x 10-10 
SEPT9           (probe P374F) 0.266 0.904 0.638 5.05 x 10-10 
LEFTY2         (probe P719F) 0.328 0.814 0.486 5.35 x 10-10 
CHI3L2           (probe E10F) 0.518 0.904 0.386 1.37 x 10-8 
TGFB3            (probe E58R) 0.219 0.695 0.476 1.37 x 10-8 
MMP2           (probe P303R) 0.070 0.570 0.500 1.26 x 10-7 
WRN              (probe P969F) 0.241 0.593 0.352 4.1 x 10-7 
SPDEF              (probe P6R) 0.192 0.567 0.375 7.24 x 10-7 
BCR               (probe P346F) 0.203 0.599 0.396 1.9 x 10-6 
MAPK1 0        (probe E26F) 0.347 0.825 0.478 4.22 x 10-5 
PF hypermethylated genes PF  ȕYDOXH Other location  ȕYDOXH ȕGLIIHUHQFH p-value 
HCK              (probe P858F) 0.787 0.291 0.496 4.23 x 10-7 
FABP3          (probe E113F) 0.829 0.400 0.429 3.14 x 10-5 
CRIP1           (probe P874R) 0.840 0.376 0.464 3.82 x 10-5 
WNT10B        (probe P993F) 0.792 0.407 0.385 1.44 x 10-3 
Genes with a methylation profile differentiating paediatric posterior fossa ependymomas from tumours located in the 
supratentorial region and spinal canal are shown. A methylation score ȕ YDOXH of one represents complete 
PHWK\ODWLRQRIDJHQH¶V&S*WDUJHWVLWHZKLOHDVFRUHRI]HURUHSUHVHQWV no methylation of a CpG target site. The p-
values shown are post Benjamini-Hochberg False Discovery Rate correction. Genes highlighted in red are 
upregulated signature genes of posterior fossa ependymomas established from gene expression array work (Taylor, 
Poppleton et al. 2005). PF = posterior fossa. 
 
4.3.4.3 Differentially methylated genes between a posterior fossa sample 
subcluster and the remaining primary ependymoma cohort 
 
Unsupervised hierarchical cluster analysis of the primary methylation cohort had 
previously identified a subgroup of nine ependymomas within a cluster of 34 posterior 
fossa tumours. These tumours were predominantly from young children and were of an 
anaplastic histology (Chapter 3, section 3.3.7). While differential gene methylation 
analysis did not identify disparity between this subgroup and the remaining posterior 
fossa tumours, differences in the methylation values of certain genes were found when 
the nine tumours were compared to the rest of the primary methylation cohort (Table 
4.20). These included THY1 (11q23.3), encoding the haemopoetic stem cell marker 
CD90 and the Wnt receptor gene FZD9 (7q11.23), which were both relatively 
hypomethylated across the smaller subgroup and therefore potentially overexpressed. 
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Table 4.20: Differentially methylated genes between the posterior fossa subgroup of 
nine tumours and the remainder of the primary ependymoma cohort. 
 
 Cluster hypomethylated 
genes 
 Cluster ȕ
value 
Remaining cohort  ȕ
value 
ȕGLIIHUHQFH  p-value 
HLA-DOA     (probe P594F) 0.299 0.655 0.356 1.21 x 10-3 
THY1               (probe P20R) 0.102 0.623 0.523 0.024 
PRKCDBP    (probe E206F) 0.242 0.581 0.339 0.024 
FZD9             (probe E458F)  0.141 0.561 0.420 0.05 
TNFRSF10D   (probe E27F) 0.481 0.842 0.432 0.05 
A methylation score ȕYDOXH RIRQHUHSUHVHQWVFRPSOHWHPHWK\ODWLRQRIDJHQH¶V&S*WDUJHWVLWHZKLOHDVFRUe of 
zero represents no methylation of a CpG target site. The p-values shown are post Benjamini-Hochberg False 
Discovery Rate correction. 
 
The cluster analysis had also identified a subgroup of five supratentorial tumours with a 
methylation profile distinct to that of the other supratentorial tumours in the cohort 
(Chapter 3, section 3.3.7). However, high resolution differential analysis failed to 
identify any significant differences in gene methylation values between this subgroup 
and either the remaining supratentorial tumours or the entire primary cohort.  
 
4.3.5 Real time qPCR validation of SNP array results 
 
Real time qPCR was performed to validate the copy number alterations found in 
particular genes of interest from the 500K SNP array analysis. Fifteen candidate genes 
were chosen (Table 4.21). All had either the potential to contribute to the pathogenesis 
of cancer based on their ontology, or had been associated with a variety of tumours, 
including ependymomas, from previous work. The focal regions of genomic imbalance 
incorporating these genes of interest were also aligned against a published map of 
normal copy number variation (CNV) across the human genome (Redon, Ishikawa et al. 
2006) to detect sites of overlap. This identified only the region encompassing TXN 
(9q31.3) to be located in an area of known CNV. Nevertheless, this gene was not 
excluded from further analysis since evidence suggests that CNV regions may facilitate 
tumourigenesis (Johnson, Wright et al. 2010).  
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Table 4.21: Fifteen candidate genes selected for real time qPCR validation. 
 
Gene Locus Reason for selection from SNP array analysis Primer efficiency (Tm)  
NSL1 1q32.3 Frequent gain in the primary intracranial cohort 91 %  (58oC) 
DNAJC25 9q31.3 Frequent gain / amplification in the primary 
intracranial cohort 
99 % (58oC) 
SEH1L 18p11.21 Frequent gain in the primary intracranial cohort 105 % (58oC) 
FILIP1 6q14.1 Frequent loss in the primary intracranial cohort 94 % (57oC) 
FRK 6q22.1 Frequent loss in the primary intracranial cohort 93 % (57oC) 
HOXA5 7p15.2 Frequent amplification in the primary intracranial 
cohort 
105 % (58oC) 
NAV1 1q32.1 Frequent gain in the intracranial recurrent cohort 
and gain associated with adverse event-free survival 
95 % (58oC) 
PPARA 22q13.31 Frequent loss in the intracranial recurrent cohort 91 % (58oC) 
CDKN2A 9p21.3 Homozygous deletion in the intracranial recurrent 
ependymoma 
100 % (58oC) 
CHI3L1 1q32.1 Frequent gain in the intracranial recurrent cohort 
and gain associated with posterior fossa 
ependymomas 
100 % (58oC) 
COL4A1 13q34 Gain associated with supratentorial (high grade) 
ependymomas 
100 % (58oC) 
TELO2 16p13.3 Gain associated with posterior fossa ependymomas 
from children aged below three years 
99 % (58oC) 
TXN 9q31.3 Gain associated with posterior fossa ependymomas 
from children aged below three years 
104 % (58oC) 
BNIPL 1q21.3 Gain associated with adverse overall survival 102 % (58oC) 
PRUNE 1q21.3 Gain associated with adverse overall survival 100 % (58oC) 
 
AJAP1 1p36.32 Control gene 93 %  (57oC) 100 % (58oC) 
ULK4 3p22.1 Control gene 95 % (at 57oC and  58oC) 
The fifteen candidate genes selected are shown, along with the two control genes used in the real time PCR 
experiments, AJAP1 and ULK4. The reason for selecting each candidate gene on the basis of the 500K SNP array 
results is also given. In addition, the corresponding primer efficiency used for the qPCR of each gene and the optimal 
annealing temperature (Tm) to attain this percentage is included. Primer efficiency was calculated as described in 
Chapter 2, section 2.4.2, using the designed primer pairs shown in Chapter 2, Table 2.2. 
 
4.3.5.1 qPCR validation of NSL1 gain 
 
Real time qPCR was performed on nine primary ependymomas for NSL1 copy number 
validation (Figure 4.8 and Appendix 10I). Copy number gain of NSL1 from the SNP 
array analysis was verified in 5/6 (83 %) expected cases by qPCR. A normal copy 
number for NSL1 was verified in 3/3 (100 %) control cases. A positive correlation 
existed between SNP array and qPCR derived NSL1 FRS\QXPEHUYDOXHV6SHDUPDQ¶V
rank correlation coefficient = 0.841; p = 0.005, two-tailed). 
 
4.3.5.2 qPCR validation of DNAJC25 gain 
 
Real time qPCR was performed on 11 primary ependymomas for DNAJC25 copy 
number validation (Figure 4.9 and Appendix 10I). Copy number gain of DNAJC25 from 
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the SNP array analysis was verified in 7/8 (88 %) expected cases by qPCR. A normal 
copy number for DNAJC25 was verified in 2/3 (67 %) control cases. A positive 
correlation existed between SNP array and qPCR derived DNAJC25 copy number 
YDOXHV6SHDUPDQ¶VUDQNFRUUHODWLRQFRHIILFLHQW S = 0.01, two-tailed). 
 
4.3.5.3 qPCR validation of FILIP1 loss 
 
Real time qPCR was performed on seven primary ependymomas for FILIP1 copy 
number validation (Figure 4.10 and Appendix 10I). Copy number loss of FILIP1 from 
the SNP array analysis was verified in 4/4 (100 %) expected cases by qPCR. A normal 
copy number for FILIP1 was verified in 2/3 (67 %) control cases. A positive correlation 
existed between SNP array and qPCR derived FILIP1 FRS\QXPEHUYDOXHV6SHDUPDQ¶V
rank correlation coefficient = 0.874; p = 0.01, two-tailed). 
 
4.3.5.4 qPCR validation of FRK loss 
 
Real time qPCR was performed on seven primary ependymomas for FRK copy number 
validation (Figure 4.11 and Appendix 10I). Copy number loss of FRK from the SNP 
array analysis was verified in 4/4 (100 %) expected cases by qPCR. A normal copy 
number for FRK was verified in 2/3 (67 %) control cases. A positive correlation existed 
between SNP array and qPCR derived FRK FRS\ QXPEHU YDOXHV 6SHDUPDQ¶V UDQN
correlation coefficient = 0.874; p = 0.01, two-tailed). 
 
4.3.5.5 qPCR validation of HOXA5 gain/amplification 
 
Real time qPCR was performed on 14 primary ependymomas for HOXA5 copy number 
validation (Figure 4.12 and Appendix 10I). Amplification of HOXA5 (copy number 
greater than five) from the SNP array was verified in 3/4 (75 %) expected cases by 
qPCR. Two other tumours (21P and 34P) revealed lower level gain of HOXA5 from the 
SNP array analysis (both copy number three). However, both of these tumours exhibited 
a higher level of genomic gain when assessed by qPCR (copy numbers 6.1 (sample 21P) 
and 4.5 (sample 34P)). A normal copy number for HOXA5 was verified in 3/8 (38 %) 
control cases, with the others revealing copy number gain. A positive correlation existed 
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between SNP array and qPCR derived HOXA5 FRS\QXPEHUYDOXHV6SHDUPDQ¶V UDQN 
correlation coefficient = 0.694; p = 0.006, two-tailed). 
 
4.3.5.6 qPCR validation of NAV1 gain 
 
Real time qPCR was performed on 12 ependymomas for NAV1 copy number validation 
(Figure 4.13 and Appendix 10I). Copy number gain of NAV1 from the SNP array 
analysis was verified in 4/4 (100 %) expected intracranial first recurrent cases and 3/3 
(100 %) expected primary cases by qPCR. A normal copy number for NAV1 was 
verified in 3/5 (60 %) control cases. A positive correlation existed between SNP array 
and qPCR derived NAV1 FRS\QXPEHUYDOXHV6SHDUPDQ¶VUDQNcorrelation coefficient 
= 0.748; p = 0.003, two-tailed). 
 
4.3.5.7 qPCR validation of CDKN2A homozygous deletion 
 
Real time qPCR was performed on five ependymomas for CDKN2A copy number 
validation (Figure 4.14 and Appendix 10I). The SNP array analysis identified one 
intracranial recurrent ependymoma (sample 18R1) to have homozygous genomic 
deletion of CDKN2A. This was verified by qPCR. Of the control tumours analysed, 
copy number gain was verified in one expected case, while a normal copy number for 
CDKN2A was verified in 3/3 (100 %) additional cases. A positive correlation existed 
between SNP array and qPCR derived CDKN2A FRS\QXPEHUYDOXHV6SHDUPDQ¶VUDQN
correlation coefficient = 0.918; p = 0.03, two-tailed). 
 
4.3.5.8 qPCR validation of CHI3L1 gain 
 
Real time qPCR was performed on nine primary ependymomas for CHI3L1 copy 
number validation (Figure 4.15 and Appendix 10I). Copy number gain of CHI3L1 from 
the SNP array analysis was verified in 5/5 (100 %) expected cases by qPCR. A normal 
copy number for CHI3L1 was verified in 4/4 (100 %) control cases. A positive 
correlation existed between SNP array and qPCR derived CHI3L1 copy number values 
(SpearmaQ¶VUDQNcorrelation coefficient = 0.895; p = 0.001, two-tailed). 
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4.3.5.9 qPCR validation of TXN gain 
 
Real time qPCR was performed on eight primary ependymomas for TXN copy number 
validation (Figure 4.16 and Appendix 10I). Copy number gain of TXN from the SNP 
array analysis was verified in 4/4 (100 %) expected cases by qPCR. A normal copy 
number for TXN was verified in 2/4 (50 %) control cases. A positive correlation existed 
between SNP array and qPCR derived TXN FRS\ QXPEHU YDOXHV 6SHDUPDQ¶V UDQN
correlation coefficient = 0.75; p = 0.035, two-tailed). 
 
4.3.5.10 qPCR validation of BNIPL gain 
 
Real time qPCR was performed on nine primary ependymomas for BNIPL copy number 
validation (Figure 4.17 and Appendix 10I). Copy number gain of BNIPL from the SNP 
array analysis was verified in 5/5 (100 %) expected cases by qPCR. A normal copy 
number for BNIPL was verified in 4/4 (100 %) control cases. A positive correlation 
existed between SNP array and qPCR derived BNIPL FRS\QXPEHUYDOXHV6SHDUPDQ¶s 
rank correlation coefficient = 0.921; p = 0.001, two-tailed). 
 
4.3.5.11 qPCR validation of PRUNE gain 
 
Real time qPCR was performed on nine primary ependymomas for PRUNE copy 
number validation (Figure 4.18 and Appendix 10I). Copy number gain of PRUNE from 
the SNP array analysis was verified in 5/5 (100 %) expected cases by qPCR. A normal 
copy number for PRUNE was verified in 4/4 (100 %) control cases. A positive 
correlation existed between SNP array and qPCR derived PRUNE copy number values 
6SHDUPDQ¶VUDnk correlation coefficient = 0.935; p = 0.001, two-tailed). 
 
4.3.5.12 qPCR of SEH1L gain, PPARA loss, TELO2 gain and COL4A1 loss  
 
Real time qPCR did not validate the copy number alterations identified in SEH1L, 
PPARA, TELO2 and COL4A1 from the SNP array study (summarised in Table 4.22 
with specific results in Appendix 10I). 
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Figure 4.8: Real time qPCR validation of NSL1 gene copy number previously ascertained on the 500K SNP array. 
qPCR was performed at 58oC with ULK4 as the control gene. P = primary. 
 
 
 
 
 
Figure 4.9: Real time qPCR validation of DNAJC25 gene copy number previously ascertained on the 500K SNP 
array. qPCR was performed at 58oC with ULK4 as the control gene. P = primary. 
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Figure 4.10: Real time qPCR validation of FILIP1 gene copy number previously ascertained on the 500K SNP array. 
qPCR was performed at 57oC with AJAP1 as the control gene. P = primary. 
 
 
 
 
 
 
Figure 4.11: Real time qPCR validation of FRK gene copy number previously ascertained on the 500K SNP array. 
qPCR was performed at 57oC with AJAP1 as the control gene. P = primary.
188 
 
 
Figure 4.12: Real time qPCR validation of HOXA5 gene copy number previously ascertained on the 500K SNP array. 
qPCR was performed at 58oC with ULK4 as the control gene. P = primary. 
 
 
 
 
 
Figure 4.13: Real time qPCR validation of NAV1 gene copy number previously ascertained on the 500K SNP array. 
qPCR was performed at 58oC with ULK4 as the control gene. P = primary, R1 = 1st recurrence. 
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Figure 4.14: Real time qPCR validation of CDKN2A gene copy number previously ascertained on the 500K SNP 
array. qPCR was performed at 58oC with ULK4 as the control gene. P = primary, R1 = recurrence. 
 
 
 
 
Figure 4.15: Real time qPCR validation of CHI3L1 gene copy number previously ascertained on the 500K SNP array. 
qPCR was performed at 58oC with ULK4 as the control gene. P = primary. 
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Figure 4.16: Real time qPCR validation of TXN gene copy number previously ascertained on the 500K SNP array. 
qPCR was performed at 58oC with ULK4 as the control gene. P = primary. 
 
 
 
 
Figure 4.17: Real time qPCR validation of BNIPL gene copy number previously ascertained on the 500K SNP array. 
qPCR was performed at 58oC with ULK4 as the control gene. P = primary. 
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Figure 4.18: Real time qPCR validation of PRUNE gene copy number previously ascertained on the 500K SNP array. 
qPCR was performed at 58oC with ULK4 as the control gene. P = primary. 
 
 
Table 4.22: Summary of real time qPCR validation results for SEH1L gain, PPARA 
loss, TELO2 gain and COL4A1 loss.  
 
Gene SNP array derived copy 
number in ependymomas 
selected for validation 
qPCR derived copy number of 
the selected ependymomas  
6SHDUPDQ¶VUDnk 
correlation coefficient 
(two-tailed) 
SEH1L Gain in 6 tumours Gain = 2 tumours 
Normal = 4 tumours 
(Validation = 33 %) 
 
R = 0.409 
p = 0.363 
 Normal in 1 tumour Loss  = 1 tumour 
(Validation 0 %) 
PPARA Loss in 3 tumours Normal =  1 tumour 
Gain = 2 tumours 
(Validation = 0 %) 
 
R = -0.434 
p = 0.454 
 Normal in 2 tumours Normal = 2 tumours 
(Validation = 100 %) 
TELO2 Gain in 3 tumours Normal  = 2 tumours 
Loss = 1 tumour 
Validation = 0 %) 
Not feasible 
COL4A1 Gain in 2 tumours Normal = 2 tumours 
(Validation = 0 %) 
Not feasible 
Since real time qPCR had failed to validate TELO2 gain and COL4A1 loss in ependymomas identified from the 500K 
SNP array analysis, other tumours in the cohort with apparently normal SNP derived copy numbers for these two 
geQHV ZHUH QRW VXEMHFWHG WR T3&5 LQ RUGHU WR DYRLG VDPSOH GHSOHWLRQ $V D FRQVHTXHQFH WKH 6SHDUPDQ¶V UDQN
correlation could not be calculated as indicated in the table. R= Spearman¶V UDQNFRUUHODWLRQFRHIILFLHQWZLWK WZR-
tailed significance value (p) underneath where calculated. Specific results are shown in Appendix 10I. 
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4.4 Discussion 
 
4.4.1 Genes potentially implicated in paediatric ependymoma pathogenesis 
 
The high resolution SNP and methylation array work presented in this chapter identified 
a number of genes potentially implicated in paediatric ependymoma pathogenesis 
through genomic imbalance, epigenetic alteration or rarely, acquired uniparental 
disomy. While it is important to consider all genes within a designated region of 
interest, certain genes identified from this work are now discussed. These include 
candidates associated with ependymoma pathogenesis from previous studies, genes 
which exhibited complementary methylation and expression profiles in ependymomas 
from different CNS locations and, in particular, fifteen SNP array derived candidates 
selected for copy number validation by qPCR (Table 4.21). The latter group were 
chosen because of detected aberrations in their copy number which were either frequent 
across primary and recurrent intracranial cohorts, or associated with particular clinical 
or prognostic subgroups. All fifteen genes had been implicated in various human 
cancers from preceding work, or had a cellular function that could potentially contribute 
to tumour pathogenesis if dysregulated.  
 
4.4.1.1 Candidate genes demonstrating frequent genomic imbalance in 
primary and recurrent intracranial ependymomas 
 
From the 500K SNP array analysis, NSL1 (1q32.3), SEH1L (18p11.21) and DNAJC25 
(9q31.3) were among the most frequently gained genes in the primary intracranial 
ependymoma cohort (Table 4.1). Both NSL1 and SEH1L promote cell division by 
encoding subunits of protein complexes responsible for the formation and function of 
kinetochores, chromosome-associated structures that mediate chromosomal segregation 
during mitosis (Kline, Cheeseman et al. 2006; Zuccolo, Alves et al. 2007). DNAJC25, 
one of the most frequently amplified genes in the cohort, encodes a member of the 
DNAJ/HSP40 group of heat shock proteins that are emerging with roles in various 
cancers (Mitra, Shevde et al. 2009). The DNAJ/HSP40 family are thought to act as 
molecular chaperones, important for optimising protein structure and function. They 
also regulate the activity of other heat shock chaperones, such as HSP70 proteins which 
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have been implicated in cancer progression (Didelot, Lanneau et al. 2007). Although 
research interest in a tumourigenic role for DNAJ/HSP40 proteins has recently 
increased, only 8/41 family members have currently been assessed (Mitra, Shevde et al. 
2009). Whereas some appear associated with tumour suppression, overexpression of 
DNAJA3 has been correlated with colorectal cancer progression (Kurzik-Dumke, 
Horner et al. 2008), while DNAJA1 reportedly contributes to the in vitro radiotherapy 
resistance of glioblastomas (Wang, Liao et al. 2006). This ependymoma study is the 
first to propose a potential oncogenic role for DNAJC25. 
 
The most common regions of focal genomic loss in the primary intracranial cohort were 
detected primarily on chromosome 6q (Table 4.2). This supported findings from the 
paediatric ependymoma CGH meta-analysis which identified chromosome 6 deletion as 
a frequent genomic alteration in primary posterior fossa tumours (Chapter 1, section 
1.5.2.2) (Kilday, Rahman et al. 2009) and an array CGH study which associated 6q loss 
with intracranial ependymomas (Mendrzyk, Korshunov et al. 2006). Putative tumour 
suppressor genes were encompassed within these focal regions of deletion, including 
FILIP1 (6q14.1) and FRK/RAK (6q22.1). FILIP1 encodes a filamin interacting protein 
whose in vitro degradation has been observed in oesophageal carcinoma cells (Shimada, 
Shiratori et al. 2009). In the CNS, the FILIP1 protein reportedly inhibits neocortical cell 
migration out of the ventricular zone (Nagano, Yoneda et al. 2002). FRK/RAK encodes 
a member of the TYR tyrosine kinase family (Lee, Wang et al. 1994). It has been 
proposed as a tumour suppressor in breast carcinoma (Yim, Peng et al. 2009), 
potentially through a mechanism promoting the stability and function of PTEN, a 
recognised tumour suppressor gene in ependymoma (Taylor, Poppleton et al. 2005; 
Johnson, Wright et al. 2010).  
 
The most common regions of focal copy number gain and loss in the intracranial 
recurrent cohort were found on chromosomes 1q and 22q respectively (Tables 4.3 and 
4.4), a feature observed and discussed further in Chapter 5. Frequent focal regions of 
gain encompassed genes implicated in a variety of processes, including cell migration 
and invasion, neurite growth and the inhibition of apoptosis. In addition, genes 
facilitating mitotic activity by encoding kinetochore associated proteins were also 
evident. The most frequently gained gene was NAV1 (1q32.1), which encodes a member 
of the neuron navigator family expressed predominantly in the central nervous system 
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(Maes, Barcelo et al. 2002). Gain of NAV1 was also evident in the primary 
ependymoma cohort where it was associated with an adverse event-free patient survival. 
NAV1 is homologous to the unc-53 gene responsible for axonal guidance in the 
roundworm Caenorhabditis elegans (Maes, Barcelo et al. 2002). Indeed, recent work 
has established that mammalian NAV1 localises to the centrosome, associates with the 
growing ends of microtubules and is potentially involved in neurite outgrowth (van 
Haren, Draegestein et al. 2009). Other gained genes such as LAMC1 (1q25.3), CENPF 
(1q41) and CDC42BPA (1q42.13) are reviewed in the fifth chapter. 
 
CBX7 (22q13.1) and PPARA (22q13.31) were encompassed within the regions most 
frequently demonstrating hemizygous loss. CBX7 encodes a member of the chromobox 
protein family implicated in gene silencing by facilitating the structural alteration of 
chromatin (Paro and Hogness 1991). It has already been proposed as a candidate tumour 
suppressor gene following expression array analysis of paediatric ependymomas 
(Suarez-Merino, Hubank et al. 2005). The peroxisome proliferator receptor encoded by 
PPARA activates the transcription of proteins responsible for fatty acid oxidation. It is 
proposed to exert a negative impact on tumours by inhibiting glycolysis and promoting 
fatty acid catabolism, thereby disrupting the metabolic pathways thought to be preferred 
by cancer cells in a state of nutritional deprivation (Grabacka and Reiss 2008). In 
neoplastic cells exposed to such stress, PPARA is also thought to interact with AMPK 
(AMP-dependent kinase) to induce cell cycle arrest, promote apoptosis, block Akt 
oncogenicity, inhibit cell proliferation, reduce cell migration and prevent inflammation. 
This tumour suppressive activity has been reported in several human cancers, including 
melanoma, (Grabacka, Plonka et al. 2006), colon cancer (Niho, Takahashi et al. 2003) 
and medullobalstoma (Urbanska, Pannizzo et al. 2008). 
 
Only one gene region of homozygous deletion was identified across the entire SNP 
array cohort of ependymomas. This was located in a recurrent supratentorial tumour on 
chromosome 9p21.3, encompassing the tumour suppressor genes CDKN2A and 
CDKN2B. Both of these cyclin-dependent kinase inhibitors regulate cell cycle G1 
progression, while CDKN2A has also been shown to control neural stem cell 
proliferation and rapidly expand progenitor cell numbers in developing neural tissue 
through its depletion (Taylor, Poppleton et al. 2005). Homozygous deletions of both 
genes are established anomalies in paediatric brain tumours such as CNS PNETs 
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(Pfister, Remke et al. 2007) and ependymomas, particularly those from a supratentorial 
location (Taylor, Poppleton et al. 2005; Johnson, Wright et al. 2010) as was the case in 
this study. Indeed, biallelic CDKN2A loss has been reported as an independent marker 
of adverse patient survival in ependymoma (Korshunov, Witt et al. 2010). Epigenetic 
inactivation of both CDKN2A and CDKN2B through promoter methylation has also 
been reported in ependymomas (Chapter 1, Table 1.7). 
 
4.4.1.2 Candidate genes demonstrating genomic or epigenetic 
abnormalities associated with ependymomas from particular CNS locations 
 
As the broad regions of genomic imbalance exhibited by spinal ependymomas from the 
SNP array study encompassed numerous genes, the identification of specific candidates 
was not feasible and therefore not performed. Nevertheless, the methylation array 
analysis identified several genes differentially methylated between spinal and 
intracranial ependymomas (Table 4.17). One such gene, EYA4 (6q23), demonstrated 
relative hypomethylation in spinal tumours. EYA4 encodes a member of the eyes absent 
transcription factor family which function through protein phosphatase activity (Tootle, 
Silver et al. 2003). Overexpression of this gene has been shown to be characteristic of 
spinal ependymomas when compared to intracranial tumours (Taylor, Poppleton et al. 
2005), implying that the expression profile of EYA4 in ependymomas could be 
influenced by its methylation status. This is supported by integrated epigenetic and 
expression analyses of oesophageal adenocarcinoma (Zou, Osborn et al. 2005) and non-
+RGJNLQ¶V O\PSKRPD (Alzein 2005), where aberrant EYA4 promoter methylation has 
been identified as a common mechanism of altered gene expression and gene silencing. 
 
The methylation array analysis also identified relative hypermethylation of RASSF1A 
(3p21.3) within the intracranial ependymoma cohort. This tumour suppressor gene 
encodes a protein with homology to the RAS effector proteins (Dammann, 
Schagdarsurengin et al. 2003). It has been shown to inhibit cell cycle progression in 
vitro (Shivakumar, Minna et al. 2002) and appears to be required for death receptor 
dependent apoptosis (Oh, Lee et al. 2006), while RASSF1A knockout mice have been 
shown to be susceptible to tumourigenesis (Tommasi, Dammann et al. 2005; Tommasi, 
Besaratinia et al. 2011). Promoter hypermethylation has been reported as a mechanism 
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of RASSF1A silencing in several malignancies (reviewed by (Dammann, 
Schagdarsurengin et al. 2003)). With regards to paediatric CNS tumours, biallelic 
hypermethylation has been reported as the primary mechanism of RASSF1A inactivation 
in medulloblastomas (Lusher, Lindsey et al. 2002), while previous reports identifying 
RASSF1A hypermethylation as a frequent epigenetic aberration in childhood intracranial 
ependymomas (Hamilton, Lusher et al. 2005; Michalowski, de Fraipont et al. 2006) 
(Chapter 1, Table 1.7) reinforce the findings presented in this work, warranting further 
assessment of this gene as a candidate tumour suppressor in paediatric ependymomas 
from this location.  
 
From the 500K SNP array analysis, HOXA5 (7p15.2) and certain other homeobox 
(HOX) family members were among the most frequently amplified genes within the 
primary intracranial ependymoma cohort (Table 4.5A). This gene family are responsible 
for regulating anteroposterior tissue patterning during embryological development 
(Dasen, Liu et al. 2003; Kmita and Duboule 2003; Taylor, Poppleton et al. 2005). In 
contrast to this SNP array finding, gene expression analyses have demonstrated the 
upregulation of several HOX genes, including HOXA5, in spinal ependymomas as 
opposed to intracranial counterparts (Korshunov, Neben et al. 2003; Taylor, Poppleton 
et al. 2005; Modena, Lualdi et al. 2006; Lukashova-v Zangen, Kneitz et al. 2007; Palm, 
Figarella-Branger et al. 2009). While this suggests the transcriptional repression of HOX 
genes may occur despite genomic amplification in intracranial ependymomas, the 
precise putative repressive mechanism of action remains unclear and requires 
evaluation. Gene promoter methylation appears an unlikely explanation from this work 
since differential analysis between spinal and intracranial tumours did not establish a 
difference in the methylation status of any HOX genes, including HOXA5.  
 
Within the paediatric intracranial ependymoma cohort, the SNP array analysis revealed  
supratentorial tumours were associated with the genomic gain of TULP4 (6q25.3), a 
gene involved in protein ubiquitination which has previously been proposed as an 
overexpressed signature gene of supratentorial ependymomas (Taylor, Poppleton et al. 
2005), and COL4A1 (13q34) which encodes the type IV alpha collagen chain of cellular 
basement membranes (Soininen, Haka-Risku et al. 1987) (Table 4.7). Exclusive 
analysis of the supratentorial ependymoma group also discovered COL4A1 gain was 
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associated with tumours of an anaplastic histology. Array work has reported the 
overexpression of COL4A1 in glial derived brain tumours such as paediatric intracranial 
ependymomas (Suarez-Merino, Hubank et al. 2005) and high grade gliomas (van den 
Boom, Wolter et al. 2003). Indeed, in vitro studies have demonstrated that normal brain 
tissue can produce and overexpress type IV collagen in response to confrontation from 
invading glioma cells (van den Boom, Wolter et al. 2003). Immunohistochemical 
analysis of gliomas has also revealed type IV collagen expression may be associated 
with regions of neoplastic vascular proliferation (Bellon, Caulet et al. 1985). These 
findings may suggest why expression of COL4A1 is increased in higher grade tumours 
as they often have a propensity for increased infiltration, invasiveness and angiogenic 
requirements. Nevertheless, explanations for the increased prevalence of SNP-array 
derived COL4A1 gain in supratentorial ependymomas remain unclear. Further 
investigation is required to elucidate whether this is a potential consequence of the 
migration and invasion of supratentorial tumours away from ependymal regions, or 
simply a reflection of the different biological microenvironments of the CNS 
compartments.  
 
The methylation array analysis identified 15 genes exhibiting relative hypomethylation 
in posterior fossa ependymomas compared to supratentorial tumours (Table 4.19). 
These included the metalloproteinase gene MMP2 (16q13) which encodes a putative 
marker of microinvasion and prognosis in ependymoma (Snuderl, Chi et al. 2008) 
(Chapter 1, Table 1.8), and three other genes, PPARG (3p25), SPDEF (6p21.3) and 
BCR (22q11.23), all designated signature genes for posterior fossa ependymomas 
because of their characteristic overexpression when compared to ependymomas from 
other CNS locations (Taylor, Poppleton et al. 2005). As with EYA4 expression in spinal 
ependymomas, this suggests that the expression profile of these three genes may be 
influenced by corresponding gene promoter methylation status, a hypothesis requiring 
validation. PPARG encodes another peroxisome proliferator receptor which controls 
fatty acid oxidation and glucose homeostasis (Picard and Auwerx 2002; Jones, Barrick 
et al. 2005). It has been reported to have tumour suppressive roles in colon cancer (Zou, 
Qiao et al. 2009) and glioblastoma (Cimini, Cristiano et al. 2005), yet oncogenic 
properties in breast carcinoma (Kourtidis, Srinivasaiah et al. 2009). SPDEF encodes a 
transcription factor, overexpression of which in vitro has been shown, in conjunction 
with ERBB2, to promote cell motility and invasiveness in breast cancer (Gunawardane, 
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Sgroi et al. 2005). While the precise function of BCR is unclear, it can act as a GTPase 
activating protein of CDC42 (Chuang, Xu et al. 1995), thereby potentially having a role 
in processes such as neurite growth, migration and cell cycle control. It is also a 
component of the BCR-ABL fusion gene found in chronic myeloid leukaemia (Grosveld, 
Verwoerd et al. 1986).  
 
Several genes demonstrating genomic gain on chromosome 1q were associated with 
primary posterior fossa ependymomas when compared to supratentorial counterparts 
from the SNP array analysis (Table 4.6). One such candidate was CHI3L1 (previously 
YKL40, 1q32.1). Gain of this gene was also a relatively common occurrence in the 
intracranial first recurrent cohort, being identified in 5/9 (55 %) tumours. Of these five 
recurrent cases, four (80 %) were located in the posterior fossa. CHI3L1 belongs to the 
chitinase gene family which function to hydrolyse the glycopolymer chitin (Funkhouser 
and Aronson 2007). Previous gene expression work has demonstrated CHI3L1 
upregulation in paediatric ependymomas when compared to normal brain and identified 
it as the most overexpressed gene at relapse in a patient-matched primary and recurrent 
tumour pair, again arising from the posterior fossa (Rand, Prebble et al. 2008). The 
encoded protein is thought to be implicated in cell migration, inflammation and 
connective tissue remodelling (Volck, Price et al. 1998; Boot, van Achterberg et al. 
1999; De Ceuninck, Gaufillier et al. 2001), with overexpression reported as an adverse 
prognostic marker in glioblastoma (Johansen, Christensen et al. 2003; Pelloski, Mahajan 
et al. 2005) and malignancies of the breast (Johansen, Christensen et al. 2003), colon 
(Cintin, Johansen et al. 1999) and ovary (Hogdall, Johansen et al. 2003). However, 
analysis of CHI3L1 overexpression in paediatric ependymomas has revealed a 
correlation only with tumour necrosis and not patient outcome (Rand, Prebble et al. 
2008). This agrees with the findings from the SNP array analysis which did not find a 
statistically significant association between CHI3L1 gain and either event-free or overall 
patient survival (Table 4.12). The SNP and methylation array analyses also identified 
abnormalities in other chitinase family members that were associated with posterior 
fossa ependymomas when analysed against tumours from other CNS locations, 
including the gain of CHIT1 (1q32.1) (Table 4.6) and the relative hypomethylation of 
CHI3L2 (1p13.3) (Table 4.19). This suggests a role for chitinase gene members in the 
pathogenesis of childhood posterior fossa ependymomas, warranting further 
investigation (Chapter 7). 
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Other genes demonstrating gain which were associated with posterior fossa 
ependymomas from the SNP array work included PARP1 (1q42.12) and AKT3 (1q44). 
While AKT3 encodes a protein kinase which regulates cell signalling and has been 
associated with maintaining the viability of glioma cells in vitro (Mure, Matsuzaki et al. 
2010), PARP1 encodes a protein implicated in DNA damage repair and cell 
proliferation, overexpression of which has been reported in numerous malignancies 
including colorectal carcinoma and primary glioblastoma multiforme (Wharton, 
McNelis et al. 2000; Nosho, Yamamoto et al. 2006). In addition, the development of 
PARP inhibition as a specific therapy for certain malignancies such as BRCA1 and 
BRCA2 deficient breast cancer is ongoing (Farmer, McCabe et al. 2005; Brown, Power 
et al. 2008; Rottenberg, Jaspers et al. 2008; Kling 2009). 
 
4.4.1.3 Candidate genes demonstrating genomic and epigenetic 
abnormalities associated with ependymomas from different paediatric 
patient age groups 
 
Twenty-four primary posterior fossa ependymomas analysed on the 500K SNP array 
were categorised equally into two groups according to patient age (below and above 
three years of age). Comparative analysis of these two subsets enabled the identification 
of genes demonstrating genomic imbalance which were associated with a particular age 
group.  
 
Gain of TELO2 (also known as CLK2, 16p13.3) was exclusive to patients aged below 
three years (Table 4.8). In the roundworm Caenorhabditis elegans, this gene regulates 
cellular processes including DNA replication, apoptosis and telomere length (Jiang, 
Benard et al. 2003). As stated in Chapter 1, section 1.5.7, telomeres cap chromosomal 
termini and erode after each mitotic division in normal somatic cells, whereas telomere 
maintenance is present in almost all malignant cells (Shay and Bacchetti 1997). As in 
the roundworm, in vitro overexpression of human TELO2 has also resulted in telomere 
maintenance and lengthening (Jiang, Benard et al. 2003), suggesting potential 
oncogenic properties for this gene. Gains incorporating TMEM18G (2p25.3) and 
HDAC10 (22q13.3) were also associated with the younger age group. While 
upregulation of TMEM18G may be involved in neural stem cell migration (Jurvansuu, 
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Zhao et al. 2008), HDAC10 encodes one of the histone deacetylases (HDACs) thought 
to contribute to tumourigenesis through the epigenetic alteration of chromatin structure 
and transcriptional repression of target genes (Rahman, Osteso-Ibanez et al. 2010). 
Indeed, the in vitro inhibition of HDACs in paediatric brain tumour cells has been 
shown to inhibit proliferation, diminish telomerase activity and promote apoptosis 
(Rahman, Osteso-Ibanez et al. 2010), while clinical trial evaluation of HDAC inhibitors 
as anti-cancer therapies are emerging for a variety of malignancies, including brain 
tumours (Galanis, Jaeckle et al. 2009; Rahman, Osteso-Ibanez et al. 2010).   
 
In contrast, gain of TXN (9q31.3) was exclusive to posterior fossa tumours from 
children aged over three years (Table 4.9). TXN encodes a member of the thioredoxin 
family, an oxidoreductase enzyme group thought to protect cancer cells against stress-
induced dysregulated oxidation and reduction processes (Powis and Kirkpatrick 2007). 
High protein expression of TXN has been associated with increased cancer cell 
proliferation, tumour angiogenesis and decreased apoptosis and has been reported in 
several malignancies such as lung, gastric and colorectal cancer (Grogan, Fenoglio-
Prieser et al. 2000; Kakolyris, Giatromanolaki et al. 2001; Raffel, Bhattacharyya et al. 
2003; Powis and Kirkpatrick 2007). Indeed, TXN overexpression in colorectal cancer 
has been reported as an independent negative marker of patient prognosis (Raffel, 
Bhattacharyya et al. 2003). The role of this gene in ependymomas from older children 
therefore merits further assessment at an expression and subsequent functional level if 
feasible, particularly as drugs inhibiting TXN and the thioredoxin redox system are now 
in clinical development (Mehta, Rodrigus et al. 2003; Ramanathan, Kirkpatrick et al. 
2007). 
 
Differential methylation analysis did not establish genes with a significantly different 
methylation value between primary ependymomas from young and older children or 
WHO grade II or III tumours. Nevertheless, unsupervised hierarchical clustering of the 
primary methylation array cohort did identify a subgroup of nine posterior fossa 
ependymomas from children aged less than three years which were predominantly of an 
anaplastic histology (Chapter 3, section 3.3.7). This small set of tumours were 
characterised by the relative hypomethylation of five genes compared to the rest of the 
primary cohort, including FZD9 (7q11.23) which encodes a member of the frizzled 
(FZD) family of receptors involved in activation of the Wnt cell signalling pathway 
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(Table 4.20). This pathway regulates cell survival, migration, and proliferation and has 
been implicated in numerous cancers (reviewed by (Taipale and Beachy 2001)). It 
remains unclear whether the hypomethylation and thereby potential overexpression of 
FZD9 identified reflects the young patient age or unfavourable tumour histology of the 
clustering subgroup. Support for anaplasia as the underpinning factor comes from a 
gene expression analysis of 34 ependymomas which found that WHO grade III tumours 
significantly overexpressed members of the Wnt pathway, including the FZD genes, 
when compared to ependymomas of classic histology (Palm, Figarella-Branger et al. 
2009). 
 
4.4.1.4 Candidate genes demonstrating genomic abnormalities associated 
with intracranial ependymomas of anaplastic histology 
 
Anaplastic supratentorial ependymomas were associated with focal regions of genomic 
gain across chromosomes 7q, 11q, 13q and 19 when compared to location-matched 
tumours of classic histology. These loci encompassed numerous genes, including FGF3 
(11q13.3), CDK8 (13q12.13), FLT1 (13q12.2) and the aforementioned COL4A1 
(13q34).  FGF3 encodes a fibroblast growth factor, overexpression of which has been  
has been associated with bladder, breast and non-small cell lung cancer (Naidu, Wahab 
et al. 2001; Tai, Sham et al. 2006; Zhang, Xie et al. 2006), while CDK8 encodes a 
cyclin dependent kinase associated with adverse prognosis in colorectal cancer 
(Firestein, Bass et al. 2008). FLT1, a gene frequently overexpressed in intracranial 
ependymoma (de Bont, Packer et al. 2008), is thought to positively regulate tumour 
angiogenesis as it encodes the receptor for vascular endothelial growth factor (VEGF) 
(Kerber, Reiss et al. 2008). The gain of FLT1 identified from this study thereby 
emphasised the association of anaplasia with increased tumour vascularity already 
established from ependymoma expression array work (Palm, Figarella-Branger et al. 
2009).  
 
High grade posterior fossa ependymomas were associated with focal regions of gain on 
chromosome 12 when compared to grade II counterparts, encompassing genes such as 
KNTC1/ROD (12q24.31). This encodes a protein responsible for mediating cell division 
(Chan, Jablonski et al. 2000), upregulation of which has been reported in hepatocellular 
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carcinoma and metastatic prostate cancer (LaTulippe, Satagopan et al. 2002; Mas, 
Maluf et al. 2009).  
 
4.4.1.5 Candidate genes on chromosome 1q demonstrating genomic 
imbalance associated with an unfavourable patient prognosis 
 
By integrating 500K SNP array findings for the primary paediatric ependymoma cohort 
with corresponding patient survival data, the genomic gain of selected genes on 
chromosome 1q was found to be associated with an unfavourable outcome. These genes 
were chosen from the numerous potential prognostic candidates on this chromosome 
arm as a consequence of preceding findings from the SNP analysis, as presented in this 
chapter. Gain of the aforementioned NAV1 (1q32.1) was associated with a worse event-
free survival (Tables 4.12 and 4.13, Figure 4.5). Focal gain within the 1q21.2 ± 21.3 
region, encompassing the genes BNIPL and PRUNE as identified by the Affymetrix® 
Netaffx annotation file (build 07.12.07), was also associated with an adverse event-free 
survival on univariate analysis and moreover, was an indicator of reduced overall 
patient survival on multivariate analysis (Tables 4.12 and 4.14, Figure 4.6). 
 
BNIPL (1q21.3) encodes two alternative transcripts, BNIPL-1 and BNIPL-2 (Bcl-
2/adenovirus E1B 19 kDa interacting protein-2 like 1 or 2) (Shen, Hu et al. 2003; Xie, 
Qin et al. 2007). Although BNIPL-1 has been reported to promote apoptosis and inhibit 
cell growth (Shen, Hu et al. 2003), overexpression of BNIPL-2 has been shown to 
increase hepatocellular cancer cell invasiveness and metastasis in vitro, whilst increase 
the rate of liver and lung metastases in nude mice in vivo following the hepatic 
implantation of tumours derived from subcutaneous xenografts (Xie, Qin et al. 2007). 
PRUNE (1q21.3) encodes a member of the DHH phosphoesterase superfamily (Aravind 
and Koonin 1998). Through interactions with proteins such as the serine-threonine 
kinase GSK-ȕ the metastasis regulating NM23-H1 and the cell adhesion controlling 
gelsolin, PRUNE is thought to promote cell motility and invasiveness respectively 
(Garzia, Roma et al. 2006; Kobayashi, Hino et al. 2006; Marino and Zollo 2007; Garzia, 
D'Angelo et al. 2008). Clinically, PRUNE overexpression has been reported as a 
frequent finding in sarcomas (Forus, D'Angelo et al. 2001) and other malignancies such 
as colorectal, pancreatic, oesophageal, gastric and breast cancer where it has been 
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associated with increased invasiveness, disease progression and adverse patient 
prognosis (Zollo, Andre et al. 2005; Kobayashi, Hino et al. 2006; Oue, Yoshida et al. 
2007; Noguchi, Oue et al. 2009). PRUNE is discussed further in subsequent chapters.  
 
As stated earlier, consideration must be given to all genes within a designated region if 
interest. While the SNP array annotation file used only acknowledged BNIPL and 
PRUNE within the 1q21.2 ± 21.3 locus, detailed analysis using the genomic database 
Ensembl revealed two other genes were also encompassed, CDC42SE1 and AF1q. 
CDC42SE1 encodes a protein that binds to the Rho GTPase CDC42 and modulates its 
activities, including the regulation of cell cycle progression, cell growth and migration, 
neurite outgrowth, neuronal development, neural progenitor polarity and fate, malignant 
transformation and cell invasiveness (reviewed by (Govek, Newey et al. 2005)); 
(Wilkinson, Paterson et al. 2005; Cappello, Attardo et al. 2006). The precise function of 
AF1q remains unclear, although it is known to form a fusion gene with MLL in 
haematological malignancies (Tse, Zhu et al. 1995), while overexpression of its encoded 
protein has been identified as an adverse prognostic marker in acute myeloid leukaemia 
(Tse, Meshinchi et al. 2004). In vitro studies have also shown AF1q overexpression 
promotes proliferation and invasiveness of breast cancer cells (Chang, Li et al. 2008). 
The recent integrated SNP and expression study of 204 ependymomas by Johnson and 
colleagues, published at the completion of this study, identified CDC42SE1 and AF1q, 
yet not BNIPL or PRUNE, as putative ependymoma oncogenes demonstrating copy-
number driven overexpression (Johnson, Wright et al. 2010). Consequently, NAV1, 
BNIPL, PRUNE, CDC42SE1 and AF1q and the proteins they encode warrant further 
evaluation within the context of establishing new markers of outcome and potential 
therapeutic targets for paediatric ependymomas. Indeed, in the sixth chapter the 
prognostic potential of NAV1 and PRUNE protein expression is assessed by 
immunohistochemistry on paediatric ependymomas from two aged-defined patient 
cohorts, each being treated uniformly within the confines of a clinical trial (UK CCLG 
1992 04 and SIOP 1999 04). This work is now being extended to assess a prognostic 
role for CDC42SE1, AF1q and BNIPL expression (Chapter 7).   
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4.4.2 Acquired uniparental disomy as a mechanism in paediatric 
ependymoma pathogenesis 
 
Whilst requiring validation, this work is the first to indicate aUPD as a potential, albeit 
infrequent, mechanism of pathogenesis in paediatric ependymoma. Focal regions of 
aUPD were identified in the primary tumour cohort, implicating genes associated with 
diverse cellular processes such as motility, invasiveness, angiogenesis, DNA replication 
and neurite development. However this was uncommon, being observed in only 2/38   
(5 %) cases (Table 4.15). As a consequence, further evaluation of aUPD in primary 
paediatric ependymomas was not performed since it appeared only relevant for an 
extremely small subset of tumours. Nevertheless, individual recurrent ependymomas 
demonstrated copy number neutral LOH at specific genomic regions which were not 
present in the FRUUHVSRQGLQJSDWLHQW¶VSULPDU\WXPRXUWKHPRVWFRPPRQHQFRPSDVVLQJ
C9orf138 within chromosome 9p22.1 (2/6 tumours; 33 %). This suggests a possible role 
for aUPD in tumour progression which may warrant further investigation. 
 
4.4.3 Accuracy of real time quantitative PCR validation 
 
The copy number alterations found in 11 of the genes identified from the 500K SNP 
array analysis and reviewed above (NSL1, DNAJC25, FILIP1, FRK, NAV1, CDKN2A, 
CHI3L1, HOXA5, TXN, BNIPL, and PRUNE) were validated in a subset of 
ependymomas using qPCR. The genomic imbalances of four other selected genes were 
unable to be validated (SEH1L, PPARA, COL4A1, TELO2). As a result, the overall 
correlation of SNP array derived copy number and qPCR derived copy number for the 
15 candidate genes analysed was significant (R = 0.664, p = 0.01, two-tailed 
6SHDUPDQ¶VUDQNWHVWFigure 4.19).  
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Figure 4.19: Overall correlation of copy number results derived from the 500K SNP array analysis (using 
the CNAG algorithm) and quantitative PCR for the 15 candidate genes of interest (as defined in Table 
4.21). 8VLQJ6SHDUPDQ¶VUDQNFRUUHODWLon (two tailed), the resulting R value was 0.664, significant at the 
0.01 level. The correlation appears relatively strong for genomic loss, copy number balance and low level 
gain, but weakens at higher copy number values. 
 
In total, 59 independent copy number gains of the 15 selected genes identified from the 
SNP array were subject to validation by qPCR. The majority were validated         
(48/59, 81 %). Eleven array-derived gene gains (19 %) were deemed false positives, 
demonstrating either a diploid copy number or genomic loss on qPCR. Validation was 
also performed on a total of twelve individual genomic losses of candidates from the 
SNP array. Of these, nine (75 %) were confirmed by qPCR with a matching copy 
number value, while three (25 %) were classed as false negatives, demonstrating either 
a normal or increased qPCR copy number value. In addition to the verification of 
genomic imbalances, validation of normal copy number was undertaken. Altogether, 50 
gene regions with a diploid copy number according to the SNP array were assessed by 
qPCR, with validation being achieved in most cases (35/50, 70 %). False normals were 
identified however, with nine cases (18 %) revealing gain on qPCR and six cases (12 
%) showing loss. Overall, qPCR appeared a relatively accurate method of confirming 
genomic loss, diploid copy number states and single copy number gains in genes 
identified from the 500K SNP array. However this precision diminished when 
attempting to validate high-level gene gain and amplification (Figure 4.19). FISH would 
have represented an appropriate alternative validation technique in such circumstances 
but was not performed due to the time constraints of the project.  
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The majority of discrepancies between the copy number results from the two methods 
can be accounted for by the unavoidable use of DNA which had to be re-extracted from 
certain tumours for the purposes of qPCR validation, since original stocks had been 
depleted as a result of the array analysis itself, or follow-on collaborative projects that 
KDGFRPPHQFHGSULRUWRWKLVSURMHFW¶VXQGHUWDNLQJsection 4.2.1.4). For example, of the 
19 ependymoma samples used in the unsuccessful validation of SEH1L, COL4A1, 
TELO2 and PPARA copy number changes identified from the SNP array, 16 (84 %) 
were reliant on tumour samples that had undergone DNA re-extraction. While there is 
clear evidence that paediatric ependymomas demonstrate histological heterogeneity 
(Chapter 1, section 1.2.4, Figure 1.1), this finding suggests that genetic diversity also 
exists between different sections cut from the same tumour and highlights the 
importance of using a single DNA source for the validation of SNP array projects in 
such cases.  
 
In contrast to SEH1L, COL4A1, TELO2 and PPARA, the successful copy number 
validation of eleven genes in this study (NSL1, DNAJC25, FRK, FILIP1, NAV1, 
CDKN2A, CHI3L1, HOXA5, TXN, BNIPL, and PRUNE) was still achieved, despite 
incorporating re-extracted ependymoma DNA samples. It can therefore be argued that 
these latter genes, demonstrating consistently identifiable genomic imbalances within 
different sections of a heterogeneous tumour, remain more appropriate to evaluate 
further as candidates of pathogenesis since these aberrations more accurately reflect the 
biological milieu of the entire tumour. Moreover, such anomalies could potentially be 
driving clonal expansion in the majority of cells comprising the tumour mass, as 
opposed to being inconsistent and inconsequential downstream mutations, although this 
requires verification through functional analysis.  
 
4.5 Summary 
 
Using Affymetrix® 500K SNP arrays and Illumina® GoldenGate® Cancer Panel I 
methylation arrays, a high resolution genomic and epigenetic analysis of paediatric 
ependymomas has been performed. While this is the first study to reveal aUPD as a 
possible yet infrequent mechanism of disease, alterations in the copy number and 
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methylation state of several genes potentially implicated in ependymoma pathogenesis 
were identified.  
 
Across primary intracranial ependymomas, the most common regions of genomic gain 
encompassed genes such as NSL1, SEH1L and DNAJC25, whereas frequent regions of 
loss harboured the putative tumour suppressor genes FILIP1 and FRK/RAK. Among 
recurrent tumours, the gain of genes encoding kinetochore associated proteins was again 
observed, while distinct focal genomic imbalances were identified including the 
frequent gain of NAV1, loss of candidates such as CBX7 and PPARA, and homozygous 
deletion of CDKN2A and CDKN2B.  
 
Other alterations were associated with particular clinical and prognostic subgroups. 
Anomalies specific to ependymoma location were evident, such as EYA4 
hypomethylation in spinal tumours and hypermethylation of RASSF1A in intracranial 
tumours. Within the intracranial cohort, supratentorial ependymomas were associated 
with the gain of genes such as TULP4 and COL4A1, whilst posterior fossa tumours 
were characterised by the hypomethylation of MMP2, PPARG, SPDEF and BCR, 
alterations in members of the chitinase gene family (CHI3L1 and CHIT1 gain, CHI3L2 
hypomethylation) and focal gains elsewhere across chromosome 1q, harbouring genes 
such as PARP1 and AKT3. Genomic imbalances associated with ependymomas from 
patients below three years of age were observed, including gains encompassing TELO2, 
TMEM18G and HDAC10, whereas gain incorporating genes such as TXN was a feature 
of tumours from older children. Focal imbalances also differentiated WHO grade III 
ependymomas from those exhibiting classic histology. Indeed, anaplastic supratentorial 
ependymomas were associated with gain of FGF3, CDK8, FLT1 and COL4A1, while 
gain encompassing KNTC1/ROD characterised high grade tumours from the posterior 
fossa. Moreover, focal gain encompassing selected candidates on chromosome 1q 
(NAV1, PRUNE, BNIPL, CDC42SE1 and AF1q) was associated with adverse patient 
survival.  
 
The genomic imbalances identified in eleven such candidate genes (NSL1, DNAJC25, 
FRK, FILIP1, NAV1, CDKN2A, CHI3L1, HOXA5, TXN, BNIPL, and PRUNE) were 
confirmed using real time qPCR. Validation of other findings from both array platforms 
is discussed in the final chapter. Expression array analysis and immunohistochemistry 
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are now required to determine whether the copy number alteration of these and all other 
candidate genes within the focal regions of imbalance presented, is sufficient to drive 
subsequent gene and protein expression. Indeed, the IHC assessment of NAV1 and 
PRUNE protein expression in a subset of paediatric ependymomas analysed on the SNP 
array has been performed, the results of which are presented and discussed in the 
penultimate chapter. Such analyses would also reaffirm which candidates display an 
expression profile in paediatric ependymoma that correlates with, and is potentially 
attributable to, an altered methylation state. Once established, the precise role of genes 
purported to drive tumourigenesis could then be ascertained functionally, using cell 
lines derived in-house from childhood ependymomas to manipulate in vitro gene 
expression. This again is discussed further in the final chapter.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
